##### CURRICULUM VITAE

##### RONALD JAY SOKOL, M.D., FAASLD

1. **PERSONAL HISTORY**

**PRESENT POSITION**:

Chief Scientific Officer, Child Health, Senior Vice President, Children’s Hospital Colorado and University of Colorado Anschutz Medical Campus

Distinguished Professor of Pediatrics with Tenure, Pediatric Gastroenterology, Hepatology and Nutrition

Associate Dean for Child Health Research, University of Colorado School of Medicine

Director and Principal Investigator, *Colorado Clinical and Translational Sciences Institute*, University of Colorado Denver, Anschutz Medical Campus

Assistant Vice Chancellor for Clinical and Translational Science, University of Colorado Denver

Bruce and Bev Wagner Family Endowed Chair for Child Health Research

Associate Director, Pediatric Liver Center

Principal Investigator, NIH Institutional T32 Training Grant - Pediatric Gastroenterology,

Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado

**ORCID: 0000-0001-7433-4095**

**PRESENT ADDRESS:**

Digestive Health Institute

Children’s Hospital Colorado, Box B290

13123 E. 16th Ave.

Aurora, Colorado 80045

 Phone: (720) 777-6669; Fax: (720) 777-7277

 E-Mail: ronald.sokol@childrenscolorado.org

**CITIZENSHIP:** USA

**MARITAL STATUS:** Married (Lori), Two Children (Skylar, Jared)

1. **EDUCATION**

1968‑1972 University of Illinois, Urbana, Bachelor of Science with High Honors

1972‑1976 University of Chicago/Pritzker School of Medicine, M.D.

1976‑1977 Pediatric Internship, University of Colorado Health Sciences Center, Denver, Colorado

1977‑1979 Pediatric Residency, University of Colorado Health Sciences Center, Denver, Colorado

1979-1980 Chief Resident in Pediatrics, University of Colorado Health Sciences Center, Denver, Colorado

1980‑1983 Fellow, Pediatric Gastroenterology and Nutrition, Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, Ohio

1. **ACADEMIC APPOINTMENTS**

1979 ‑ 1980 Instructor in Pediatrics, University of Colorado School of Medicine, Denver, Colorado

1983 - 1988 Assistant Professor of Pediatrics, University of Colorado School of Medicine, Denver, Colorado

1986- 1998 Co-Founder and Medical Director of Pediatric Liver Center, University of Colorado Health Sciences Center (UCHSC) and Children’s Hospital Colorado, Denver, Colorado

* 1. Associate Professor of Pediatrics with Tenure, University of Colorado School of Medicine, Denver, Colorado

1993-2004 Program Director, Pediatric Gastroenterology, Hepatology and Nutrition Fellowship Training Program, University of Colorado School of Medicine and Children’s Hospital Colorado, Denver, Colorado.

1995-present Professor of Pediatrics with Tenure, University of Colorado School of Medicine, Denver, Colorado (Post Tenure Review in 2012 and 2017)

1996-1999 Medical Director, Pediatric Liver Transplantation Program, University of Colorado Denver and Children’s Hospital Colorado.

1998-2008 Program Director, Pediatric General Clinical Research Center, University of Colorado and Children’s Hospital Colorado, Denver, Colorado

1999-2022 Vice Chair of Clinical and Translational Research, Department of Pediatrics, University of Colorado School of Medicine

2005-present Graduate School Faculty, University of Colorado Denver, Denver, Colorado

2006-2022 Chief, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of Colorado School of Medicine.

2006-2008 Director, Colorado Program for Clinical and Translational Sciences, University of Colorado Denver

2008-present Director and Principal Investigator, Colorado Clinical and Translational Sciences Institute, University of Colorado Denver

2009-2022 Director, Digestive Health Institute, Children’s Hospital Colorado

2015-present Assistant Vice Chancellor for Clinical and Translational Science, University of Colorado Denver

2022-present Chief Scientific Officer, Child Health, and Senior Vice President, Children’s Hospital Colorado and University of Colorado Anschutz Medical Campus

2022-present Associate Dean, Child Health Research, University of Colorado School of Medicine

2022-present Distinguished Professor, University of Colorado

1. **HOSPITAL, GOVERNMENT OR OTHER PROFESSIONAL POSITIONS**

1996-1999 Medical Director, Pediatric Liver Transplantation Program, UCHSC and Children’s Hospital Colorado, Denver, Colorado

1998-present Associate Medical Director, Pediatric Liver Center, University of Colorado Denver and Children’s Hospital Colorado, Denver, Colorado

2006-2022 Department Head of Gastroenterology, Hepatology and Nutrition, Children’s Hospital Colorado, Denver, Colorado

2009-2022 Director, Digestive Health Institute, Children’s Hospital Colorado, Aurora, Colorado

2022- present Chief Scientific Officer, Child Health and Senior Vice President, Children’s Hospital Colorado

1. **HONORS, SPECIAL RECOGNITIONS AND AWARDS**

1968‑1972 Edward J. James Scholar, University of Illinois, Urbana

1969 Phi Kappa Phi, University of Illinois, Urbana

1971 Phi Beta Kappa, University of Illinois, Urbana

1972 Bronze Tablet (upper 1% of graduating class), University of Illinois, Urbana

1976 Alpha Omega Alpha, University of Chicago/Pritzker School of Medicine

1984 Society for Pediatric Research Young Investigator Award ‑­ Honorable Mention

1986 Basil O'Connor Award, March of Dimes

1990 Mead Johnson Award for Nutritional Research, American Institute of Nutrition

1992, 1995 American Men and Women of Science (citation)

1994-2021 Best Doctors in America (citation)

1996-97 Best Doctors in America: Central Region (citation)

1996-1998 President, North American Society for Pediatric Gastroenterology and Nutrition

1998-1999 American Men and Women of Science, 20th Edition (citation)

2000 Outstanding Teaching Award, Clinical Science Ph.D. Program, University of Colorado Health Sciences Center

2002-2009 Chair, Steering Committee, Biliary Atresia Clinical Research Consortium, NIDDK, NIH

2002-2006 America’s Top Pediatricians (citation), *Consumers’ Research Council of America*

2002 Mead Johnson Excellence in Teaching, Third Quarter 2002; Letter of Commendation, Cincinnati Children’s Hospital Medical Center

2003 2003 Nutrition Award of the American Academy of Pediatrics, Committee on Nutrition

2004-2009 Chair and Principal Investigator, Cholestatic Liver Disease Consortium, ORD/NCRR/NIDDK, National Institutes of Health

2004 Hall of Honor, Cincinnati Pediatric Historical Society, Cincinnati, OH

2004-2020 Marquis Who’s Who in Medicine and Healthcare, 5th - 10th Edition

2005-2020 Marquis Who’s Who in America, 60th - 70th Edition

2006-2009 Chair, Steering Committee of Rare Diseases Clinical Research Network, ORD/NCRR/NIH

2006-2008 Top Doctors in Denver, *5280 Magazine*

2006 National Commission on Digestive Diseases (NCDD), Liver and Biliary Systems Working Group, National Institutes of Health

2007, 2009 America’s Top Physicians, *Consumer’ Research Council of America*

2008 - present Principal Investigator and Director, Colorado Clinical and Translational Sciences Institute, University of Colorado Denver

2009 James E. Strain M.D. Award in Pediatrics, Children’s Hospital Colorado Medical Staff, Aurora, CO

2009 Pediatric Liver Research Award, Alpha-1 Kids and the Alpha-One Association

2009 Harry Shwachman Award (for major, life-long scientific contributions to the field of pediatric gastroenterology, hepatology, and nutrition), from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN)

2009 2009 Medical Honors Award, Invisible Disabilities Advocate

2009-present Chair, Childhood Liver Diseases Research Network (ChiLDReN), NIH/NIDDK

2010-2022 Arnold Silverman, MD Endowed Chair in Digestive Health, Children’s Hospital Colorado, Aurora, Colorado

2011-2022 America’s Top Doctors, 10th - 20th editions, *Castle Connolly Medical, Ltd*.

2011 Marqui’s Who's Who in Science and Engineering 2011-2012 (11th Edition)

2011-2022 Top Doctors, *U.S. News and World Report*

2014-2019 Governing Board, American Association for the Study of Liver Diseases

2014 2014 Best Doctors in Denver, *Denver Business Journal*

2014 Fellow of the American Association for the Study of Liver Diseases (FAASLD)

2015 Career Teaching Scholar Award, Department of Pediatrics, University of Colorado School of Medicine and Children’s Hospital Colorado

2015 William and Rebecca Balistreri Lectureship in Hepatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

2017 President-Elect, American Association for the Study of Liver Diseases

2018 President, American Association for the Study of Liver Diseases

2018-2021 NIDDK Advisory Council, National Institute of Diabetes and Digestive and Kidney Diseases, NIH

2019 Past President, American Association for the Study of Liver Diseases

2019 2019 Peak of Excellence Award, American Liver Foundation, Rocky Mountain Chapter, Denver, Colorado

2020-2023 Clinical and Translational Science Award (CTSA) Program Steering Committee, National CTSA Consortium, NCATS, NIH

2020 2020 Sass-Kortsak Award, Canadian Association for the Study of the Liver-Canadian Liver Foundation, in recognition for outstanding contributions in the field of Pediatric Hepatology

2021 Top Pediatric Gastroenterologist, Top Doctors, Colorado Magazine

2021 Dan W. Thomas Keynote Lecture, Children’s Hospital of Los Angeles, University of Southern California School of Medicine, Los Angeles, CA, August 13, 2021

2021-2022 Search Committee for Director of National Center for Advancing Translational Science (NCATS), NIH

2022-present Bruce and Bev Wagner Family Endowed Chair for Child Health Research

2022-present Subgroup Chair, NINDS Mitochondrial Common Data Elements Committee, National Institute of Neurological Disorders and Stroke, NIH

2022-present Steering Committee, Coalition for Pediatric Medical Research

2022 CU Distinguished Professor, University of Colorado

1. **MEMBERSHIP AND LEADERSHIP POSITIONS IN PROFESSIONAL ORGANIZATIONS**

1982 New York Academy of Sciences

1983 North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN)

 Offices Held and Committees:

 **President 1996-1998**, President elect 1994-1996, Past-President 1998-2000

 Training and Education Committee 1985-1989

 Chair of Research Committee 1990-1993

 Executive Council 1990-1992

 Chair of Hepatology Committee 2001-2003

 Chair and member of Advocay/Public Policy Committee, 2005-2010

 Chair of Publications Committee 1998-2000, member 2006-2010

 Nominating Committee 1996, Chair 2001-2002

 Chair, Shwachman Award Committee 1995, 1996

 Board member (NASPGHAN representative), Federation of Societies for Gastroenterology and Hepatology, 1997-1998

 President’s Advisory Committee, 2001-present

 NASPGHAN President’s Liaison Committee, American Liver Foundation representative, 2001-2006

 Chair, NASPGHAN Task Force for Application to American Board of Pediatrics for Certificate of Added Qualification for Pediatric Transplantation Hepatology, 2002-2004

 Chair, North American Society for Pediatric Gastroenterology and Nutrition Name Change Task Force, 2000

 Regional Reporter, Workforce Survey of Pediatric Gastroenterology, NASPGHAN, 2003

 Task Force on Collaborative Research, NASPGHAN 2002

 Chair, Task Force for Feasibility of Public Policy/Advocacy Committee of NASPGHAN 2003

 NASPGHAN Educational Activities and Conferences:

Chairman and Organizer, Seventh NASPGHAN/Ross Seminar on Pediatric Gastroenterology, Scottsdale, AZ, February 1988

 Organizer of 8th Annual NASPGHAN/Ross Seminar on Pediatric Gastroenterology, February, 1989, Scottsdale, Arizona, February, 1989

 Chair, Scientific Program Committee, Abstract Reviewer and Plenary Session Moderator, NASPGHAN Annual Meeting, Chicago, Illinois, Nov. 2-3, 1990

Chair, NASPGHAN/Mead Johnson Research Symposium for Pediatric Gastroenterology Fellows and Junior Faculty. Palm Springs, California, March14‑17, 1991

 Chairman, Scientific Program Committee, Abstract Reviewer and Plenary Session Moderator, NASPGHAN Annual Meeting, Chicago, Illinois, Nov. 1‑2, 1991

 Chairman, NASPGHAN/Mead Johnson Research Symposium for Pediatric Gastroenterology Fellows and Junior Faculty. Ft. Lauderdale, Florida, Mar 26‑9, 1992

 Chairman, Scientific Program Committee, Abstract Reviewer and Plenary Session Moderator, NASPGHAN Annual Meeting, Chicago, Illinois, Oct 30‑31, 1992

 Chairman, NASPGHAN/Mead Johnson Research Symposium for Pediatric Gastroenterology Fellows and Junior Faculty, Ft. Lauderdale, Florida, April 1‑4, 1993

Planning and Organizing Committee. Fourth Joint Meeting of NASPGHAN-ESPGAN, October 1994, Houston, TX, 1993-1994

 Session Organizer and Chair, “Liver disease”, Postgraduate Course, NASPGHAN Annual Meeting, Oct 14-15 1994

 Chair of Scientific Program and Organizing Committee, 1995 Annual NASPGHAN Meeting

 Co-Director, Postgraduate Course, NASPGHAN Annual Meeting, Nov 2., 1995, Chicago, IL.

 Chair of Scientific Program and Organizing Committee, 1996 NASPGHAN Annual Meeting, Denver, Colorado

 Co-Director, Postgraduate Course, "Pediatric Gastroenterology and Nutrition - state-of-the-art - 1996", NASPGHAN Annual Meeting, Denver, Colorado, Oct. 3, 1996

 Organizing Committee, 5th Joint Meeting of European Society of Pediatric Gastroenterology, Hepatology and Nutrition and the NASPGHAN, May 27-30, 1998, Toulouse, France, 1997-1998 .

 International Executive Committee and Host Executive Committee, First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition - Boston, MA, August, 2000, 1997-2000

 Scientific Program Committee, NASPGHAN annual Meeting, 1997-1998

 Working Group Coordinator, 1st World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Boston, MA, 1998-2000

Scientific Program Committee, 1st World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Boston, MA, 1998-2000

 Organizer and Moderator, “Pediatric Liver Transplantation”, AGA/NASPGHAN symposium at Digestive Disease Week, May 21, 2003, Orlando, FL., 2003

1983 Western Society of Pediatric Research

1984 American Gastroenterological Association (AGA)

 Nominating Committee of the Growth, Development, and Nutrition Section 1998

1984 American Association for the Study of Liver Diseases (AASLD)

 Offices Held and Committees:

 Membership Committee 1993-1996

 Program Evaluation Committee 1997-1999

 Education Committee 2002-2006

 Clinical Research Committee 2009-2010

 Basic Research Committee 2010-2013

 Nominating Committee 2010-2011

 Federal Agencies Liaison Committee 2012-2016

 Scientific Program Committee 2013

 Search Committee for Executive Director 2014

 Councilor, Governing Board 2014-2015

 Senior Councilor, Governing Board 2016

 Scientific Program Committee 2016-18, Chair 2018

 Financial Planning Taskforce 2016

 Chair, Innovation Fund Taskforce and Review Committee 2016-2018

 Member, AASLD Foundation Board of Directors 2016-2017

 Digestive Disease Week Council 2016-2018

 President-Elect (2017)

 **President (2018)**

 Group of 8 Representative (2016-18) and Chair (2017-2018)

 Chair, Distinguished Awards Review Committee, AASLD, 2018

 Past-President (2019)

 Chair, Nominating Committee 2019

 Distinguished Awards Committee, 2019

 Chief Executive Officer Search Committee, 2019

1985 American Society for Parenteral and Enteral Nutrition

1986 Colorado Society for Parenteral and Enteral Nutrition

 Board of Directors, Colorado Society for Parenteral and Enteral Nutrition, 1987-1990

1987 Fellow of the American Academy of Pediatrics

1988 Society for Pediatric Research

1989 American Institute of Nutrition

1. American Society for Clinical Nutrition
2. Oxygen Society
3. Program Directors Association, General Clinical Research Centers
4. American Pediatric Society
5. Association for Patient-Oriented Research

2009 Association for Clinical and Translational Science

2012 ARPKD/CHF Alliance, Professional Advisory Board

1. **MAJOR COMMITTEE AND SERVICE RESPONSIBILITIES**
2. **Department of Pediatrics, University of Colorado School of Medicine**

1989‑1992 Department of Pediatrics Research Committee

1998 Committee on Research Needs, Department of Pediatrics

1. Co-chair, Task Force on Strategic Directions/Balance, Department of Pediatrics, UCD and Children’s Hospital Colorado, Denver, CO

2004-present Scholarship Oversight Committee for Fellowship Training Programs, University of Colorado School of Medicine, Denver, CO

2005-2022 Committee on Fellowship Education, Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, CO

2007-2011 Research Committee, Department of Pediatrics, UC School of Medicine

2009 Chair, Subcommittee on Clinical and Translational Research, and member of Executive Committee, Strategic Planning for Child Health Research, Children’s Hospital Colorado and UC Denver, Aurora, CO

2010-present Executive Committee, NIH K12 Child Health Research Career Development Program, Department of Pediatrics, University of Colorado School of Medicine

2010-2016 Pediatric Leadership Planning Committee, Department of Pediatrics, UC Denver and Children’s Hospital Colorado, Aurora, CO

2010-present Research Executive Steering Committee, Children’s Hospital Colorado Research Institute and Department of Pediatrics, UC Denver and Children’s Hospital Colorado, Aurora, CO

2014-2022 Department of Pediatrics External Review Response Committee, University of Colorado School of Medicine

2016-2022 Vice Chairs Committee, Department of Pediatrics

2018-present Research Planning, Commmittee, Children’s Hospital Colorado-CU Anschutz Child Health Research Strategic Plan

1. **School of Medicine, University of Colorado**

1988‑2000 Board of Directors of the CU‑CSU Consortium for Human Nutrition

1989‑1990 UC Denver HSC Human Subjects Committee

1990-1997 UCHSC Hepatobiliary Research Center Education and Research Committee

1990‑1997 UCHSC Hepatobiliary Research Center Administrative Committee

1994-1996 Director, Human Investigation/Genetics Core of UCHSC Hepatobiliary Research Center

1994-2015 Pediatric Surgery Residency Evaluation Committee, UC Denver and Children’s Hospital Colorado

1999-2012 Polycystic Kidney Disease Research Group Advisory Board, UC Denver

2004-2020 Clinical Translational Research Advisory Committee (CTRAC), School of Medicine, UC Denver, Denver, CO

2004-2005 Search Committee, Chief of Division of Gastroenterology and Hepatology, Department of Medicine, University of Colorado School of Medicine, Denver, CO

2004-2005 Regional Translational Research Center Steering Committee, UCD, Denver, CO

2006-2015 Colorado Multiple Institutional Review Board Advisory Committee, Children’s Hospital Colorado and UC Denver

2006-2008 Search Committee, Chair of Department of Pediatric Pathology, UCDHSC and Children’s Hospital Colorado

2007-present Executive Committee, Univesity of Colorado School of Medicine

2009-2014 Advisory Committee, Colorado Health Outcomes Program (COHO), University of Colorado SOM

2011-present Research Advisory Forum for University of Colorado Hospital and the University of Colorado School of Medicine

2012-2014 Search Committee, Biomedical Informatics and Personlized Medicine Division, Department of Medicine, University of Colorado School of Medicine

2014-2015 Search Committee, Director of Barbara Davis Center Basic and Translational Research Division, University of Colorado School of Medicine

2015-present Internal Advisory Committee, NINDS K12 Training Program in Pediatric Neurology, University of Colorado School of Medicine

2018-2019 Search Committee, Division Chief, Gastroenterology and Hepatology, Department of Medicine, University of Colorado School of Medicine

2022-present Associate Dean for Child Health Research, Dean’s

2023 Dean’s Special Committee on Research Space Allocation

1. **University of Colorado Denver – Anschutz Medical Campus**

1983‑1990 Co‑director of Pediatric Nutritional Support Team at University of Colorado Denver

1987‑1988 Interdepartmental Steering Committee on Nutrition, UC Denver

1991‑1992 Ad Hoc Physician Communication Task Force, University Physicians, Inc., UCHSC

1996-present Member, Association of Transplant Physicians and Surgeons, University of Colorado Denver

1999-present Gastroenterology Fellowship Committee, UC Denver

1999-2002 Ad Hoc Faculty Senate Committee on Research Infrastructure, UC Denver

 Clinical Sciences Ph.D. Program, UC Denver

* 1. Pediatric Cardiology Section Chief Search Committee, UC Denver and CHCO

2007 Discovery, Creativity & Innovation Task Force, Chancellor’s office, University of Colorado Denver

2008-present Director and Principal Investigator, Colorado Clinical and Translational Sciences Institute

2010-2022 Chair, Grant Review Panel, Boettcher Foundation-Webb Waring Biomedical Research Awards for University of Colorado

2010 Grant Review Panel member, Boettcher Foundation-Webb Waring Biomedical Research grants for Small Institutions

2010 Search Committee member for Director of Pediatric Diabetes Clinical Care and Translational Research, Barbara Davis Center for Childhood Diabetes

2012 Planning Committee for Clinical and Research Enterprise Data Warehouse (CREW) at University of Colorado Denver

2103 Steering Committee, Office of Clinical Research Project, Office of Clinical Research Initiatives, University of Colorado President’s Office

2014 OnCore Advisory Committee, Officer of Vice Chancellor of Research, University of Colorado Denver

2014 Governance Committee, Center for Biomedical Informatics and Personalized Medicine, University of Colorado Denver

2015-present Assistant Vice Chancellor for Clinical and Translational Science, University of Colorado Denver

2015 University/UC Health Research Committee, University of Colorado Denver

2018-present OnCore Advisory Committee, University of Colorado Denver

2019-present Advisory Board – Anschutz Health and Wellness Center

2019-2020 Search Committee, Director of Health Data Compus, Enterprise Data Warehouse for University of Colorado Anschutz Medical Campus

2019–present Executive Committee, SPARK-REACH program, CU Innovations, University of Colorado Anschutz Medical Campus

2019-present Internal Advisory Board, University of Colorado Nutrition and Obesity Research Center (NORC)

2020-present Internal Advisory Board, University of Colorado Cancer Center

2020 Boettcher Foundation Biomedical Research Innovation Fund, CU-Anschutz grant reviewer

2021-presnt Advisory Committee, Center for Drug Discovery, Skaggs School of Pharmacy and Pharmaceutical Science, University of Colorado Anschutz Medical Campus

2023-present Research Space Committee, University of Colorado School of Medicine

2023 Search Committee, Director of Adult and Child Center for Health Outcomes and Delivery Science, University of Colorado School of Medicine

1. **Children’s Hospital Colorado (CHCO) and University of Colorado Hospital (UCH)**

1983‑1990 Pediatric Nutritional Support Committee, University of Colorado Hospital

1985‑1990 Nutrition Subcommittee of the Pharmacy and Therapeutics Committee, University of Colorado Hospital

1986‑1998 Co-founder and Medical Director of Pediatric Liver Center, UC Denver and Children’s Hospital Colorado

1988-present Adult and Pediatric Liver Transplantation Evaluation Committee, UC Denver, UCH and Children’s Hospital Colorado

1988‑1990 UCH Medical Staff Bylaws Committee

* 1. Co‑chairman, Pediatric Inpatient Program Subcommittee, CHCO/UCHSC Affiliation Implementation Plan

1990 Advisory Committee for Appointment of Chairman of Radiology at Children’s Hospital Colorado, Denver

1990-1991 Co‑chair, Ad Hoc Committee on Central Line Procedures, Children’s Hospital Colorado

1998 Chair, Research Group, and member of Oversight Committee, Future Planning Project, Children’s Hospital Colorado, Denver, CO

1998-present Associate Medical Director of Pediatric Liver Center and Liver Transplantation Program, Children’s Hospital Colorado and UCDHSC

1998-2001 Region 8 Representative, Pediatric Transplantation Committee, United Network for Organ Sharing

2001 Conference Organizing Committee, “Research Ethics in Pediatrics: Building a culture of integrity”, CHCO

2002-2003 Coordinators/Liaisons Planning Committee, thee New Children’s Hospital at Fitzsimmons

2002-2009 Board of Directors, Children’s Hospital Colorado Foundation Research Institute, Aurora, CO

2003-present Physician Advisory Council, Clinical Information System, Children’s Hospital Colorado, Denver, CO

2005-2009 Executive Committee, Children’s Hospital Colorado Foundation Research Institute, Denver, CO

2009-2022 Service Line Director, Digestive Health Institute, Children’s Hospital Colorado, Aurora, Colorado

2010-2016 Children’s Hospital Colorado Research Infrastructure - Consultants Committee

2011-present Research Advisory Committee for University of Colorado Hospital and the University of Colorado School of Medicine

2011-2021 Obesity Leadership Group, Children’s Hospital Colorado

2012-2014 Remedy Informatics Steering Committee, Children’s Hospital Colorado Research Institute

2012-2017 Clinical Research Management System (CRMS) Steering Committee, Children’s Hospital Colorado

2015-2017 Research Policy and Process Task Force, University of Colorado Health System

2017-2022 Scientific Steering Committee, Children’s Hospital Colorado Research Institute

2018-present Child Health Research Planning Committee, Strategic Planning for Child Health Research Enterprise, CHCO and University of Colorado School of Medicine

2018-2019 Liaison to Mechanistic Clinical Research and Clinical Trials Work Group, Child Health Research Planning Committee, Strategic Planning for Child Health Research Enterprise, CHCO and University of Colorado School of Medicine

2019-2021 Sequencing and Synthesis Work Group, Strategic Planning for Child Health Research Enterprise, CHCO and University of Colorado School of Medicine

2022-present Children’s Hospital Affiliation Governance Committee, University of Colorado School of Medicine and Children’s Hospital Colorado

2022-present Chief Scientific Officer, Child Health

2022-present Research Committee of the Board of Directors, Children’s Hospital Colorado

2022-present Strategic Leadership Council, Children’s Hospital Coloado

1. **State and National Committees, Tasks Forces, Boards and Commissions (see also Section 6)**

1992‑1994 NIDDK, NIH Ad Hoc Diagnostic Criteria Committee (Neonatal Liver Disease)

1994-1996 National Hepatitis Detection, Treatment, and Prevention Program, Pediatric faculty member.

1995-2006 Scientific Advisory Board member, Studies for Pediatric Liver Transplantation.

1996-2004 Local Principal Investigator, Studies of Pediatric Liver Transplantation (SPLIT) registry

1996-1998 Scientific Program Committee, World Congress of Gastroenterology, Vienna, Austria, September, 1998

1997-1998 Scientific Committee, International Meeting - “Viral hepatitis throughout infancy to adulthood”, Brussels, Belgium, May, 1998.

1999-2008 Funding Committee, Studies of Pediatric Liver Transplantation (SPLIT) registry.

1999-2006 Pediatric Steering Committee, A Multi-centered Group to Study Acute Liver Failure - NIH RO1

2002-2009 Chair of Steering Committee, member of Executive Committee, Biliary Atresia Clinical Research Consortium, NIDDK, National Institutes of Health

2002-present Childhood Liver Disease Research Network (ChiLDReN, formerly BARC and CLiC and ChiLDREN) committees: Chair of Executive Committee, Chair of Network Steering Committee, MITOHEP Protocol Committee Chair (2005-present), Director of Administrative Core (2005-present), LOGIC Protocol Committee Chair (2005-2009), Data Committee, Patient Advocacy Group Committee Chair, Strategic Planning Committee Chair (2012-2013 and 2016-17), Portal Hypertension Elastography Protocol Committee (2015), Chair of Global Publications Committee (2013-present)

2003 Search Committee for Director of Liver Branch, National Institute of Diabetes, Digestive and Kidney Diseases, NIH

2004-2008 Action Plan for Liver Disease Committee, “Pediatric Liver Diseases”, National Institute of Diabetes, Digestive and Kidney Diseases, NIH

* 1. Grant Steering Committee, Studies in Pediatric Liver Transplantation (SPLIT) NIDDK grant

2004-2012 Associate Member and Protocol Committee member, Children’s Oncology Group, “The treatment of Down syndrome children with transient myeloproliferative disease”

2004-2010 Scientific Advisory Committee, Children’s Research Institute, Children’s National Medical Center, Washington, D.C.

2004-2009 Chair, Steering Committee, and Principal Investigator of Cholestatic Liver Disease Consortium, a Rare Disease Clinical Research Center, NCRR/NIDDK/ORD, NIH

2005 Chair, Data and Safety Monitoring Board Reorganization Subcommittee of the Rare Disease Clinical Research Network, ORD/NCRR, NIH

2005-present North American Primary Sclerosing Cholangitis Registry Working Group

2005-present Operations Committee, Studies of Primary Sclerosing Cholangitis (STOPSC), North American PSC Registry

2005 International Working Group on Acute Liver Failure, “Definition and Prognostic Factors in Children”, London, United Kingdom

2005-2006 Organizing Committee, NIDDK Research Workshop “Screening and Outcomes in Biliary Atresia”, Sept. 2006, Bethesda, MD

2006-2008 Chair, Steering Committee of Rare Diseases Clinical Research Network, ORD/NCRR/NIH

2006-2010 National Commission on Digestive Diseases (NCDD), Liver and Biliary Systems Working Group, National Institutes of Health

2009-2013 CTSA Consortium Child Health Oversight Committee, Operations Group

2009-present External Advisory Committee, Harvard Catalyst Clinical and Translational Sciences Center, Boston, MA

2009-2015 Chair of External Advisory Committee, “Being Me”, an NIH-SEPA grant funded program, Children’s National Medical Center, Washington, D.C.

2009-2012 Chair of External Advisory Committee, University of Michigan Institute for Clinical and Health Research, Ann Arbor, MI

2009-present Chair, External Advisory Committee, University of Cincinnati Center for Clinical and Translational Science and Training, Cincinnati, OH

2010-present Chair, External Advisory Committee, Conduits (Institute of Clinical and Translational Sciences), Icahn School of Medicine at Mount Sinai, New York City, NY

2010-2014 Best Pharmaceuticals for Children Act Gastrointestinal Disease Therapeutics Working Group, National Institute of Child Health and Human Development, NIH

2010-2011 Nominating Committee, Society for Pediatric Research

2011 Ad Hoc Committee of Evaluators for Promotion Committee Consideration, Harvard Medical School, Boston MA

2011 Ad Hoc Clinical Research Scientific Advisory Committee, Children’s Hospital Boston, Boston MA

2014-present National Center for Advancing Translational Science (NCATS) - Accrual to Clinical Trials Project Working Group, NIH

2014 Strategic Planning Retreat, Yale Center for Clinical Investigation, New Haven, CT

2015-16 Common Metrics for CTSA Program Committee: Resources and Services, NCATS, NIH

2016-present External Advisory Committee (Chair 2020-present), Yale Center for Clinical Investigation, Yale University School of Medicine, New Haven, CT

2018-present External Advisory Committee, University of Arkansas Medical Scienes Translational Research Institute

2018-2022 National Advisory Council, National Institute of Diabetes, Digestive and Kidney Diseases, NIH

2018 Food and Drug Administration Expert Panel, October 2018

2020-2022 National Steering Committee, CTSA Consortium, National Center for Advancing Translational Science (NCATS), NIH

2020-present External Advisory Board, Columbia University Digestive Disease Research Center, New York.

2020-present External Advisory Committee, University of California San Francisco Clinical and Translational Sciences Institute, San Francisco, CA

2020-present External Advisory Committee, Rare Diseases Clinical Research Network Data Management and Coordinating Center (DMCC), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

2022-present Steering Committee, The Coalition for Pediatric Medical Research

2022-present National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), NINDS Common Data Elements (CDEs) Version 2.0 Working Group for the Mitochondrial Disease CDE, member of the GI/Hepatology and Nutrition Subgroup.

**F. Community Service or Public Health Activities**

* Alpha One Foundation

2005-present Clinical Resource Center Director, Children’s Hospital Colorado

2011-present Medical and Scientific Advisory Board

2012-present Clinical Resource Centers Working Group

* American Liver Foundation

1988‑1990 Board of Directors, Rocky Mountain Chapter of the American Liver Foundation

1996-present Scientific Advisory Committee, Rocky Mountain Chapter of American Liver Foundation.

1997-2006 Board of Directors, Rocky Mountain Chapter of the American Liver Foundation

1997-2000 Chairman, Scientific Committee for “*Pediatric Liver Research Agenda-2000: a blueprint for the future”*, American Liver Foundation.

 1997-2003 National Board of Directors, Executive Committee and Medical Advisory Committee, American Liver Foundation.

 1997-2006 Chairman, Children's Liver Council, American Liver Foundation.

 1997-2000 Liver Allocation Policy Working Group, American Liver Foundation

 2000-2004 ALF/AASLD Partnership Committee

 2000-2008 ALF/AASLD Resident Scholar Travel Award Subcommittee, American Liver Foundation

 2002-2012 Co-Chair, Biliary Atresia Fund for the Cure, American Liver Foundation

2004-2009 Grants Review Committee, American Liver Foundation

 2007-2013 National Board of Directors, American Liver Foundation

 2008-2012 AASLD/ALF Public Policy Joint Task Force

 2010-2012 ALF Mission Committee

* Children’s Digestive Health and Nutrition Foundation

 1998-2000 Board of Directors, Children’s Digestive Health and Nutrition Foundation.

 2000-2004 Advisory Committee, Children’s Digestive Health and Nutrition Foundation

* Cystic Fibrosis Foundation

April, 1990 Cystic Fibrosis Foundation Consensus Conference on "Nutritional Assessment and Management in Cystic Fibrosis"

 1999-2005 Project Advisory Committee, Cystic Fibrosis Foundation Therapeutics Development Grants Program

 1999-2001 Cystic Fibrosis Foundation Consensus Committee on CF Adult Care

 1999-2008 Working Group on Epidemiology of Cystic Fibrosis Liver Disease

 2001-present Professional Education Committee, Cystic Fibrosis Foundation

 2007-present Protocol Review Committee, Cystic Fibrosis Foundation Therapeutics Development Network

* Alagille Syndrome Alliance
	1. Scientific Advisory Board, Alagille Syndrome Alliance

 2003-2007 Medical Advisory Board, Alagille Syndrome Alliance

 2010-present Medical Advisory Board, Alagille Syndrome Alliance

* Crohn’s and Colitis Foundation of America
	1. Scientific Advisory Committee, Rocky Mountain Chapter of the National Foundation for Ileitis and Colitis, Inc.

 2008-2018 Oversight Committee, Crohn’s and Colitis Foundation of America Pediatric Research IBD Network

* Denver Metro Regional Science and Engineering Fair

 2013 Volunteer Judge

* Round Up River Ranch Camp, Gypsum, Colorado

2012-present Volunteer Camp Doctor

2013-present Medical Advisory Board

* PFIC Network Inc.

2019-present Medical Advisory Board

**G. Consulting Positions:**

* 1. Advisory Board Member, Eastman Center for Nutritional Research at East Tennessee State University, Johnson City, TN

2006-2012 Consultant, Studies to Treat or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Study, NIH U01-DK061230, George Washington University, Washington, D.C.

1. **LICENSURE AND BOARD CERTIFICATION**

**Licensure:** Colorado M.D. #22037

 Ohio M.D. #45637

**Board Certification:**

American Board of Pediatrics, Board Certification in Pediatrics (written and oral) #25653 ‑ February, 1, 1981; Recertification: October, 1997 and May 7, 2004

American Board of Pediatrics, Pediatric Gastroenterology Sub‑Board, Board Certification #240‑ November 1, 1990; Recertification: October, 1997, May 7, 2004, April 26, 2019.

American Board of Pediatrics, Pediatric Transplant Hepatology, Board Certification #77, November 17, 2010; Recertification, April 26, 2019.

National Board of Examiners ‑ July 1, 1977 ‑ #172307

Pediatric Advance Life Support Certification – September 2001, April 2005, October 2007, August 2009, August 2011, August 2017.

1. **INVENTIONS, INTELLECTUAL PROPERTY AND PATENTS HELD OR PENDING**

1. U.S. patent No. 6,069,167 - “Use of antioxidant agents to treat cholestatic liver disease.” (Patent issued May 30, 2000 to The Regents of the University of Colorado.

2. Australian patent No. 724620 - “Use of antioxidant agents to treat cholestatic liver disease.” (Patent issued January 25, 2001, to The Regents of the University of Colorado).

3. U.S. Patent No. 6,596,762 - “Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis.” (Patent issued July 22, 2003 to The Regents of the University of Colorado)

4. European Patent No. 0893040 – “Use of antioxidant agents to treat cholestatic liver disease.” (Patent issued January 15, 1997 to Ronald J. Sokol, MD).

5. Canadian Patent No. 2,242,991 - “Use of antioxidant agents to treat cholestatic liver disease.” (Patent issued July 7, 2007 to Ronald J. Sokol, MD).

1. **REVIEW AND REFEREE WORK**
2. **SERVICE ON EDITORIAL BOARDS**

* 1. "Selected Review" Editor of *Journal of Pediatric Gastroenterology and Nutrition*

1997-1998 Journal Editorial Board, *Hepatology*

1999-2013 Journal Editorial Board, *Gastroped*, the electronic journal of Pediatric Gastroenterology, Hepatology and Nutrition

1999-2016 Journal Editorial Board, *Liver Transplantation*

1999-2006 Journal Editorial Board, *Journal of Pediatrics*

2000-2006 Guest Editor, *Journal of Pediatrics*

2000-2001 Guest Editor, *Seminars in Liver Disease* (December 2001 issue: *Genetic and Metabolic Basis of Pediatric Liver Diseases*)

* 1. Associate Editor, *Journal of Pediatric Gastroenterology and Nutrition*

2004-2014 Associate Editor, *Seminars in Liver Disease*

2006-2010 Thomson MICROMEDEX Editorial Board

2007 Guest Editor, *Seminars in Liver Disease* (August, 2007 issue: *“Pediatric Hepatology: Translating discoveries into practice”)*

2007-2018 Journal Editorial Board, *Hepatology*

2014-present Journal Editorial Board, *Orphanet Journal of Rare Diseases*

1. **GRANT REVIEW COMMITTEES AND STUDY SECTIONS**

**National Institutes of Health:**

March 26, 1987 Special Study Section, SBIR Grant Applications, NIDDK, NIH

March 23, 1993 NIDDK, NIH General Medicine A‑1 Study Section

Feb 6-8, 1995 Ad Hoc Member of General Medicine A-2 Study Section, NIDDK, National Institutes of Health

Dec.7-9, 1998 National Institutes of Health Site Visit Team, General Clinical Research Center, Columbia University, New York City.

Dec 3-5, 2000 Special Emphasis Review Panel (ZDK1 GRB-7 [J1]), NIDDK, NIH.

Dec. 18, 2001 Special Emphasis Review Panel (ZDK1 GRB-7 [J1]), NIDDK, NIH

May 4-5, 2003 Special Emphasis Panel (ZDK1 GRB-3 [M1]), NIDDK, NIH

Dec. 14, 2004 Special Emphasis Review Panel (ZDK 1 GRB-7 [J1]), NIDDK, NIH

Mar. 8, 2005 Special Emphasis Review Panel (ZDK 1 GRB-4 [M2 M]), NIDDK, NIH

March 15, 2006 Special Emphasis Review Panel (ZDK1 GRB-R [M3]), Liver Immunology, NIDDK, NIH

July 18, 2008 Special Emphasis Panel (ZDK1 GRB-8 [01 1]), NIDDK, NIH

Mar. 13, 2009 Special Emphasis Panel (ZDK1 GRB-R [M4 1]), Digestive Diseases and Nutrtion Mentored and Training Awards, NIDDK, NIH

Mar. 24, 2009 Initial Review Group (ZDK1 GRB-7 [M1 2]), NIDDK, NIH

April 2009 Initial Review Panel, NIH Director’s New Innovator Awards, NIH

December 2010 Special Emphasis Panel/Scientific Review Group (ZDK1 GRB-6 (J2), NIDDK, NIH

July 11, 2017 Special Emphasis Review Panel, Opportunities for Collaborations at the NIH Clinical Center grants (ZRG1 PSE B60), NIH

2018-2021 Member of National Advisory Council for NIDDK, and restricted from participating on Grant Reviews and NIH Study Sections during this time

**Other National or Foundation:**

* 1. American Liver Foundation Grants Review Committee

May, 1988 Medlantic Research Foundation Review Panel, "The Nutritional and Health Impact of Sucrose Polyester"

Nov., 1990 Grant Reviewer for Canadian Cystic Fibrosis Foundation

1993-present Cystic Fibrosis Foundation, Professional Education Grant Review Committee (Annual)

1995-1998 Grant Review Committee, NASPGHAN New Investigator Grant

Jan.1998 Ad hoc reviewer, March of Dimes Research Grant Program Committee.

May 1998 Ad Hoc Committee for Promotion Review, Harvard Medical School, Boston, MA

2001-present *Ad hoc* reviewer, Clinical Research Committee, Cystic Fibrosis Foundation Therapeutics, Inc.

* 1. *Ad hoc* grant reviewer, Cystic Fibrosis Foundation Clinical Research Committee
1. Reviewer for biliary atresia fact sheet, MCHB/HRSA newborn screening project

March 2010 Israel Science Foundation, Legacy Heritage Fund grant reviews

July 2018 "Translational consortia for rare disease research” grant review for the German Federal Ministry for Education and Research (BMBF)

**Local Review Panels:**

2002-2008 Grant review committee, Pilot/Feasibility Projects, Pediatric General Clinical Research Center, UCHSC and Children’s Hospital Colorado, Denver, CO

2010-2022 Chair of Grant Review Committee, Boettcher Foundation-Webb-Waring Biomedical Research Awards Program, Unversity of Colorado (Annual)

2013-present Grant Review Committee, Children’s Hospital Colorado Research Institute and Child Health Research Enterprise, Aurora, CO

2018 Grant reviewer, University of Colorado Aschutz Medical Campus review of applications for Edward Mallinckrodt, Jr Foundation Early-Stage Investigator grant program, Aurora, CO

1. **REVIEWER FOR JOURNALS**

Acta Paediatrica

American Journal of Clinical Nutrition

American Journal of Diseases of Children

American Journal of Gastroenterology

American Journal of Medical Genetics

American Journal of Physiology

Annals of Surgery

Archives of Biochemistry and Biophysics

Archives of Disease in Childhood

Biochemical Medicine and Metabolic Biology

BioMed Research International

Cell Research

Clinical Gastroenterology and Hepatology

Clinical and Investigative Medicine

Digestive Diseases and Science

European Journal of Pediatrics

Free Radical Biology and Medicine Gastroenterology

Gut

Hepatology

Hepatology Communications

Human Immunology

Immunodeficiency Reviews

International Journal of Pharmaceutics

Journal of the American College of Nutrition

Journal of American Medical Association

Journal of Biological Chemistry

Journal of Cellular Biochemistry

Journal of Clinical Gastroenterology

Journal of Clinical Immunology

Journal of Clinical Investigation

Journal of Cystic Fibrosis

Journal of Gastroenterology and Hepatology

Journal of Hepatology

Journal of Inherited Metabolic Disease

Journal of Laboratory and Clinical Medicine

Journal of Neurological Sciences

Journal of Nutrition

Journal of Pediatric Gastroenterology and Nutrition

Journal of Pediatrics

Journal of Pediatric Surgery

Journal of Pediatric Infectious Disease

Journal of Pharmacology and Experimental Therapeutics

Journal of Rheumatology

Laboratory Investigation

Lancet

Lipids

Liver

Liver International

Liver Transplantation and Surgery

Mayo Clinic Proceedings

Molecular Genetics and Metabolism

Molecular Medicine

Mount Sinai Journal of Medicine

Nature Communications

Neurochemistry International

Neurology

New England Journal of Medicine

Nutrition

Nutrition and Cancer

Nutrition Research

Orphanet Journal of Rare Diseases

Paediatric and Perinatal Epidemiology

Pediatric Research

Pediatrics

Pediatrics International

Pediatric Pulmonology

PLOS Medicine

 Scanning Microscopy International

Science Translational Medicine

Therapy

Translational Pediatrics

Transplantation

**D. REVIEWER FOR PROFESSIONAL SOCIETIES AND SCIENTIFIC MEETINGS**

1989‑1990 Member, Abstract Selection Committee, American Association for the Study of Liver Disease

January 1993 Abstract Reviewer, American Pediatric Society/Society for Pediatric Research annual meeting, Gastroenterology and Nutrition Subsection

January 1993 Ad Hoc Reviewer for Canadian Cystic Fibrosis Foundation. "Vitamin K and CF Patient Management" Summary Statement

May 4, 1994 Platform Session Moderator. "Gastroenterology & Nutrition". Society for Pediatric Research Annual Meeting, Seattle, Washington.

May 17, 1994 Abstract Reviewer and Platform Session Moderator, "Intestinal Gene Expression", American Gastroenterology Association Annual Meeting, New Orleans, LA.

Nov. 19 94 American Board of Pediatrics, Field Tester, Pediatric Gastroenterology Board examination.

January, 1995 Abstract Reviewer, "Cell Injury, Hepatotoxicity, and Pharmacology" section, Annual Meeting of American Association for Study of Liver Diseases.

Oct., 1996 Abstract Reviewer, Nutrition Section, Western Federation for Clinical Research Meeting, February, 1997, Carmel, CA.

Sept., 1998 Abstract review chair and Chair of Oral Abstract Presentation Session, Metabolic liver diseases/immunology/ethanol-related liver diseases, World Congress of Gastroenterology, Sept. 6-11, 1998, Vienna, Austria

1998 Grant reviewer, The Israel Science Foundation, The Israel Academy of Sciences and Humanities.

1998 Workshop organizer, abstract reviewer and moderator, “Factors involved in growth and weight gain in Cystic Fibrosis,” Twelfth Annual North American Cystic Fibrosis Conference. October 17, 1998, Montreal, Quebec, Canada

2001-present Metabolic and Genetic Disease Abstract Review Committee, American Association for the Study of Liver Disease

2002 *Ad hoc* reviewer, Professional Education Committee, Wilson Disease Clinical Guidelines, AASLD

1. **INVITED EXTRAMURAL LECTURES, PRESENTATIONS AND VISITING PROFESSORSHIPS**
2. "Nutrition and Chronic Liver Disease of Childhood." *Mead Johnson Nutrition Seminar*, Colorado Springs, CO, July 1983
3. Research Conference: "Intestinal Absorption of Vitamin E in Man," Grand Rounds: "Human Vitamin E Deficiency‑‑ Does It Really Exist?" Visiting Pediatric Gastroenterologist at UCLA‑Harbor Medical Center, Los Angeles, CA, March 28-29, 1984
4. "Biliary Atresia and Reovirus Type 3 Infection", *17th Annual Birth Defect Conference Workshop*, Denver, CO, June 6‑19, 1984
5. "Milk Protein Intolerance”, Quarterly Update in Pediatrics, UCHSC, April 27, 1984, Denver, Colorado.
6. "Aspirin and Reye Syndrome" and "The Infant with Bloody Stools".  *27th Annual Pediatric Program*, Department of Pediatrics, University of Colorado School of Medicine, Aspen, Colorado, August 6‑7, 1984
7. "Wilson's Disease”, *Quarterly Update in Pediatrics*, UCHSC, November 8, 1984, Denver, Colorado.
8. Invited Scientist. "Intestinal Absorption of Vitamin E in Childhood Cholestasis"; "Physiology of Gastrointestinal Function". Eastman Chemical Company, Kingsport, Tennessee, February 1985,
9. Grand Rounds: “Vitamin E Deficiency in Childhood"; Research Conference: "Effect of Vitamin E on Copper Hepatotoxicity". Visiting Pediatric Gastroenterologist at University of Texas at San Antonio, March 1985, San Antonio, Texas.
10. "Spitting Up‑‑What's All the Fuss?", Family Practice Review Course, UCHSC, June, 1985, Denver, Colorado.
11. Invited speaker at Workshop: "Neurologic Role of Vitamin E", *XIII International Congress of Nutrition*, Brighton, England, August 1985,
12. "Vitamin A and E in Childhood Liver Disease". *Postgraduate Course* *at Annual Clinical Congress of the American Society for Parenteral and Enteral Nutrition*, Dallas, Texas, February 9, 1986,
13. Grand Rounds: "Vitamin E Deficiency Syndromes in Children", University of Texas at Dallas Medical Center, Southwestern Medical School, February 12, 1986, Dallas, Texas.
14. Invited Participant to Closed Workshop: *"Total Parenteral Nutrition in Pediatrics".* *International Institute of Infant Nutrition and Gastroenterology*, Buffalo, New York, March 20‑22, 1986
15. Invited Participant, NIDDK/Cystic Fibrosis foundation Conference, "Nutrition in Cystic Fibrosis", Aprile 1986, Bethesda, MD
16. Invited Participant. *"Nutrition in Cystic Fibrosis", National Institute of Arthritis, Digestive Disease and Kidney Disease/Cystic Fibrosis Foundation Conference*, April 1‑4, 1986, Bethesda, Maryland.
17. "Follow Up of Neonatal Gastrointestinal Disorders". *Lula 0. Lubchenco Symposium in Neonatal/Perinatal Medicine,* Denver, Colorado, June 3, 1986,
18. Organizer and Moderator, "Parenteral Nutrition‑associated Liver Disease", *North American Society for Pediatric Gastroenterology Symposium at Annual Meeting of American Association for the Study of Liver Diseases*, November, 1986, Chicago, Illinois.
19. "Vitamin E and Cholestasis". *Special Conference on the Liver and Biliary Tract*, Denver, Colorado, December 4‑5, 1986
20. Invited Speaker: "Diagnosis and Treatment of Vitamin E Deficiency in Cholestasis". *International Symposium on Vitamin E*, Kyoto, Japan, December 4­-5, 1986
21. "Nutritional Consequences of Chronic Cholestasis".  *Workshop at American Society for Parenteral and Enteral Nutrition Annual Meeting*, February 1987, New Orleans, LA.
22. Visiting Pediatric Gastroenterologist, Grand Rounds, "Use and Abuse of Vitamin E in Pediatrics"; Lecture, "Use of Vitamin E in Premature Infants"; Lecture, "TPGS‑Vitamin E Absorption and Treatment During Chronic Cholestasis". Hospital Saint‑Justine, Montreal, Quebec, April 1‑3, 1987
23. "Pediatric Nutritional Support ‑‑ Childhood Diseases.”  *Colorado Society for Parenteral and Enteral Nutrition Annual Meeting*, May 29, 1987, Denver, Colorado.
24. Invited lectures, "Medical Management of Neonatal Cholestasis", "Fulminant Hepatic Failure in Infants and Children".  *Institute for Pediatric Medical Education conference on Pediatric Hepatology*, Aspen, Colorado, August 1987.
25. Invited speaker, "Vitamins and Minerals ‑‑ Importance After Enzymes?" *Advances in the Clinical Care and Treatment of Cystic Fibrosis Patients*, Dallas, TX, February 11‑13, 1988.
26. "Acute Fulminant Hepatic Failure in Children", "Vitamin E and the Pediatric Gastroenterologist"*. Seventh Ross Seminar on Pediatric Gastroenterology*, Scottsdale, Arizona, February, 1988.
27. “Pediatric Nutritional Support Teams". *Colorado Society for Parenteral and Enteral Nutrition Annual Meeting*, September 9, 1988. "
28. "Vitamin E deficiency neuropathy in children with fat malabsorption*". New York Academy of Sciences International Meeting on Vitamin E*, November 1988, New York City, New York.
29. "Vitamin E Requirements and Supplementation in the Newborn ‑‑ Particularly the Low‑Birth Weight Infant".  *Postgraduate Course, American Society for Parenteral and Enteral Nutrition 13th Clinical Congress*, February 1989, Miami Beach, Florida.
30. Invited lectures: "Newborn Screening in Cystic Fibrosis‑‑the Colorado Experience". "Vitamin E and the Pediatric Gastroenterologist”, *Eighth Ross Seminar on Pediatric Gastroenterology*, Scottsdale, Arizona, February 1989.
31. "Vitamin E and GI Disorders".  *Meet the Professor Luncheon, American Gastroenterology Association Annual Meeting*, May 1989, Washington, D. C.
32. Invited lectures: "Vitamin E and the Neonate", "Vitamin E Deficiency in Older Children and Adults". *Advances in Perinatal and Pediatric Nutrition Conference*, Stanford University, California, July 17‑19, 1989
33. Invited lecture: "Nutritional Issues in Cystic Fibrosis". *11th Annual Conference on Pediatric Disease, Institute for Pediatric Medical Education*, August 2‑4, 1989., Aspen, Colorado.
34. Invited lecture: "Advances in the Care of Childhood Liver Disease", workshop: "The Jaundiced Infant". *32nd Annual Pediatric Program*, University of Colorado School of Medicine, Aspen, Colorado, August 7‑8, 1989.
35. Invited lecture: "Do Patients with Cystic Fibrosis Need Fat‑soluble Vitamins?" *Third Annual North American Cystic Fibrosis Conference*, Tarpon Springs, Florida, Nutrition Symposium, October 13, 1989.
36. Invited lectures: "Special Nutritional Concerns in Chronic Liver Disease", "Nutritional Issues in Cystic Fibrosis*". Annual Post Graduate Convention, School of Medicine of Loma Linda University*, Loma Linda, California, February 27, 28, 1990
37. Invited Participant, “Ursodeoxycholic Acid and CF". *Cystic Fibrosis Foundation Consensus Conference*, Tyson's Corner, Virginia, February 26, 1990.
38. Invited lecture: "Vitamin E Deficiency Neuropathy". *Symposium at Federation of American Societies for Experimental Biology Annual Meeting*, Washington D.C., April 1990
39. Cystic Fibrosis Foundation Consensus Conference on Nutritional Assessment and Management in CF, Tysons Corner, Virginia, April 17‑18, 1990.
40. Invited speaker: "Vitamin E Deficiency in Humans". *Pediatric Nutrition and Metabolism,* *Institute for Pediatric Medical Education Conference*. Aspen, Colorado, July 2‑5, 1990
41. Lectures: "Gastrointestinal and Nutritional Aspects of Cystic Fibrosis".  *CF 101 Symposium*, *Fourth Annual North American and International Cystic Fibrosis Conference*. Dallas, TX, October 4, 1990.
42. "Fat‑soluble Vitamin Status in Screened Infants." *IVth International Conference on Newborn Screening for Cystic Fibrosis*. Estes Park, Colorado, October 9, 1990.
43. Special lecture: "Acquired and Non‑acquired Vitamin E Deficiency Syndrome". *Japanese Society of Pediatric Gastroenterology and Nutrition Annual Meeting.*  Takarazuka, Japan, October 18, 1990.
44. Visiting Lecturer. Eisai Products, Inc., "Pathogenesis of Vitamin E Deficiency Neurologic Syndromes". Tokyo, Japan, October 23, 1990.
45. Pediatric Grand Rounds, University of New Mexico School of Medicine, Department of Pediatrics. "Nutritional Issues in Cystic Fibrosis/Vitamin E Deficiency," Albuquerque, NM, March 28, 1991.
46. Visiting Professor, Children's Hospital Medical Center, Cincinnati, OH. Grand Rounds ‑‑ "The Coming of Age of Vitamin E," Research presentation ‑‑ "Oxidative Liver Injury in Animal Models". April 2‑3, 1991.
47. Symposium at 1991 North American Cystic Fibrosis Conference, "Recognition and Management of CF‑Associated Liver Disease". Dallas, TX., October 3, 1991.
48. Round table Discussion. Moderator at 1991 *North American Cystic Fibrosis Conference*, Dallas, TX, "Vitamin Therapy in Cystic Fibrosis", October 3, 1991.
49. Invited Lectures. "Lipid Peroxidation in Cholestasis". "Vitamin Deficiency and Substitution in Cholestasis". *Falk Symposium No. 63: Pediatric Cholestasis: Novel approaches to treatment*. Titisee, Germany. October 9‑10, 1991.
50. "Free radicals in cholestatic liver injury." *Mead Johnson Neonatal Nutrition Research Symposium*, Palm Springs, California, November 18, 1991.
51. Pediatric Grand Rounds, Johns Hopkins University School of Medicine, Department of Pediatrics. "The Coming of Age of Vitamin E". December 4, 1991, Baltimore, MD.
52. Mead Johnson Research Center Seminar. "Lipid peroxidation and free radical hepatic injury in cholestasis ‑ modification by antioxidants". Evansville, IN, April 21, 1992.
53. Invited speaker, Lectures: "Hepatic Failure", "Mitochondrial Disorders of the Liver", and "Nutritional concerns in the Pre‑Liver Transplantation Patient". *"Pediatric Hepatology and Liver Transplantation."* *Institute for Pediatric Medical Education Conference*. Aspen, Colorado, July 27‑31, 1992.
54. Invited Lecture. "Mechanisms of hepatic copper toxicity". IN: *Metals and the Liver* Symposium at 27th Annual Meeting of European Association for the Study of the Liver, Vienna, Austria, August 26, 1992,
55. Invited Lectures. "Role of Endoscopy in Cystic Fibrosis", "Vitamin and Mineral Supplementation", Sixth North American Cystic Fibrosis Conference. Washington, DC. October 16-17, 1992.
56. Invited Lecture. "Alterations in Vitamin Metabolism and Its Consequences in Cholestatic Liver Disease". *American Association for the Study of Liver Diseases Postgraduate Course*, "Newer Aspects on Alcohol, Nutrition and Hepatic Encephalopathy". Chicago, IL, November 1, 1992.
57. Meet‑The‑Professor Luncheon. "Pediatric Liver Disease". *American Association for the Study of Liver Diseases Annual Meeting*, Chicago, IL, November 1, 1992.
58. Invited Participant. "Micronutrient Deficiencies in Cystic Fibrosis". *NIDDK/Cystic Fibrosis Foundation Workshop on Nutrition in Cystic Fibrosis.*  Chevy Chase, MD. January 11‑13, 1993.
59. Glaxo Visiting Professor in Pediatric Gastroenterology and Nutrition. Lectures: "Free radical mechanisms in the pathogenesis of cholestasis". "Vitamin E deficiency in Man". Texas Children's Hospital, Baylor University School of Medicine, Houston, TX., April 12‑14, 1993.
60. Pediatric Grand Rounds, Children’s Hospital Colorado, Denver, CO. "Vitamin E: Uses and abuses in Pediatrics", April 23, 1993.
61. Invited Lecture. "Free Radical Injury, Glutathione Deficiency, and Lipid Peroxidation in TPN-Cholestasis" IN: *Twenty-Five Years of Total Parenteral Nutrition in the Infant: A Symposium on TPN-Associated Cholestasis*. Children's Memorial Hospital, Chicago, IL, June 18-19, 1993.
62. Invited speaker. "Children's liver problems - Advances in treatment". *Digestive Diseases Symposium, Mt. Sinai Health Care System*, Cleveland, Ohio, September 8, 1993.
63. Invited speaker. "The role of breast feeding in cystic fibrosis".  *Human Milk Banking Association of North America, Ninth Annual Conference.* September 17, 1993, Denver, Colorado.
64. Pediatric Grand Rounds, "Mitochondrial hepatopathies - a new classification of liver diseases", Research Conference, "Lipid peroxidation, glutathione and TPN liver disease". University of Minnesota School of Medicine, Department of Pediatrics. October 6, 1993, Minneapolis, MN
65. Invited Speaker: "Fat soluble-vitamins: Deficiencies and beyond*". Minnesota Chapter of American Society for Parenteral and Enteral Nutrition, Annual Fall Meeting*, October 8, 1993, Mayo Clinic, Rochester, MN.
66. Poster Review Session Moderator. "CF/Pancreas/Nutrition" and "Liver-Clinical" posters. NASPGN 7th Annual Meeting, Nov. 5, 1993, Chicago, IL.
67. Chairman, Symposium on "Micronutrients in Cystic Fibrosis", Lecture: "Vitamins A and E in CF". *Seventh Annual North American Cystic Fibrosis Conference*, October 16, 1993, Dallas, TX.
68. Ralph Plateau Visiting Professor, Tulane University Medical Center, Department of Pediatrics. Grand Rounds: "Advances in the treatment of pediatric liver disease". Housestaff lecture: "Fat-soluble vitamin deficiencies". Research lecture: "Oxidant hepatic injury in pediatric liver disease", December 1-3, 1993, New Orleans, LA.
69. Ray Kroc Visiting Professorship in Pediatrics (Ronald McDonald Children’s Charities), Texas Tech University Medical Center, El Paso, TX, Lectures: "Gastroesophageal reflux in children", "Neonatal Cholestasis", "Chronic Diarrhea", "Update on Liver Transplantation", "Fat-Soluble Vitamins in Cystic Fibrosis", "GI Manifestations of Cystic Fibrosis", "Pediatric Inflammatory Bowel Disease", "Parenteral Nutrition in Childhood", "Viral Hepatitis in Children", January 10-14, 1994.
70. Invited Speaker: "Diagnosis and Management of Hepatitis C", *American Academy of Pediatrics, Spring Meeting*, Denver, Colorado, May 1994.
71. Invited Speaker: "Bile Acids and Free Radical Liver Injury", Webb-Waring Lung Institute Research Conference, Denver, Colorado, April 1994
72. Invited Participant and Speaker. National Digestive Disease Advisory Board symposium on Biliary Atresia - Etiology and Pathogenesis. Bethesda, MD, Sept 26, 1994
73. Invited Speaker: "Liver Disease in Cystic Fibrosis". *Postgraduate Course on Gastrointestinal Disease problems in children and young adults.* American College of Gastroenterology Annual Meeting, San Francisco, CA, October 2, 1994.
74. Invited Speaker: "Advances in Diagnosis and Treatment of Cholestasis". *NASPGN Postgraduate Course*. Chicago, IL, October 14-15, 1994.
75. Invited Speaker: "Vitamin E - Deficiencies and Beyond". *Advances in Pediatric Nutrition Course*, Johns Hopkins Children's Center, November 14-16, 1994, Baltimore, MD.
76. Visiting Professor, Hospital for Sick Children, Toronto, Ontario, Canada, Pediatric Grand Rounds: "Advances in the Treatment of Childhood Liver Disease", Research Seminar: "Free Radical Mechanisms in Cholestatic Liver Injury", January 31 - February 2, 1995
77. Invited Lecturer: “Mechanism of cholestatic liver injury - Are free radicals involved?” Colorado State University School of Veterinary Medicine, Fort Collins, CO, February 16, 1995
78. Invited Speaker: “Hepatic mitochondria and bile acid cytotoxicity”. *Rocky Mountain Oxygen Club,* Denver, CO, February 21, 1995
79. Invited Speaker: “Update on hepatitis viral infection and vaccination in children”. *National Hepatitis Diagnosis, Treatment and Prevention Program*, Ft. Worth Children’s Hospital, Ft. Worth, TX, April 10, 1995.
80. Invited Speaker: “Human vitamin E assessment, deficiency and replacement”, “Nutritional support in chronic liver disease”. *Fifth Annual Advances and Controversies in Clinical Nutrition*, Mayo Foundation, Scottsdale, AZ, April 20-22, 1995.
81. Invited Speaker: “Update on hepatitis viral infection and vaccination in children”. *NHDTP Program*, Geisinger Clinic, Department of Pediatrics, Danville, PA, April 25, 1995.
82. Invited Speaker: “New roles for antioxidants”. *American Gastroenterological Association Post-Graduate Course*, San Diego, CA, May 13-14, 1995.
83. Organizer and Speaker: “Inborn errors of vitamin E metabolism”*. AGA Research Symposium on “Vitamin E in Biology and Nutrition*”, San Diego, CA, May 15, 1995.
84. Invited Speaker: “Debate on Interferon for Hepatitis C Virus in Children*”. First International Symposium on Pediatric Gastroenterology and Nutrition.* Montreal, Quebec, Canada, June 22, 1995.
85. Invited Speaker: “Oxidant Stress in Cholestatic Liver Disease”. *American Association for the Study of Liver Diseases, Single Topic Research Conference, “Oxidant Stress and Liver Disease*”. Arlie, VA, June 22-25, 1995.
86. “Antioxidants in Pediatric Gastroenterology”, “Nutritional Support in Cystic Fibrosis”. *Advances in Perinatal and Pediatric Nutrition Postgraduate Course*. Stanford University Medical Center, Stanford, CA, July 10-12, 1995.
87. Invited Speaker: “Hepatitis viruses and Vaccination in Infants and Children*”. National Hepatitis Disease Prevention and Treatment Program*. “CU in Aspen CME Course”, Aspen, CO., August 9, 1995.
88. Invited Speaker: “Mechanisms of Copper Toxicity”. *7th International Symposium on Wilson’s Disease and Menkes’ Disease*. Baden, Austria, August 25-27, 1995.
89. Invited Speaker: “Enteral Support in Pediatric Patients”. Department of Pediatrics, Khon Kaen University, Khon Kaen, Thailand, October 17, 1995.
90. Visiting Speaker: “Free Radicals and Liver Injury”. Ramathibordee Hospital, Chulalongkorn University, Bangkok, Thailand, October 18, 1995.
91. Visiting Speaker: “The Medical Management of Neonatal Cholestasis”. North Sumatra University and Medan Hospital, Indonesian Association of Pediatrics. Medan, Indonesia, October 19, 1995.
92. Invited Plenary Lecture: “Medical Management of Liver Disorders. Symposium: “Clinical Applications of Enteral Nutrition in Pediatric Patients”. *4th Pediatric Scientific Meeting, Chapter of Pediatricians - Academy of Medicine, Singapore, and Pediatric Medical Society, Singapore*, October 21, 1995
93. Invited Lecturer: “Clinical Applications of Enteral Nutrition in Pediatric Patients”. University of Indonesia and Chip to Mangmumkusomo Hospital, Jakarta, Indonesia. October 22, 1995
94. Moderator, Early Morning Workshop: "Antioxidants and cytoprotection", AASLD Annual Meeting, Chicago, IL., Nov 7, 1995
95. Invited Speaker: “Antioxidants and Your Good Health”. *Millett Symposium*, Presbyterian/St. Luke’s Medical Center, Denver, Colorado, January 27, 1996.
96. Visiting Professor: Lectures: “Clinical aspects of vitamin E metabolism”; “Oxidant-mediated liver injury in cholestasis”. Department of Pediatric Gastroenterology and Nutrition, Children’s Hospital of Philadelphia and the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. March 3, 1996.
97. Visiting Professor: Grand Rounds: “Advances in treatment of pediatric liver disease”; Research Seminar: “Cholestatic liver injury: oxidant-antioxidant imbalance?”, St. Louis University Medical Center, St. Louis, Missouri, March 19-20, 1996.
98. Invited speaker: "Mechanisms of oxidant injury," and "Oxidant hepatic injury in copper hepatotoxicosis." *American College of Veterinary Internal Medicine Forum*, May 23-26, 1996, San Antonio, Texas.
99. Invited speaker: "Recent advances in metabolic liver diseases: the mitochondrial hepatopathies", Pathophysiology of liver cell injury", and "Management of end-stage liver disease."  *Aspen Conference on Pediatric Disease*, Institute for Pediatric Medical Education. July 28 - August 2, 1996, Aspen, Colorado.
100. Visiting Professor: Pediatric Grand Rounds - "The expanding spectrum of mitochondrial disorders", Gastroenterology Research Lecture - "Role of mitochondrial free radical generation in cholestatic liver injury." Yale University Medical Center, Sept. 17-18, 1996, New Haven, Connecticut.
101. Invited Speaker: *IV International Course on Pediatric Gastroenterology and Hepatology*. Lectures: "Nutritional complications and treatment in children with liver diseases", "Liver diseases associated with parenteral nutrition", "Mechanisms of liver injury in cholestasis", and "Update on hepatitis viruses," plus a review of clinical hepatology cases. Nov. 21 - 23, 1996, Instituto da Crianca do Hospital das Clinicas, University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
102. Invited Speaker, "Biliary atresia: new insights into cause and treatment."  *Meet The Researcher Symposium, American Liver Foundation*, Oct. 6, 1996, Denver, Colorado
103. Co-Chair, Workshop on "Latest Nutrition and GI Research", Tenth Annual North American Cystic Fibrosis Conference, Orlando, FL., Oct. 24, 1996
104. Moderator, Early Morning Workshop: "Oxidant stress and liver disease," AASLD Annual Meeting, Chicago, IL., Nov. 10, 1996
105. Course Faculty. Lectures: "Acute and chronic diarrhea" and "Inflammatory Bowel Disease". Breakfast Seminar: "Hepatitis A virus (HAV), Hepatitis B virus (HBV), HBV vaccine, Hepatitis C virus (HCV)." *Practical Pediatrics CME Course*, American Academy of Pediatrics, Jan. 16-19, 1997, Keystone, Colorado.
106. Invited speaker and Session Chair (Vitamin E deficiency): "Malabsorption of vitamin E and its consequences." *International Symposium on Vitamin E,* Feb. 25-26, 1997, Kyoto International Conference Hall, Kyoto, Japan.
107. Invited speaker: "Advances in vitamin E research: the isolated vitamin E deficiency syndrome." "Reovirus infection and the pathogenesis of choledochal cysts." Research Institute of Development, Aging, and Oncology, Thoko University School of Medicine, Sendai, Japan.
108. Invited speaker. "Living-related liver transplantation in children." *Controversies in Transplantation Symposium.* University of Colorado and Mayo Clinic, April 3-6, 1997, Breckenridge, Colorado.
109. Special lecture: "Total parenteral nutrition-related liver disease."  *5th Congress of the Asian Pan Pacific Society of Pediatric Gastroenterology and Nutrition (APPSPGN).* April 10-13, 1997, Taipei, Taiwan.
110. State of the Art lecture: "Oxidative injury and the use of antioxidants in liver disease." Sponsored by Clinical Practice Section and Growth, Development and Nutrition Section, American Gastroenterological Association, Digestive Disease Week, May 12, 1997, Washington, D.C.
111. Invited lecture: "Management of nutritional complications of cholestasis." *Postgraduate Training Course, 30th Annual Meeting of European Society of Paediatric Gastroenterology and Nutrition (ESPGAN),* May 21, 1997, Thessaloniki, Greece.
112. Invited speaker: “Pathogenesis of parenteral nutrition-related liver injury*,” Annual Meeting of the Colorado Society for Parenteral and Enteral Nutrition.* August 15, 1997, Denver, Colorado
113. Plenary Session Chair, Poster Session Moderator, 30th Annual Meeting of the European Society of Paediatric Gastroenterology and Nutrition, Thessaloniki, Greece, May 1997
114. Meet the Professors Breakfast for Fellows, North American Society for Pediatric Gastroenterology and Nutrition, Toronto, Ontario, Nov. 1, 1997
115. Meet the Professor Luncheon. “Wilson’s disease.” Post-graduate course of the American Association for the Study of Liver Diseases, Chicago, IL., Nov. 8, 1997
116. Moderator, Early Morning Workshop, “Molecular mechanisms of liver cell death”, Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, IL, Nov. 9, 1997
117. Early Morning Workshop Moderator, “Molecular mechanisms of liver cell death.”  *48th Annual Meeting of the American Association for the Study of Liver Diseases*, November 9, 1997, Chicago, IL.
118. Society for Gastrointestinal Nurse Assistants, “Pathophysiology of copper and liver hepatic toxicity”, *Annual Meeting of Society of Gastrointestinal Nurse Assistants*, Hepatology Special Interest Group, November 9, 1997, Chicago, IL.
119. Invited lecture. “Mitochondria and oxidant stress in bile acid hepatocyte toxicity”, Pediatric GI/Nutrition Division, Children’s Hospital Medical Center, November 12, 1997, Cincinnati, OH.
120. Pediatric Grand Rounds, “Advances in pathogenesis and treatment of childhood liver diseases.” November 21, 1997, Children’s Hospital Colorado, Denver, CO.
121. Guest Lecturer, “Role of mitochondria and free radicals in the pathogenesis of cholestatic liver injury”, Children’s Hospital of Philadelphia, November 24, 1997, Philadelphia, PA.
122. Citywide GI Grand Rounds, “A baby with no bile salts,” December 5, 1997, University of Colorado Health Sciences Center, Denver, CO.
123. Invited speaker. “Neonatal cholestasis: prompt recognition and management” and “Liver failure: options in management”. 2nd Biennial Convention, *Continuing Dilemma in Pediatric Digestive and Nutritional Disorders*. Philippine Society of Pediatric Gastroenterology and Nutrition. January 22-23, 1998, Manila, Philippines.
124. Special Lecturer. “Management of portal hypertension in children.” Department of Pediatrics, University of Philippines General Hospital, January 21, 1998, Manila, Philippines.
125. Invited Speaker. “EBV and Post-transplantation lymphoproliferative disease.” March 14, 1998, *Controversies in Transplantation*. University of Colorado School of Medicine, Breckenridge, CO.
126. Doug Jones Visiting Professor of Pediatrics, Dartmouth University Medical Center. “Case presentation discussion - infant with cystic fibrosis and chronic liver disease.” April 17, 1998, Lebanon, New Hampshire.
127. Keynote Speaker. “New Developments in Liver and GI Tract Disease in Cystic Fibrosis*.” Northern New England Cystic Fibrosis Consortium Group Meeting*, April 18, 1998, Woodstock Inn, Woodstock, Vermont.
128. Roundtable discussant. “Treatment of Hepatitis B and C in Childhood*.” International Congress on Viral Hepatitis throughout Infancy and Adulthood*, May 26, 1998, Brussels, Belgium.
129. Visiting Speaker. “Role of TPGS-vitamin E in the treatment of vitamin E deficiency during chronic cholestasis”, Eastman Fine Chemicals, Eastman Chemical Company April 30, 1998, Kingsport, TN.
130. Invited speaker. “Antioxidants and pediatric liver disease.” Postgraduate Course, Department of Pediatrics, La Faculte de Medecine, Universite Catholique de Louvain, May 1998, Brussels, Belgium.
131. Invited speaker. “Mitochondria in pediatric liver diseases”, Postgraduate Course*, ESPGHAN/NASPGN 5th Joint meeting,* May 27, 1998, Toulouse, France.
132. Invited speaker. “Oxidative hepatic injury in cholestasis and copper-overload.” Reactive oxygen species in pediatric gastrointestinal and liver disease symposium, *ESPGHAN/NASPGN 5th Joint Meeting*, May 30, 1998, Toulouse, France.
133. Invited speaker. “Mitochondrial hepatopathies.” *2nd Biennial Alex Mowat Paediatric Hepatology Update*, June 1, 1998, King’s College School of Medicine, London, UK.
134. Invited speaker. “Cell injury in cholestasis and bile acid toxicity”. *Idun Pharmaceuticals Liver Disorders Minisymposium*. July 17, 1998, La Jolla, CA.
135. Invited faculty. “Fatty liver and mitochondrial cytopathies,” “Cystic fibrosis related liver disease,” “New technologies: ERCP and MR/Cholangiography,” “Liver transplantation mini symposium: Care by the referring physician*.” 20th Annual Aspen Conference on Pediatric Disease: Pediatric Hepatology and Liver Transplantation.* Institute for Pediatric Medical Education. July 26-31, Aspen, Colorado.
136. Chair and Organizer of Symposium, “Advances in Viral Hepatitis in Infancy and Childhood, World Congress of Gastroenterology, Sept. 6-11. 1998, Vienna, Austria.
137. Chair and Organizer of Symposium, “Advances in the diagnosis and treatment of gastroesophageal disease in childhood, World Congress of Gastroenterology, Vienna, Austria.
138. Chair and Organizer of “Day of North America - Advances in genetics and the practice of gastroenterology”, World Congress of Gastroenterology, Sept. 6-11. 1998, Vienna, Austria
139. Invited speaker. “Revised Consensus Statement on Hepatobiliary Disease.” Symposium - Consensus conference highlights: diabetes, liver and aerosolized antibiotics*. Twelfth annual North American Cystic Fibrosis Conference.* October 16, 1998, Montreal, Quebec, Canada.
140. Invited speaker. “CF-associated liver disease - diagnosis and management.” Rise-and-shine and luncheon roundtables. *Twelfth Annual North American Cystic Fibrosis Conference.* October 17, 1998, Montreal, Quebec, Canada
141. Faculty, Meet the Faculty Breakfast for Fellows, *12th Annual Meeting of North American Society for Pediatric Gastroenterology and Nutrition*, October 22-24, 1998, Orlando, FL.
142. Faculty, Meet the Expert Breakfast Session, “Antioxidants”, *12th Annual Meeting of North American Society for Pediatric Gastroenterology and Nutrition*, October 22-24, 1998, Orlando, FL.
143. Panel member, Case Presentations, Postgraduate Course*, 12th Annual Meeting of North American Society for Pediatric Gastroenterology and Nutrition*, October 22, 1998, Orlando, FL.
144. Co-chair, Plenary Session III, 12th Annual Meeting of the North American Society for Pediatric Gastroenterology and Nutrition, October 24, 1998, Orlando, FL.
145. Moderator, Research Workshop, “Role of Mitochondria in Liver Disease”, Annual meeting of the American Association for the Study of Liver Diseases, Nov. 9, 1998, Chicago, Illinois.
146. Invited speaker. “Mechanisms of cholestatic liver injury”, *Division of Pediatric Gastroenterology and Nutrition, Mount Sinai School of Medicine*, December 9, 1998, New York, NY.
147. Invited Faculty Member. "Liver disease in Cystic Fibrosis - preventable or inevitable?", "Mechanisms of liver injury in childhood - is this a radical approach?" *18th Ross/North American Society for Pediatric Gastroenterology and Nutrition Seminar on Gastroenterology and Nutrition*, March 25-28, 1999, Carefree, Arizona.
148. Keynote speaker, *Eighteenth Annual Edward Pratt Lectures*- *Pediatric Resident Research Symposium*. "The evolution of vitamin E as an antioxidant." May 20, 1999. Children's Hospital Medical Center, Cincinnati, Ohio.
149. International Guest Speaker, *First International Conference on Gastroenterology, Hepatology and Nutrition in Pediatrics*, "Nutritional support in chronic liver diseases", "Shwachman-Diamond's syndrome", "History and present situation of the etiology of viral hepatitis", "Ursodeoxycholic acid utilization", "Treatment of acute liver failure", "Gene therapy and pediatric gastroenterology and hepatology". June 19-22, 1999, Universidade Federal de Sao Paulo/Escola Paulista de Medicina, Renaissance Hotel, Sao Paulo, Brazil.
150. Invited speaker. "Treatment of cholestasis", "Fat-soluble vitamins in Alagille syndrome." *International Conference on Alagille Syndrome*, Alagille Syndrome Alliance, July 31-August 1, 1999, Milwaukee, Oregon.
151. Invited speaker. "Liver histology in Navajo Neuropathy." *Navajo Neuropathy Study Group*. September 24, 1999, St. Joseph's Hospital, Phoenix, AZ.
152. Moderator, organizer and course instructor. "Pathogenesis, epidemiology and clinical features of CF liver disease." "Medical management of CF liver disease: to URSO or not to URSO?" CF Liver Disease 101- Early Bird Short Course, *Thirteenth Annual North American Cystic Fibrosis Conference*, October 7, 1999, Seattle Washington.
153. Invited Discussant. "Life-threatening *Clostridium difficile* enterocolitis in a toddler with CF", Physicians' Grand Rounds, *Thirteenth Annual North American Cystic Fibrosis Conference*, October 7, 1999, Seattle Washington.
154. Invited speaker. "New recommendations for managing liver disease in cystic fibrosis*", 6th Annual Post-graduate course of the North American Society for Pediatric Gastroenterology and Nutrition*, October 21, 1999, Denver, Colorado.
155. Co-chair, Plenary Session II, Thirteenth Annual Meeting, North American Society for Pediatric Gastroenterology and Nutrition, October 23, 1999, Denver, Colorado.
156. Invited speaker, "Biliary atresia - an infectious, immune, or autoimmune disease, or all of the above," *AASLD/NASPGN Symposium, "Viral infections in liver and hepatobiliary diseases: pathophysiology and therapy", 50th Annual Meeting of American Association for the Study of Liver Disease*, Nov. 5, 1999, Dallas, Texas
157. Meet-the-Professor Luncheon, "Liver failure and mitochondrial disease"*, 50th Annual Meeting of American Association for the Study of Liver Disease*, Nov. 6, 1999, Dallas, Texas.
158. Early Morning Workshop Moderator, "Oxidant-mediated liver injury", *50th Annual Meeting of American Association for the Study of Liver Disease*, Nov. 9, 1999, Dallas, Texas.
159. Guest Lecture, "Reye Syndrome - 2000 Update," *103rd Annual Meeting of the Japan Pediatric Society*, April, 16, 2000, Wakayama, Japan.
160. Invited faculty: Lecture - "Potential etiologies of biliary atresia", Meet the Professor Luncheon - "Portal hypertension in children." *Update in Pediatric Liver Transplantation*, The Recanati/Miller Transplantation Institute and the Jack and Lucy Clark Department of Pediatrics, The Mount Sinai Hospital of Mount Sinai-New York University Health, May 2, 2000, New York, New York.
161. Co-chair, Research Forum abstract session, "Liver Injury and Fibrosis", American Association for the Study of Liver Diseases session at Digestive Diseases Week, May 19-24, 2000, San Diego, CA.
162. Invited faculty: Lectures: "Chronic HCV infection: a pediatric perspective," "Cystic fibrosis liver disease," "Mitochondrial cytopathies,” “Post-transplant care: viral prophylaxis and surveillance," "Post-transplant lymphoproliferative disease". *Pediatric Hepatology and Liver Transplantation, 22nd Aspen Conference on Pediatric Disease*, The Institute for Pediatric Medical Education, July 24-28, 2000, Snowmass, Colorado.
163. Basic Science Research Breakfast moderator. "Mechanisms of liver cell injury*". World Congress of Pediatric Gastroenterology, Hepatology and Nutrition*, October 8, 2000, Boston, Massachusetts.
164. Invited lecture, “Scarring in the Liver in Glycogen Storage Disease”. *Glycogen Storage Disease Association annual meeting*, September 8, 2000, Denver, Colorado.
165. Invited speaker, “Mechanisms of mitochondrial injury”. *New Directions in Drug-Induced Liver Injury: Mechanisms and Test Systems*, National Institutes of Health workshop, October 17-18, 2000, Bethesda, MD.
166. Early Morning Workshop moderator, “Mitochondria in liver disease”, *American Association for the Study of Liver Diseases annual meeting*, October 30, 2000, Dallas, TX.
167. Early Morning Workshop moderator, “Oxidant-mediated liver injury”, *American Association for the Study of Liver Diseases annual meeting*, October 31, 2000, Dallas, TX.
168. Invited speaker, “Pediatric liver diseases that persist into adulthood”, Clinical *Update in Hepatology, 2001 Spring Postgraduate Course*, American Association for the Study of Liver Diseases, March 2-3, 2001, Marina Del Rey, California.
169. Grand Rounds and visiting professor, “Biologic and Clinical Roles of Antioxidants in Human Health”, Children’s National Medical Center, March 9, 2001, Washington, D.C.
170. Invited participant, “Fat-soluble vitamins in Cystic Fibrosis”, *Consensus Conference-CF Pediatric Nutrition, Cystic Fibrosis Foundation and NASPGN*, March 28-29, 2001, Bethesda, MD.
171. Invited speaker, “Metabolic liver disease: the approach to diagnosis and management in the Developing World” (state of the art lecture), and “Chronic viral hepatitis in children: who, when & how to treat?” *7th Congress of the Asian-Pan Pacific Society for Pediatric Gastroenterology, Hepatology and Nutrition*, April 21-24, 2001, Cairns, Australia.
172. Invited participant, Consensus Conference on Cystic Fibrosis Pediatric Nutrition, Cystic Fibrosis Foundation and NASPGN, March 28-29, 2001, Bethesda, MD.
173. Invited faculty, “Oxidative effects on mitochondria”, *3rd International Scientific Conference on Alpha-1: the challenge of a genetic condition*, June 19-22, 2001, Airlie Conference Center, Airlie, Virginia.
174. Invited speaker, “Role of antioxidants in liver disease”, “Emerging mitochondrial hepatopathies and gastroenteropathies”, *Second International Symposium on Pediatric Gastroenterology Hepatology and Nutrition*, June 21-23, 2001, Montreal, Quebec, Canada
175. Guest speaker, “Wilson disease: when metabolic diseases grow up.” Northwest Gastroenterology Meeting, Seattle, Washington, August 23, 2001
176. Guest faculty speaker, “Oxidative stress and mitochondrial dysfunction in the pathogenesis of cholestatic liver injury.” Gastroenterology Division, Department of Medicine, University of Washington School of Medicine, August 24, 2001, Seattle, Washington
177. Guest lecturer, “Biologic and clinical role of antioxidants in childhood health.” Madigan Army Hospital, August 24, 2001, Fort Lewis, Washington
178. Invited speaker, “Role of antioxidants in human health and disease”, *Grand Rounds*, Micromedix, Inc., October 9, 2001, Englewood, Colorado
179. Moderator, Early Morning Basic Research Workshop, “Oxidant Hepatic Injury”, 52nd Annual meeting of the American Association for the Study of Liver Diseases, Nov. 13, 2001, Dallas, TX
180. Invited speaker, *Pediatric Grand Rounds*, “Clinical role of antioxidants in pediatric and adult health”, *Research lecture*, “Mitochondria and oxidant hepatic injury in cholestasis”, Department of Pediatrics, UCLA School of Medicine and Mattel Children’s Hospital at UCLA, November 1-2, 2001, Los Angeles, California
181. Invited faculty, “Institutional Review Board Considerations”, Working group facilitator– “Viral hepatitis”, “Non-viral liver diseases”, *Clinical Trails in Pediatric Gastroenterology*, Johns Hopkins University School of Medicine, April 5-6, 2002, Baltimore, MD.
182. “Pediatric Clinical Research at Children’s Hospital Colorado– from the bench to the bedside”, Colorado’s Bio Breakfast at Fitz, April 24, 2002, Gateway Conference Center, Aurora, CO.
183. Invited speaker, “The pathogenesis of biliary atresia: the importance of novel genes and infections.” *Neonatal Cholestasis topic symposium*. Pediatric Academic Societies meeting, May 7, 2002, Baltimore, MD.
184. Visiting Lecturer, “The role of oxidative stress and mitochondrial perturbations in bile acid-induced hepatocyte apoptosis and necrosis”. Children’s Hospital Oakland Research Institute (CHORI), May 20, 2002, Oakland CA.
185. Invited speaker, “Treatment of Pediatric Cholestasis”, *AGA/NASPGHAN Clinical Symposium: “Pediatric Cholestasis”,* Digestive Disease Week, May 21, 2002, San Francisco, CA.
186. Guest faculty, “Biliary atresia: etiology”, “Non-alcoholic steatohepatitis in children – a growing problem”, “Mitochondrial cytopathies – the last metabolic frontier”, “Wilson’s disease – heavy metal management”, “Management of cholestasis”, “Liver transplantation – interim management”, “PTLD – a persistent threat – monitoring/surveillance/management.” 24th Annual Aspen Conference – Pediatric Hepatology and Liver Transplantation. July 22-25, 2002, Snowmass Village, CO
187. Guest speaker, “Alpha-one antitrypsin liver disease”, Alpha Beaters Annual Meeting, Alpha-one Foundation, August 3, 2002, Denver, CO.
188. Visiting Professor, Pediatric Evening Seminar: “Diagnosis and treatment of hepatitis in children”. Grand Rounds: “Antioxidants and Human Health”. Department of Pediatrics, Carolinas Medical Center, September 10-11, 2002, Charlotte, North Carolina.
189. Meet the Professor Breakfast, “Acute Liver Failure in Children”. North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting, October 26, 2002, San Antonio, TX.
190. Postgraduate Course Faculty, “Mitochondrial Hepatopathies: Inherited and acquired liver disease”, 53rd Annual Meeting of the American Association for the Study of Liver Diseases, November 2, 2002, Boston, MA.
191. Meet the Professor Luncheon, “Treatment of complications of cholestasis”, 53rd Annual Meeting of the American Association for the Study of Liver Diseases, November 2, 2002, Boston, MA.
192. Breakfast workshop, “Diagnosis and treatment of pediatric cholestatic liver diseases”, 53rd Annual Meeting of the American Association for the Study of Liver Diseases, November 4, 2002, Boston, MA.
193. Invited Faculty, “Biliary abnormalities in the newborn”, Hepatology Associates Course, 53rd Annual Meeting of the American Association for the Study of Liver Diseases, November 3, 2002, Boston, MA.
194. Visiting Professor, “Viral infection as an etiology of perinatal form of biliary atresia”, Department of Pediatrics, Juntendo University Medical School, November 22, 2002, Juntendo University, Tokyo, Japan.
195. Invited Lecturer, “Pathogenesis of biliary atresia: genes, viruses and autoimmunity”. 29th Meeting of the Japanese Congenital Biliary Atresia Society, November 23, 2002, Juntendo University, Tokyo, Japan.
196. Guest Faculty, “Bile acid-induced liver injury as a consequence of cholestasis”. Pediatric Single Topic Conference – Biliary atresia. American Association for the Study of Liver Disease, December 6-8, 2002, Emory Conference Center, Atlanta, GA.
197. Course Co-Director, Pediatric Single Topic Conference – Biliary Atresia, American Association for the Study of Liver Diseases, Dec. 6-8, 2002, Emory Conference Center, Atlanta, GA
198. Invited Speaker, “Biliary atresia – a model for immune mediated bile duct injury”, Citywide GI Grand Rounds, January 4, 2003, University of Colorado Health Sciences Center, Denver, CO
199. Pediatric Grand Rounds, “Update on Hepatitis A, B and C”, East Tennessee State University – Quillen School of Medicine, February 5, 2003, Johnson City, TN
200. Visiting Professor, Pediatric Grand Rounds, “Biliary atresia – 2400 years and counting…”; The Fred and Suzanne Biesecker Pediatric Liver Center Scientific Mini-symposium, “Research Initiatives in BARC: an overview”. June 4, 2003, Children’s Hospital of Philadelphia and the University of Pennsylvania School of Medicine, Philadelphia, PA
201. Invited speaker, “Biliary atresia- what we know and what we don’t know”, The 3rd Annual Liver Transplant Family Educational Seminar and Picnic, June 27-28, 2003, Green, Bay, WI.
202. Invited speaker, “Clinical and research advances in biliary atresia – 2500 years and counting…”, Department of Pediatrics, Emory University School of Medicine, August 19, 2003, Atlanta, GA.
203. Invited participant, “Clinical Studies in Pediatric Organ Transplantation: Defining Priorities and Feasibility”, American Society for Transplantation and National Institute of Allergy and Infectious Diseases, N.I.H., Sept. 14-15, 2003, Bethesda, MD
204. Invited speaker, “Clinical Findings in Biliary Atresia – Clues to Potential Etiologies.” AASLD/NASPGHAN Pediatric Symposium, “Liver and Biliary Tract Developments: New genes, new clinical insights.” AASLD Annual Meeting, October 24, 2003, Boston, MA.
205. Moderator for Meet the Professor Lunch, “Pediatric Cholestatic Syndromes”, AASLD Annual Meeting, October 25, 2003, Boston, MA.
206. Organizing Committee and Session Chair, “Cystic Fibrosis Antioxidant Workshop”, Cystic Fibrosis Foundation, November 10-12, 2003, Baltimore, MD
207. Invited speaker, “Vitamin E in cystic fibrosis: evidence for deficiency state and review of literature on supplementation,” Cystic Fibrosis Antioxidant Workshop, Cystic Fibrosis Foundation, November 10-12, 2003, Baltimore, MD.
208. Invited Professor, “Prolonged cholestasis in the infant – diagnosis and treatment”, “Antioxidants and Pediatric Gastrointestinal Diseases”, Fifth International Pre-Congress Course on Pediatric Gastroenterology, Mexican Association of Gastroenterology, November 15-16, 2003, Boca del Rio, Veracruz, Mexico
209. Invited speaker, “Neonatal cholestasis”, “Metabolic liver diseases”, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Board Review Course, February 26-28, 2004, Tampa, FL.
210. Invited speaker, “Clinical and research advances in biliary atresia: the BARC and the BITE”. 5th Alex Mowat Symposium on Pediatric Liver Disease, King’s College Hospital, Denmark Hill, London, United Kingdom, April 5, 2004.
211. Invited speaker, “Cell death in cholestasis and oxidative stress”. Drug Hepatotoxicity Symposium, 2nd World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, July 6, 2004, Paris, France.
212. Meet the Professor Breakfast, “Molecular defects in cholestasis”. 2nd World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, July 6, 2004, Paris, France.
213. Guest faculty, “Biliary atresia – bile duct development and pathogenesis”, “Mitochondrial cytopathies”, “NAFLD in children- pathogenesis and clinical approach”, “Wilson disease and hemochromatosis – blue genes and rusty nails”, “The SPLIT database – current North American practices and outcomes in pediatric liver transplantation”, “PTLD and EBV – from bench to bedside”. 26th Annual Aspen Conference on Pediatric Liver Disease and Liver Transplantation, July 18-23, 2004, Snowmass Village at Aspen, Colorado
214. Invited speaker, “Non-alcoholic fatty liver disease in children – relationship to insulin resistance and type 2 diabetes,” Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, ” July 27, 2004, Denver, CO
215. Invited lecture, “Antioxidants, nutrition and cystic fibrosis.” 18th Annual North American Cystic Fibrosis Conference, October 14, 2004, St. Louis, MO.
216. Workshop organizer and moderator, “Oxidative Stress and Antioxidants”, 18th Annual North American Cystic Fibrosis Conference, October 14, 2004, St. Louis, MO
217. “Biliary Atresia “, Meet the Professor Luncheon, Post Graduate Course at 55th Annual Meeting of the American Association for the Study of Liver Disease, October 30, 2004, Boston, MA.
218. “Neonatal cholestasis”, Early Morning Workshop, 55th Annual Meeting of the American Association for the Study of Liver Disease, November 1, 2004, Boston, MA.
219. “Unraveling the mystery called biliary atresia”, Gerard Odell Lecture, Department of Pediatrics Grand Rounds, University of Wisconsin Medical School, November 18, 2004, Madison, WI.
220. Visiting Professor, “Clinical and Research Advances in Biliary Atresia” – Pediatric Grand Rounds, “Neonatal Cholestasis- evaluation and management” – Resident lecture, “Oxidative stress and mitochondria in cholestasis and steatocholestasis” – combined GI divisions research lecture. Departments of Pediatrics and Internal Medicine, University of Texas Southwestern School of Medicine, February 16-17, 2005, Dallas, TX.
221. Invited speaker, “Testing and Transplanting the Liver in Alpha-1 antitrypsin deficiency”. *Alpha-1 Association 14th Education Conference*, June 10-12, 2005, Dallas/Fort Worth, TX.
222. Invited speaker, “Alpha-one antitrypsin liver disease – causes and treatment.” *Alpha-one Foundation Education Day*, August 6, 2005, National Jewish Medical and Research Center, Denver, CO.
223. Invited speaker, “Let there be bile – understanding cholestatic liver injury”. *William F. Balistreri Symposium and Festschrift,* September 9, 2005, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
224. Invited speaker, “Prognostic criteria for Acute Liver Failure in Children”, *Joint ESPGHAN and NASPGHAN Single Topic Conference on Acute Liver Failure in Children*, September 23-24, 2005, London, United Kingdom.
225. Invited speaker, “Prolonged cholestasis in infants”, and “Gastrointestinal manifestations of mitochondrial disease”. VII International Postgraduate Course “Pediatric Gastroenterology”, Gastroenterology National Week, November 20, 2005, Mexico City, Mexico.
226. Invited speaker, “Rationale against therapy in children (Hepatitis B Virus),” *AASLD Single Topic Conference, Controversies in the management of pediatric liver disease: hepatitis B, C and NAFLD*. March 3-4, 2006, Emory Conference Center, Atlanta, GA.
227. Visiting Professor, National Institutes of Health, NIDDK Intramural Program, “Biliary atresia – from bile to bedside”, March 9, 2006, NIH Clinical Center, Bethesda, MD
228. Invited speaker, “Proposal for a high dose steroid regimen after Kasai operation”, *European Federation for Biliary Atresia Research meeting*, June 28, 2006, Leibnizhaus der Universitat Hannover, Hannover, Germany
229. Invited speaker, “North American BARC studies – epidemiology, pathogenesis and treatment”, *European Biliary Atresia Registry Symposium*, June 30, 2006, Leibnizhaus der Universitat Hannover, Hannover, Germany.
230. Invited speaker, “Biliary atresia- What’s new in 2006”, “Neonatal cholestasis – management: pruritus”, “TPN-associated cholestasis”, “Mitochondrial cytopathies made easy”, “Wilson disease”, “Portal hypertension: pulmonary vascular complications”, “The SPLIT database – current North American practices and outcomes in pediatric liver transplantation”, “Post-transplant lymphoproliferative disease and EBV infections”.  *28th Annual Aspen Conference on Pediatric Disease: Pediatric Liver and Liver Transplantation*, Cincinnati Children’s Hospital, July 16-21, 2006, Snowmass Village, Colorado.
231. Invited speaker, “Metabolic liver diseases in infancy”, *Transplant Hepatology Certificate of Added qualification Review Course*, American Association for the Study of Liver Diseases, September 16-17, 2006, Chicago, IL.
232. Visiting Professor, “Pathogenesis of Biliary Atresia – where we are in 2006”, “Improving outcomes in pediatric transplantation: lessons from the Studies in Pediatric Liver Transplantation (SPLIT)”, The Hospital for Sick Children, September 14, 2006, Toronto, Ontario, Canada.
233. Invited Speaker, “Obstacles to making an early diagnosis of biliary atresia”, *Screening and Outcomes in Biliary Atresia - an NIDDK, HRSA, ORD Workshop*, September 11-12, 2006, Bethesda, MD
234. Invited Speaker, “Biliary Atresia Research Consortium: Conducting translational research in childhood liver disease”, *National Advisory Council of NIDDK Meeting*, NIH, Sept. 20, 2006, Bethesda, MD.
235. Invited Speaker, “The Rare Diseases Clinical Research Network (A collaborative effort between NCRR and the Office of Rare Diseases)”, *National Advisory Research Resources Council Meeting*, NIH, Sept. 21, 2006, NIH, Bethesda, MD.
236. Invited Speaker, “Vitamin E in Cystic Fibrosis – truth or consequences”, *North American Cystic Fibrosis Annual Meeting*, November 3, 2006, Denver, CO
237. Invited Speaker, “Primary Sclerosing Cholangitis in Pediatrics”, *Third Annual PSC Partners Seeking a Cure Conference*, April 14, 2007, Hyatt Regency Tech Center, Denver, CO
238. Invited Speaker, “What is Cystic Fibrosis liver disease?”, *Cystic Fibrosis Foundation Williamsburg Conference,* June 1-3, 2007, Williamsburg, VA.
239. Invited participant, “Liver disease in Cystic Fibrosis”, Williamsburg Conference, Cystic Fibrosis Foundation, June 1-3, 2007, Williamsburg, VA
240. Invited Speaker, “Alpha One Liver Disease - What’s New in 2007?”, *Moving Mountains COPD Conference*, Colorado COPD Connection/Alphabeaters Partners For Progress, August 11, 2007, Denver, CO
241. Panel chair and speaker, “Funding Options for Rare Diseases Research”, *Conference on Clinical Research for Rare Diseases*, sponsored by Rare Diseases Clinical Research Network, National Institutes of Health, September 5, 2007, Bethesda, MD.
242. Invited speaker, “Wilson’s disease – coping with copper”, *NASPGHAN Post-graduate course, NASPGHAN annual meeting*, Oct. 25, 2007, Salt Lake City, Utah
243. Early Morning Workshop speaker, “Nutrition and chronic liver disease in children”, *AASLD Annual Meeting,* November 4, 2006, Boston, MA.
244. Workshop Organizer and co-Moderator, “Vitamins in Cystic Fibrosis”, North American Cystic Fibrosis Annual Meeting, Cystic Fibrosis Foundation, Nov. 3, 2006, Denver, CO.
245. Visiting Professor, “Pediatric Liver Transplantation: Successes and opportunities” (Pediatric Grand Rounds), “Wilson’s disease in childhood: coping with copper”, *Arkansas Children’s Hospital, University of Arkansas Health Sciences Center*, December 3-4, 2007, Little Rock, AR.
246. Invited speaker, “Mitochondrial hepatopathies – emerging genotypes and clinical phenotypes. *Annual Meeting of Society for Inherited Metabolic Disorders*, March 3-5, 2008, Pacific Grove, California
247. Visiting Professor, “What is Cystic Fibrosis liver disease?”, “Wilson disease in children and adults – coping with copper*”, Department of Pediatrics, Stanford University School of Medicine and Lucille Packard Children’s Hospital,* March 5, 2008, Palo Alto, California.
248. Invited speaker, “TPN-related liver disease – hope on the horizon”, Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition annual meeting, March 22, 2008, COEX Convention Center, Seoul, Korea.
249. Invited speaker, “Treatment of hepatitis B in children”, Postgraduate Course 2008, *Viral Hepatitis: present and future,* Asian Pacific Association for the Study of the Liver, The 19th Conference, March 23, 2008, COEX Convention Center, Seoul, Korea.
250. Chair, Poster Presentation Session, “Hepatitis B”; Chair, Platform Session, “Metabolic and Autoimmune Diseases”, Asian Pacific Association for the Study of the Liver, Seoul, Korea, March 2007. Seoul, Korea
251. Invited speaker, “Update on biliary atresia”, “Metabolic liver disease in children”, “Nutritional management in childhood liver disease”, “Childhood viral hepatitis*”, Pediatric Liver Update 2008*, Faculty of Medicine, University of Malaya Medical Center, March 27, 2008, Kuala Lumpur, Malaysia.
252. Invited speaker, “Clinical Research in USA – Pediatric Liver Research Consortia”, *2nd National Paediatric Research Conference*, Faculty of Medicine, University of Malaya Medical Center, March 28, 2008, Kuala Lumpur, Malaysia.
253. Keynote speaker, “Biliary Atresia- advances and opportunities”, “A global view of pediatric liver diseases”, *Pediatric Liver Disease Symposium*, Pacific Northwest Chapter of American Liver Foundation, March 11-12, 2008, Seattle, Washington.
254. Cade R. Alpard Lecture in Pediatric Liver Disease and Liver Transplantation, “Biliary atresia 2008 – challenges and opportunities,” Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, April 23-24, 2008, Houston, TX.
255. Invited Speaker, “Steatocholestasis – mechanisms of liver injury in inherited metabolic liver disease”, Digestive Disease Center seminar, Baylor College of Medicine, April 14, 2008, Houston, TX.
256. Invited Speaker, “Cholestasis, xanthomas, pruritus and biliary diversion”, “Scientific and clinical research update and your family’s role”, “Fat-soluble vitamin deficiencies in AGS”, *4th International Symposium on Alagille Syndrome*, June 27-29, 2008, San Mateo, CA
257. Faculty Speaker, “Cystic fibrosis associated liver disease”, “Mitochondrial cytopathies – new causes, new paradigms”, “Neonatal cholestasis – management issues”, “Portal hypertension: pulmonary vascular complications”, “Post-transplantation lymphoproliferative disease and EBV infection”, “MELD-PELD – Does it work?”, *Advances in Pediatric Liver Disease and Liver Transplantation*, 30th Annual Aspen Conference on Pediatric Gastrointestinal Disease, July 20-25, 2008, Snowmass Village, Colorado
258. Invited Speaker, “Mitochondrial Hepatopathies*”, Symposium 1 - Metabolic Disorders and Liver: Novel Diagnostic and Therapeutic Strategies, World Congress of Pediatric Gastroenterology, Hepatology and Nutrition 3*, August 16-20, 2008, Iguassu Falls, Brazil.
259. Chair, Symposium 1 – Metabolic disorders and liver, World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, August 18, 2008, Iguassu Fall, Brazil
260. Guest Lecturer, “Translating your scientific interests into a career”, *Medical Student Summer Research Program*, University of Cincinnati School of Medicine, October 3, 2008, Cincinnati, OH
261. Roundtable discussant, “Building and sustaining the relationships that build and sustain trust in biomedical research”, *TIES2 Project Workshop*, American Indian and Alaska Native Programs, University of Colorado Denver, Given Institute, October 13-14, 2008, Aspen, CO
262. Meet the Professor Luncheon, “Nutrition in chronic liver disease in children”, *Post- Graduate Course* at The Liver Meeting, Annual Meeting of the American Association for the Study of Liver Disease, November 1, 2008, San Francisco, CA.
263. Faculty Speaker, “Can vitamin E help in liver disease?”, *NASPGHAN-CDHNF 2008 Post-Graduate Course, “Challenges in Nutrition*”, November 13, 2008, San Diego, CA
264. Nutrition Learning Lunch Speaker, “Obesity and chronic liver disease/vitamin E and liver disease”, *NASPGHAN-CDHNF 2008 Post-Graduate Course, “Challenges in Nutrition*”, November 13, 2008, San Diego, CA
265. Grand Rounds Speaker, “Translational Strategies in Pediatric Research – the Road to a Cure for Biliary Atresia”, *Pediatric Grand Rounds*, Children’s Hospital of San Diego, November 2, 2009, San Diego, CA.
266. Invited speaker, “NIH-funded Consortium for Studies of Pediatric Liver Transplantation (SPLIT)”, *Building a Research Center: Frontiers in Liver Transplantation*, December 8, 2008, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO.
267. Invited speaker, “Acute hepatic failure and encephalopathy: lessons from a national collaborative study.” Pediatric Academic Societies Meeting, May 5, 2009, Baltimore, MD.
268. Invited speaker, “Non-alcoholic fatty liver disease in children – pathogenesis and clinical approach. *Special Interest Group on Obesity, Academic Pediatric Association*, Pediatric Academic Societies Meeting, May 4, 2009, Baltimore, MD.
269. Invited speaker, “Rare disease research in children as a paradigm for clinical and translational research”, *Symposium on Clinical and Translational Science, Delaware Health Sciences Alliance Research Conference*, May 6, 2009, University of Delaware, Newark, Delaware.
270. Invited speaker, “Developing and building clinical research teams.” *How to take advantage of the NIH roadmap: developing and building a collaborative research group*. AGA Institute Committee Sponsored Symposium, Digestive Disease Week, May 31, 2009, Chicago, IL.
271. Invited speaker, “Latest liver research in alpha one antitrypsin deficiency – the Cholestatic Liver Disease Consortium”. 18th Annual National Education Conference, Alpha-1 Association, June 6 , 2009, San Francisco, CA
272. Moderator, “Models of liver disease and therapeutics”, Cystic Fibrosis Liver Disease Clinical Research Workshop, National Institutes of Diabetes, Digestive and Kidney Diseases, NIH, June 8-9, 2009, Bethesda, MD.
273. Invited Speaker, “Rare disease research as a model for translational research in children”, University of California Irvine and Children’s Hospital of Orange County, June 17, 2009, Irvine, CA.
274. Pediatric Grand Rounds, “Biliary atresia - pathogenesis and treatment”, Hopital Infantil de Mexico, Instituto Nacional de Salud, June 19, 2009, Mexico City, Mexico.
275. Post-graduate course faculty, “Primary sclerosing cholangitis in children”, *Immunology, Allergy and Inflammation in Pediatric Gastroenterology Course*, Hopital Infantil de Mexico, Instituto Nacional de Salud, June 19, 2009, Mexico City, Mexico.
276. Invited speaker and panelist, “Sharing Across Diseases Panel”, *Advancing Rare Diseases Research Through Networks and Collaboration*, ORDR, NCRR, NIH, Natcher Conference Center, National Institutes of Health, July 16, 2009, Bethesda, MD
277. Keynote Address, “The Next Nexus for Pediatric Research: Innovation Intersecting Implementation”, *Ceremony for Endowed Chair in Transplant Hepatology to John Bucuvalas, MD*, Cincinnati Children’s Hospital Medical Center, July 22, 2009, Cincinnati, OH.
278. Panel member, “IDeA CTSA Collaborations: Opportunities and Challenges.” Western Region COBRE-INBRE Scientific Conference. Sept. 16-19, 2009, Big Sky, Montana.
279. Invited speaker, “Acute Liver Failure in Children”, Children’s National Medical Center and George Washington University School of Medicine, October 7, 2009, Washington, D.C.
280. Invited speaker, “Strategic Goal Panel Discussion, Child Health”, CTSA Consortium Steering Committee Face-to-Face Meeting, October 8, 2009, Rockville, MD.
281. Postgraduate course faculty, “Mitochondrial liver disease – Amping up the liver”, Postgraduate Course at Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), November 12, 2009, National Harbor, MD.
282. Meet the Professor Luncheon Faculty, “Alagille Syndrome and Mitochondrial Liver Disease”, Postgraduate Course at Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), November 12, 2009, National Harbor, MD.
283. Invited speaker, “Post Transplantation Lymphoproliferative Disease”, Controversies in Transplantation, University of Colorado Denver, March 5-7, 2010, Breckenridge, CO.
284. Invited speaker, “Development of the Colorado Clinical and Translational Sciences Institute”, Northern Colorado Health Research Coalition, March 12, 2010, Fort Collins, Colorado.
285. Invited Faculty speaker, “Biliary atresia: what BARC has taught us”, “Autoimmune hepatitis – etiology, diagnosis and treatment,” Wilson disease- coping with copper”, “Mitochondrial cytopathies made easy”, Portal hypertension-pulmonary vascular complications”, “PTLD and EBV-evolving concepts”. *Advances in Pediatric Liver Disease and Liver Transplantation*, 32nd Annual Aspen Conference on Pediatric Gastrointestinal Disease, July 12-16, 2010, Snowmass Village, Colorado
286. Pediatric Grand Rounds speaker, “Solving complex reare liver diseases: from molecules to medicines”, Department of Pediatrics, University of Colorado School of Medicine and Children’s Hospital Colorado, September 3, 2010, Aurora, CO
287. Invited speaker, “The Childhood Liver Research and Education Network”, NIH Corner Seminar at American Association for the Study of Liver Disease annual meeting, October 31, 2010, Boston, MA
288. Invited speaker, “Parenteral nutrition liver injury and toxicity”, Joint Annual Meeting of the Israel Association for the Study of the Liver, the Israel Gastroenterology Association and the Israel Society for Pediatric Gastroenterology and Nutrition, January 26, 2011, Eliat, Israel.
289. Invited speaker, “Mitochondrial Hepatopathies”, Annual Meeting of the Israel Society for Pediatric Gastroenterology and Nutrition, January 28, 2011, Eilat, Israel.
290. Invited speaker, “The Colorado Clinical and Translational Sciences Institute (CCTSI) – a vehicle for transformation of research and patient care”. Association of Clinical Research Professionals Front Range Chapter, March 7, 2011, Aurora, Colorado.
291. Invited speaker, “Medical Research: How is it conducted and interpreted?” Osher Lifelong Learning Institute, University of Denver, March 9, 2011, Denver, Colorado
292. Invited speaker, “Vaccine-related opportunities through the CCTSI”, 1st Annual Colorado Vaccine Summit, March 11, 2011, Longmont, Colorado
293. Invited speaker, “Metabolic Liver Disease in Childhood”, Advances in Pediatric Hepatobiliary and Pancreatic Diseases, PAS Topic Symposium, Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting, April 29, 2011, Denver, CO.
294. Meet the Professor Breakfast session, “Careers in Academic Pediatric Gastroenterology and Hepatology”, Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting, May 1, 2011, Denver, CO
295. Chair and Panel member, “Update on Hepatitis A-E,” American Academy of Pediatrics Review and Education Program, May 1, 2011, Denver, CO.
296. Invited NIH Roundtable Panel Member, “The mechanisms of vitamin E and potential biomarkers relevant for clinical studies”, at “Roundtable Meeting: Current research and future directions for vimtain E treatment of nonalcoholic fatty liver disease”, National Institutes of Health/National Center for Complementary and Alternative Medicine”, May 2, 2001, Bethesda, Maryland.
297. Invited speaker and Co-Chair, “Update on Hepatitis in Children of the Western World”, Viral Hepatitis- Update in 2011 - Asian Society for Pediatric Research Symposium, Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting, May 3, 2011, Denver, CO.
298. Invited speaker, “Child Health Research in the CTSA Consortium”, What the CTSA Consortium can Do for You Symposium, American Thoracic Society 2011 International Meeting, May 16, 2011, Denver, Colorado.
299. Visiting Professor, “Mitochondrial Hepatopathies”, “Parenteral nutrition associated liver disease – new concepts, new models”, Division of GI, Hepatology and Nutrition, Department of Pediatrics, University of California San Francisco School of Medicine, May 18-19, 2011, San Francisco, CA.
300. Invited speaker, “Autoimmune hepatitis in children”, Pediatric Liver Disease Update for the Primary Care Provider, Department of Pediatrics, California Pacific Medical Center, May 21, 2011, San Francisco, CA.
301. Invited speaker, “Current research in Alagille Syndrome”, Liver transplantation in Alagille Syndrome – indications and outcomes”, Liver transplantation in Alagille Syndrome-follow-up”, 5th International Symposium on Alagille Syndrome, June 24-26, 2011, Evanston, IL
302. Invited speaker, “Cystic Fibrosis Gastrointestinal Problems – What can you do?”, 24th National Family Cystic Fibrosis Education Conference, “Cystic Fibrosis in the Spotlight: Taking a Leading Role”, Cystic Fibrosis Research, Inc., July 30, 2011, Redwood City, CA.
303. Keynote Speaker, “The CCTSI – University of Colorado’s CTSA since 2008”, REDCap (Research Electronic Database Capture) Annual Meeting, August 4, 2011, Breckenridge, CO.
304. Introduction to 2011 NASPGHAN Distinguished Service Awardee (Ivor Hill, MD), North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting, October 21, 2011, Orlando, FL
305. Invited speaker, “Advances in Neonatal Cholestasis”, “Parenteral nutrition-associated cholestasis – is it the PN or the Intestinal Failure?”, Annual Neonatology Symposium, Vanderbilt University Department of Pediatrics, November 3, 2011, Nashville, TN
306. Invited speaker: “Parenteral Nutrition Associated Liver Injury: New insights from a novel mouse model”, Children’s and Family Research Institute, University of British Columbia and BC Children’s Hospital, January 16, 2012, Vancouver, BC, Canada
307. Course Faculty, “Metabolic Liver Diseases”, “Autoimmune Liver Diseases in Childhood”, “Viral Hepatitis Management”, Advances in Pediatric Gastroenterology, Hepatology and Nutrition 2012, Harvard Medical School and Children’s Hospital Boston, April 12-15, 2012, Cambridge, Massachusetts
308. Invited speaker,” Mitochondrial hepatopathies”, The Laura Dribin Mitochondrial Symposium, Children’s Hospital of Philadelphia, Mar 1, 2012, Philadelphia, PA
309. Visiting Professor, “Parenteral Nutrition Associated Liver Injury: New insights into pathogenesis from a novel mouse model”, Division of Gastroenterology, Hepatology and Nutrition, Children’s Hospital of Philadelphia, March 2, 2012, Philadelphia, PA
310. Invited speaker, “Liver Transplantation and Mitochondrial Hepatopathies”, Challenging the Paradigms: Liver transplantation for metabolic disease, Children’s Hospital of Pittsburgh, May 4, 2012, Pittsburgh, PA
311. Invited speaker, “Mitochondriopathies – diagnosis and management”, “Advances in nutritional management in patients with chronic liver disease”, “Drug induced hepatotoxicity”, 14th Brazilian Congress of Pediatric Gastroenterology, June 5-9, 2012, Sao Paulo, Brazil.
312. Invited Symposium speaker, “The Childhood Liver Disease Research and Education Network”, Rare Disease Clinical Research Network Symposium, DIA 2012- Collaborate to Innovate annual meeting, June 27, 2012, Philadelphia, PA
313. Invited faculty, “Diagnosis, management and outcomes of biliary atresia”, “TPN-associated cholestasis (alias IFALD)”, “Autoimmune hepatitis: etiology, diagnosis and treatment”, “Wilson’s disease 2012”, “The expanding spectrum of mitochondrial hepatopathies”, “Portal hypertension: pulmonary vascular complications”, Post-transplant lymphoproliferative disease and EBV”. 34th Annual Aspen Conference on Pediatric Gastrointestinal Disease: Advances in Pediatric Liver Disease and Liver Transplantation, July 16-20, 2012, Snowmass Village, Colorado.
314. Invited faculty, “Early detection and emerging management of genetic and metabolic liver disease”, Post-Graduate Course, World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, November 14, 2012, Taipei, Taiwan.
315. Invited participant, International Research Conference on Alpha1 Antitrypsin Deficiency, “Alpha-1 antitrypsin liver disease: Science and therapeutic potential 50 years later”, Alpha-1 Foundation, April 11-12, 2013, Barcelona, Spain.
316. Invited Speaker, “Biliary Atresia: New advances, New Therapies.” Pediatric Grand Rounds. Royal Children’s Hospital, May 1, 2013, Brisbane, Queensland, Australia.
317. Invited Speaker, “Mitochondrial Hepatopathies: Transformation of a Rare Disease in the Era of Genomics”, Dean of Medicine Lecture Series, The University of Queensland School of Medicine, May 1, 2013, Brisbane, Queensland, Australia.
318. Meeting Organizer and Speaker, “University of Colorado-Colorado State University CCTSI Summit”, August 20, 2013, Loveland, Colorado.
319. Invited Faculty, “Primary Sclerosing Cholangitis in Children”, Frontiers in Pediatric Gastroenterology, Hepatology and Nutrition 2013, Harvard Medical School, MassGeneral Hospital for Children, November 8-9, 2013, Boston, Massachusetts
320. Invited Speaker, “General Discussion”, Clinical Trials Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases, Alpha-1 Foundation, February 3-4, 2014, Bethesda, MD
321. Invited Speaker, “How multi-center collaboration facilitates studies of biliary atresia: Steroids and beyond…”, Pediatric Academic Societies Annual Meeting, May 4, 2014, Vancouver, BC, Canada.
322. Invited Speaker, “Hepatitis C: What the pediatric infectious disease specialist needs to know”, Pediatric Academic Societies Annual Meeting, May 6, 2014, Vancouver, BC, Canada.
323. Invited Faculty, “Biliary atresia – immunopathogenesis, evidence-based screening and monitoring”, “Intestinal failure –associated cholestasis (IFAC)”, “Autoimmune hepatitis – etiology, diagnosis and treatment”, “Wilson disease”, “ The expanding spectrum of mitochondrial hepatopathies”, “Portal Hypertension: Pulmonary vascular complications”, “ Post-transplant lymphoproliferative disease and EBV “, 36th Annual Aspen Conference on Pediatric Gastrointestinal Disease: Advances in Pediatric Liver Disease and Liver Transplantation, July 13-18, 2014, Snowmass, Colorado
324. Meeting Organizer and Speaker, “Second Annual University of Colorado-Colorado State University CCTSI Summit”, August 15, 2014, Longmont, Colorado
325. Invited Speaker, “What causes parenteral nutrition associated cholestasis? From Mouse to Man”, Dell Medical School at University of Texas at Austin, Dell Children’s Medical Center, September 4, 2014, Austin, TX.
326. Invited Faculty, “Report from the START Project”, “Basic Research on Biliary Atresia in Denver”, Panel Discussion – Treatment and Outcome of Biliary Atresia. The First International Congress on Biliary Atresia and Related Diseases, October 16-17, 2014, Berlin, Germany.
327. Invited Speaker, “Closing Remarks-Initiatives of the CTSA national program in next era strategies”, US Department of Health and Human Services, Office for Human Research Protections (OHRP) Research Community Forum, “Next era strategies to elevate human research protection”, March 12, 2015, Denver, Colorado
328. Invited Speaker, “ASBT and treatment of bile acid transport disorders,” AASLD and Industry Colloquium: Novel Targets and Therapies in Liver Disease, March 20-21, 2015, Durham, North Carolina.
329. Invited Speaker, “The association of Mitochondrial Hepatopathies and childhood liver cancer”, Society for Inherited Metabolic Disorders 38th Annual Meeting, March 28-31, 2015, Salt Lake City, Utah.
330. Invited Speaker and Organizing Committee, “CTSAs and Veterinarians”, One Health: Integrating the Veterinarian Scientist and Biomedical Research Enterprise, Office of Research Infrastructure Program, Office of the Director, National Institutes of Health, April 7-8, 2015, Lister Hill Auditorium, NIH, Bethesda, MD.
331. Invited Speaker, “Liver disease in the Adolescent”, Breakfast with the Expert, Digestive Disease Week 2015, May19, 2015, Washington D.C.
332. Invited speaker, “Pediatric non-alcoholic fatty liver disease: an increasing public health issue”, *Challenges and Opportunities in Pediatric Liver Diseases Seminar*, Digestive Disease Week 2015, May19, 2015, Washington D.C.
333. Invited Speaker, “ChiLDReN Research Study”, “Alpha-1 Liver Research Panel”, “Meet the Experts”, 24th Annual National Education Conference, Alpha-1 Foundation, Garden Grove, CA, July 24-26, 2015.
334. Meeting Organizer and Speaker, “Obesity/Diabetes – Cardiovascular Research in Colorado”, Third Annual University of Colorado-Colorado State University CCTSI Summit, August 18, 2015, Longmont, Colorado
335. Invited Moderator, “Bringing Research to the Community” Panel Discussion, Children’s Hospital Colorado Research Day, September 21, 2015, Aurora, CO.
336. Invited Faculty, “Pathogenesis of Parenteral Nutrition Associated Cholestasis: Bugs, Drugs and Slugs”, “ The Balistreri Rounds – Clinical-Pathologic Discussion”, William and Rebecca Balistreri Lectureship in Hepatology, Division of Gastroenterology, Hepatology and Nutrition, September, 2015, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
337. Invited speaker, “Treatment prospects for patients with Progressive Familial Cholestasis”, In *New Treatments for Cholestatic and Biliary Disorders: Pediatric and Adult Populations*, Special Interest Group program at The Liver Meeting (Annual AASLD Meeting), November 13, 2015, San Francisco, CA.
338. Invited Speaker, “Genetic liver diseases in children and adults.” 20th Annual Virginia Liver Symposium and Update in Gastroenterology, Virginia Commonwealth University, March 26, 2016, Richmond, VA.
339. Visiting Professor, Benjamin Tvedt Memorial Lecture, “Pathogenesis of Parenteral Nutrition Associated Cholestasis: Bugs, Drugs and Slugs,” Stead Family Department of Pediatrics, University of Iowa Carver School of Medicine, April 1, 2016, Iowa City, IA.
340. Invited Speaker, “Parenteral nutrition related liver disease and the microbiome”, AASLD Pediatric Clinical Symposium on *The Intestinal Microbiome and Pediatric Liver Disease*, Digestive Disease Week, May 24, 2016, San Diego, CA.
341. Moderator, “Pediatric and Metabolic Liver Disease”, *AASLD Research Forum*, Digestive Disease Week, May 24, 2016, San Diego, CA.
342. Invited Speaker, “Pediatric Cholestatic Diseases”, *AASLD Midyear Course: Clinical Hepatology: State of the Art Management*, June 25-26, 2016, Chicago, IL.
343. Invited Faculty, “Biliary atresia: closer to understanding the cause”, “Parenteral Nutrition Associated Cholestasis: new developments, new approaches”, “Wilson Disease: new approaches to diagnosis and therapy”, “Mitochondrial Hepatopathies: hope around the corner?”, “Autoimmune Hepatitis: diagnosis and treatment”, “Portal Hypertension: HPS and Portopulmonary hypertension”, Post-Transplant Lymphoproliferative Disease and EBV”. *38th Annual Aspen Conference on Pediatric Gastrointestinal Disease: Advances in Pediatric Liver Disease and Liver Transplantation*, July 11-15, 2016, Snowmass, Colorado.
344. Meeting Organizer and Speaker, “Genomics and Regenerative Medicine in Colorado”, Fourth Annual University of Colorado-Colorado State University CCTSI Summit, August 17, 2016, Longmont, Colorado
345. Invited Webinar Speaker, “Inborn errors of bile acid synthesis and metabolism: diagnosis, novelties and therapeutics”, *AASLD Cholestasis Special Interest Group Webinar*, September 27, 2016, Alexandria, Virginia.
346. Invited Speaker, “Interaction of Environmental and Genetic Factors in Liver Disease: Parenteral Nutrition-Associated Cholestasis”, Pediatric Hepatology Symposium, 5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Montreal, October 8, 2016, Quebec, Canada.
347. Invited Speaker, “Genetic Testing in Pediatric Liver Disease”, *Post Graduate Course at The Liver Meeting,* AASLD Annual Meeting, November 11-15, 2016, Boston, MA.
348. Invited Faculty, “Introduction to AASLD Journals”, and Moderator of Abstract Presentations, APASL-AASLD Joint Workshop: Methodology Training for Clinical Research, *26th Conference of Asian Pacific Association for the Study of the Liver (APASL),* February 15, 2017, Shanghai, China.
349. Invited Speaker, “Pediatric Inherited Liver Disease: Are we ready for a precision medicine approach?”, *26th Conference of Asian Pacific Association for the Study of the Liver (APASL),* February 18, 2017, Shanghai, China.
350. Invited Faculty, “Metabolic Liver Diseases: Mitochondrial Liver Disease, Wilson disease, Alpha-1 antitrypsin deficiency, Glycogen Storage Disease, Hereditary Tyrosinemia”, and speaker at Breakfast Workshop- Metabolic liver diseases, *Essential Pediatric GI-NASPGHAN Review Course 2017*, February 23-25, 2017, Scottsdale, AZ
351. Invited Speaker, “Lipid emulsions and intestinal failure associated liver disease”, *AGA Hot Topics in Parenteral Nutrition Symposium, Digestive Disease Week*, May 9, 2017, Chicago, IL
352. Invited Speaker, “Nutrition support of the cholestatic patient”, *Nutrition and Pediatric Liver Disease NASPGHAN/AASLD Symposium, Digestive Disease Week*, May 9, 2017, Chicago, IL
353. Meeting Organizer and Invited Speaker, “Biliary atresia: a clinical challenge in the 21st century”. *Biliary Atresia: A Clinical and Translational Science Research Workshop*, National Institute of Diabetes, Digestive and Kidney Disease, NIH, June 28, 2017, Bethesda, MD
354. Speaker and Moderator of Panel Discussion, “New Research Technologies and Innovation on Campus”, *Third Annual Clinical Research Symposium,* August 15, 2017, Children’s Hospital Colorado, Aurora, Colorado
355. Meeting Organizer and Speaker, “Microbiome – from Methods to Collaboration”, *5th Annual University of Colorado- Colorado State University CCTSI Summit,* August 16, 207, Thornton, Colorado.
356. Dame Sheila Sherlock Inaugural Visiting Professor, “Intestinal Failure Associated Liver Disease – Mechanisms from Mouse to Man”, Division of Gastroenterology and Hepatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, September 26-27, 2017, Philadelphia, Pennsylvania.
357. Invited Faculty, “Conflicts of Interest in Biomedical Research”, Session Chair (Abstract Presentations), Workshop Moderator (Metabolic and Cholestatic Diseases), *EASL-AASLD Masterclass 2017*, December 14-16, 2017, Paris, France.
358. Invited Faculty, “Liver disease research in children”, Young Investigator Research Methodology Workshop, *27th Annual Meeting of the Asian Pacific Association for the Study of the Liver*, March 14, 2018, New Delhi, India.
359. Invited Speaker, “Mitochondrial Hepatopathies”, Pediatric Hepatology Symposium, *27th Annual Meeting of the Asian Pacific Association for the Study of the Liver*, March 16, 2018, New Delhi, India.
360. Invited Speaker, “Intestinal Failure Associated Liver Disease – Burden and Management”, Pediatric Hepatology Symposium*, 27th Annual Meeting of the Asian Pacific Association for the Study of the Liver*, March 16, 2018, New Delhi, India
361. Invited Speaker, “Meet the Experts: Alpha-1 antitrypsin deficiency”; Moderator, Main Plenary Session II, *International Liver Congress, European Association for the Study of Liver (EASL)*, April 13-16, 2018, Paris, France
362. Invited Faculty, “Special Populations: Research in Children”, AASLD Young Investigators Workshop, *XIII National Congress of the Mexican Association for Hepatology (AMH),* June 13-16, 2018, Cancun, Mexico.
363. Invited Speaker, “Pediatric Liver Disease: what a gastroenterologist and hepatologist needs to know”, State of the Art Lecture, *XIII National Congress of the Mexican Association for Hepatology (AMH*), June 13-16, 2018, Cancun, Mexico
364. Invited Faculty, “Workshop on NFALD in Children and Teenagers - Pan American Perspectives”, *XIII National Congress of the Mexican Association for Hepatology (AMH)*, June 13-16, 2018, Cancun, Mexico
365. Invited Speaker, “Intestinal Failure Associated Liver Disease: Insights into pathogenesis and treatment”, Dr. Paul Angulo Lecture, *XIII National Congress of the Mexican Association for Hepatology (AMH),* June 13-16, 2018, Cancun, Mexico
366. Invited Faculty, “Biliary Atresia: Closer to Understanding the Cause”, “Parenteral Nutrition -Associated Liver Disease: New Developments, New Approaches”, “Wilson’s Disease: Approaches to Diagnosis and Therapy”, “Mitochondrial Hepatopathies: Recognition and Management”, “Portal Hypertension: HPS and Portopulmonary Hypertension”, “Post-Transplant lymphoproliferative disease and EBV”, *40th Annual Aspen Conference on Pediatric Gastrointestinal Disease: Advances in Pediatric Liver Disease and Liver Transplantation*, July 16-20, 2018, Snowmass, Colorado.
367. Invited Faculty, “Liver disease research in children”, Liver research training opportunities in North America”, Faculty judge for poster session, AASLD/ALEH Workshop of Investigation, *XXV ALEH Congress, Association Latinamericana para el Estudio del Higado*, September 20-23, 2018, International Convention Center, Punta Cana, Dominican Republic.
368. Organizer and Invited Faculty, “Conflicts of Interest: Academics vs. Industry”, Co-Chair and Organizer, *AASLD-EASL Masterclass*, November 29- December 1, 2018, Orlando, Florida.
369. Invited Speaker, “Leveraging your campus resources for funding and interdisciplinary project: CTSA’s and beyond”, Investigator Workshop, *2019 Western Medical Research Confer*ence, January 25, 2019, Carmel, California.
370. Visiting Professor, “Intestinal Failure Associated Liver Disease: From Mouse to Man”, Pediatric Grand Rounds, Department of Pediatrics, Geffen School of Medicine, University of California at Los Angeles, February 8, 2019, Los Angeles, CA.
371. Visiting Professor, “Mitochondrial Hepatopathies: Diagnosis and Management”, Metabolism lecture series, Geffen School of Medicine, University of California at Los Angeles, February 8, 2019, Los Angeles, CA.
372. Invited Keynote Speaker, “Translating your scientific interests into a rewarding research career”, Pediatric Research Symposium, Department of Pediatrics, Baylor College of Medicine, April 9, 2019, Texas Children’s Hospital, Houston, TX.
373. Invited Seminar, “Unraveling the pathogenesis of Intestinal Failure Associated Liver Disease”, Children’s Hospital, Helsinki University Central Hospital, May 2, 2019, Helsinki, Finland.
374. Opponent for PhD Dissertation Defense by Anna Kerola, MD, “Native liver fibrosis in biliary atresia – from pathobiology to clinical outcomes.” University of Helsinki Faculty of Medicine, May 3, 2019, Helsinki, Finland.
375. Invited Speaker, “The influence of pediatric and genetic cholestatic diseases on the adult”, “Biliary Atresia – advances in etiology and pathogenesis”. Annual Meeting of the Israel Association for the Study of the Liver, June 13-15, 2019, Eilat, Israel.
376. Invited Moderator: “My story. How I ended up participating in research: The family and patient perspective”. 5th Annual Clinical Research Symposium, August 20, 2019, Children’s Hospital Research Institute, Aurora, Colorado.
377. Invited Speaker, Keynote Address: “Outcomes for the Future: How do we improve on the status quo?”, Single Topic Conference: *Chronic Liver Disease Management for the Gastroenterologist,* 2019 NASPGHAN Annual Meeting, October 16, 2019, Chicago, Illinois.
378. Invited Panel, “Group Discussion of Difficult Cases”, Single Topic Conference: *Chronic Liver Disease Management for the Gastroenterologist,* 2019 NASPGHAN Annual Meeting, October 16, 2019, Chicago, Illinois.
379. Invited Speaker, The Milton Grand Lecture, “Insights into Pathogenesis and Management of Parenteral Nutrition Associated Liver Disease”, Department of Pediatrics Grand Rounds, Albert Einstein School of Medicine, Children’s Hospital at Montefiore, December 18, 2019, New York City, New York.
380. Invited faculty speaker, “Biliary atresia – prompt diagnosis and screening”. *Annual Aspen Conference on Pediatric Gastrointestinal Disease*, Cincinnati Children’s Hospital, July 14, 2020, Virtual meeting.
381. Invited speaker: “Insights into pathogenesis of IFALD through animal models.” 11th Zealand Pharma Short Bowel Syndrome Expert Meeting (Virtual). October 1, 2020.
382. Invited speaker: “Mitochondrial Disorders: Re-examining the role of liver transplantation.” AASLD/NASPGHAN Pediatric Symposium, Medical and Ethical Dilemmas of Patient and Organ Selection for Liver Transplantation, The Liver Meeting Digital Experience, AASLD Annual Meeting, November 13, 2020.
383. Sass-Kortsak Award Lecture, “Intestinal Failure Associated Liver Disease: The Gut-Lipid-Liver Axis”. Canadian Liver Meeting (Virtual). Canadian Association for the Study of the Liver (CASL) and the Canadian Liver Foundation, May 5, 2021.
384. Invited Symposium speaker: “The Childhood Liver Disease Research Network (ChiLDReN):
Achievements that have reached the (future) patient.” Symposium: Rare liver disease - the value of collaboration. 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Vienna, Austria (and Virtual), June 5, 2021
385. Invited Faculty Speaker: “Intestinal failure associated liver disease – What’s new?” 43rd Annual Aspen Conference on Pediatric Gastrointestinal Disease: Advances in Pediatric Liver Disease and Liver Transplantation. Virtual Meeting, July 13, 2021.
386. Invited Faculty Speaker: “Considerations of COVID in PFIC.” 2021 PFIC Family Conference, PFIC Advocacy and Research Network, Virtual Conference, July 17, 2021.
387. Pediatric Grand Rounds Speaker, “Insights in Intestinal Failure Associated Liver Disease: A triumph for children with short bowel syndrome.” Children’s Hospital of Los Angeles, August 13, 2021, Virtual.
388. Inaugural Dan W. Thomas Keynote Lecture, “Mitochondrial Hepatopathies: Recognition and Management”. SoCal Pediatric Gut Club 2021 Program, Children’s Hospital of Los Angeles, August 13, 2021, Virtual.
389. Invited Faculty Speaker. “WES Diagnosis Challenges in Neonatal Liver Failure”. The Third Annual Pediatric Liver Disease and Transplantation Symposium: Advanced Management of Acute Liver Failure. Columbia University, New York, December 11, 2021, Virtual.
390. Invited Speaker, “Neonatal jaundice– Early Recognition is The Key!” Liver Disease in Infants and Children Symposium. Pediatric Academic Societies 2022 Annual Meeting Denver Colorado, April 24, 2022
391. Invited Speaker, “Introduction to the ChiLDReN Network”, 2022 PFIC Network Scientific Conference, Pittsburgh, PA, April 29, 2022, Virtual.
392. Invited speaker: “Wilson disease – diagnosis and treatment”, May 31, 2022, 4th Year Pediatric Liver Transplant Fellow Lecture Series, Society for Pediatric Liver Transplantation (SPLIT), Virtual.
393. Visiting Professor, “Intestinal Failure Associated Liver Disease – the Gut – Lipid – Liver Axis”, Pediatric GI Annual Fellowship Symposium, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of California San Francisco, June 2-4, 2022, San Francisco, CA
394. Keynote Lecture and Faculty: “Neonatal cholestasis and biliary atresia: challenges for the 21st century”, Biliary Atresia and Related Diseases (BARD-Bruges) Second International and Interdisciplinary Congress. Bruges, Belgium June 17-18, 2022.
395. Keynote Address, Taiwan Liver Foundation Lecture: “Parenteral Nutrition Associated Liver Disease - From Understanding the Disease Mechanism and Role of the Gut-Lipid-Liver Axis to Improved Patient Management”,Taiwan Society for Pediatric Gastroenterology, Hepatology and Nutrition (TSPGHAN) Annual Meeting, Taipei, Taiwan. September 3, 2022.
396. Invited speaker: “Wilson disease – diagnosis and treatment”, October 18, 2022, 4th Year Pediatric Liver Transplant Fellow Lecture Series, Society for Pediatric Liver Transplantation (SPLIT), Virtual.
397. Invited speaker: “Peroxisomal diseases and bile acid synthesis disorders”, February 28, 2023, 4th Year Pediatric Liver Transplant Fellow Lecture Series, Society for Pediatric Liver Transplantation (SPLIT), Virtual.
398. Invited Chair and Moderator: “Genetic Liver Disease: a New Perspective”. Pediatric Academic Societies 2023 Annual Meeting, Washington D.C., April 29, 2023.
399. Invited Keynote Speaker, “How to have a fulfilling and fun career in pediatric research”, Resident Research Day, University of Colorado Department of Pediatrics and Children’s Hospital Colorado, Aurora, Colorado, June 2, 2023.
400. Invited Speaker, “The Scope of Biliary Atresia Translational Research”, Symposium on Biliary Atresia: Controversies, Insights, Treatments, Health Sciences and Research Building, Emory University, Atlanta, Giorgia. June 12, 2023.
401. Invited Faculty Speaker, “Intestinal failure associated liver disease (IFALD) – acute and chronic phases – prevention vs. therapy?”, 45th Annual Aspen Conference on Pediatric Gastrointestinal Disease – Advances in Pediatric Liver Disease and Liver Transplantation. Snowmass Village, Colorado, July 10, 2023.
402. Invited Faculty Speaker, “Mitochondrial Hepatopathies: diagnosis, biomarkers and therapies, including liver transplantation”, 45th Annual Aspen Conference on Pediatric Gastrointestinal Disease – Advances in Pediatric Liver Disease and Liver Transplantation. Snowmass Village, Colorado, July 13, 2023.
403. Invited Faculty Speaker, “Post-Transplant Lymphoproliferative Disease – prevention and treatment?”, 45th Annual Aspen Conference on Pediatric Gastrointestinal Disease – Advances in Pediatric Liver Disease and Liver Transplantation. Snowmass Village, Colorado, July 14, 2023.
404. **TEACHING RECORD**

**A. WARD/CLINIC ATTENDING DUTIES**

1983-present: Supervision and bedside teaching of fellows, residents and medical students, outpatient pediatric gastroenterology and liver clinic, 4-12 hours per week, University of Colorado Hospital and Children’s Hospital Colorado, Aurora, CO

1983-present: Supervision and bedside teaching of fellows, residents and medical students, inpatient pediatric GI and Liver Service, 4-12 weeks per year, Children’s Hospital Colorado, Aurora, CO

**B. KEY ADMINISTRATIVE POSITIONS**

1. Fellowship Program Director, Pediatric Gastroenterology, Hepatology and Nutrition Training Program, University of Colorado Denver School of Medicine, Department of Pediatrics, 1993-2004
2. Course co-organizer, Transplant Hepatology Certificate of Added Qualification (CAQ) Review Course, American Association for the Study of Liver Disease, NASPGHAN, American Soceity of Transplatnation, ILTS, Sept. 16-17, 2006, Chicago, IL.
3. Principal Investigator, NIH T32 Training Grant in Pediatric Gastroenterology, 2005- present.
4. Pediatric Gastroenterology and Hepatology Fellowship Oversight Committee, 2007- present

**C. UNDERGRADUATE AND GRADUATE COURSE TEACHING:**

1. 1983-present. "Pediatric Gastrointestinal Diseases", *Junior Medical Students Lecture Series*, University of Colorado Denver School of Medicine.
2. 1990-2005. Principles of Nutrition Course for freshmen medical students, *University of Colorado School of Medicine.* "Fat‑soluble vitamins", "Antioxidants and Vitamin E deficiency in man".
3. 1999-2008. Clinical Sciences Graduate Program - CLSC 7300 course, Course Co-Director: “General Clinical Research Center (GCRC) Scientific Advisory Committee Review Process”, *University of Colorado Denver, Ph.D. Program in Clinical Sciences*, winter quarter, 1999; summer quarter, 2000; winter quarter, 2000; summer quarter, 2001; winter quarter 2001; winter quarter, 2002; winter quarter 2003, winter quarter 2004, second semester 2005, second semester 2006, second semester 2007, second semester 2008.
4. 1999-2005. Clinical Sciences Graduate Program - CLSC 6500 course: “Topics in Pediatric Research”, *University of Colorado Denver, Ph.D. Program in Clinical Sciences*, winter quarter, 1999-00; summer quarter, 2000-01; winter quarter, 2001-02, winter quarter 2002-03; winter quarter, 2003-4, winter quarter 2004-5.
5. 2004-2008. Clinical Sciences Graduate Program Intensive Course Series – Topics in Research Methods, “General Clinical Research Center Research Opportunities”, *University of Colorado Denver, Ph.D. Program in Clinical Sciences*, Denver, CO
6. 2005-2008. Clinical Sciences Graduate Program, CLSC 7101 – Grant Writing I and CLSC 7102 – Grant Writing II, *University of Colorado Denver, Ph.D. Program in Clinical Sciences*, Denver, CO.
7. 2004-2009. Clinical Sciences Graduate Program, CRTP 6503 course, *University of Colorado Denver, Ph.D. Program in Clinical Sciences*, Denver, CO

**D. LOCAL LECTURES AND TEACHING:**

1. "Acute Diarrhea", "Total Parenteral Nutrition", "Hepatitis", "Chronic Diarrhea", "Total Parenteral Nutrition in the Neonate", "Neonatal Cholestasis". *Pediatric Housestaff Core Lectures, UCSHC*, 1983‑1996.
2. "Reye Syndrome ‑ Current Controversies", *Pediatric Grand Rounds*, *UCHSC*, December 16, 1983.
3. "Chronic Diarrhea in Childhood", 1984, "Chronic Diarrhea in Childhood". *Family Practice Review Course*, UCHSC, 1983.
4. "Development of GI Function". *CHCO Newborn Fellows*, January, 1984.
5. "Congenital Anomalies of GI Tract", January 23, 1986, "Congenital Anomalies of GI Tract". *Genetic Health Associate Program*, February 16, 1984.
6. "GI Emergencies", October 21, 1986, "Diarrhea‑‑a Rational Approach to Therapy". *CHAP Lecture Series,* February 16, 1984.
7. "Neonatal Cholestasis and Alagille Syndrome". *Tri‑County Clinic ‑‑ Sheridan Branch, Lecture to Staff***,** June 14, 1984.
8. "Vitamin E Deficiency in Children". *Department of Pediatrics, Lutheran Medical Center*, July 3, 1984.
9. "Alagille Syndrome". *Department of Nursing, Staff Inservice*, July, 1984.
10. "Professor's Rounds". *Junior Medical Students*, August 24, 1984.
11. "Acute Diarrhea", *Child Health Associate Program Lecture*, September 11, 1984, October 5, 1985, January 11, 1987, January, 1988.
12. "Introduction to Clinical Medicine Preclerkship". Sophomore Medical Students, May, 1984.
13. *City‑wide Gastroenterology Conference*, 1983, "Vitamin E Deficiency"; 1984, "Wegener's Granulomatous Colitis"; 1985, "Wilson's Disease"; 1986, "Recurrent Pseudomembranous Colitis".
14. "Total Parenteral Nutrition in Pediatrics". *Fitzsimmons Army Hospital Pediatric Housestaff Lecture*, January, 1985.
15. "Abdominal Examination", Sophomore Medical Students, February, 1985, 1986, 1987, ‑‑ Preceptor.
16. "Pediatric Gastrointestinal Diseases", *Sophomore Medical Student Clinical Pathophysiology Course***,** March, 1985, March, 1986.
17. "Acute Hepatitis”, *Child Health Associate Program*, Denver, Colorado, April 8, 1986.
18. "Use and Abuse of Vitamin E in Pediatrics". *Pediatric Grand Rounds*, University Hospital, Denver, Colorado, April 11, 1986.
19. "Total Parenteral Nutrition in Pediatrics", "Hepatitis". *Fitzsimmons Army Hospital, Department of Pediatrics*, Denver, Colorado, 1988.
20. "Mitochondrial Oxidant Injury in Copper Hepatotoxicity". *University of Colorado Health Sciences Center, Hepatobiliary Center Retreat*, September 9, 1988.
21. "Stable Isotope Studies in Patients with Isolated Vitamin E Deficiency Syndrome". *University of Colorado Health Sciences Center, Neurology Grand Rounds*, December 7, 1988.
22. "Fat ­soluble vitamins". *University of Colorado Health Sciences Center, Principles of Nutrition Course for Freshman Medical Students*, January, 1989, February, 1990. February, 1991.
23. "Pediatric Liver Transplantation ‑‑ What's New in 1989". *University of Colorado Health Sciences Center, Pediatric Grand Rounds*, March 17, 1989,
24. "Advances in Treating Childhood Liver Diseases". *American Liver Foundation, Rocky Mountain Chapter‑‑Meet the Researchers*, April 1, 1989, Denver, Colorado.
25. "Cyanosis of Cirrhosis". *Citywide Gastroenterology Conference*, April 7, 1989, Denver, Colorado.
26. "A cherubic child with mega hepatomegaly. Glycogen Storage Disease Type III". *Citywide Gastroenterology Conference*, March 2, 1990, Denver, Colorado.
27. "An Update on Hepatitis (A‑E)". *Office Pediatrics Update*, Children’s Hospital Colorado, Denver, Colorado, February 28, 1991.
28. "Update on Hepatitis*". Fitzsimmons Army Medical Center*, April 30, 1991, Denver, Colorado
29. "Vitamin E Metabolism". *GI Physiology/Nutrition and Metabolism Course*, May 6, 1991, Denver, Colorado.
30. "Alphabet Soup of Hepatitis Viruses". *Little Kids: Big Problems conference*. Hyatt Regency Hotel, June 21, 1991, Denver, Colorado.
31. "CPC ‑ an adolescent with liver failure and cerebral edema". *Pediatric Grand Rounds*, Children’s Hospital Colorado, Denver, Colorado, January 3, 1992.
32. "Free radical mechanisms in hepatic copper overload and cholestasis." *Webb‑Waring Lung Institute Research Conference.*  February 24, 1992, UCHSC.
33. “Bile Acids and the Liver in the Newborn: The Good, the Bad, and the Ugly." *Developmental Biology Seminar Series.*  March 12, 1992, UCHSC.
34. "Free radical generation in the pathogenesis of cholestatic liver disease." *UCHSC Hepatobiliary Research Center conference*. March 19, 1992.
35. "Colon Cancer in Children". *Citywide Gastroenterology Conference*, Denver, Colorado. September 5, 1992.
36. "Free radical mechanisms in cholestatic liver injury". *UCHSC Hepatobiliary Research Center Retreat*. September 18, 1992, Florissant, Colorado.
37. "Therapy for severe gastroesophageal reflux in neonates: A debate on Nissen, Thal, and Medical Management". *Perinatal Education Conference*, Children’s Hospital Colorado, Denver, Colorado, November 24, 1992.
38. "Fat-Soluble Vitamins". *GI Physiology Lecture Series*. Division of Gastroenterology, Department of Medicine: UCHSC, June 11, 1993.
39. "Update on the Hepatitis Viruses". *Department of Pathology clinical update*, Children’s Hospital Colorado, November 8, 1994.
40. “Do antioxidants reduce cholestatic liver injury?” *UCHSC Hepatobiliary Research Center Advance*, September 22-24, 1995, Florissant, Colorado.
41. "Blue genes and yellow eyes in an adolescent." *Citywide Gastroenterology Grand Rounds*, September 6, 1996, UCHSC, Denver Colorado.
42. "Diagnosis and management of fulminant hepatic failure in children." *Pediatric Critical Care Fellows lecture*, June 10. 1997, Children’s Hospital Colorado, Denver, Colorado.
43. "Hepatitis C viral infection in childhood: diagnosis, natural history and treatment." *Pediatric Hematology/ Oncology Conference*, July 17, 1997, Children’s Hospital Colorado, Denver, Colorado.
44. “Oxidative stress and liver injury." *Pediatric Gastroenterology/Pediatric Surgery Conference*, July 21, 1997, Children’s Hospital Colorado, Denver, Colorado.
45. “Neonatal hydrops and metabolic liver disease.” *Neonatology Seminar*, October 16, 1997, Children’s Hospital Colorado, Denver, Colorado.
46. “Bile acid synthesis defects”, *Pediatric Gastroenterology/Hepatology/Nutrition Topic Conference*, February 3, 1998, Children’s Hospital Colorado, Denver, Colorado.
47. “Reovirus and the etiology of biliary atresia.” *Pediatric Surgery/GI Conference*, March 16, 1998, Children’s Hospital Colorado, Denver, Colorado.
48. “Use of Magnetic Resonance cholangiography in pediatrics.” *Pediatric Surgery/GI Conference*, August 17, 1999, Children’s Hospital Colorado, Denver, Colorado.
49. “Neonatal cholestasis - the jaundiced infant”. *Colorado Kaiser Permanente Group pediatric conference*, November, 19, 1998, Denver, Colorado.
50. "Antioxidants and mitochondrial injury in cholestasis." *Center for Human Nutrition Weekly Seminar*, University of Colorado Health Sciences Center, February 29, 1999, Denver, Colorado.
51. "Shwachman syndrome - new developments." *Topic Conference, Pediatric GI/Hepatology/Nutrition Section*, August 4, 1999, Children’s Hospital Colorado, Denver, Colorado
52. "The pathogenesis of liver injury in cholestasis - or - hepatocytes under the influence of bile acids." *Department of Pediatrics Research Conference*, February 15, 2000, UCHSC, Denver, Colorado.
53. "Etiology of biliary atresia", *Pediatric GI Topic Conference*, May 2, 2000, Children’s Hospital Colorado, Denver.
54. "Reye's syndrome - 2000", *Pediatric GI Topic Conference*, May 9, 2000, Children’s Hospital Colorado, Denver, CO.
55. "Oxidative stress and cholestatic liver injury - from the mitochondria to the bedside." *Adult GI Research Conference*, Dept. of Medicine, June 23, 2000, University of Colorado Health Sciences Center, Denver, CO.
56. “Liver disease in Cystic fibrosis,” *UCSHC Pediatric Pulmonology weekly conference*, September 14, 2000, National Jewish Hospital, Denver, CO.
57. “New developments in biliary atresia”, *The 2000 American Liver Foundation Pediatric Liver Update,* September 23, 2000, Denver, CO.
58. “Biologic and Clinical Roles of Antioxidants in Human Health”, *Pediatric Grand Rounds*, Children’s Hospital Colorado and UCHSC, March 23, 2001, Denver, CO.
59. “Scarring in the liver in childhood liver diseases”, *The 2001 American Liver Foundation Pediatric Liver Update,* September 28, 2000, Denver, CO.
60. “NIH Research Opportunities and the Pediatric GCRC at Children’s Hospital Colorado,” *Special Lecture*, Children’s Hospital Colorado, April 117, 2002, Denver, CO.
61. “Post transplantation lymphoproliferative disease – a persisting threat.” *Pediatric GI Topic Conference*, October 3, 2002, Children’s Hospital Colorado, Denver, CO.
62. “Advances in biliary atresia – 3000 years and counting…”, *Pediatric Grand Rounds*, Children’s Hospital Colorado and UCHSC, October 4, 2002, Denver, CO.
63. “Getting involved in clinical research during your academic career: Advice for clinicians and bench researchers”, Junior Faculty Interest Group, Department of Pediatrics, UCHSC, March 10, 2003.
64. “Research opportunities in the Pediatric GCRC for Junior Faculty”. Junior Faculty Retreat, Department of Pediatrics, University of Colorado School of Medicine, April, 2004, Denver, CO.
65. “Pediatric GCRC and Research Support”. Retreat for Fellows, Children’s Hospital Colorado, October 7, 2004, Denver, CO
66. “New directions in research of childhood liver diseases”. Pediatric Liver Update, American Liver Foundation, October 9, 2004, Denver, CO
67. “Research Opportunities at Children’s Hospital Colorado.” Department of Surgery Research Retreat, University of Colorado School of Medicine, August 27, 2005, UCDHSC Fitzsimmons campus, Denver, CO
68. “Overview of current research in pediatric liver disease”, Pediatric Liver Update, American Liver Foundation, October 8, 2005, Children’s Hospital Colorado, Denver, CO.
69. “NIH Roadmap and Future of Clinical Research”, University of Colorado School of Medicine Dept. of Pediatrics Junior Faculty Retreat, November 7, 2005, Denver, Colorado
70. “University of Colorado CTSA Application: Colorado Clinical Translational Sciences Institute”. Colorado BioScience Association meeting, University of Colorado Denver, January 23, 2007
71. “Wilson disease – coping with copper”. GI Grand Rounds, UC Denver, May 30, 2008
72. “Overview of the CCTSI”, Nineteenth Annual New Faculty Career Development Workshop, University of Colorado School of Medicine, Feb. 2, 2012
73. “Town Hall meetings – Updates on the CCTSI”. Annual meetings at CU Anschutz from 2009-2022.
74. “Using a mouse model of PNAC to drive new therapiers for the future”. Fall 2022 Digestive Health Institute Research Symposium, Children’s Hospital Colorado, September 15, 2022.

**E. TRAINEES AND MENTEES**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Fellow/Trainee** | **Training Period** | **Source of Funding** | **Research Project** | **Current Position** |
| Michael Narkewicz, MD | 1986-89 | Children’s Hospital Colorado (CHCO) | Fetal glucose and protein metabolism  | Professor of Pediatrics, University of Colorado School of Medicine, Aurora, CO |
| Rebecca Occena, MD | 1990-1993 | CHCO | Manometry in GERDAssessing Vitamin A status in cholestasis | Private Practice, Wilmington, Delaware |
| Nancy Krebs, MD | 1990-1993 | Pew Foundation | Zinc metabolism in CF and in preterm infants | Professor of Pediatrics, Division Director, University of Colorado School of Medicine, Aurora, Colorado |
| David Easley, MD | 1992-1995 | CHCO | Zinc absorption in CF | Associate Professor, Texas A&M SOM |
| Brigitte Winklhoefer-Roob, MD | 1993-1995 | Max Kade Foundation | Oxidative stress and bile acid toxicity | Professor of Medicine, University of Graz, Austria |
| K. Shivaram, MD | 1993-1995 | CHCO | Vitamin A metabolism in liver disease and CF | Private Practice, Illinois |
| W. Stokes Houck, MD | 1884-1997 | Cystic Fibrosis Foundation (CFF), NIH T32 | Hepatic injury in rat model of TPN related liver disease | Associate Clinical Professor, Carolina Medical Center, Charlotte, NC |
| Andrew Feranchak, MD | 1995-1999 | CFF, NIH T32 | Ion channels regulation in cholangiocytes | Professor of Pediatrics, Division Director, University of Pittsburgh School of Medicine  |
| Henry Thompson, MD | 1996-1999 | CFF, NIH T32 | Fetal Hepatic folate metabolism | Practice, Boise Idaho and Asst. Clinical Professor, Univ. of Utah SOM |
| Baruch Yerushalmi, MD | 1997-2000 | CFF, American Liver Foundation | Hepatocyte apoptosis and bile acid toxicity | Head, Pediatric Gastroenterology Unit, Ben-Gurion University of the Negev, Beersheba, Israel |
| Eric Gumpricht, PhD | 1997-2003 | NIH Nutrition T32 | Role of glutathione in cholestatic liver injury | Scientist at ISAGENIX International |
| Robert Kramer, MD | 1998-2001 | CFF, NIH T32 | Fatty acid metabolism in rodent models of obesity | Professor of Pediatrics, University of Colorado School of Medicine, Aurora, CO |
| Edwin Liu, MD | 1999-2002 | CHCO, CFF | Immune mechanisms in celiac disease | Professor of Pediatrics, University of Colorado School of Medicine, Aurora, CO |
| Gregory Kobak, MD | 2000-2003 | CFF | Mechanisms of liver injury in steatocholestasis | Senior Instructor of Pediatrics, University of Colorado School of Medicine, Aurora, CO |
| Elizabeth Utterson, MD | 2002-2003 | CFF | Clinical Year | Associate Professor of Pediatrics, Washington University School of Medicine, St. Louis, MO |
| Jason Soden, MD | 2003-2006 | CFF, NIH T32 | Mechanisms of apoptosis in steatocholestasis | Professor of Clinical Pediatrics, University of Colorado School of Medicine, Aurora, CO |
| John Whitworth, MD | 2003-2006 | NIH T32 | Pulmonary vascular complications of portal hypertension | Associate Professor, University of Tennessee Health Science Center, Memphis, TN |
| Barrett Barnes, MD | 2004-2007 | CFF, NIH T32 | Cholangiocytes as antigen presenting cells | Associate Professor of Pediatrics, University of Virginia SOM, Charlottesville, VA |
| Jane Keng, MD | 2004-2007 | CHCO, NIH T32 | Insulin resistance and fatty liver in the fetus | Practice, Fort Worth, TX |
| Karina Irizarry, MD | 2005-2008 | CFF, NIH T32 | Hypoxic injury and inflammation in the intestine | Practice, Tampa-St. Petersburg, FL |
| Vince Mukkada, MD,  | 2005-2009 | CFF, NIH T32 | Regulation of intestinal permeability and the Eosinophil | Associate Professor of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio |
| Brandy Lu, MD | 2006-2009 | CFF, NIH T32 | Humoral autoimmunity in mouse model of biliary atresia | Deceased(Assistant Professor of Pediatrics, University of California San Francisco Medical Center, San Francisco, CA) |
| Samantha Woodruff, MD | 2006-2009 | CHCO, NIH T32 | Eosinophilic esophagitis and non-invasive sampling of the esophagus | Associate Professor of Clinical Pediatrics, Univ. of Colorado School of Medicine, Aurora Colorado  |
| David Brumbaugh, MD | 2007-2010 | CFF, NIH T32 | Fetal programming of insulin resistance and fatty liver in human infants | Associate Professor of Pediatrics, University of Colorado School of Medicine, Aurora, CO  |
| Christine Waasdorp, MD | 2007-2010 | CHCO, NIH T32 | Immunologic regulation of Hepatitis C Virus vertical transmission | Associate Professor of Pediatrics, University of Colorado School of Medicine, Aurora, CO  |
| Steven Colson, MD, MSCS | 2008-2011 | CHCO, NIH T32 | Hypoxia and inflammation in inflammatory bowel disease | Clinical Asst. Professor of Pediatrics, Oregon Health Sciences University, Portand, Oregon |
| Jillian Sullivan, MD | 2008-2011 | NIH T32, CFF | Role of fructose and uric acid metabolism in childhood NASH and NAFLD | Associate Professor of Pediatrics, University of Vermont School of Medicine, Burlington, VT |
| Shawna Schroeder, MD | 2009-2012 | NIH T32 | Mechanisms of bacterial protection in eosinophilic esophagitis  | Associate Professor of Pediatrics, Phoenix Children’s Hospital, AZ  |
| Thomas Flass, MD, MS | 2009-2012 | NIH T32, CFF | Role of intestinal micriobiome in Cystic Fibrosis Liver Disease | Private Practice in Pediatric GI, Montana (2012) |
| Amy Feldman, MD | 2010-2013 | NIH T32 | Role of B-cells in pathogenesis of mouse model of biliary atresia | Associate Professor of Pediatrics, University of Colorado School of Medicine, Aurora, CO  |
| Pamela Puthoor, MD | 2011-2014 | NIH T32 | Epigenetic regulation of Regulatory T-cells in mouse model of inflammatory bowel disease | Practice, MNGI Digestive Health, Children’s Hospital of Minnesota, Minneapolis, MN  |
| Sarah Kinder, MD | 2011-2014 | CHCO Funds | Nutritional modulation of fecal microbiome in inflammatory bowel disease | Senior Instructor, University of Colorado School of Medicine, Aurora, CO  |
| Padade Vue, MD | 2011-2014 | NIH T32 | Immune pathogenesis of parenteral nutrition associated liver disease in a mouse model | Sr. Instructor, University of Colorado School of Medicine, Aurora, CO |
| Shahan Fernando, MD | 2012-2015 | NIH T32 | Eosinophils and esophageal fibrosis | Assistant Professor of Pediatrics, Phoenix Children’s Hospital, Arizona  |
| Mary Boruta, MD | 2012-2015 | NIH T32, CFF | Molecular regulation of colonic motility genes in chronic constipation | Assistant Professor of Pediatrics, Duke University Hospital, Durham, NC  |
| Melissa Sheiko, MD | 2012-2015 | NIH T32 | Immune control of vertical transmission of Hepatitis C Virus | Private Practice in Pediatric GI, Portland, Oregon  |
| Gillian Noel, MD | 2013-2016 | NIH T32 | Multiple resistant infections in transplant patients | Assistant Professor, Duke University Hospital, Durham, NC |
| Pooja Mehta, MD | 2013-2016 | NIH T32, CFF | Behavioral aspects and treatment adherence in pediatric Eosinophilic Esophagitis | Assistant Professor, University of Colorado School of Medicine, Aurora, CO  |
| Shelly Rustagi, MD | 2013-2016 | CHCO Funds | Intestinal stem cell development during inflammation | Assistant Professor, Wright State University, Dayton Children’s Hospital, Dayton, OH  |
| Nathalie Nguyen, MD | 2014-2017 | NIH T32 | Barrier Function and Eosinophilic Esophagitis | Assistant Professor, University of Colorado School of Medicine, Aurora, CO  |
| Kristina Leinwand, DO | 2014-2017 | NIH T32 | Role of intestinal cannabis receptors in colon inflammation | Assistant Professor of Pediatrics, Oregon Health Sciences University, Portland, OR |
| Dania Molla-Hosseini, MD | 2014-2017 | CFF, CHCO Funds | Analysis of autoantibodies in Biliary Atresia using novel autoantibody microarray | Assistant Professor of Pediatrics, University of Colorado School of Medicine, Aurora, CO  |
| Keith Hazleton, MD, PhD | 2015-2018 | NIH T32, CFF | Microbiome in cystic fibrosis, mechanisms of C. difficile colonization | Assistant Professor, University of Arizona, Tucson, AZ |
| Caroline Hall, MD, PhD | 2015-2019 | NIH T32 | Creatine transport and role in the small intestine | Assistant Professor, University of Colorado School of Medicine, Aurora, CO |
| Jacob Mark, MD | 2015-2018 | CHCO Funds | Endoscopy training metrics, chronic pancreatitis | Assistant Professor, University of Colorado School of Medicine, Aurora, CO |
| Alexandra Kilgore, MD | 2016-2019 | NIH T32 | Role of NK cells in cholestatic liver disease | Assistant Professor, University of Colorado School of Medicine, Aurora, CO |
| Marisa Gallant-Stahl, MD, MSCS | 2016-2019 | NIH T32 | Regional variation in incidence of Celiac Disease | Assistant Professor, University of Colorado School of Medicine, Aurora, CO |
| Lindsey Gumer, MD | 2016-2019 | CHCO Funds | T cell function in inflammatory bowel disease | Assistant Professor, University of Colorado School of Medicine, Aurora, CO |

1. **GRANT SUPPORT**
2. **NATIONAL INSTITUTES OF HEALTH GRANT AWARDS:**

**ACTIVE GRANTS:**

2021-2025 ***“NIH RECOVER: A Multi-site Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults”.*** Mountain States Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Consortium. NIH-NHLBI, 0T2HL161847-01. MPI - Ronald J. Sokol, Kristine Erlandson, and others. Total costs for Colorado budget, 5 years: $7,907,456

2021-2022 ***“Community Engagement Research Alliance (CEAL) Against COVID-19 Disparities”.*** NIH NHLBI Non-Federal 1OT2HL156812-01. MPI - Ronald J. Sokol MD, Donald Nease, MD, Ricardo Gonzalez-Fisher, MD. Total costs, first 6 months: $685,129.

2021-2023 ***“Implementation and Real-World Effectiveness of Monoclonal Antibodies to Treat High-Risk Outpatients with COVID-19”*.** NIH-NCATS, MPI - Ronald J. Sokol, MD, Adit Ginde MD. UL1 TR002535-03S3 and UL1 TR002535-04S2, Total costs year 1: $5,449,454, Direct Costs year 1: $3,504,472. Total Costs 2 years: $8,699,359

2020-2025 ***“Institutional Training Grant in Pediatric Gastroenterology****”*, NIH-NIDDK 1 T32 DK067009-16, PI – Ronald J. Sokol, M.D., Cara Mack, M.D., Direct Costs year 1 $404,262, Total Costs year 1 $432,894, Total Direct Costs 5 years 1,808,905, Total Costs 5 years $1,928,845.

2018-2023 ***“Colorado Clinical and Translational Sciences Institute”,*** NIH-NCATS, PI - Ronald J. Sokol, MD, UL1 TR002535, Total costs year 1: $7,881,024, Direct Costs year 1: $5,829,717; Total costs 5 years: $42,117,516 on No Cost Extension

2020-2021***“Colorado Clinical and Translational Sciences Institute”,* CCTSI Participation in the National COVID Cohort Collaborative (N3C),** Administrative Supplement, NIH-NCATS, PI - Ronald J. Sokol, MD, UL1 TR002535-03S2, Total costs year 1: $99,812, Direct Costs year 1: $64,188.

2018-2023 ***“Institutional Career Development Core - Colorado Clinical and Translational Sciences Institute”,*** NIH-NCATS, PI - Ellen Burnham, MD, Co-PI - Ronald J. Sokol, MD, NIH-NCATS, KL2 TR002534, Total costs year 1: $910,310, Direct Costs year 1: $842,880; Total costs 5 years: $4,551,550 on No Cost Extension

2020-2023 **“*Celiac disease signatures in Down syndrome (KL2 Admin Suppl”), “Institutional Career Development Core - Colorado Clinical and Translational Sciences Institute****”,* NIH-NCATS, PI - Ellen Burnham, MD, Co-PI - Ronald J. Sokol, MD, NIH-NCATS, KL2 TR002534-03S1, Total costs year 1: $140,430, Direct Costs year 1: $130,028; Total costs 3 years: $421,290

2019-2020 ***“Colorado Clinical and Translational Sciences Institute”,* INCLUDE Administrative Supplement**, NIH-NCATS, PI - Ronald J. Sokol, MD, UL1 TR002535-02S1, Total costs year 1: $775,742, Direct Costs year 1: $498,870.

2018-2023 ***“NRSA Training Program - Colorado Clinical and Translational Sciences Institute”,*** NIH-NCATS, PI - Lisa Cicutto, PhD, Co-PI – Ronald J. Sokol, MD; NIH-NCATS, TL1 TR002533, Total costs year 1: $558,236, Direct Costs year 1: $537,507; Total costs 5 years: $2,783,180 on No Cost Extension

2016-2022 **“*Colorado Center of Childhood Liver Disease Research Network - Acceleration Supplement”*,** NIH-NIDDK, U01DK062453-16S1, PI - Ronald J. Sokol, MD, Direct costs year 14: $37,875, Total costs year 14: $44,375. On N o Cost Extension

2008-2024 **“*Longitudinal Study of Cystic Fibrosis Liver Disease”,***Cystic Fibrosis Foundation and NIDDK, CFF NARKEW17AB0, PI- Michael Narkewicz, Co-Investigator – Ronald J. Sokol, MD, Total Costs current year, $1,097,000.

2019-2024 **“*Colorado Center of Childhood Liver Disease Research Network”*,** NIH-NIDDK, U01DK062453, PI - Ronald J. Sokol, MD, Direct costs year 20: $515,700, Total costs year 20: $631,501. Total Costs 5 years: $2,553,421.

2019-2024 **“*Colorado Center of Childhood Liver Disease Research Network”*,** NIH-NIDDK, 3U01DK062453-18S1, PI - Ronald J. Sokol, MD, Direct costs year 19: $228,081, Total costs year 19: $228,081

2019-2024 **“*Colorado Center of Childhood Liver Disease Research Network”*,** NIH-NIDDK, 3U01DK062453-18S2, PI - Ronald J. Sokol, MD, Direct costs year 18: $129,131, Total costs year 18: $136,164.

2019-2024 **“*Colorado Center of Childhood Liver Disease Research Network”*, Translational Science Acceleration Supplement**, NIH-NIDDK, 3U01DK062453-19S1, PI - Ronald J. Sokol, MD, Direct costs: $311,177, Total costs: $381,388.

2020-2023 ***“Colorado Clinical and Translational Sciences Institute”,* NIH Prior Approval Process Professional Administrative Supplement**, NIH-NCATS, PI - Ronald J. Sokol, MD, UL1 TR002535-03S1, Total costs year 1: $91,829, Direct Costs year 1: $59,054, Total costs 3 years: $322,233, Direct Costs 3 years: $207,224. On no cost extension.

2023-2030 ***“Colorado Clinical and Translational Sciences Institute”,*** NIH-NCATS, PI - Ronald J. Sokol, MD, MPI -Janine Higgins, PhD, A1 grant submission, UM1 TR004399, Total costs 7 years: $53,587,303. Priority score 22, funding decision pending.

**COMPLETED GRANTS (NIH):**

1982 *Postdoctoral Research Fellowship* ‑ Lipids-Atherosclerosis‑Nutrition T32 Training Program, National Institute of Heart, Lung and Blood, NIH HL‑07460 - $17,000.

1983 *“Vitamin E and hepatocyte transport in copper toxicity,”* Biomedical Research Grant Program, Division of Research Resources, NIH, BSRG‑05357 ‑ $12,000.

1986‑1987 *"Copper, Vitamin E, and Hepatic Injury",* NIH Hepatobiliary Research Center, NIH 1P30-DK34914, Pilot Feasibility Project Grant, total direct costs: $30,630.

* 1. *"Effect of Vitamin E on Hepatocyte Structure and Function."* NIH F.I.R.S.T. Award (PI), R29-DK 38446-01; total direct costs $350,000.
	2. *"Oxidant hepatic injury in cholestasis."* NIH R01‑DK38446‑06 (PI), direct costs year one: $127,930; total direct costs: $395,103.

1996-2000 *“Genetic and environmental causes of celiac disease”.* NIH R01-DK50979-01, PI - Marian Rewers, M.D.; Co-investigator- Ronald J. Sokol, MD. Direct costs year one: $111,900.

1997-2001 *"Oxidant hepatic injury in cholestasis".* NIH R01-DK38446-09 (PI), direct costs year one: $180,090 total direct costs: $716,290; total costs: $1,066,612.

1997-2001 *"Nutritional etiology of prediabetic autoimmunity".* NIH R01-DK49654-01, PI - Jill Norris, Co-investigator- Ronald J. Sokol, MD: direct costs year one: $207,614, total costs $2,008,009.

1997-1999 *“The pathogenesis of neonatal cholestatic liver disease”.* NIH R03-DK53754, PI - Lela Lee, Co-investigator- Ronald J. Sokol, MD. Direct costs year one $47,929, total costs $147,642.

* 1. *“Pediatric General Clinical Research Center”*, UCHSC, NIH 5M01 RR00069-34. Program Director - Ronald J. Sokol, M.D., PI - Richard Krugman, M.D. Direct costs year 5: $1,724,227. Total Direct Costs 5 yrs.: $8,815,096.

2000 *"NASPGN-World Congress of Pediatric Gastroenterology",* NIH R13-DK58427, PI- Harland Winter, M.D., RJ Sokol - Co-investigator. $40,000 direct costs.

* 1. *“A multi-center group to study acute liver failure”.* NIH R01-DK58369, PI - William Lee, M.D., Local PI - Ronald J. Sokol. Direct costs year one $365,505, Direct costs 5 yrs. $1,680,882, Total costs 5 yrs. $2,278,420.

2001-2006 *“Pediatric General Clinical Research Center”*, UCHSC, NIH 5M01 RR00069-41. Program Director - Ronald J. Sokol, M.D., PI- Richard Krugman, M.D., Total Costs, year 5: $3,593,007, Total Direct Costs 5 yrs.: $15,354,549, Total costs 5 yrs.: $16,884,197.

2001-2006 *“Oxidant hepatic injury in cholestasis”.* NIH R01-DK38446-13, PI – Ronald J. Sokol, MD. Direct costs year one $212,500, Total direct costs: $1,062,500, Total costs: $1,595,198

* 1. *"Nutritional etiology of prediabetic autoimmunity".* NIH R01-DK49654, PI - Jill Norris, Co-investigator- Ronald J. Sokol, MD. Direct costs year one: $207,614, total costs $2,008,009.
	2. *“Genetic and environmental causes of celiac disease”.* NIH R01 DK/AI50979-06, PI - Marian Rewers, M.D., Co-investigator- Ronald J. Sokol, MD. Direct costs year one: $188,000.

2004-2009 “*Studies in Pediatric Liver Transplantation*”. NIH 1 U01 DK061693-01A1. PI – Anne Lindblad, PhD, Local PI – Ronald J. Sokol, MD. Total costs year one: $940,000, total costs 5 years: $4,700,000

2002-2012 *“Etiology and treatment of biliary atresia and idiopathic neonatal hepatitis”.* NIH 1 UO1-DK062453, PI - Ronald J. Sokol, M.D. Direct costs year seven: $614,128; total costs year seven, $614,128; Total costs $1,761,366.

2005-2010 *“Institutional Training Grant - Pediatric Gastroenterology”*, NIH 1 T32 DK067009-01, PI – Ronald J. Sokol, M.D., Direct Costs year one $227,547, Total Costs year five $247,246, Total Costs 5 years $1,082,424.

2004-2012 “*Rare Liver Disease Network*”. NIH 1 U54 DK 078377, PI – Ronald J. Sokol, MD. Direct costs year five: $667,166; total costs year five: $750,000; total costs 5 years $3,750,000.

2005-2010 “*A Multi-Center Group to Study Acute Liver Failure in Children*,” U01 DK072146-01, PI – Robert Squires, MD, Local PI – Ronald J. Sokol, MD. Direct costs, year two $517,695, Total costs 5 years $5,814,254.

2005-2010 “*Functional Outcomes in Pediatric Liver Transplantation”,* NIH 1 R01 HD045694-01A1, PI – Estella Alonso, MD (Northwestern University), Local PI- Ronald J. Sokol, M.D, Direct Costs Year One: $421,088, Total Costs Year One: $537,910, Total Grant Costs (direct and indirect costs for 5 years): $2,247,040

2006-2008 *“Pediatric General Clinical Research Center”*, UCDHSC, NIH 5M01 RR00069-44. Program Director - Ronald J. Sokol, M.D., PI- Richard Krugman, M.D., Total Costs, year two: $3,652,468, Total costs 5 yrs.: $19,434,966

2009-2011 *“CTSA Administrative Supplement ARRA grants”,* UL1RR025780-02S1, -02S2, -02S3, -02S4, -02S5, -02S6, Total Costs of $3,405,690.

2010-2011 *Rare Liver Disease Network ARRA Supplemental Grant*, 3U54DK078377-05S1, Total Costs of $153,974.

* 1. “*Colorado Clinical and Translational Sciences Institute*”, NIH/NCRR(NCATS) UL1RR025780 (UL1TR000154), KL2RR025779 (KL2TR000156), TL1RR025778 (TL1TR000155). PI – Ronald J. Sokol, MD, Direct Costs year 1: $12,525,311, Total Costs year 1: $ 15,231,131, Total Costs 5 years: $76,155,655
1. *“Colorado Clinical and Translational Sciences Institute”,* NIH-NCATS, UL1TR000154- 05S1, KL2TR000156-05S1, TL1TR000155-05S1. PI – Ronald J. Sokol, MD, Direct Costs year 6: $5,243,175, Total Costs year 6: $ 6,827,535 Close out supplement.

2007-2013 *“Nutritional Etiology of Prediabetic Autoimmunity.”* NIH R01 DK049654. PI - Jill Norris, Co-investigator- Ronald J. Sokol, MD. Direct Costs, year 1: $391,108, Direct Cost 5 yrs.: $2,007,277.

2009-2014 *“Colorado Center for Childhood Liver Disease Research and Education*,” NIH 2U01DK062453-08. PI – Ronald J. Sokol, MD, Direct costs year 12: $957,725, Total Costs year 12 $964,258, Direct Costs 5 yrs.: $3,933,196, Total Costs 5 yrs.: $4,278,150

2010-2015 *“Institutional Training Grant in Pediatric Gastroenterology”*, NIH 1 T32 DK067009-06, PI – Ronald J. Sokol, M.D., Direct Costs year 1 $236,740, Total Costs year 1 $254,446, Total Costs 5 years $1,534,453.

* 1. *“Non-Alcoholic Fatty Liver Disease and Obstructive Sleep Apnea: Mechanistic Links Between Hypoxemia and Liver injury*”, NIH-NIDDK K23 DK085150, PI-Shikha Sundaram, MD, MSCI, Mentor- Ronald J. Sokol, MD, Direct costs year 2: $166,492 , Total costs year 2:$ 178,382 , Total costs 5 years: $891,910.

2014-2015 *“University of Pittsburgh Clinical and Translational Science Institute”*, NIH-NCATS UL1TR000005-09S1, PI- Steven Reis, MD, Co-PI- Ronald J. Sokol, MD, Direct Costs: $6,384,683, Total Costs: $6,883,047

2015-2017 *“Colorado Clinical and Translational Sciences Institute; i-Corps Pilot Program Supplement”,* 3UL1TR001082-03S1, PI- Ronald J. Sokol, MD, Direct Costs: 24,500, Total Costs $38,876

2013-2018 *“Colorado Clinical and Translational Sciences Institute”,* NIH-NCATS, UL1TR001082, TL1TR001081, KL2TR001080, PI-Ronald J. Sokol, MD, Total costs year 2: $12,564,000 Total Costs 5 years: $51,656,921

2014-2018 *“Colorado Clinical and Translational Sciences Institute”,* NIH-NCATS, UL1TR001082-02S1, PI-Ronald J. Sokol, MD, Total costs year 1:$116,165, Direct Costs year 1: $74,945

2018-2019 *“Colorado Clinical and Translational Sciences Institute” Administrative Supplement* “OnCore Expansion and Acceleration at the CCTSI”*,* NIH-NCATS, PI-Ronald Sokol, MD, NIH-NCATS, UL1 TR002535-01S1, Total costs year 1: $1,339,032, Direct Costs year 1: $861,114.

2014-2020 “*Colorado Center of Childhood Liver Disease Research Network”*, NIH-NIDDK, U01DK062453, PI-Ronald J. Sokol, MD, Direct costs year 13: $637,672, Total costs year 13: $696,784, Direct Costs 5 yrs: $1,758,212, Total Costs 5 years: $1,896,784.

2015-2020 *“Institutional Training Grant in Pediatric Gastroenterology”*, NIH 1 T32 DK067009-11, PI – Ronald J. Sokol, M.D., Cara Mack, M.D., Direct Costs year 1 $361,781, Total Costs year 1 $385,769, Total Direct Costs 5 years 1,808,905.00, Total Costs 5 years $1,928,845.

1. **OTHER GRANT SUPPORT:**

**ACTIVE GRANTS:**

2006-2024 Cholestatic Liver Disease Consortium/Childhood Liver Disease Research Network (ChiLDReN) support, Alpha One Foundation, total 5 yr. costs $550,000

**COMPLETED GRANTS:**

1982 Postdoctoral Research Fellowship, American Liver Foundation: $6,500.

1984 *“Role of vitamin E in hepatocyte transport,”* Children's Liver Foundation Research Grant: $5,000.

1985 “Studies of vitamin E deficiency,” Eastman Chemical Products, Inc., total costs‑ $13,000.

1986‑1989 *"Effect of Vitamin E on Hepatocyte Bile Acid Transport During Cholestasis",* March of Dimes, Basil O'Connor Award, $78,000 total direct costs.

* 1. "Study of Colyte® in Children." Reed and Carnrick, Inc., PI, total direct costs $40,000

1987-1990 "Treatment of vitamin E deficiency during childhood cholestasis with d‑alpha tocopherol polyethylene glycol 1000 succinate (TPGS)", National Organization for Rare Disorders. Total direct costs $39,987.

1989 Eastman Chemical Products, Inc., Equipment Grant, total costs- $13,900.

1997-2000 Cystic Fibrosis Foundation Research Development Program, PI - Frank Accurso, M.D.; Faculty member, direct costs 1997-1998: $400,000.

* 1. *NUC30903 “A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of 52 weeks lamivudine treatment at a dose of 3 mg/kg in pediatric subjects with chronic hepatitis B.”* Local Principal Investigator; Glaxo/Wellcome; total costs, $14,526
	2. *NUC30926, “An Extended, Stratified, Follow-on Study in Pediatric Subjects with Chronic Hepatitis B Who Have Completed Previous Lamivudine Studies.”* Local Principal Investigator, Glaxo-SmithKline – total costs, $13,000.
	3. *"The safety, viral kinetics and pharmacokinetics of Pegasys after multiple doses in young children with chronic hepatitis C infection."* Local Co-Principal Investigator, Roche Laboratories, Inc.

1996-2004 *Studies in Pediatric Liver Transplantation (SPLIT)* research group, Local Principal Investigator, Fujisawa, Roche Laboratories

2002-2005 *“A preliminary clinical research study on antioxidant therapy for biliary atresia in infants and children”,* Madigan Foundation, total direct costs, $22,750

2005-2009 Supply Agreement with Mead Johnson Nutritionals, Inc., for Pregestimil infant formula for 140 infants in Biliary Atresia Research Consortium study, Steroids in Biliary Atresia Randomized Trial.

2006 *“Mechanisms of hepatic injury in cholestasis”*, Children’s Hospital Colorado Research Institute, $77,736.

1. **TRAINING GRANT FUNDING:**

**ACTIVE GRANTS:**

2020-2025 ***“Institutional Training Grant in Pediatric Gastroenterology”*,** NIH 1 T32 DK067009-16, PI – Ronald J. Sokol, M.D., Cara Mack, M.D., Direct Costs year 1 $404,262, Total Costs year 1 $432,894, Total Direct Costs 5 years $1,808,905.00, Total Costs 5 years $1,928,845.

 **COMPLETED GRANTS:**

2015-2020 ***“Institutional Training Grant in Pediatric Gastroenterology”*,** NIH 1 T32 DK067009-11, PI – Ronald J. Sokol, MD, Cara Mack, M.D., Direct Costs year 1 $361,781, Total Costs year 1 $385,769, Total Direct Costs 5 years $1,808,905.00, Total Costs 5 years $1,928,845.

1985-2005 Faculty member and Associate Director (1999-2005), ***NIH Gastrointestinal Disease Training Grant***, NIDDK, National Institutes of Health, T32 DK7038-28 (UCDHSC), PI – Dennis Ahnen, MD

1991-2012 Faculty member, ***NIH Nutrition Training Grant***, NIDDK, National Institutes of Health, T32 DK07658 (UCDHSC), PI - K. Michael Hambidge, M.D., direct costs, 1997-1998 - $99,587.

1993-1995 Max Kade Foundation, Post Doctoral Research Fellowship Award; Sponsor for Dr. Brigitte Winklhofer-Roob; $45,000 direct costs.

1995-1996 First Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Andrew P. Feranchak, M.D., $30,000 direct costs.

1995-1996 Second Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Stokes Houck, III, M.D., $32,000 direct costs.

1996-1997 First Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Henry Thompson, M.D., $30,000 direct costs.

1996-1997 Second Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Andrew P. Feranchak, M.D., $32,000 direct costs.

1997-1998 Second Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Henry Thompson, M.D., $32,000 direct costs.

1997-1998 Third Year Research Fellowship Award, Cystic Fibrosis Foundation, Co-sponsor for Andrew P. Feranchak, M.D., $45,000 direct costs.

1998-1999 Fourth Year Research Fellowship Award, Cystic Fibrosis Foundation, Co-sponsor for Andrew P. Feranchak, M.D., $48,000 direct costs.

1998-1999 Second Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Baruch Yerushalmi, M.D., $38,000 direct costs.

1998-1999 First Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Robert Kramer, M.D., $36,000 direct costs.

* 1. Second Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Robert Kramer, M.D., $38,000 direct costs.
	2. Third Year Research Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Baruch Yerushalmi, M.D., $54,223 direct costs
	3. American Liver Foundation Evelyn and James Silver Memorial, Greater New York Chapter Postdoctoral Research Fellowship, Sponsor for Baruch Yerushalmi, M.D., $10,000 direct costs.
	4. Second Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Edward Liu, M.D., $40,000 direct costs
	5. First Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Greg Kobak, M.D., $36,500 total costs.
	6. Second Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Greg Kobak, M.D., $43,750 total costs.
	7. Third Year Research Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Greg Kobak, M.D., $62,590 total costs.

2002-2004 First- and Second-Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Elizabeth Carlson, M.D., $42,000, first year total costs. (COLSON02B0)

* 1. Postdoctoral Research Fellow grant, American Liver Foundation, Sponsor for Greg Kobak, MD $10,000 total costs
	2. 1st and Second Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Sponsor for Jason Soden, M.D., $42,000, first year total costs
	3. 1st and Second Year Clinical Fellowship Award, Cystic Fibrosis Foundation, Co-sponsor for Jane Keng, M.D., $42,000, first year costs
1. Fulbright Grant to Dr. Way Seah Lee, University of Malaysia, Host- Ronald J. Sokol, MD, Total Costs $15,750.
2. **BIBLIOGRAPHY**

**H-Index = 96, >28,390 citations, i10 index 291 (by Google Scholar, as of July 28, 2023)**

**A. ORIGINAL PUBLICATIONS (PEER-REVIEWED):**

1. Sokol RJ and Bowden RA: An Erysipelas‑like scalp cellulitis due to haemophilus influenza type B. J Pediatr 1980; 96:60.
2. Snodgrass W, Rumack BH, Sullivan JB, Peterson RG, Chase HP, Cotton EK, Sokol RJ: Selenium: Childhood poisoning and cystic fibrosis. Clin Toxicol 1981; 18:211.
3. Sokol RJ, Lichtenstein PK, Farrell MK: Quinacrine hydrochloride‑induced yellow discoloration of the skin in children. Pediatrics 1982; 69:232‑233.
4. Heubi JE, Lichtenstein PK, Daugherty CC, Farrell MK, Sokol RJ, Rothbaum RJ, Suchy FJ, Balistreri WF: Clinical, biochemical, and pathologic findings in mild (stage 1) Reye's Syndrome. J Nat'l Reye's Syndr Found 1982; 3:11‑18.
5. Sokol RJ and Iannaccone ST: Normal vitamin E status in spinal muscular atrophy. Ann of Neurol 1983; 13:328‑330.
6. Oestreich ARE, Sokol RJ, Suchy FJ, Heubi JE: Renal abnormalities in arteriohepatic dysplasia and nonsyndromic intrahepatic biliary hypoplasia. Annales de Radiologie 1983; 26:203‑209.
7. Sokol RJ, Bove KE, Heubi JE, Iannaccone ST: Vitamin E deficiency during chronic childhood cholestasis: Presence of sural nerve lesion prior to two and one half years of age. J Pediatr 1983; 103:197‑204.
8. Sokol RJ, Heubi JE, Iannaccone ST, Bove KE, Balistreri WF: Mechanism causing vitamin E deficiency during chronic childhood cholestasis. Gastroenterology 1983; 85:1172-­1182.
9. Lichtenstein PK, Heubi JE, Daugherty CC, Farrell MK, Sokol RJ, Rothbaum RJ, Suchy FJ, Balistreri WF: Grade I Reye's Syndrome: A frequent cause of vomiting and liver dysfunction following varicella and upper respiratory tract infection. N Engl J Med 1983; 309:133.
10. Sokol RJ, Farrell MK, Heubi JE, Tsang R, Balistreri WF: Comparison of vitamin E and 25‑hydroxy-vitamin D absorption during chronic childhood cholestasis. J Pediatr 1983; 103:712‑717.
11. Sokol RJ, Heubi JE, Balistreri WF: Intrahepatic "cholestasis facies": Is it specific for Alagille Syndrome? J Pediatr 1983; 103:205‑208.
12. Sokol RJ, Heubi JE, Iannaccone ST, Bove KE, Balistreri WF: Vitamin E deficiency with normal serum vitamin E concentrations in children with chronic cholestasis. N Engl J Med 1984; 310:1209‑1212.
13. Sokol RJ, Farrell MK, McAdams AJ: An unusual presentation of Wegener Granulomatosis mimicking inflammatory bowel disease. Gastroenterology 1984; 87:426-­432.
14. Sokol RJ, Balistreri WF, Hoofnagle J, Jones EA: Vitamin E deficiency in adults with chronic liver disease. Am J Clin Nutr 1985; 41:66‑72.
15. Sokol RJ, Guggenheim MA, Iannaccone ST, Miller CA, Silverman A, Balistreri WF, Heubi JE: Improved neurologic function after long‑term correction of vitamin E deficiency in children with chronic cholestasis. N Engl J Med 1985; 313:1580‑1585.
16. Sokol RJ, Francis PD, Gold SH, Ford DM, Lum GM, Ambruso DR: Orthotopic liver transplantation for acute fulminant Wilson's disease. J Pediatr 1985; 107:549‑552.
17. Abman SH, Reardon MC, Accurso FJ, Hammond KB, Sokol RJ: Hypoalbuminemia at diagnosis as a marker for severe respiratory course in infants with cystic fibrosis identified by newborn screening. J Pediatr 1985; 107:933‑935.
18. Sokol RJ, Guggenheim MA, Heubi JE, Iannaccone ST, Butler‑Simon N, Jackson V, Miller C, Balistreri NW, Silverman A: Frequency and clinical progression of vitamin E deficiency neurologic disorder in children with prolonged neonatal cholestasis. Am J Dis Child 1985; 139:1211‑1215.
19. Sokol RJ, Heubi JE, McGraw C, Balistreri WF: Correction of vitamin E deficiency in children with chronic cholestasis: II. Effect on gastrointestinal and hepatic function. Hepatology 1986; 6:1263‑1269.
20. Motil KJ, Adelson JW, Halpin TC, Jr, Sinatra FR, Sokol RJ, Udall JN: Guidelines for training in pediatric gastroenterology. Gastroenterology 1987; 93:432‑433.
21. Stumpf DA, Sokol RJ, Bettis D, Neville H, Ringel S, Angelini C, Bell R: Friedreich's disease: V. Variant form with vitamin E deficiency and normal fat absorption. Neurology 1987; 37:68‑74.
22. Sokol RJ, Heubi JE, Butler‑Simon N, McClung HJ, Lilly JR, Silverman A: Treatment of vitamin E deficiency during chronic childhood cholestasis with oral d-­alpha tocopheryl polyethylene glycol‑1000 succinate. Gastroenterology 1987; 93:975‑985.
23. Traber MG, Sokol RJ, Ringel SP, Neville HE, Thellman CA, Kayden HJ: Lack of tocopherol in peripheral nerves of vitamin E‑deficient patients with peripheral neuropathy. N Engl J Med 1987; 317:262‑265.
24. Sokol RJ, Butler‑Simon NA, Bettis D, Smith D, Silverman A: Tocopherol polyethylene glycol‑1000 succinate therapy for vitamin E deficiency during chronic childhood cholestasis: neurologic outcome. J Pediatr 1987; 111:830‑836.
25. Sokol RJ, Kayden HJ, Bettis DB, Traber MG, Neville H, Ringel S, Wilson WB, Stumpf DA: Isolated vitamin E deficiency in the absence of fat malabsorption ‑ familial and sporadic cases: characterization and investigations of causes. J Lab Clin Med 1988; 111:548‑559.
26. Brown WR, Sokol RJ, Levin M, Silverman A, Tamaru T, Lilly JL, Hall RJ, Cheney M: Lack of correlation between infection with Reovirus 3 and extrahepatic biliary atresia or neonatal hepatitis. J Pediatr 1988; 113:670‑676.
27. Sokol RJ, Devereaux M, Traber MG, Shikes RH: Copper toxicity and lipid peroxidation in isolated rat hepatocytes: effect of vitamin E. Pediatr Res 1989; 25:55‑62.
28. Narkewicz MR, Janoff EN, Sokol RJ, Levin MD: Blastocystic hominis gastroenteritis in a hemophiliac with acquired immune deficiency syndrome. J Pediatr Gastroenterol Nutr 1989; 8:125‑128.
29. Sokol RJ, McCabe ERB, Kotzer AM, Langendoerfer S: Pitfalls in diagnosing galactosemia: False negative newborn screen following red blood cell transfusion. J Pediatr Gastroenterol Nutr 1989; 8:266‑267.
30. Sokol RJ, Kim YS, Hoofnagle JH, Heubi JE, Jones EA, Balistreri WF: Intestinal malabsorption of vitamin E in primary biliary cirrhosis. Gastroenterology 1989; 96:479‑486.
31. Hambidge KM, Sokol RJ, Fidanza SJ, Jacobs MA: Plasma manganese concentrations in infants and children receiving parenteral nutrition. JPEN 1989; 13:168‑171.
32. Broxson EH, Jr., Sokol RJ, Githens JH: Normal vitamin E status in sickle hemoglobinopathies in Colorado. Am J Clin Nutr 1989; 50:497‑503.
33. Sokol RJ, Reardon MC, Accurso FJ, Stall C, Narkewicz M, Abman SH, Hammond Y,B. Fat‑soluble vitamin status during first year of life in infants with cystic fibrosis identified by newborn screen. Am J Clin Nutr 1989; 50:1064‑1071.
34. Sokol RJ, Butler‑Simon N, Heubi JE, Iannaccone ST, McClung HI, Accurso F, Hammond K, Heyman M, Sinatra F, Riely C, Perrault J, Levy 1, Silverman A: Vitamin E deficiency neuropathy in children with fat malabsorption: Studies in cystic fibrosis and chronic cholestasis. Ann NY Acad Sci 1989; 570:156‑169.
35. Traber MG, Sokol RJ, Burton GW, Ingold KU, Pappas AM, Huffaker JE, Kayden HJ: Impaired ability of patients with familial isolated vitamin E deficiency to incorporate alpha tocopherol into lipoproteins secreted by the liver. J Clin Invest 1990; 85:397‑407.
36. Heubi JE, Sokol RJ, McGraw CA: Comparison of total serum lipids measured by two methods. J Pediatr Gastroenterol Nutr 1990; 10:468‑472.
37. Sokol RJ, Stall C: Anthropometric evaluation of children with chronic liver disease. Am J Clin Nutr 1990; 52:203‑208.
38. Sokol RJ, Khandwala RA, Devereaux MW, Narkewicz MR, Sondheimer N: Effect of vitamin E on transport processes in isolated rat hepatocytes. J Pediatr Gastroenterol Nutr 1990; 11:261‑267.
39. Poh‑Fitzpatrick MB, Zaider E, Sciales C, Sokol RJ, Tobin CE, Knobler E, Sadick NS, Silverberg M, Levy J: Cutaneous photosensitivity and coproporphyrin abnormalities in the Alagille syndrome. Gastroenterology 1990; 99:831‑835.
40. Sokol RJ, Devereaux MW, Mireau G, Hambidge KM, Shikes RH: Oxidant injury to hepatic mitochondrial lipids in rats with dietary copper overload: modification by vitamin E deficiency. Gastroenterology 1990; 99:1061‑1071.
41. Taylor SF, Sondheimer JM, Sokol RJ, Silverman A, Wilson HL: Noninfectious colitis associated with short gut syndrome in infants. J Pediatr 1991; 119:24‑28.
42. Sondheimer JM, Sokol RJ, Taylor SF, Silverman A, Zelasney B: Safety, efficacy and tolerance of intestinal lavage in pediatric patients undergoing diagnostic colonoscopy. J Pediatr 1991; 119:148‑152.
43. Narkewicz, MR, Sokol RJ, Beckwith B, Sondheimer J, Silverman A: Liver involvement in Alper's Disease. J Pediatr 1991; 119:260‑267.
44. Pappas AM, Cambre RC, Citino SB, Sokol RJ: Reversal of vitamin E deficiency in captive elephants and black rhinoceros with d‑alpha‑tocopheryl polyethylene glycol 1000 succinate. J Zoo Wildlife Med 1991; 22:309‑317.
45. Sokol RJ, Johnson KE, Karrer FM, Narkewicz MR, Smith D, Kam I: Improvement of cyclosporine absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet 1991; 338:212-215.
46. Sokol RJ, Devereaux MW, Khandwala RA: Effect of dietary lipid and vitamin E on hepatic mitochondrial lipid peroxidation in the bile duct‑ligated rat. J Lipid Res 1991; 32:1349‑1357.
47. Hammond KP, Abman SH, Sokol RJ, Accurso FJ: Efficacy of statewide newborn screening for cystic fibrosis based on persistent elevations of serum immunoreactive trypsinogen. N Engl J Med 1991; 325:769‑774.
48. Huang L‑S, Kayden H, Sokol RJ, Breslow JL: Apo B gene nonsense and splicing mutations in a compound heterozygote for familial hypobetalipoproteinemia. J Lipid Res 1991; 32:1341‑1348.
49. Sokol RJ, Reardon MC, Accurso FJ, Stall C, Narkewicz MR, Abman SH, Hammond KB: Fat soluble vitamins in infants identified by cystic fibrosis newborn screening. Pediatr Pulmonol 1991; Suppl 7:52‑55.
50. Accurso FJ, Sokol RJ, Hammond KB, Abman SH: Early respiratory course in infants with cystic fibrosis: Relevance to newborn screening. Pediatr Pulmonol 1991; Suppl 7:42‑45.
51. Ramsey BW, Farrell PM, Pencharz P and the Consensus Committee (Sokol RJ): Nutritional assessment and management in cystic fibrosis: A consensus report. Am J Clin Nutr 1992; 55:108‑116.
52. Hayward AR, Schriber M, Sokol RJ: Vitamin E supplementation reduces the incidence of diabetes but not insulinitis in NOD mice. J Lab Clin Med 1992; 119:503‑507.
53. Bronstein MN, Sokol RJ, Abman SH, Chatfield KB, Hammond KB, Hambidge KM, Stall CD, Seltzer WK, Accurso FJ: Pancreatic insufficiency, growth and nutritional status in infants identified with cystic fibrosis by newborn screening. J Pediatr 1992; 120:533-540.
54. Ciotti M, Yeatman MT, Sokol RJ, Owens IS: Altered coding for a strictly conservative di-glycine in the major bilirubin UDP-glucuronosyltransferase of a Crigler-Najjar Type I patient. J Biol Chem 1992; 267:3257-3261.
55. Rusakow LS, Hammond KB, Abman SH, Sokol RJ, Seltzer W, Accurso FJ: Immunoreactive trypsinogen in infants with cystic fibrosis complicated by meconium ileus. Screening 1993; 2:13‑17.
56. Aanpreung P, Beckwith B, Galansky S, Sokol RJ: Association of paucity of interlobular bile ducts with prune belly syndrome. J Pediatr Gastroenterol Nutr 1993; 16:81­-86.
57. Occena RO, Taylor SF, Robinson CC, Sokol RJ: Association of Cytomegalovirus with Menetrier's disease in childhood: Report of two new cases with a review of literature. J Pediatr Gastroenterol Nutr 1993;17:217-224.
58. Traber MG, Sokol RJ, Kohlschatter A, Yokata T, Muller DPR, Dufour R, Kayden HJ. Impaired discrimination between stereoisomers of ‑tocopherol in patients with familial isolated vitamin E deficiency. J Lipid Res 1993; 34:201‑210.
59. Sokol RJ, Devereaux MW, Khandwala RA, O'Brien K: Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes. Hepatology 1993; 17:869‑881.
60. Sokol RJ, Devereaux MW, O'Brien K, Khandwala RA, Lehr J: Abnormal hepatic mitochondrial respiration and cytochrome C oxidase activity in rats with long-term copper overload. Gastroenterology 1993; 105:178‑187.
61. Sokol RJ, Butler‑Simon N, Conner C, Heubi JE, Sinatra F, Suchy F, Heyman MB, Perrault J, Rothbaum RJ, Levy J, Iannaccone ST, Shneider B, Rosenblum JL, Koch T, Narkewicz MR: Multicenter trial of D‑alpha tocopheryl polyethylene glycol‑1000 succinate for treatment of vitamin E deficiency in children with chronic cholestatic liver disease. Gastroenterology 1993; 104:1727-1735.
62. Sokol RJ, Twedt D, McKim JM, Jr., Devereaux MW, Karrer F, Kam I, Von Steigman G, Narkewicz MR, Bacon BR, Britton RS, Neuschwander-Tetri BA: Oxidant injury to hepatic mitochondria in Wilson's disease patients and Bedlington terriers with copper toxicosis. Gastroenterology, 1994;107:1788-1798.
63. Doerflinger N, Linder C, Quahchi K, Gyapay G, Weissenbach J, LePaslier D, Rigault P, Belal S, Ben Hamida C, Hentati F, Ben Hamida M, Pandolfo M, di Donato S, Sokol RJ, Kayden H, Landrieu P, Durr A, Brice A, Goutieres F, Kohlschütter A, Sabouraud P, Benomar A, Yahyaouli M, Mandel J-L, Koenig M: Ataxia with vitamin E deficiency: Refinement of genetic localization and analysis of linkage disequilibrium using new markers in 14 families. Am J Hum Genetics 1995; 56:1116-1124.
64. Ouahchi K, Arita M, Kayden H, Hentati F, Ben Hamida M, Sokol RJ, Araj H, Inoue K, Mandel J-L, Koenig M: Ataxia with isolated vitamin E deficiency is caused by mutations in the -tocopherol transfer protein. Nat Gen 1995; 9:141‑145.
65. Bayliss EA, Hambidge KM, Lilly JR, Jacobs MG, Stewart BA, Sokol RJ: Hepatic concentrations of zinc, copper and manganese in infants with extrahepatic biliary atresia. J Trace Elem Med Biol 1995; 9:40-43.
66. Ramirez RO, Sokol RJ, Hays T, Silverman A: Familial occurrence of cavernous transformation of the portal vein. J Pediatr Gastroenterol Nutr 1995; 21:313-318.
67. Ciotti M, Yeatman MT, Sokol RJ, Owens IS. Altered coding for a strictly conserved di-glycine in the major bilirubin UDP-glucuronosyltransferase of a Crigler-Najjor type I patient. J Biol Chem 1995;270:3284-3291.
68. Sokol RJ, Winklhofer-Roob B, McKim JM, Jr., Devereaux MW: Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology 1995; 109:1249-1256.
69. Hoffenberg EJ, Narkewicz MR, Sondheimer JM, Smith DJ, Silverman A, Sokol RJ: Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) presenting in infancy with cholestasis. J Pediatr 1995; 127: 220-224
70. Sondheimer JM, Sokol RJ, Narkewicz MR, Tyson RW: Anastomotic ulceration - A late complication of ileocolonic anastomosis. J Pediatr, 1995; 127:225-230.
71. Alonso EM, Sokol RJ, Hart J, Tyson RW, Narkewicz MR, Whitington PF: Fulminant hepatitis associated with centrolobular hepatic necrosis in young children. J Pediatr 1995; 127:888-894.
72. Abdel-Rahman A, Parks JK, Devereaux MW, Sokol RJ, Parker WD, Rosenberg AA: Developmental changes in newborn lamb brain mitochondrial activity and post asphyxial lipid peroxidation. Proc Soc Exp Biol 1995; 209:170-177.
73. Narkewicz MR, Smith D, Silverman A, Vierling J, Sokol RJ. Clearance of chronic hepatitis B virus infection in young children by alpha interferon treatment. J Pediatr 1995; 127:815-818.
74. Sokol RJ, McKim JM Jr., Devereaux MW: Alpha tocopherol ameliorates oxidant injury in isolated copper-overloaded rat hepatocytes. Pediatr Res 1996; 39:259-263.
75. Sokol RJ, Taylor SF, Devereaux MW, Khandwala RA, Shikes RH, Mireau G: Hepatic oxidant injury associated with glutathione depletion during total parenteral nutrition in weanling rats. Am J Physiol 1996;270 (Gastrointest. Liver Physiology):G691-G700.
76. Easley DJ, Carter B, Rosenberg A, Wooton S, Martinez L, Sokol RJ: Congenital nonchylous ascites due to intestinal malrotation. J Pediatr Gastroenterol Nutr, 1995;23:86-88.
77. LePage G, Champagne J, Ronco N, Lamarre A, Osberg I, Sokol RJ, Roy CC: Supplementation with carotenoids corrects lipid peroxidation in children with cystic fibrosis. Am J Clin Nutr 1996;64:87-93.
78. Du EZ, Wang S-L, Kayden HJ, Sokol RJ, Curtiss LK, Davis RA: Translocation of apolipoprotein B across the endoplasmic reticulum is blocked in abetalipoproteinemia. J Lipid Res 1996;37:1309-1315.
79. Price MR, Sartorelli KH, Karrer FM, Narkewicz MR, Sokol RJ, Lilly JR: Management of esophageal varices by endoscopic variceal ligation in children. J Pediatr Surg, 1996;31:1056-1059.
80. Karrer FM, Price MR, Bensard DD, Sokol RJ, Narkewicz MR, Smith DJ, Lilly JR: Long term results with Kasai’s operation for biliary atresia. Arch Surg 1996;131:493-496.
81. Riepenhoff-Talty M, Gouvea V, Evans MJ, Svensson L, Hoffenberg E, Sokol RJ, Uhnoo I, Greenberg SJ, Schakel K, Zhaori G, Fitzgerald J, Chong S, El-Yousef M, Nemeth A, Brown M, Piccoli D, Hyams J, Ruffin D, Rossi T: Detection of Group C rotavirus in infants with extrahepatic biliary atresia. J Infect Dis. 1996;174:8-15.
82. Hoffenberg EJ, Deutsch J, Smith S, Sokol RJ: Circulating antioxidant levels in children with inflammatory bowel disease. Am J Clin Nutr 1997;65:1482-1488.
83. Hoffenberg EJ, Rothenberg SS, Bensard D, Sondheimer J, Sokol RJ. Outcome after exploratory laparoscopy for unexplained abdominal pain in childhood. Arch Pediatr Adolesc Med 1997;151:993-998.
84. Sokol RJ, McKim JM, Jr., Goff MC, Devereaux MW, Ruyle SZ, Han D, Packer L, Everson G. Vitamin E reduces oxidant injury to mitochondria and hepatotoxicity of intravenous taurochenodeoxycholic acid in the rat. Gastroenterology 1998;114: 164-174.
85. Narkewicz MR, Smith D, Gregory C, Lear J, Osberg I, Sokol RJ. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroent Nutr 1998, 26:49-55.
86. Shivaram KN, Winklhofer-Roob BW, Straka MS, Devereaux MW, Everson G, Mierau GW, Sokol RJ: The effect of idebenone, a coenzyme Q analogue, on hydrophobic bile acid toxicity to isolated rat hepatocytes and hepatic mitochondria. Free Rad Biol Med 1998;25:480-492.
87. Tyler DL, Sokol RJ, Oberhaus SM, Le M, Karrer FM, Narkewicz MR, Tyson RW , Murphy JR, Low R, Brown WR. Detection of reovirus RNA in hepatobiliary tissues from patients with extrahepatic biliary atresia and choledochal cysts. Hepatology 1998;27:1475-1482.
88. Burwinkel B, Amat L, Gray GF, Matsuo N, Muroya K, Narisawa K, Sokol RJ, Vilaseca MA, Kilimann MW. Variability of biochemical and clinical phenotype in X-linked liver glycogenosis with mutations in the phosphorylase kinase *PHKA2* gene. Human Genet 1998;102:423-429.
89. Setchell KDR, Schwarz M, O’Connell NC, Lund EG, Davis DL, Lathe R, Thompson HR, Tyson RW, Sokol RJ, Russell DW. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7α-hydroxylase gene causes severe neonatal liver disease. J Clin Invest 1998;102:1690-1703.
90. Harned RK 2nd, Thompson HR, Kumpe DA, Narkewicz MR, Sokol RJ. Partial splenic embolization in five children with hypersplenism: effects of reduced-volume embolization on efficacy and morbidity. Radiology 1998;209:803-806
91. Sokol RJ, Devereaux MW, Khandwala R. Effect of oxypurinol, a xanthine oxidase inhibitor, on hepatic injury in the bile duct-ligated rat. Pediatr Research 1998;44:397-401.
92. Sokol RJ, Durie PR and the Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. Recommendations for management of liver and biliary tract disease in cystic fibrosis. J Pediatr Gastroenterol Nutr 1999;28 (Suppl. 1):S1-S13.
93. Sokal EM, Sokol RJ, Cormier V, Lacaille F, McKiernan P, Van Spronsen FJ, Bernard O, Saudubray JM. Liver transplantation in mitochondrial respiratory chain disorders. Eur J Pediatr 1999;158(Suppl 2):S81-S84.
94. Feranchak AP, Tyson RW, Narkewicz MR, Karrer FM , Sokol RJ. Orthotopic liver transplantation in a child with fulminant hepatic failure due to primary Epstein-Barr infection. Liver Transplant Surg 1998;4:469-476.
95. Narkewicz MR, Krebs N, Karrer F, Orban-Eller K, Sokol RJ. Correction of hypozincemia following liver transplantation in children is associated with reduced urinary zinc loss. Hepatology 1999;29:830-833.
96. Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Karrer FM. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999;29:442-447.
97. Holve S, Hu D, Shub M, Tyson RW, Sokol RJ. Liver disease in Navajo neuropathy. J Pediatr 1999;135:482-93.
98. Feranchak AP, Sontag MK, Wagener JS, Hammond KB, Accurso FJ, Sokol RJ. Prospective long-term study of fat-soluble vitamin status in children with cystic fibrosis diagnosed by newborn screen. J Pediatr 1999;135:601-610.
99. Gumpricht E, Devereaux MW, Dahl R, Sokol RJ. Glutathione status of isolated rat hepatocytes affects bile acid-induced cellular necrosis but not apoptosis. Toxicol Appl Pharmacol. 2000; 164:102-11.
100. Hoffenberg EJ, Bao F, Eisenbarth GS, Uhlhorn C, Haas JE, Sokol RJ, Rewers M. Transglutaminase antibodies in children with a genetic risk for celiac disease. J Pediatr 2000; 137:356-360.
101. Ingram JD, Yerushalmi B, Connell J, Karrer F, Tyson RW, Sokol RJ. Hepatoblastoma in a neonate- a hypervascular presentation mimicking hemangioendothelioma. Pediatr Radiol. 2000 30:794-7.
102. Yerushalmi B, Dahl R, Gumpricht E, Yerushalmi B, Devereaux MW, Sokol RJ. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology 2001; 33:616-26.
103. Sokol, RJ, Straka MS, Dahl R, Devereaux MW, Yerushalmi B, Gumpricht E, Elkins N, Everson G. Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobic bile acids. Pediatr Res 2001; 49: 519-531.
104. Miga D, Sokol RJ, MacKenzie T, Narkewicz MR, Smith D, Karrer F, Lilly JR. Survival after first variceal hemorrhage in patients with biliary atresia. J Pediatr 2001;139:291-296
105. Kramer R, Sokol RJ, MacKenzie T, Yerushalmi B, Thompson HR, Liu E, Hoffenberg E, Narkewicz MR. Large volume paracentesis in the management of ascites in children. J Pediatr Gastroenterol Nutr 2001;33:245-249.
106. Vu TH, Tanji K, Holve SA, Bonilla E, Sokol RJ, Snyder RD, DiMauro S, De Vivo D. Navajo neurohepatopathy: a mitochondrial DNA depletion syndrome? Hepatology 2001 34:116-120
107. Kane, R, Solomon, H, Friedman, B, Heffron, T, DePaulo, J, Sokol, R J, Karrer, F., Narkewicz, M. R., Orban-Eller, K., Maller, E. S., Higuchi, N., Mazariegos, G., Smith, A., Atkinson, P., Bucuvalas, J., Balistreri, W. F., Ryckman, F., Klekamp, C., Roden, J., ... Spaith, E. (2001). Studies of pediatric liver transplantation (SPLIT): Year 2000 outcomes. Transplantation, 72(3), 463-476. https://doi.org/10.1097/00007890-200108150-00018
108. Liu E, Hoffenberg EJ, Kaye RD, Sokol RJ. Endoscopic dilation of an ileocolonic stricture in an infant with short gut syndrome. Gastrointest Endosc. 2001;54:533-535.
109. Deutsch GH, Sokol RJ, Stathos TH, Knisely AS. Proliferation to paucity: evolution of bile duct abnormalities in a case of Alagille syndrome. Pediatric and Developmental Pathology 2001;4:559-563.
110. Lee LA, Sokol, RJ, Buyon JP. Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry. Pediatrics 2002;109:E11.
111. Fleitz J, Rumelhart S, Goldman F, Ambruso D, Sokol RJ, Pacini D, Quinones R, Holida M, Lee N, Tannous R, Giller R. Successful allogeneic hematopoietic stem cell transplantation (HSCT) for Shwachman-Diamond Syndrome. Bone Marrow Transplant 2002;29:75-79.
112. Jonas MM, Kelley DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell S, Sokal EM, for the International Pediatric Lamivudine Investigator Group (…Sokol RJ…) Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13
113. Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Ashmead JW, Wenger DA. Niemann-pick disease type C in neonatal cholestasis at a North American center. J Pediatr Gastroenterol Nutr 2002;35:44-50
114. Gumpricht E, Dahl R, Yerushalmi B, Devereaux MW, Sokol RJ. Nitric oxide ameliorates hydrophobic bile acid-induced apoptosis in isolated rat hepatocytes by non-mitochondrial pathways. J Biol Chem 2002;277:25823-25830
115. Holmes RD, Orban-Eller K, Karrer FR, Rowe DT, Narkewicz MR, Sokol RJ. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation 2002; 74:367-72.
116. McDiarmid SV, Avand R, Lindblad AS, and the Principal Investigators (… Sokol RJ…) and Institutions of the Studies of Pediatric Liver Transplantation (SPLIT) Research Group. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation 2002;74:173-181
117. Holmes RD, Sokol, RJ. Epstein-Barr virus and post transplant lymphoproliferative disease. Pediatr Transplant. 2002;6:456-64.
118. Bezerra JA, Tiao G, Ryckman FC, Alonso M, Sabla GE, Shneider B, Sokol RJ, Aronow BJ. Genetic induction of proinflammatory immunity in children with biliary atresia. Lancet 2002;360:1653-1659.
119. Narkewicz MR, Sondheimer HM, Ziegler JW, Otanni Y, Lorts A, Shaffer EM, Horgan JG, Sokol RJ. Hepatic dysfunction following the Fontan procedure. J Pediatr Gastroenterol Nutr 2003;36:352-7.
120. Nadeau K, Klingensmith G, and Sokol RJ. Case report: nonalcoholic steatohepatitis in a teenage girl with type 2 diabetes. Curr Opin Pediatr. 2003;15:127-31.
121. Sokol RJ, Mack C, Narkewicz MR, Karrer FR. Pathogenesis and Outcome of Biliary Atresia: Current Concepts. J Pediatr Gastroenterol Nutr 2003;37:4-21.
122. Burch JM, Sokol RJ, Narkewicz MR, Reichlin M, Frank MB, MacKenzie T, Marchbank A, Lee LA. Autoantibodies in mothers of children with neonatal liver disease. J Pediatr Gastroenterol Nutr 2003;37:262-267
123. Hoffenberg EJ, MacKenzie T, Barriga KJ, Eisenbarth GS, Bao F, Erlich H, Haas JE, , Sokol RJ, Taki I, Norris J, Rewers M. A prospective study of the incidence of childhood celiac disease. J Pediatr 2003;143:308-314
124. Kauffman LD, Jones RH, Sokol RJ, Awad JA, Rewers MJ, Norris JM. Urinary F2-isosprostanes in young healthy children at risk for type 1 diabetes mellitus. Free Rad Biol Med 2003;35:551-557
125. Kurbegov AC, Setchell KDR, Haas J, Mierau G, Narkewicz MR, Bancroft JD, Karrer FM, Sokol RJ. Biliary Diversion for Progressive Familial Intrahepatic Cholestasis: Improved Liver Morphology and Bile Acid Profile. Gastroenterology 2003;125:1227-1234
126. Zhang D-Y, Sabla G, Shivakumar P, Tiao G, Sokol RJ, Mack C, Shneider B, Aronow B, and Bezerra JA. Coordinate expression of regulatory genes differentiates embryonic and perinatal forms of biliary atresia. Hepatology 2004;39:954-962
127. Gumpricht E, Dahl R, Devereaux MW, Sokol RJ. Beta-carotene prevents bile acid-induced cytotoxicity in the rat hepatocyte: Evidence for an antioxidant and anti-apoptotic role of beta carotene in vitro. Pediatr Res 2004;55:814-21.
128. Hoffenberg EJ, Emery LM, Barriga KJ, BaoF, Taylor J, Eisenbarth GS, Haas JE, Sokol RJ, Taki I, Norris JN, and Rewers M. Clinical features of children with screening-identified evidence of celiac disease. Pediatrics 2004;113:1254-59
129. Mack CL, TuckerRM, Sokol RJ, Karrer FM, KotzinBL, Superina R, Whitington PFand MillerSD. Biliary atresia is associated with CD4+ Th1 cell-mediated inflammation within portal tracts. Pediatr Res 2004;56:79-87
130. Kobak GE, Bland SD, Sokol RJ, Narkewicz MR. Interferon treatment for chronic hepatitis B: enhanced response in children less than 5 years old. J Pediatr 2004;145:340-345.
131. Gumpricht E, Devereaux MW, Traber M, Sokol RJ. Enrichment of rat hepatic organelles by vitamin E administered subcutaneously. Free Rad Biol Med 2004;37:1712-1717.
132. Gumpricht E, Dahl RE, Devereaux MW, Sokol RJ. Licorice compounds, glycyrrhizin and 18β- glycyrrhetinic acid, are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes. J Biol Chem 2005;280:10556-10563.
133. Sokol RJ, Mack CL. Optimizing outcomes and bridging biliary atresia into adulthood. Hepatology 2005 41:231-233
134. Das BB, Narkewicz MR, Sokol RJ, Chen TY, Bali D, Li SC, Matthews MR, Mierau GW, Ivy DD. Amylopectinosis disease isolated to the heart with normal glycogen branching enzyme activity and gene sequence. Pediatr Transplant. 2005;9:261-5.
135. Mack C, Sokol RJ. Unraveling the pathogenesis of biliary atresia. Pediatr Res 2005;57(Part 2):87-94R.
136. Norris, JM, Katherine Barriga K, Hoffenberg E, Taki I, Haas J, Emery LM, Eisenbarth GS, Sokol RJ, Erlilich HA, Rewers M. Timing of gluten introduction in the infant diet affects risk of celiac disease autoimmunity. JAMA 2005;293:2343-2351.
137. Mack CL, Tucker RM, Sokol RJ, Kotzin BL. Armed CD4Th1 effector cells and macrophage activation are associated with bile duct injury in a murine model of biliary atresia. Clin Immunol 2005;115:200-209.
138. Kobak GE, DahlR, DevereauxMW, GumprichtE, TraberM, Doctor RB, Sokol RJ. Increased susceptibility of fat-laden Zucker rat hepatocytes to bile acid-induced oncotic necrosis: an *in vitro* model of steatocholestasis. J Lab Clin Med 2005;145:247-62.
139. Condino AA, IvyDD, NarkewiczMR, O’ConnorJJ, WhitworthJ, ClaussenL, DoranA,and Sokol RJ. Portopulmonary hypertension in pediatric patients. J Pediatr 2005; 147:20-6
140. Leonard SW, GumprichtE, Devereaux MW, SokolRJ, TraberMG. Quantitation of rat liver vitamin E metabolites by LC-MS during high-dose vitamin E administration. J Lipid Res 2005;46:1068-75.
141. Sokol RJ, Dahl R, Devereaux MW, Yerushalmi B, Gumpricht. Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids. J Pediatr Gastroenterol Nutr 2005;41:235-43.
142. Utterson EC, Shepherd RW, Sokol RJ, Bucuvalas JC, Rosenthal P, Schneider B, McDiarmid SV, Anand R, the SPLIT Research Group. Biliary atresia: clinical profiles, risk factors and outcomes of 755 patients listed for liver transplantation. J Pediatr. 2005;147:180-185
143. Feranchak AP, King R, Ramirez RO, Corkill M, Shivaram KN, Narkewicz MR, Sokol RJ. Comparison of indices of vitamin A status in children with chronic liver disease. Hepatology. 2005;42:782-792
144. NarkewiczMR, KasaragodA, LuciaMS, PflummerS, SokolRJ, Stenmark K. Connective tissue growth factor expression is increased in biliary epithelial cells in biliary atresia. J Pediatr Surg 2005; 40:1721-5.
145. Liu E, Dobyns E, Parikh CR, MacKenzie T, Karrer FM, Narkewicz MR, Sokol RJ. Characterization of acute liver failure and development of a continuous risk of death staging system in children. J Hepatol. 2006; 44:134-141. Sep 14, 2005 [Epub ahead of print]
146. Shneider BL, Brown MB, Haber B, Whitington PF, Schwarz K, Squires R, Bezerra J, Shepherd R, Rosenthal P, Hoofnagle JH, Sokol RJ, and the Biliary Atresia Research Consortium. A multicenter study of the outcome of biliary atresia in the United States, 1997-2000. J Pediatr 2006; 148:467-74.
147. Squires RH, Shneider B, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, Dhawan A, Rosenthal P, Rodriguez-Baez N, Murray KF, Horslen S, Martin MG, Lopez MJ, Soriano H, McGuire BM, Jonas M, Yazigi N, Shepherd RW, Schwarz K, Lobritto S, Thomas DW, Lavine JE, Karpen S, Ng V, Kelly D, Simonds N, Hynan L. Acute liver failure in children: the first 348 patients in the Pediatric Acute Liver Failure Study Group. J Pediatr 2006;148:652-658
148. Sokol RJ, Devereaux M, Dahl R, Gumpricht E. “Let there be bile” – understanding hepatic injury in cholestasis. J Pediatr Gastroenterol 2006;43(1 Suppl):S4-9.
149. Mustacich DJ, Leonard SW, Devereaux MW, Sokol RJ and Traber MG. Alpha-tocopherol regulation of hepatic cytochrome P450s and ABC transporters in rats. Free Rad Biol Med 2006;41:1069-78
150. Stene LC, Honeyman MC, Hoffenberg EJ, Haas JE, Sokol RJ, Emery L, Taki I, Norris JM, Erlich HA, Eisenbarth GS, Rewers M. Rotavirus infection frequency and risk of coeliac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol 2006;101:2333-40.
151. Whitworth JR, Mack CL, O’Connor, JA, Narkewicz MR, Mengshol S, Sokol RJ. Acute hepatitis and liver failure associated with influenza A infection in children. J Pediatr Gastroenterol Nutr 2006;43:536-8.
152. Mack CL, Tucker RM, Lu BR, Sokol RJ, Fontenot AP, Ueno R, Gill RG. Cellular and humoral autoimmunity directed at bile duct epithelia in murine biliary atresia. Hepatology 2006;44:1231-9.
153. Barnes BH, Narkewicz MR, Sokol RJ. Spontaneous perforation of the bile duct in a toddler: the role of Endoscopic Retrograde Cholangiopancreatography in diagnosis and therapy. J Pediatr Gastroenterol Nutr 2006;43:695-97
154. Cantin, AM, White TB, Cross CE, Jay-Forman H, Sokol RJ, Borowitz D. Antioxidants in cystic fibrosis. Conclusions from the CF Antioxidant Workshop, Bethesda, Maryland, November 11-12, 2003.Free Rad Biol Med 2007; 42:15-31.
155. Brady H, Lamb MM, Sokol RJ, Ross CA, Seifert JA, Rewers MJ, Norris JM. Plasma micronutrients are associated with dietary intake and environmental tobacco smoke exposure in a pediatric population. Public Health Nutr 2007Feb 20;:1-7 [Epub ahead of print]
156. Lee W, Sokol RJ. Mitochondrial hepatopathies: advances in genetics and pathogenesis. Hepatology 2007;45:1555-1565
157. Kahn MG, Kaplan D, Sokol RJ, DiLaura R. Configuration challenges: implementing translational research policies in electronic medical records. Acad Med 2007;82:661-669
158. Mack CL, Falta MT, Sullivan AK, Karrer F, Sokol RJ, Freed BM, Fontenot AP. Oligoclonal expansions of CD4+ and CD8+ T-cells in the target organ of patients with biliary atresia. Gastroenterology 2007;133:278-287.
159. Soltys KA, Mazariegos GV, Squires RH, Sindhi RK, Anand R, the SPLIT Research Group (…Sokol RJ…). Late graft loss or death in pediatric liver transplantation: an analysis of the SPLIT database. Am J Transplant 2007;7:2165-71.
160. Soden J, Devereaux MW, Haas JE, Gumpricht E, Dahl R, Gralla J, Traber MG, Sokol RJ. Subcutaneous vitamin E ameliorates liver injury in an *in vivo* model of steatocholestasis. Hepatology 2007;46:485-95
161. Sokol RJ, Shepherd RW, Superina R, Bezerra JA, Robuck P, Hoofnagle JH. Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop. Hepatology 2007;46:566-81.
162. Belkind-Gerson J, Guarino A, Sokol RJ. The 2008 World Congress Working Group Reports - an opportunity for a world-wide consensus to impact children's digestive health. J Pediatr Gastroenterol Nutr 2007;45:172-3
163. DeRusso PA, Ye W, Shepherd R, Haber BA, Shneider BL, Whitington PF, Schwarz KB, Bezerra J, Rosenthal P, Karpen S, Brown M, Sokol RJ; Biliary Atresia Research Consortium. Growth failure and outcomes in infants with biliary atresia: a report from the Biliary Atresia Research Consortium. Hepatology 2007; 46:1632-1638.
164. Papas KA, Sontag MK, Pardee CH, Sokol RJ, Sagel SD, Accurso FJ, Wagener JS. Efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis. J Cyst Fibros. 2008;7:60-67. 2007 Jun 12; [Epub ahead of print].
165. Petersen C, Harder D, Abola Z, Alberti D, Becker T, Chardot C, Davenport M, Deutschmann A, Kobayashi H, Kvist N, Leonhardt J, Melter M, Pakarinen M, Pawlowska J, Petersons A, Pfister E-D, Rygl M, Schreiber R, Sokol RJ, Ure BM, Veiga C, Verkade H, Wildhaber B, Yerushalmi B, Kelly D. European Biliary Atresia Registries - Summary of a Symposium. Eur J Pediatr Surg. 2008;18:111-6.
166. Laguna TA, Sontag MK, Osberg I, Wagener JS, Accurso FJ, Sokol RJ. Decreased total serum co-enzyme Q10 concentrations: a longitudinal study in children with cystic fibrosis. J Pediatr 2008;153:402-407. (May 29, Epub ahead of print]
167. Sundaram SS, Bove KE, Lovell M, Sokol RJ. Mechanisms of Disease: Inborn errors of bile acid synthesis. Nat Clin Pract Gastroenterol Hepatol. 2008;5:456-68. 2008 [Jun 24, Epub ahead of print]
168. Gumpricht E, Devereaux MW, Dahl R, Soden JS, Sparagna GC, Leonard SW, Traber MG, Sokol RJ. Developmental changes in susceptibility of rat liver mitochondria to bile acid-induced permeability transition: Potential role of alpha tocopherol. Pediatr Res 2008;64:498-504. [Jun 25;Epub ahead of print]
169. Lu BR, Gralla J, Liu E, Dobyns EL, Narkewicz MR, Sokol RJ. Evaluation of a scoring system for assessing prognosis in pediatric acute liver failure. Clin Gastroenterol Hepatol 2008;6:1140-1145 PMID: 18928939
170. Ng VL, Fecteau A, Shepherd R, Magee J, Bucuvalas J, Alonso E, McDiarmid S, Cohen G, Anand R; Studies of Pediatric Liver Transplantation Research Group (…Sokol RJ…). Outcomes of 5-year survivors of pediatric liver transplantation: report on 461 children from a North American multicenter registry. Pediatrics 2008;122:e1128-35.
171. Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, Nguyen T, Paulus K, Merkel PA; Rare Diseases Clinical Research Network (… Sokol RJ…). [Clinical research for rare disease: opportunities, challenges, and solutions.](http://www.ncbi.nlm.nih.gov/pubmed/19013090?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Mol Genet Metab. 2009;96:20-6. Epub 2008 Nov 13. PMID: 19013090
172. Soden JS, Narkewicz MR, Haas JE, Sokol RJ. Hepatic venoocclusive disease and HHV-7 infection in primary agammaglobulinemia. J Pediatr 2009;154:299-302. PMID: 19150678
173. Rand EB, Karpen SJ, Kelly S, Mack CL, Malatack JJ, Sokol RJ, Whitington PF. Treatment of neonatal hemochromatosis with exchange transfusion and intravenous immunoglobulin. J Pediatr 2009;155:566-71., E Pub ahead of print, July, 2009 PMID: 19560784
174. Whitworth, JR, Ivy DD, Gralla J, Narkewicz MR, Sokol RJ. Pulmonary vascular complications in asymptomatic children with portal hypertension. J Pediatr Gastroenterol Nutr. 2009;49:607-12. PMID: 19820411
175. Soden JS, Lovell M, Sokol RJ. Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure. J Pediatr 2010;156:327-31. PMID: 20105644
176. Alonso EM, Limbers CA, Neighbors K, Martz K, Bucuvalas JC, Webb T, Varni JW; Studies of Pediatric Liver Transplantation (SPLIT) Functional Outcomes Group (FOG) (…Sokol RJ…). [Cross-sectional analysis of health-related quality of life in pediatric liver transplant recipients.](http://www.ncbi.nlm.nih.gov/pubmed/19846110?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2) J Pediatr. 2010 Feb;156(2):270-6.e1. Epub 2009 Oct 28. PMID 19846110
177. Alsultan A, Sokol RJ, Lovell MA, Thurman G, Ambruso DR. Long term G-CSF-induced remission of ulcerative colitis-like inflammatory bowel disease in a patient with glycogen storage disease 1b and evaluation of associated neutrophil function. Pediatr Blood Cancer 2010;55:1410-3. Sept 9 (Epub ahead of print). PMID 20830779
178. Law YM, Rice M, Mack CL, Sokol RJ, Parsley L, Ivy D. Cardiopulmonary manifestations of portovenous shunts from congenital absence of the portal vein: pulmonary hypertension and pulmonary vascular dilatation. Pediatr Transplantation 2010; 15:E162-168, June 20 (Epub ahead of print); PMID 20565694
179. Campsen J, Zimmerman MA, Narkewicz MR, Sokol RJ, Mandell MS, Kam I, Dovel D, Karrer FM. Choledochoduodenostomy in pediatric liver transplantation. Pediatr Transplantation 2011;15:237-9. Jan. 9, Epub ahead of print. PMID: 21214697
180. Russo P, Magee JC, Boitnott J, Bove KE, Raghunathan T, Finegold M, Haas J, Jaffe R, Kim GE, Magid M, Melin-Aldana H, , White F, Whitington P, Sokol RJ, for the Biliary Atresia Research Consortium (BARC). Design and validation of the Biliary Atresia Research Consortium histological assessment system for cholestasis in infancy. Clin Gastroenterol Hepatol 2011;9:357-362.e2, Jan 13 (Epub ahead of print). PMID 21238606
181. Limbers CA, Neighbors K, Martz K, Bucuvalas JC, Webb T, Varni JW, Alonso EM, on behalf of Studies of Pediatric Liver Transplantation Functional Outcomes Group (FOG) (..Sokol RJ…). Health-related quality of life in pediatric liver transpant recipients compared to other chronic disease groups. Pediatr Transplant 2011;15:245-253. Epub 2010 Dec 29. PMID 21199214.
182. Martin SR, Alvarez F, Anand R, Song C, Yin W, SPLIT Research Group (…Sokol RJ…). Outcomes in children who underwent transplantation for autoimmune hepatitis. Liver Transpl 2011;17:393-401 PMID 21445922
183. Superina R , Magee JC, Brandt ML,Healey PJ, Tiao G, Ryckman F, Karrer FM, Iyer K, Fecteau A, West K, Burns RC, Flake A, Lee H, Lowell JA, Dillon P, Colombani P, Ricketts R, Li Y, Moore J, Wang KD and the Childhood Liver Disease Research and Education Network (…Sokol RJ…). The anatomic pattern of biliary atresia identified at time of Kasai hepatoportoenterostomy and early postoperative clearance of jaundice are significant predictors of transplant-free survival. Annals Surg 2011;254:577-585. PMID 21869674
184. Li M, Riddle SR, Frid MG, El Kasmi KC, McKinsey TA, Sokol RJ, Strassheim D, Meyrick B, Yeager ME, Flockton AR, McKeon BA, Lemon DD, Horn TR, Anwar A, Barajas C, and Stenmark KR. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunology 2011;187:2711-22. Epub 2011 Aug 3. PMID: 21813768
185. Varni JW, Limbers CA, Sorensen LG, Neighbors K, Martz K, Bucuvalas JC, Alonso EM; Studies of Pediatric Liver Transplantation Functional Outcomes Group (…Sokol RJ…). [PedsQL™ Cognitive Functioning Scale in pediatric liver transplant recipients: feasibility, reliability, and validity.](http://www.ncbi.nlm.nih.gov/pubmed/21184184) Qual Life Res. 2011 Aug;20(6):913-21. Epub 2010 Dec 24. PMID: 21184184
186. Simpson M, Brady H, Yin X, Seifert J, Barriga K, Hoffman M, Bugawan T, Baron AE, Sokol RJ, Eisenbarth G, Erlich H, Rewers M, Norris JM. No association of vitamin D intake or 25[OH] D levels in childhood with risk for islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia. 2011;54:2779-88. (Epub 2011 Aug 20 ahead of print). PMID: 21858504
187. Miloh T, Anand R, Yin W, Vos M, Kerkar N, Alonso E, for the Studies of Pediatric Liver Transplantation Research Group (…Sokol RJ…). Pediatric liver transplantation for primary sclerosing cholangitis. Liver Transplant 2011;17:925-933. PMID 21506253
188. Sullivan JS, Sundaram SS, Pan Z, Sokol RJ. Parenteral nutrition supplementation in biliary atresia patients listed for liver transplantation. Liver Transpl. 2012;18:120-8. doi: 10.1002/lt.22444. [Epub ahead of print]. PMID: 21987426
189. El Kasmi KC, Anderson AL, Devereaux MW, Harris JK, Fillon S, Lovell M, Finegold M, Sokol RJ. Toll-Like Receptor 4 Dependent Kupffer Cell Activation and Liver Injury in a Novel Mouse Model of Parenteral Nutrition and Intestinal Injury. Hepatology 2012;55:1518-28. doi: 10.1002/hep.25500. Epub 2012 Mar 18. PMID: 22120983
190. Miller MR, Sokol RJ, Narkewicz MR, Sontag MK. Pulmonary function in individuals who underwent liver transplantation: From the US cystic fibrosis foundation registry. Liver Transpl. 2012;18:585-93, doi: 10.1002/lt.23389. [Epub ahead of print]. PMID: 22271602
191. CTSA Principal Investigators, Shamoon H, Center D, Davis P, Tuchman M, Ginsberg H, Califf R, Stephens D, Mellman T, Verbalis J, Nadler L, Shekhar A, Ford D, Rizza R, Shaker R, Brady K, Murphy B, Cronstein B, Hochman J, Greenland P, Orwoll E, Sinoway L, Greenberg H, Jackson R, Coller B, Topol E, Guay-Woodford L, Runge M, Clark R, McClain D, Selker H, Lowery C, Dubinett S, Berglund L, Cooper D, Firestein G, Johnston SC, Solway J, Heubi J, Sokol R, Nelson D, Tobacman L, Rosenthal G, Aaronson L, Barohn R, Kern P, Sullivan J, Shanley T, Blazar B, Larson R, FitzGerald G, Reis S, Pearson T, Buchanan T, McPherson D, Brasier A, Toto R, Disis M, Drezner M, Bernard G, Clore J, Evanoff B, Imperato-McGinley J, Sherwin R, Pulley J. [Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS).](http://www.ncbi.nlm.nih.gov/pubmed/22507116) Clin Transl Sci. 2012 Apr;5(2):121-9. doi: 10.1111/j.1752-8062.2012.00401.x. Epub 2012 Mar 27. PMID: 22507116 . PMCID: PMC3335735
192. Kamath BM, Whitington PF, Piccoli DA, Magee JC, Sokol RJ for the Childhood Liver Disease Research and Education Network (ChiLDREN). Pancreatic insufficiency is not a prevalent problem in Alagille syndrome. J Pediatr Gastroentero Nutr 2012; Nov;55(5):612-614. PMID: 22614108
193. Ng VL, Alonso EM, Bucuvalas JC, Cohen G, Liimbers CA, Varni JW, Mazariegos G, Magee J, McDiarmid SV, Anand R: Studies of Pediatric Liver Transplantation (SPLIT) Research Group (…Sokol RJ…). Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience. J Pediatr 2012;160:820-6. PMID: 22192813
194. Shneider BL, Magee JC, Bezerra JA, Haber B , Karpen SJ, Raghunathan T, Rosenthal P, Schwarz K, Suchy FJ, Kerkar N, Turmelle Y, Whitingotn PF, Robuck PR, Sokol RJ, for the Childhood Liver Disease Research and Education Network (ChiLDREN). Efficacy of fat soluble vitamin supplementation in infants with biliary atresia. Pediatrics 2012;130:e607-614, originally published online August 13, 2012 DOI: 10.1542/peds.2011-1423 PMID: 22891232
195. Shneider BL, Abel B, Haber B, Karpen SJ, Magee JC, Romero R, Schwarz K, Bass L, Kerkar N, Miethke A, Rosenthal P, Turmelle Y, Sokol RJ for Childhood Liver Disease Research and Education Network (ChiLDREN). Portal Hypertension in Children and Young Adults with Biliary Atresia. J Pediatr Gastroenterol Nutr. 2012;55:567-573. PMID: 22903006
196. Nel E, Sokol RJ, Comparcola D, Nobili V, Hardikar W, Gana JC, Abarca K, Wu J-F, Chang M-H, Renner JK. Viral Hepatitis in Children. J Pediatr Gastroenterol Nutr. 2012 Nov;55(5):500-505. PMID: 22983372
197. Mack CL, Feldman A, Sokol RJ. Clues to the etiology of bile duct injury in biliary atresia. Semin Liver Dis 2012;32:307-16. PMID 23397531
198. Lu BR, Zhang S, Narkewicz MR, Belle SH, Squires RH, Sokol RJ. Evaluation of the Liver Injury Unit scoring system to predict survival in a multinational study of pediatric acute liver failure. J Pediatr 2013 May; 162(5):1010-1016. PMID:23260095
199. Schwarz KB, Haber BH, Rosenthal P, Mack CL, Moor J, Bove K, Bezerra JA, Karpen SJ, Kerkar N, Schneider BL, Turmelle YP, Whitington PF, Molleston JP, Murray KF, Ng VL, Romero R, Wang KS, Sokol RJ, Magee JC for Childhood Liver Disease Research and Education Network. Extra-hepatic anomalies in infants with biliary atresia: results of a large prospective North American multi-center study. Hepatology 2013 Nov;58(5):1724-31. doi: 10.1002/hep.26512.

 PMID:23703680

1. Mack CL, Anderson KM, Aubrey MT, Rosenthal P, Sokol RJ, Freed BM. Lack of HLA predominance and HLA shared epitopes in biliary atresia. *SpringerPlus* 2013, **2**:42, Epub 2013 Feb 8. PMID: 23505615. PMCID: PMC3595468
2. Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, Anand R, Yin W; Studies of Pediatric Liver Transplantation Research Group (…Sokol RJ…). [Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.](file:///%5C%5Cchildrens%5Cpubmed%5C23696264) Liver Transpl. 2013 Jul;19(7):730-40. doi: 10.1002/lt.23659. PMID:23696264
3. Sundaram SS, Alonso E, Haber B, Magee JC, Fredericks E, Kamath B, Bezerra J, Karpen S, Kerkar N, Rosenthal P, Schwarz K, Shepherd R, Shneider B, Whitington P, Limbers C, Varni JW, Robuck P, Sokol RJ for the Childhood Liver Disease Research and Education Network (ChiLDREN). Health related quality of life in biliary atresia patients surviving with their native liver. J Pediatr. 2013; 163(4):1052-1057, Epub 2013 Jun 6, PMID: 23746866
4. Molleston JP, Sokol RJ, Karnsakul W, Miethke A, Horslen S, Magee JC. Romero R, Squires R Jr., Van Hove JLK for the Childhood Liver Disease Research and Education Network (ChiLDREN). Evaluation of the child with suspected mitochondrial liver disease. J Pediatr Gastroenterol Nutr 2013;57: 269-276, PMID: 23783016
5. Lee WS, Sokol RJ. Mitochondrial hepatopathies: Advances in genetics, therapeutic approaches and outcomes. J Pediatr. 2013 Oct;163(4):942-8. doi: 10.1016/j.jpeds.2013.05.036. Epub 2013 Jun 28, PMID: 23810725
6. El Kasmi KC, Anderson AL, Devereaux MW, Zhang W, Setchell KDR, Sokol RJ. Phytosterols promote liver injury and Kupffer cell activation in parenteral nutrition associated liver disease. Sci Transl Med. 2013 Oct 9;5(206):206ra137. doi: 10.1126/scitranslmed.3006898. PMID: 24107776
7. [Alonso EM](file:///%5C%5Cchildrens%5Cpubmed%3Fterm%3DAlonso%20EM%5BAuthor%5D%26cauthor%3Dtrue%26cauthor_uid%3D23902630), [Martz K](file:///%5C%5Cchildrens%5Cpubmed%3Fterm%3DMartz%20K%5BAuthor%5D%26cauthor%3Dtrue%26cauthor_uid%3D23902630), [Wang D](file:///%5C%5Cchildrens%5Cpubmed%3Fterm%3DWang%20D%5BAuthor%5D%26cauthor%3Dtrue%26cauthor_uid%3D23902630), [Yi MS](file:///%5C%5Cchildrens%5Cpubmed%3Fterm%3DYi%20MS%5BAuthor%5D%26cauthor%3Dtrue%26cauthor_uid%3D23902630), [Neighbors K](file:///%5C%5Cchildrens%5Cpubmed%3Fterm%3DNeighbors%20K%5BAuthor%5D%26cauthor%3Dtrue%26cauthor_uid%3D23902630), [Varni JW](file:///%5C%5Cchildrens%5Cpubmed%3Fterm%3DVarni%20JW%5BAuthor%5D%26cauthor%3Dtrue%26cauthor_uid%3D23902630), [Bucuvalas JC](file:///%5C%5Cchildrens%5Cpubmed%3Fterm%3DBucuvalas%20JC%5BAuthor%5D%26cauthor%3Dtrue%26cauthor_uid%3D23902630); [Studies of Pediatric Liver Transplantation (SPLIT) Functional Outcomes Group (FOG)](file:///%5C%5Cchildrens%5Cpubmed%3Fterm%3D%22Studies%20of%20Pediatric%20Liver%20Transplantation%20%28SPLIT%29%20Functional%20Outcomes%20Group%20%28FOG%29%22%5BCorporate%20Author%5D) (…Sokol RJ…). Factors predicting health-related quality of life in pediatric liver transplant recipients in the functional outcomes group. Pediatr Transplant. 2013 Nov;17(7):605-11. doi: 10.1111/petr.12126. Epub 2013 Aug 1. PMID: 23902630
8. Mealer M, Kittelson J, Thompson BT, Wheeler AP, Magee JC, Sokol RJ, Moss M, Kahn MG. Remote source document verification in two national clinical trials networks: feasibility, accuracy and challenges. PLOS One. 2013 Dec 5;8(12):e81890. doi: 10.1371/journal.pone.0081890. PMID: 24349149
9. Sundaram SS, Sokol RJ, Capocelli KE, Pan Z, Sullivan JS, Robbins K, Halbower AC. Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric Non-Alcoholic Fatty Liver Disease. J Pediatr. 2014 Apr;164(4):699-706. e1. doi: 10.1016/j.jpeds.2013.10.072. Epub 2013 Dec 7. PMID: 24321532
10. Gallagher RC, Lam C, Wong D, Cederbaum S, and Sokol RJ. Significant hepatic involvement in ornithine transcarbamylase deficiency. J Pediatr. 2014 Apr;164(4):720-725.e6. doi: 10.1016/j.jpeds.2013.12.024. Epub 2014 Jan 30, PMID 24485820
11. Mazariegos G, Shneider B, Burton B, Fox I, Hadzic N, Kishnani P, Morton DH, McIntire S, Sokol RJ, Summar M, White D, Chcavanon V, Vockley J. Liver transplantation for pediatric metabolic disease. Mol Genet Metab. 2014 Apr;111(4):418-27. doi: 10.1016/j.ymgme.2014.01.006. Epub 2014 Jan 17. PMID 24495602
12. Sorensen LG, Neighbors K, Martz K, Zelko F, Bucuvalas JC, Alonso EM; Studies of Pediatric Liver Transplantation (SPLIT) Research Group and the Functional Outcomes Group (FOG) (… Sokol RJ…). J Pediatr. 2014 Jul;165(1):65-72.e2. doi: 10.1016/j.jpeds.2014.03.032. Epub 2014 May 5. PMID: 24801243
13. SambrottaM, StrautnieksS, PapouliE, RushtonP, ClarkBE, ParryDA, LoganCV, NewburyLJ, KamathBM, LingS, Grammatikopoulos T, WagnerBE, MageeJC, SokolRJ, Mieli-VerganiG, University of Washington Center for Mendelian Genomics, SmithJD, JohnsonCA, McCleanP, SimpsonMA, KniselyAS, BullLN, Thompson RJ. Mutations in *TJP2* cause progressive cholestatic liver disease. Nat Genet. 2014 Apr;46(4):326-8. doi: 10.1038/ng.2918. Epub 2014 Mar 9. PMID: 24614073
14. Fenner EK, Boguniewicz J, Tucker RM, Sokol RJ, Mack CL. High dose IgG therapy mitigates bile duct targeted inflammation and obstruction in a mouse model of biliary atresia. Pediatr Res 2014 Jul;76(1):72-80. doi: 10.1038/pr.2014.46. Epub 2014 Apr 11. PMID: 24727948
15. Bezerra JA, SpinoC, Magee JC, Shneider BL, Rosenthal P, Wang KS, Erlichman J, Haber B, Hertel PM, Karpen SJ, Kerkar N, Loomes KM, Molleston JP, Murray KF, Romero R, Schwarz KB, Shepherd R, Suchy FJ, Turmelle YP, Whitington PF, Moore J, Sherker AH, Robuck PR, Sokol RJ, Childhood Liver Disease Research and Education Network (ChiLDREN). Use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia: The START randomized clinical trial. JAMA. 2014 May 7;311(17):1750-9. doi: 10.1001/jama.2014.2623. PMID: 24794368
16. El Kasmi KC, Pugliese S, Riddle SR, Anderson AL, Frid MG, Li M, Pullamsetti SS, Savai R, Nagel MA, Fini MA, Graham BB, Tuder RM, Friedman JE, Eltschig HK, Sokol RJ, Stenmark KR. Adventitial fibroblasts induce a distinct pro-inflammatory/pro-fibrotic macrophage phenotype in pulmonary hypertension. J Immunol. 2014 Jul 15;193(2):597-609. doi: 10.4049/jimmunol.1303048. Epub 2014 Jun 13. PMID: 24928992
17. Ng VL, Haber B, Magee JC, Miethke A, Murray KF, Michail S, Karpen SJ, Turmelle Y , Karpen SJ, Kerkar N, Molleston JP, Romero R, Rosenthal P, Schwarz K, , Shneider BL, Alonso EM, Sokol RJ and Childhood Liver Disease Research and Education Network (ChiLDREN). Medical Status of 219 Children with Biliary Atresia Surviving Long-Term with their Native Livers: Results from a North American Multicenter Consortium. [J Pediatr.](http://www.ncbi.nlm.nih.gov/pubmed/25015575) 2014 Sep;165(3):539-546. PMID: 25015575
18. Venkat VL, Shneider BL, Magee JC, Turmelle Y, Arnon R, Bezerra JA, Hertle P, Karpen SJ, Kerkar N, Loomes KM, Molleston J, Murray KF, Ng VL, Raghunathan T, Rosenthal P, Schwartz K, Sherker AH, Sokol RJ, Teckman J, Wang K, Whitington PF, and Heubi JE, for the Childhood Liver Disease Research and Education Network (ChiLDREN). Total serum bilirubin predicts fat-soluble vitamin deficiency better than serum bile acids in infants with biliary atresia. J Pediatr Gastroenterol Nutr 2014 Dec;59(6):702-7. PMID: 25419594
19. Harris JK, El Kasmi KC, Anderson AL, Devereaux MW, Fillon SA, Robertson CE, Wagner BD, Stevens MJ, Pace NR, Sokol RJ. Specific microbiome changes in a mouse model of parenteral nutrition induced liver injury and intestinal inflammation. PLoS ONE 2014 Oct 20;9(10):e110396. PMID 25329595
20. Sullivan JS, Le MT, Pan Z, Rivard C, Love-Osborne K, Robbins K, Johnson RJ, Sokol RJ, Sundaram SS. Oral fructose absorption in obese children with non-alcoholic fatty liver disease. Pediatr Obes. 2015 Jun;10(3):188-95. PMID: 24961681
21. Ye W, Rosenthal P, Magee JC, Whitington PF, for the Childhood Liver Disease Research and Education Network (…Sokol RJ…). Factors determining delta-bilirubin levels in biliary atresia infants. J Pediatr Gastroenterol Nutr. 2015 May;60(5):659-63. PMID 25564820
22. Teckman J, Rosenthal P, Abel R, Bass LM, Michail S, Murray KF, Rudnick DA, Thomas DW, Spino C, Arnon R, Hertel PM, Heubi J, Kamath BM, Karnsakul W, Loomes KM, Magee JC, Molleston JP, Romerol R, Schneider BL, Sherker AH, Sokol RJ for the Childhood Liver Disease Research Network (ChiLDReN). Baseline analysis of a young Alpha-1-antitrypsin deficiency liver disease cohort reveals frequent portal hypertension. J Pediatr Gastroenterol Nutr 2015 Jul;61(1):94-101. PMID: 25651489
23. Flass T, Tong S, Frank DN, Wagner BD, Robertson CE, Kotter CV, Sokol RJ, Zemanick E, Accurso F, Hoffenberg EJ, Narkewicz MR. Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. PLoS ONE 2015;Feb 6;10(2):e0116967, PMID: 25658710
24. Kamath BM, Chen Z, Romero R, Fredericks E, Alonso E, Arnon R, Karpen S, Loomes KM, Miethke A, Murray KF, Rosenthal P, Schwarz KB, Subbarao G, Teckman J, Turmelle YP, Wang K, Sokol RJ, Magee J, for the Children Liver Disease Research and Education Network (ChiLDREN). Quality of life and its determinants in a multi-center cohort of children with Alagille syndrome and liver disease. J Pediatr. 2015; Aug; 167(2):390-396. PMID: 26059338
25. Sokol RJ. Portopulmonary Hypertension: Opportunities for Precision Pediatrics. J Pediatr Gastoenterol Nutr 2015; Sept; 61: 268-69. PMID: 26111300
26. Lee WS, Sokol RJ. Intestinal Microbiota, Lipids and the Pathogenesis of Intestinal Failure-Associated Liver Disease (IFALD). J Pediatr 2015 Sep; 167(3):519-26. PMID:26130113
27. Mouzaki M, Bass LM, Sokol RJ, Piccoli DA, Quammie, C, Loomes KM, Heubi JE, Hertel PM, Scheenstra R, Furuya K, Kutsch E, Spinner NB, Robbins KN, Venkat V, Rosenthal P, Beyene J, Baker A, Kamath BM. Early life predictive markers of liver disease outcome in an international, multi-center cohort of children with Alagille syndrome. Liver International 2016 May;36(5):755-60. Epub 2015 Aug 18. [Epub ahead of print] PMID: 26201540
28. Leung, DH, Ye W, Molleston JP, Weymann A, Ling S, Paranjape SM, Romero R, Schwarzenberg SJ, Palermo J, Alonso EM, Murray KF, Marshall BC, Sherker AH, Siegel MJ, Krishnamurthy R, Harned R, Karmazyn B, Magee JC, Narkewicz MR, on behalf of the Cystic Fibrosis Liver Disease Network (CFLD NET) (…Sokol RJ…). Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis. J Pediatr 2015; Oct;167(4):862-868. PMID:26254836
29. Wang KS, The Committeee on Fetus and Newborn, and The Childhood Liver Disease Research Network, Moss RL, Caty MG, Davidoff A, Fallat ME, Heiss KF, Holcomb G, Meyers RL, Thorne V, Watterberg KL, Aucott S, Benitz WE, Cummings JJ, Eichenwald EC, Goldsmith J, Poindexter BB, Puopolo K, Stewart DL, Barfield WD, Goldberg J, Lacaze T, Keels EL, Raju TN, Couto J, Kerkar N, Karpen SJ, Sokol RJ, Schwarz KB, Mogul DB, Harpavat S. Newborn Screening for Biliary Atresia. Pediatrics. 2015 Dec;136(6):e1663-9. doi: 10.1542/peds.2015-3570. PMID: 26620065
30. Shneider BL, Magee JC, Karpen SJ, Rand E, Narkewicz MR, Bass LM, Schwarz K, Whitington PF, Bezerra JA, Kerkar N, Haber B, Rosenthal P, Turmelle Y, Molleston J, Murray KF, Ng V, Wang KS, Romero R, Squires RH, Arnon R, Sherker AH, Moore J, Ye W, Sokol RJ for the Childhood Liver Disease Research and Network (ChiLDReN). Total serum bilirubin within three months of hepatoportoenterostomy predicts short-term outcomes in biliary atresia. J Pediatr 2016;170:211-17. .e1-2. doi: 10.1016/j.jpeds.2015.11.058. Epub 2015 Dec 24. PMID 26725209
31. Sokol RJ. Molecular chaperones as therapy for PFIC: Not so fast! J Pediatr Gastroenterol Nutr 2016 Mar;62(3):360-2. doi: 10.1097/MPG.0000000000001109. PMID: 26771769
32. Verkade HJ, Bezerra JA, DavenportM, Schreiber RA, Mieli-Vergani G, Hulscher JB, Sokol RJ, Kelly DA, Ure B, Whitington PF, Samyn M, Petersen C. Biliary Atresia and Other Cholestatic Childhood Diseases: Advances and Future Challenges. J Hepatology 2016 May; 65:631-42. doi: 10.1016/j.jhep.2016.04.032aaa. Epub 2016 May 6. PMID: 27164551
33. Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimback JK, Ramsay MAE, Sitbon O, Sokol RJ. International Liver Transplant Society (ILTS) Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation. 2016 Jul;100(7):1440-52. doi: 10.1097/TP.0000000000001229. PMID: 27326810
34. Sokol RJ. Newborn screening for biliary atresia – bilirubin or bust? J Pediatr Gastroenterol Nutr.(In Press) 2016 Sept; 63 (3): 312-13. Publish ahead of Print. doi: 10.1097/MPG.0000000000001242. PMID 27101537
35. SundaramSS, HalbowerA, PanZ, RobbinsK, CapocelliKE, KlawitterJ, ShearnCT, SokolRJ. Nocturnal Hypoxia Induced Oxidative Stress Promotes Progression of Pediatric Non-Alcoholic Fatty Liver Disease. J Hepatology 2016 Sep;65(3):560-9. doi: 10.1016/j.jhep.2016.04.010. Epub 2016 Aug 5. PMID: 27501738
36. Sokol RJ. A New Old Treatment for Vitamin E Deficiency in Cholestasis. J Pediatr Gastroenterol Nutr 2016;63(6):577-78. PMID:27429361
37. Sundaram SS, Mack CL, Feldman A, Sokol RJ. Biliary atresia: Indications and timing of liver transplantation and optimization of pre-transplant care. Liver Transpl. 2017;23(1): 96-109. PMID: 27650268
38. Woodruff SA, Sontag MK, Accurso FJ, Sokol RJ, Narkewicz MR. Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen. J Cystic Fibrosis 2017; 16:139-45. PMID: 27555301
39. Feldman AG, Sokol RJ, Hardison RM, Alonso EM, Squires RH, Narkewicz MR, Pediatric Acute Liver Failure Study Group. Lactate and Lactate: Pyruvate Ratio in the Diagnosis and Outcomes of Pediatric Acute Liver Failure. J Pediatrics 2017 Mar; 182:217-222. e3. doi: 10.1016/j.jpeds.2016.12.031. Epub 2017 Jan 12. PMID: 28088395
40. Russo P, Magee JC, Anders RA, Bove KE, Chung C, Cummings OW, Finegold MJ, Finn LS, Kim GE, Lovell MA, Magid MS, Melin-Aldana H, Ranganathan S, Shehata BM, Wang LL, White FV, Chen Z, Spino C; Childhood Liver Disease Research and Education Network (ChiLDReN; …Sokol RJ…). [Key Histopathologic Features of Liver Biopsies That Distinguish Biliary Atresia From Other Causes of Infantile Cholestasis and Their Correlation With Outcome: A Multicenter Study.](https://www.ncbi.nlm.nih.gov/pubmed/27776008) Am J Surg Pathol. 2016 Dec;40(12):1601-1615. PMID: 27776008
41. Wang KS, Tiao G, Bass LM, Hertel PM, Mogul D, Kerkar N, Clifton M, Azen C, Rosenthal P, Stewart D, Superina R, Arnon R, Bozic M, Brandt ML, Dilon PA, Fecteau A, Iyer K, Kamath B, Karpen S, Karrer F, Loomes KM, Mack C, Mattei P, Miethke A, Soltys K, Turmelle YP, West K, Zagory J, Goodhue C, Shneider BL, and Childhood Liver Disease Research Network (ChiLDReN; …Sokol RJ…). Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis. Hepatology 2017 May;65(5):1645-1654. PMID: 28027587
42. Shneider BL, Moore J, Kerkar N, Magee J, Ye W, Karpen SJ, Kamath B, Molleston J, Bezerra JA, Murray K, Loomes K, Whitington PF, Rosenthal P, Squires RH, Guthery S, Arnon R, Schwarz KA, Turmelle Y, Sherker AH, Sokol RJ for the Childhood Liver Disease Research Network. Initial Assessment of the Infant with Neonatal Cholestasis – Is this Biliary Atresia? PLoS ONE 2017 May 11;12(5):e0176275. doi: 10.1371/journal.pone.0176275. eCollection 2017. PMID: 28493866
43. Ng VL, Sorensen LG, Alonso EM, Fredericks EM, Ye W, Moore J, Karpen SJ, Shneider BL, Kamath BM, Molleston JP, Bezerra JA, Murray KF, Loomes KM, Whitington PF, Rosenthal P, Squires RH, Wang K, Guthery SL, Arnon R, Schwarz KB,. Turmelle YP, Haber BH, Sherker AH, Magee JC, Sokol RJ and the Childhood Liver Disease Research Network (ChiLDReN). Neurodevelopmental Outcome of Young Children with Biliary Atresia and Native Liver: Results from the Childhood Liver Diseases Research Network (ChiLDReN).  J Pediatr. 2018 May;196:139-147.e3. doi: 10.1016/j.jpeds.2017.12.048. Epub 2018 Mar 5. PMID: 29519540
44. Lee WS, Wong SY, Ivy DD, Sokol RJ. Hepatopulmonary Syndrome and Portopulmonary Hypertension in Children: Recent Advances in Diagnosis and Management. J Pediatr. 2018 May;196:14-21.e1. doi: 10.1016/j.jpeds.2017.12.068. Epub 2018 Mar 5. PMID: 29514741
45. El Kasmi KC, Vue PM, Anderson AL,Devereaux MW, Balasubramaniyan N, Woods C, Wright CJ, McKenna S, Suchy FJ, and Sokol RJ. Macrophage-derived IL-1β-NFkB signaling mediates Parenteral Nutrition Associated Cholestasis. Nat Commun. 2018 Apr 11;9(1):1393. doi: 10.1038/s41467-018-03764-1. PMID: 29643332
46. Sundaram SS, Halbower A, Klawitter J, Pan Z, Robbins K, Cappocelli KE, Sokol RJ. Treating obstructive sleep apnea and chronic intermittent hypoxia improves pediatric NAFLD severity. J Pediatr. 2018 Jul;198:67-75.e1. doi: 10.1016/j.jpeds.2018.03.028. Epub 2018 May 8. PMID: 29752170
47. Bezerra JA, Wells RG, Mack CL, Karpen SJ, Hoofnagle J, Doo E, Sokol RJ. BILIARY ATRESIA: Clinical and Research Challenges for the 21st century. Hepatology 2018; 68:1163-1173. PMID:29604222
48. Larson AA, Baker PR II, Milev MP, Press C, Sokol RJ, Cox MO, Lekostaj JK, Stence AA, Bossler AD, Mueller JM, Prematilake K, Tadjo TF, Williams CA, Sacher M, Moore SA. *TRAPPC11* and *GOSR2* mutations associate with hypoglycosylation of α-dystroglycan and muscular dystrophy**.** Skelet Muscle 2018 May 31;8(1):17. doi: 10.1186/s13395-018-0163-0. PMID: 29855340
49. Loomes KM, Spino C, Goodrich NP, Hangartner TN, Marker AE, Heubi JE, Kamath BM, Shneider BL, Rosenthal P, Hertel PM, Karpen SJ, Kerkar N, Molleston JP, MJurry KF, Schwarz KB, Squires RH, Teckman J, Turmelle YP, Whitington PF, Sherker AH, Magee JC, Sokol RJ for the Childhood Liver Disease Research Network (ChiLDReN). Bone Density in Children with Chronic Liver Disease Correlates with Growth and Cholestasis. Hepatology. 2019 Jan;69(1):245-257. doi: 10.1002/hep.30196. Epub 2018 Dec 27. PMID: 30063078
50. Alonso EM, Ye W, Hawthorne K, Venkat V, Loomes KM, Mack CL, Hertel PM, Karpen SJ, Kerkar N, Molleston JP, Murray KF, Romero R, Rosenthal P, Schwarz KB, Shneider BL, Suchy FJ, Turmelle YP, Wang KS, Sherker AH, Sokol RJ, Bezerra JA, Magee JC and the ChiLDReN Network. Impact of Steroid Therapy on Early Growth in Infants with Biliary Atresia: The multi-center START trial. J Pediatr. 2018 Nov; 202:179-185.e4. doi: 10.1016/j.jpeds.2018.07.002. Epub 2018 Sep 21. PMID: 30244988
51. Shneider GL, Spino C, Kamath BM, Magee JC, Whitington JF, Setchell KD, Miethke A, Molleston JP, Mack CL, Squires RH, Murray KF, Loomes KM, Rosenthal P, Karpen SJ, Leung DH, Guthery SL, Thomas D, Sherker AH, Sokol RJ, for the Childhood Liver Disease Research Network (ChiLDReN). Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in Alagille Syndrome. Hepatol Commun. 2018 Sep 24;2(10):1184-1198. doi: 10.1002/hep4.1244. eCollection 2018 Oct. PMID: 30288474
52. Mack CL, Spino C, Whitington PF, Bezerra JA, Moore J, Goodhue C, Ng V, Karpen SJ, Venkat V, Loomes KM, Wang K, Sherker AH, Magee JC, Sokol RJ. A Phase I/IIa Trial of Intravenous Immunoglobulin (IVIg) Therapy Following Portoenterostomy in Infants with Biliary Atresia (PRIME Study). J Pediatr Gastroenterol Nutr. 2019 Apr;68(4):495-501. doi: 10.1097/MPG.0000000000002256 PMID: 30664564
53. Berauer J-P, Mezina AI, Okou DT, Sabo A, Hegde MR, Chopra P, Perlmutter DH, Bull LN, Thompson RJ, Loomes KM, Spinner NB, Rajagopalan R, Guthery SL, Moore B, Shneider BL, Magee JC, Kamath BM, Molleston JP, Bezerra JA, Murray KF, Alonso EM, Rosenthal P, Squires RH, Sherker AH, Sokol RJ, Wang KS, for the Childhood Liver Disease Research Network ChiLDReN), Karpen SJ. Identification of *PKD1L1* Gene Variants in Children with the Biliary Atresia Splenic Malformation Syndrome. Hepatology. 2019 Sep;70(3):899-910. doi: 10.1002/hep.30515. Epub 2019 Mar 21. PMID: 30664273
54. Feldman AG, Sokol RJ. Neonatal Cholestasis: Emerging molecular diagnostics and potential novel therapeutics. Nat Rev Gastroenterol Hepatol. 2019 June; 16 (6): 346-360. doi: 10.1038/s41575-019-0132-z. PMID: 30903105
55. Kim S, Moore J, Bednarek J, Bezerra JA, Goodhue C, Karpen SJ, Loomes KM, Magee JC, Ng VL, Sherker AH, Smith C, Spino C, Venkat V, Wang K, Whitington PF, Sokol RJ, Mack CL, for the Childhood Liver Disease Research Network. Correlation of Immune Markers with Outcomes in Biliary Atresia Following Intravenous Immunoglobulin Therapy. Hepatol Communic 2019 Mar 25;3(5):685-696. doi:10.1002/hep4.1332. PMID: 31061956
56. Sundaram SS, Swidersak-Syn M, Sokol RJ, Halbower AC, Capocelli KE, Pan Z, Robbins K, Diehl AM. Nocturnal Hypoxia Activation of the Hedgehog Signaling Pathway in Pediatric NAFLD disease severity. Hepatol Communic 2019 Apr 17;3(7):883-893. doi: 10.1002/hep4.1354. eCollection 2019 Jul. PMID: 31334441
57. Squires JE, Ng VL, Hawthorne K, Henn L, Sorensen LG, Fredericks EM, Alonso EM, Murray KF, Loomes KM, Karpen SJ, Cavallo LA, Molleston JP, Bezerra JA, Rosenthal P, Squires RJ, Wang KS, Schwarz KB, Arnon R, Magee JC, Sokol RJ, Childhood Liver Disease Research Network (ChiLDReN). Neurodevelopmental Outcomes in Pre-School and School Aged Children with Biliary Atresia and their Native Liver: Results from the Childhood Liver Disease Research Network. J Pediatr Gastroenterol Nutr 2020 Jan;70(1):79-86. doi: 10.1097/MPG.0000000000002489.PMID: 31503218
58. Balasubramaniyan N, Devereaux MW, Orlicky D, Sokol RJ, Suchy, FJ. Upregulation of miR-let7a-5p Leads to Decreased Expression of ABCC2 in Obstructive Cholestasis. Hepatol Communic 2019 Sep 27;3(12):1674-1686. doi: 10.1002/hep4.1433. eCollection 2019 Dec. PMID: 31832574
59. Khalaf RT, Sokol RJ. New insights into intestinal failure associated liver disease in children. Hepatology 2020 Apr; 71 (4):1486-1498. doi: 10.1002/hep.31152. Epub 2020 Mar 18. PMID: 32003009
60. Jestin M, Kapnick SM, Tarasenko TN, Burke CT, Zerfas PM,Diaz F, Vernon H, Singh LN, Sokol RJ, McGuire PJ. Mitochondrial disease disrupts hepatic allostasis and lowers the threshold for immune-mediated liver toxicity. Mol Metab. 2020 Jul;37:100981. doi: 10.1016/j.molmet.2020.100981. Epub 2020 Mar 26. PMID: 32283081
61. Kamath BM, Spino C, McLain R, Magee JC, Fredericks EM, Setchell KD, Miethke A, Molleston JP, Mack CL, Squires RH, Alonso EM, Murray KF, Loomes KM, Jensen MK, Karpen SJ, Rosenthal P, Thomas D, Sokol RJ, Shneider BL, for the Childhood Liver Disease Research Network (ChiLDReN). Unraveling the relationship between itching, scratch scales, and biomarkers in children with Alagille syndrome. Hepatol Commun. 2020 May 26;4(7):1012-1018. doi: 10.1002/hep4.1522. eCollection 2020 Jul.. PMID: 32626833: PMC7327199
62. Lee, WS, Chew KS, Ng RT, El Kasmi KC, Sokol RJ. Intestinal Failure-Associated Liver Disease (IFALD): Insights into Pathogenesis and Advances in Management. Hepatol Int. 2020 May;14(3):305-316. doi: 10.1007/s12072-020-10048-8. Epub 2020 Apr 30. Hepatol Int. 2020. PMID: 32356227
63. Cooper DM, Guay-Woodford L, Blazar BR, Bowman S, Byington CL, Dome J, Forthal D, Konstan MW, Kuppermann N, Liem RI, Ochoa Jr ER, Pollock BH, Price OA, Ramsey BW, Ross LF, Sokol RJ, Wright RJ, Re-Opening Schools Safely: The Case for Collaboration, Constructive Disruption of Pre-COVID Expectations, and Creative Solutions. J Pediatr2020 Aug;223:183-185. doi: 10.1016/j.jpeds.2020.05.022. Epub 2020 May 21. PMID: 32445649
64. Teckman J, Rosenthal P, Hawthorne K, Spino C, Bass LM, Murray KF, Kerkar N, Magee JC, Karpen S, Heubi JE, Molleston JP, Squires RH, Kamath BM, Guthery SL, Loomes KM, Sherker AH, Sokol RJ, ChiLDReN (Childhood Liver Disease Research Network). Longitudinal Outcomes in Young Patients with Alpha-1-Antitrypsin Deficiency with native liver reveal that neonatal cholestasis is a poor predictor of future portal hypertension. J Pediatr. 2020 Dec; 227:81-86. e4. doi: 10.1016/j.jpeds.2020.07.031. Epub 2020 Jul 11. PMID: 32663593
65. FeldmanAG, Sokol RJ. Recent Developments in diagnostics and treatment of neonatal cholestasis. Semin Pediatr Surg. 2020 Aug;29(4):150945. doi: 10.1016/j.sempedsurg.2020.150945. Epub 2020 Jul 23. PMID: 32861449
66. Shneider BL, Goodrich NP, Ye W, Sawyers C, Molleston JP, Merion RM, Leung DH, Karpen SJ, Kamath BM, Cavallo L, Wang K, Teckman JH, Squires JE, Sundaram SS, Rosenthal P, Romero R, Murray KF, Loomes KM, Jensen MK, Bezerra JA, Bass LM, Sokol RJ, Magee JC, Childhood Liver Disease Research Network (ChiLDReN). Nonfasted Liver Stiffness Correlates with Liver Disease Parameters and Portal Hypertension in Pediatric Cholestatic Liver Disease. Hepatol Commun. 2020 Aug 5;4(11):1694-1707. doi: 10.1002/hep4.1574. eCollection 2020 Nov. PMID: 33163838
67. Venkat V, Ng VL, Magee JC, Ye W, Hawthorne K, Harpavat S, Molleston JP, Murray KF, Wang KS, Soufi N, Bass LM, Alonso EM, Bezerra JA, Jensen MK, Kamath BM, Loomes KM, Mack CL, Rosenthal P, Shneider BL, Squires RH, Sokol RJ, Karpen SJ, for the Childhood Liver Disease Research Network (ChiLDReN). Modeling outcomes in children with biliary atresia with native liver after 2 years of age. Hepatol Commun. 2020 Oct 3;4(12):1824-1834. doi: 10.1002/hep4.1602. eCollection 2020 Dec. PMID: 33305153
68. Kamath BM, Ye W, Goodrich NP, Loomes KM, Romero R, Heubi JE, Leung DH, Spinner NB, Piccoli DA, Alonso EM, Guthery SL, Karpen SJ, Mack CL, Molleston JP, Murray KF, Rosenthal P, Squires JE, Teckman J, Wang KS, Thompson R, Magee JC,Sokol RJ; Childhood Liver Disease Research Network (ChiLDReN). [Outcomes of Childhood Cholestasis in Alagille Syndrome: Results of a Multicenter Observational Study.](https://pubmed.ncbi.nlm.nih.gov/33313463/)  Hepatol Commun. 2020 Jan 22;4(3):387-398. doi: 10.1002/hep4.1468. eCollection 2020 Mar. PMID: 33313463
69. Karpen SJ, Kamath BM, Alexander JJ, Ichetovkin I, Rosenthal P, Sokol RJ, Dunn S, Thompson RJ, Heubi JE. Use of a Comprehensive 66-Gene Cholestasis Sequencing Panel in 2171 Cholestatic Infants, Children, and Young Adults. J Pediatr Gastroenterol Nutr 2021 May 1;72(5):654-660. doi: 10.1097/MPG.0000000000003094. PMID: 33720099
70. van Wessel DBE, Thompson RJ, Gonzales E, Jankowska I, Shneider BL, Sokal E, Grammatikopoulos T, Kadaristiana A, Jacquemin E, Spraul A, Lipiński P, Czubkowski P, Rock N, Shagrani M, Broering D, Algoufi T, Mazhar N, Nicastro E, Kelly D, Nebbia G, Arnell H, Fischler B, Hulscher JBF, Serranti D, Arikan C, Debray D, Lacaille F, Goncalves C, Hierro L, Muñoz Bartolo G, Mozer-Glassberg Y, Azaz A, Brecelj J, Dezsőfi A, Luigi Calvo P, Krebs-Schmitt D, Hartleif S, van der Woerd WL, Wang JS, Li LT, Durmaz Ö, Kerkar N, Hørby Jørgensen M, Fischer R, Jimenez-Rivera C, Alam S, Cananzi M, Laverdure N, Targa Ferreira C, Ordonez F, Wang H, Sency V, Mo Kim K, Chen HL, Carvalho E, Fabre A, Quintero Bernabeu J, Alonso EM, Sokol RJ, Suchy FJ, Loomes KM, McKiernan PJ, Rosenthal P, Turmelle Y, Rao GS, Horslen S, Kamath BM, Rogalidou M, Karnsakul WW, Hansen B, Verkade HJ; Natural Course and Prognosis of PFIC and Effect of Biliary Diversion Consortium. Impact of genotype, serum bile acid concentrations and surgical biliary diversion on native liver survival in FIC1 deficiency. Hepatology. 2021 Aug;74(2):892-906. doi: 10.1002/hep.31787. Epub 2021 Jul 13. PMID: 33666275
71. Hertel PM, Bull LN, Thompson RJ, Goodrich NP, Ye W, Magee JC, Squires RH, Bass LM, Heubi JE, Kim GE, Ranganathan S, Schwarz KB, Bozic MA, Horslen SP, Clifton MS, Turmelle YP, Suchy FJ, Superina RA, Wang KS, Loomes KM, Kamath BM, Sokol RJ, Shneider BL; Childhood Liver Disease Research Network (ChiLDReN). [Mutation Analysis and Disease Features at Presentation in a Multi-Center Cohort of Children with Monogenic Cholestasis.](https://pubmed.ncbi.nlm.nih.gov/34016879/) J Pediatr Gastroenterol Nutr. 2021 Aug 1;73(2):169-177. doi: 10.1097/MPG.0000000000003153. PMID: 34016879
72. Hertel PM, Hawthorne K, Kim S, Finegold MJ, Shneider BL, Squires JE, Gupta N, Bull LN, Murray KF, Kerkar N, Ng VL, Molleston JP, Bezerra JA, Loomes KM, Taylor SA, Schwarz KB, Turmell YP, Rosenthal P, Magee JC, Sokol RJ, and the Childhood Liver Disease Research Network (ChiLDReN). Presentation and Outcomes of Infants with Idiopathic Cholestasis: A Multi-Center Prospective Study. J Pediatr Gastroenterol Nutr. 2021 Oct 1;73(4):478-484. doi: 10.1097/MPG.0000000000003248. PMID: 34310436. PMID: 3431043
73. Benam CH, Baler G, Duke R, McNeal DM, Muller, KA, Bodine C, Morrato E, Sokol RJ. Fostering Innovation at Academic Medical Centers: The Case of University of Colorado Anschutz Medical Campus. J Clin Transl Sci. 2021 May 17;5(1):e148. doi: 10.1017/cts.2021.792. eCollection 2021. PMID: 3452728
74. Ghosh S, Devereaux MW, Anderson AL, Gehre S, Reisz J, D’Alessandro A, Orlicky D, Lovell M, El Kasmi KC, Shearn CT, Sokol RJ. NFkB regulation of LRH-1 and *ABCG5/8* potentiates phytosterol role in the pathogenesis of parenteral nutrition associated cholestasis. Hepatology. 2021 Dec;74(6):3284-3300. doi: 10.1002/hep.32071. Epub 2021 Aug 27. PMID: 34310734
75. El KasmiKIC, GhoshS, AndersonAL, DevereauxMW, Balasubramaniyan N, D’Alessandro A, Orlicky DJ, Suchy FJ, Shearn CT, Sokol RJ. Pharmacologic activation of farnesoid X receptor prevents parenteral nutrition associated cholestasis in mice. Hepatology 2022 Feb;75(2):252-265. doi: 10.1002/hep.3210s1. Epub 2021 Dec 7. PMID: 34387888
76. Leung DH, Sorensen LG, Ye W, Hawthorne K, Kamath BM, Ng V, Loomes KM, Fredericks E, Alonso E, Bezerra J, Horslen S, Karpen SJ, Molleston J, Rosenthal P, Sokol RJ, Squires R, Wang K, Magee J, for Childhood Liver Disease Research Network (ChiLDReN). Neurodevelopmental Outcomes in Children with Inherited Cholestatic Liver Disease and Native Liver: Results of a Multicenter Prospective Observational Study. J Pediatr Gastroenterol Nutr. 2022 Jan 1;74(1):96-103. doi: 10.1097/MPG.0000000000003337. E Pub 2021 Oct 22. PMID: 34694263
77. Balasubramaniyan N, Devereaux MW, Sokol RJ, Suchy FJ. miR-199a-5p Regulates the Expression of *ABCB11* in Obstructive Cholestasis. J Biol Chem. 2021 Dec;297(6):101400. doi: 10.1016/j.jbc.2021.101400. Epub 2021 Nov 12. PMID: 34774795
78. Feldman AG, Sokol RJ. Neonatal Cholestasis: Updates on Diagnostics, Therapeutics and Prevention. Neoreviews. 2021 Dec 1;22(12): e819-e836. doi: 10.1542/neo.22-12-e819.PMID: 34850148
79. Boster J, Feldman A, Mack CL, Sokol RJ, Sundaram SS. Malnutrition in biliary atresia: assessment, management, and outcomes. Liver Transpl. 2022 Mar; 28 (3):483-92. Oct 20. doi: 10.1002/lt.26339. Epub 2021 Nov 10. PMID: 3466924
80. El Kasmi KC, Anderson AL, Devereaux MW, Balasubramaniyan N, Lovell M,Suchy FJ, Shearn CT, Sokol RJ. Interrupting Tumor Necrosis Factor-Alpha Signaling Prevents Parenteral Nutrition Associated Cholestasis in Mice. JPEN J Parenter Enteral Nutr.
JPEN Journal ofParenteral and Enteral Nutrition. 2021:1-11.https://doi.org/10.1002/jpen.22792EL KASMIET AL1106Nutr.2022;46:1096–1106.https://doi.org/10.1002/jpen.2279JParenterEnteral2022;46;1096-1106. <https://doi.org/10.1002/jpen.2279>. Epub 2021 Nov 18. PMID: 34664730
81. Fischler B, Czubkowski P, Dezsofi A, Liliemark U, Socha P, Sokol RJ, Svensson JF, Davenport M. Incidence, impact, and treatment of ongoing CMV infection in patients with biliary atresia in four European Centres. J Clin Med. 2022 Feb 11;11(4):945. doi: 10.3390/jcm11040945.PMID: 35207217
82. Bass LM, Ye W, Hawthorne K, Leung DH, Murray KF, Molleston JP, Romero R, Karpen S, Rosenthal P, Loomes KM, Wang KS, Squires RH, Miethke A, Ng VL, Horslen S, Jensen MK, Sokol RJ, Magee J, Shneider BL, ChiLDReN. The Risk of Variceal Hemorrhage and Pre-Transplant Mortality in Children with Biliary Atresia. Hepatology. 2022 Sept; 76 (3): 712-726. doi: 10.1002/hep.32451. PMID: 35271743
83. Shneider BL, Kamath BM, Magee JC, Goodrich NP, Loomes KM, Ye W, Spino C, Alonso EM, Molleston JP, Bezerra JA, Wang KS, Karpen SJ, Horslen SP, Guthery SL, Rosenthal P, Squires R, Sokol RJ, Childhood Liver Disease Research Network (ChiLDReN). Use of Funded Multicenter Prospective Longitudinal Databases to Inform Clinical Trials in Rare Diseases – Examination of Cholestatic Liver Disease in Alagille Syndrome. Hepatol Commun. 2022 Aug;6(8):1910-1921. doi: 10.1002/hep4.1970. Epub 2022 May 4. PMID: 35506349
84. Shneider BL, Spino C, Kamath BM, Magee JC, Ignacio RV, Huang S, Horslen SP, Molleston JP, Miethke AG, Kohli R, Leung DH, Jensen M, Loomes KM, Karpen SJ, Mack CL, Rosenthal P, Squires RH, Baker A, Rajwal S, Kelly D, Sokol RJ, Thompson RJ; for ChiLDReN and UK IMAGO/IMAGINE Investigators. Impact of Long-term Administration of Maralixibat on Children with Cholestasis Secondary to Alagille syndrome. Hepatol Commun.  2022 Aug;6(8):1922-1933. doi: 10.1002/hep4.1992. Epub 2022 Jun 7. PMID: 35672955
85. Kamath BM, Alonso EM, Heubi HE, Karpen SJ, Sundaram SS, Shneider BL, Sokol RJ. Fat-soluble Vitamin Assessment and Supplementation in Cholestasis. Clinics in Liver Disease 2022; Aug;26(3):537-553. doi: 10.1016/j.cld.2022.03.011. Epub 2022 Jun 25. PMID: 35868689
86. Porto A, Pan Z, Zhou W, Sokol RJ, Klaczkiewicz K, Sundaram SS. Sugar Intake is Associated with Histologic Disease Severity in Adolescents with Non-Alcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2022 Nov 1;75(5):666-674. doi: 10.1097/MPG.0000000000003578. Epub 2022 Jul 28. PMID: 35897136
87. Chaidez A, Pan Z, Sundaram SS, Boster J, Lovell M, Sokol RJ, Mack CL. The Discriminatory Ability of FibroScan® Liver Stiffness Measurement, Controlled Attenuation Parameter and FibroScan®-aspartate aminotransferase to Predict Severity of Liver Disease in Children. Hepatol Commun. 2022 Nov;6(11):3015-3023. doi: 10.1002/hep4.1983. Epub 2022 Sep 7. PMID: 36069338
88. Leung DH, Devaraj S, Goodrich NP, Chen X, Rajapakshe D, Ye W, Andreev V, Minard CG, Guffey D, Molleston JP, Bass LM, Karpen SJ, Kamath BM, Wang KS, Sundaram SS, Rosenthal P, McKiernan P, Loomes KM, Jensen MK, Horslen SP, Bezerra JA, Magee JC, Merion RM, Sokol RJ, Shneider BL, Alonso E, Bass L, Kelly S, Riordan M, Melin-Aldana H, Bezerra J, Bove K, Heubi J, Miethke A, Tiao G, Denlinger J, Chapman E, Sokol R, Feldman A, Mack C, Narkewicz M, Suchy F, Sundaram SS, Van Hove J, Garcia B, Kauma M, Kocher K, Steinbeiss M, Lovell M, Loomes KM, Piccoli D, Rand E, Russo P, Spinner N, Erlichman J, Stalford S, Pakstis D, King S, Squires R, Sindhi R, Venkat V, Bukauskas K, McKiernan P, Haberstroh L, Squires J, Rosenthal P, Bull L, Curry J, Langlois C, Kim G, Teckman J, Kociela V, Nagy R, Patel S, Cerkoski J, Molleston JP, Bozic M, Subbarao G, Klipsch A, Sawyers C, Cummings O, Horslen SP, Murray K, Hsu E, Cooper K, Young M, Finn L, Kamath BM, Ng V, Quammie C, Putra J, Sharma D, Parmar A, Guthery S, Jensen K, Rutherford A, Lowichik A, Book L, Meyers R, Hall T, Wang KS, Michail S, Thomas D, Goodhue C, Kohli R, Wang L, Soufi N, Thomas D, Karpen S, Gupta N, Romero R, Vos MB, Tory R, Berauer JP, Abramowsky C, McFall J, Shneider BL, Harpavat S, Hertel P, Leung D, Tessier M, Schady D, Cavallo L, Olvera D, Banks C, Tsai C, Thompson R, Doo E, Hoofnagle J, Sherker A, Torrance R, Hall S, Magee J, Merion R, Spino C, Ye W; Childhood Liver Disease Research Network. Serum biomarkers correlated with liver stiffness assessed in a multi-center study of pediatric cholestatic liver disease. Hepatology. 2023 Feb 1;77(2):530-545. doi: 10.1002/hep.32777. Epub 2022 Nov 3. PMID: 36069569
89. HarpavatS, Hawthorne K, Setchell KD, Rivas MN, Henn L, Beil C, Karpen SJ, Ng V, Alonso EM, Bezerra JA, Guthery SL, Horslen S, Loomes KM, McKiernan P, Magee JC, Merion R, Molleston JP, Rosenthal P, Thompson R, Wang KS, Sokol RJ, Shneider BL, for Childhood Liver Disease Research Network (ChiLDReN). Serum bile acids as a new prognostic marker in biliary atresia following portoenterostomy. Hepatology. 2022 Sep 21. doi: 10.1002/hep.32800. Online ahead of print. PMID: 36131538
90. Shearn CT, Anderson AL, Devereaux MW, Orlicky DH, Michel C, Petersen DR, Miller CG, Harpavet S, Schmidt EE, Sokol RJ. The autophagic protein p62 is a target of reactive aldehydes in human and murine cholestatic liver disease. PLoS One. 2022 Nov 15;17(11):e0276879. doi: 10.1371/journal.pone.0276879. eCollection 2022. PMID: 36378690
91. Felzen A, van Wessel DBE, Gonzales E, Thompson RJ, Jankowska I, Shneider BL, Sokal E, Grammatikopoulos T, Kadaristiana A, Jacquemin E, Spraul A, Lipiński P, Czubkowski P, Rock N, Shagrani M, Broering D, Nicastro E, Kelly D, Nebbia G, Arnell H, Fischler B, Hulscher JBF, Serranti D, Arikan C, Polat E, Debray D, Lacaille F, Goncalves C, Hierro L, Muñoz Bartolo G, Mozer-Glassberg Y, Azaz A, Brecelj J, Dezsőfi A, Calvo PL, Grabhorn E, Hartleif S, van der Woerd WJ, Kamath BM, Wang JS, Li L, Durmaz Ö, Kerkar N, Jørgensen MH, Fischer R, Jimenez-Rivera C, Alam S, Cananzi M, Laverdure N, Ferreira CT, Guerrero FO, Wang H, Sency V, Kim KM, Chen HL, de Carvalho E, Fabre A, Bernabeu JQ, Zellos A, Alonso EM, Sokol RJ, Suchy FJ, Loomes KM, McKiernan PJ, Rosenthal P, Turmelle Y, Horslen S, Schwarz K, Bezerra JA, Wang K, Hansen BE, Verkade HJ; NAtural course and Prognosis of PFIC and Effect of biliary Diversion (NAPPED) Consortium. Genotype-phenotype relationships of p.E297G, p.D482G and predicted protein truncating mutations in bile salt export pump deficiency. JHEP Rep. 2022 Nov 16;5(2):100626. doi: 10.1016/j.jhepr.2022.100626. eCollection 2023 Feb. PMID: 36687469
92. Shearn CT, Anderson AL, Miller CG, Noyd RC, Devereaux MW, Balasubramaniyan N, Orlicky GJ, Schmidt EE, Sokol RJ. Thioredoxin Reductase 1 regulates hepatic inflammation and macrophage activation during acute cholestatic liver injury. Hepatol Commun. 2023 Jan 10;7(1):e0020. doi: 10.1097/HC9.0000000000000020. eCollection 2023 Jan 1. PMID: 36633484
93. Ghosh S, Devereaux MW, Anderson AL, El Kasmi KC, Sokol RJ. STAT3 role in the protective effect of FXR agonist in parenteral nutrition associated cholestasis. Hepatol Commun. 2023 Feb 27;7(3):e0056. doi: 10.1097/HC9.0000000000000056. eCollection 2023 Mar 1. PMID: 36848082.
94. Wynia MK, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, Mayer DA, Ong TC, Russell S, Steele J, Stocker HR, Wogu AF, Zane RD, Sokol RJ, Ginde AA. Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. medRxiv. 2022 Jan 11:2022.01.09.22268963. doi: 10.1101/2022.01.09.22268963. Preprint. PMID: 35043117. Chest. 2023 May;163(5):1061-1070. doi: 10.1016/j.chest.2022.10.020. Epub 2022 Oct 28. PMID: **36441040**
95. Ghosh S, Devereaux MW, Orlicky DJ, Sokol RJ. Pharmacologic inhibition of HNF4α prevents parenteral nutrition associated cholestasis in mice. Sci Rep 2023 May 12;13(1):7752.doi: 10.1038/s41598-023-33994-3. Published Erratum: Sci Rep. 2023 Jul 19;13(1):11673.

 doi: 10.1038/s41598-023-38001-3. PMID: **37173326**

1. Squires JE, Miethke AG, Valencia CA, Hawthorne K, Henn L, VanHove J, Squires RH, Bove K, Horslen S, Kohli R, Molleston JP, Romero R, Alonso EM, Bezerra JA, Guthery SL, Hsu E, Karpen SJ, Loomes KM, Ng VL, Rosenthal P, Mysore K, Wang KS, Friederich MW, Magee JC, Sokol RJ, on behalf of Childhood Liver Disease Research Network (ChiLDReN). Clinical Spectrum and Genetic Causes of Mitochondrial Hepatopathy Phenotype in Children. Hepatol Commun 2023 May 15;7(6):e0139. doi: 10.1097/HC9.0000000000000139. eCollection 2023 Jun 1. PMID: 37184518
2. Sokol RJ, Gonzales EM, Kamath BM, Baker A, Vig P, Mogul DB, Garner W, Hansen BE, Jacquemin E, Thompson RJ. Predictors of 6-Year Event-Free Survival in Patients with Alagille Syndrome Treated with Maralixibat, an Ileal Bile Acid Transporter Inhibitor. Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502. Online ahead of print. PMID: 37278241
3. [Thaweethai T](https://jamanetwork.com/searchresults?author=Tanayott+Thaweethai&q=Tanayott+Thaweethai), [Jolley SE](https://jamanetwork.com/searchresults?author=Sarah+E.+Jolley&q=Sarah+E.+Jolley), [Karlson EW](https://jamanetwork.com/searchresults?author=Elizabeth+W.+Karlson&q=Elizabeth+W.+Karlson), et al., …. for the RECOVER Consortium (…Sokol RJ…). Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023 Jun 13;329(22):1934-1946. doi: 10.1001/jama.2023.8823.PMID: 37278994
4. Kemme S, Canniff JD, Feldman AG, Garth KM, Li S, Pan Z, Sokol RJ, Weinberg A, Mack CL. Cytomegalovirus in Biliary Atresia is associated with increased pre-transplant death, but not decreased native liver survival. Hepatol Commun. 2023 Jul 17;7(8):e0175. doi: 10.1097/HC9.0000000000000175. eCollection 2023 Aug 1. PMID: 37471052
5. Thompson RJ, Artan R, Baumann U, Calvo PL, Czubkowski P, Dalgic B, D'Antiga L, Di Giorgio A, Durmaz Ö, Gonzalès E, Grammatikopoulos T, Gupte G, Hardikar W, Houwen RHJ, Kamath BM, Karpen SJ, Lacaille F, Lachaux A, Lainka E, Loomes KM, Mack CL, Mattsson JP, McKiernan P, Ni Q, Özen H, Rajwal SR, Roquelaure B, Shteyer E, Sokal E, Sokol RJ, Soufi N, Sturm E, Tessier ME, van der Woerd WL, Verkade HJ, Vittorio JM, Wallefors T, Warholic N, Yu Q, Horn P, Kjems L.Interim Results from an Ongoing, Open-Label, Single-Arm Trial of Odevixibat in Progressive Familial Intrahepatic Cholestasis. JHEP Rep. 2023 Apr 29;5(8):100782. doi: 10.1016/j.jhepr.2023.100782. eCollection 2023 Aug. PMID: 37456676.

**MANUSCRIPTS SUBMITTED**

1. Guthery SL, Moore MB, Thirumangalakudi L, Yandell M, Bull L, Kamath BM, Karpent SJ, Loomes KM, Sokol RJ, Thompson RT, Alonso EM, Asai A, Bell CA, Horslen S, Magee JC, Molleston JP, Rosenthal P, Shnerider BL, Spinner NB, Squires RH, Wang KS, Teckman, for the Childhood Liver Disease Research Network (ChiLDReN). Exome sequencing identifies the *USP20* gene as a candidate modifier of severe liver disease in childhood A1AT deficiency. Submitted (Sci Rep)
2. Teckman J, Rosenthal P, Ignacio RV, Spino C, Bass LM, Horslen S, Wang K, Magee JC, Karpen SJ, Asai A, Molleston JP, Squires RH, Kamath BM, Guthery S, Loomes KM, Shneider B, Sokol RJ, for Childhood Liver Disease Research Network (ChiLDReN). Neonatal Cholestasis in Children with Alpha-1-AT Deficiency is a Risk for Earlier Severe Liver Disease with Male Predominance. Submitted (Sci Rep)
3. Taylor SA, Harpavat S, Miska J, Gromer K, Andreev V, Loomes KM, Bezerra JA, Jarasvaraparn C, Wang K, Horslen S, Rosenthal P, Teckman J, Valentino PL, Ng VL, Karpen SJ, Sokol RJ, Chandel NS, Alonso EM, Mack CL for the Childhood Liver Disease Research Network (ChiLDReN). Distinct immune-metabolic signatures at diagnosis of biliary atresia are associated with future survival with native liver. Submitted (Hepatology)
4. Van Hove JLK, Friederich MW, Strode DK, Van Hove RA, Miller KR, Estrella J, Gabel L, Horslen S, Kohli R, Lovell MA, Miethke A, Molleston JP, Romero R, Squire J, Squires R, Alonso E, Guthery SS, Kamath B, Loomes K, Rosenthal P, Shneider B, Valentino P, Sundaram SS, Magee J, Sokol RJ, on behalf of the Childhood Liver Disease Research Network (ChiLDReN). Protein biomarkers GDF15 and FGF21 to Differentiate Mitochondrial Hepatopathies from Other Pediatric Liver Diseases. Submitted (Hepatology)
5. Stahl MG, Shaw JR, Eduthan NP, Rachubinsi AL, Smith K, Galbraith MD, Sokol RJ, Chavan S, Leaton LA, Kichula KM, Norman PJ, Norris JM, Liu E, Espinosa J. Multi-omics assessment of genetic risk for celiac disease in Down Syndrome. Submitted (J Pediatr Gastroenterol Nutr). Preprint, medRxiv. **doi:** https://doi.org/10.1101/2022.09.27.22280436
6. Boster JM, Goodrich NP, Spino C, Loomes KM, Alonso EM, Kamath BM, Sokol RJ, Karpen S, Miethke A, Shneider B, Molleston J, Kohli R, Horslen S, Guther S, Rosenthal P, Valention P, Teckman J, Sundaram SS, and the Childhood Liver Disease Research Network (ChiLDReN). Sarcopenia in School-aged Children with Genetic Intrahepatic Cholestasis and its Correlation with Bone Mineral Density. Submitted (Hepatol Communic)
7. Shearn CT, Anderson AL, Devereaux MW, El Kasmi K, Sokol RJ. Expression of circadian regulatory genes is dysregulated by increased cytokine production in mice subjected to concomitant intestinal injury and parenteral nutrition. Submitted (PLOS One)
8. Sindhu Pandurangi, Reena Mourya, Shreya Nalluri, Lin Fei, Shun Dong, Sanjiv Harpavat, Stephen L Guthery, Girish S. Rao, Philip Rosenthal, Ronald J Sokol, Kasper S. Wang, Estella M. Alonso, Evelyn K. Hsu, Saul J. Karpen, Kathleen M Loomes, John C. Magee, Benjamin L. Shneider, Robert H. Squires, Jeffrey H. Teckman, Jorge A Bezerra, and Childhood Liver Disease Research Network. Diagnostic Accuracy of Serum Matrix Metalloproteinase-7 as a Biomarker of Biliary Atresia in a Large North American Cohort. Submitted (Hepatology)
9. Brigham D, Capocelli K, Hoffenberg EJ, Sokol RJ. Gastrointestinal Polypoid Lesions Associated with Extrahepatic Portal Vein Obstruction: Portal Hypertensive Polyps. Submitted (J Clinical Case Reports)

**B. BOOKS and MONOGRAPHS**

1. Hambidge KM, Sokol RJ, Fidanza S, Krebs N: *Guidelines for Pediatric Parenteral Nutrition*. Handbook for Children’s Hospital Colorado. 1992
2. Executive Editor. Sokol RJ: *Children's Liver Research Agenda - a Scientific Blueprint to Help Families Coping with Liver Disease*, American Liver Foundation, 1996
3. Hambidge, KM, Krebs NF, Sokol RJ, Fidanza S: *Guidelines for Use of Pediatric Parenteral Nutrition*. University of Colorado Health Sciences Center and Children’s Hospital Colorado. 1997.
4. Editor. Sokol RJ: *Pediatric Liver Research Agenda 2000 – a blueprint for the future*, Children's Liver Council of the American Liver Foundation, 2000 (99 pp.) and *J Pediatr Gastroenterol Nutr* 2002;35: Supplement 1:S1-S57
5. Editor. Sokol RJ: *Report of the Working Groups-2000 - "A Global Plan for the Future of the Digestive and Nutritional Health of Children".* FirstWorld Congress of Pediatric Gastroenterology, Hepatology and Nutrition. Boston, MA. 2000, (264 pp.) and *J Pediatr Gastroenterol Nutr* 2002;35: Supplement 2:S1-S23
6. Editor. Suchy FJ, Sokol RJ, Balistreri WF (eds): *Liver Disease in Children*, *2nd Edition*, Lippincott, Williams & Wilkins, Philadelphia, 2001 (992 pp.)
7. Guest Editor. Sokol RJ, Feranchak AD (eds):  *Genetic and metabolic basis of pediatric liver diseases.* (Complete Issue) *Seminars in Liver Disease*, 2001;21:469-595.
8. Editor. Suchy FJ, Sokol RJ, Balistreri WF (eds): *Liver Disease in Children*, 3*nd Edition*, Cambridge University Press, New York, 2007 (1,030 pages)
9. Guest Editor. Sokol RJ: *Pediatric liver disease: translating discoveries into practice*. (Complete Issue) *Seminars in Liver Disease*, 2007;27: 231-322.
10. Editor. Sokol RJ, Daniels SR. *The Future of Pediatrics: a Festschrift for M. Douglas Jones, Jr., MD.*  *J Pediatr* 2007 (Suppl) 151: S1-S36
11. Guest Editor, *FISPGHAN Working Group Reports for 3rd World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, J Pediatr Gastroenterol Nutr* 2008;47:214-272
12. Editor. Suchy FJ, Sokol RJ, Balistreri WF (eds): *Liver Disease in Children*, *4th Edition*, Cambridge University Press, Cambridge, 2014 (815 pages)
13. Editor. Suchy FJ, Sokol RJ, Balistreri WF, Bezerra JA, Mack CL, Shneider BL (eds): *Liver Disease in Children*, *5th Edition*, Cambridge University Press, Cambridge, 2021 (861 pages)
	* 1. **C. BOOK CHAPTERS, INVITED ARTICLES & REVIEWS**

1. Sokol RJ and Barkin R: Pyloric Stenosis. Emergindex(R), 1984.

 2. Balistreri WF and Sokol RJ: Nutritional consequences of chronic cholestasis in childhood: vitamin E deficiency. In: Holm E, Kasper H (eds). *Proceedings of Falk Symposium #41*, *Metabolism and Nutrition in Liver Disease*. MTP Press Limited, Lancaster, 1985, pp. 181‑190.

 3. Hammond KB, Reardon MC, Accurso FJ, Abman SH, Cotton EK, Pinney M, Fisher C, Sokol RJ, Ask CG, Watts DC, Bonner M‑A: Early detection and follow‑up of cystic fibrosis in newborns: The Colorado experience. In: *Genetic Disease: Screening and Management*. Alan R. Liss, Inc., 1986. pp. 81‑101.

 4. Sokol RJ: Medical management of the infant or child with chronic liver disease. Sem Liv Dis 1987; 7:155‑167.

 5. Accurso F, Reardon M, Abman S, Pinney M, Cotton E, Sokol RJ, Hammond K: Early abnormalities in infants with cystic fibrosis diagnosed through newborn screening. Insights into Pediatrics: Clinical Implications of Screening for Cystic Fibrosis in the Newborn. Proceedings of a meeting held in Peterborough, UK, June, 1986. 1987; 1:29‑33.

 6. Sokol RJ: Diagnosis and treatment of vitamin E deficiency during cholestasis. In: Hayaishi 0, Mino M (eds): *Clinical and Nutritional Aspects of Vitamin E*. Elsevier, Amsterdam, 1987. pp. 169‑181.

 7. Kayden HJ, Sokol RJ, Traber MG: Familial vitamin E deficiency in the absence of fat malabsorption. In: Hayaishi 0, Mino M (eds): *Clinical and Nutritional Aspects of Vitamin E*. Elsevier, Amsterdam, 1987. pp. 193‑197.

 8. Sokol RJ: Vitamin E deficiency and neurologic disease. Ann Rev Nutr 1988; 8:351‑373.

 9. Sokol RJ: Vitamin E and neurologic function in man. Free Rad Biol Med 1989; 6:189‑207.

10. Sokol RJ: "Vitamin E in Human Health". Vitamin Information Status Paper. Hoffmann‑LaRoche, Basel, 1989.

11. Sokol RJ: Medical Management of Neonatal Cholestasis. In: Balistreri WF, Stocker JT (eds): *Pediatric Hepatology*. Hemisphere, New York, 1990, pp 41‑76.

12. Sokol RJ: Fulminant Hepatic Failure in Infants and Children. In: Balistreri WF, Stocker JT (eds): *Pediatric Hepatology*. Hemisphere, New York, 1990, pp 315‑362.

13. Sokol RJ: Vitamin E and neurologic deficits. Advances in Pediatrics 1990, 37:119­-148.

14. Sokol RJ. Accurso F, Abman SH, Hammond K, Stall C: Nutritional issues in cystic fibrosis. In: Balistreri WF, Vanderhoof J (eds), *Pediatric Gastroenterology and Nutrition*. Chapman Hall Medical 1990, pp 273‑295,

15. Silverman A, Sokol RJ: Liver and Pancreas. In: Hathaway W, Hay W, Paisley J, Groothuis J (eds): *Current Pediatric Diagnosis and Treatment*. 10th Edition. Lange Medical Publications, Los Altos 1990, pp 573‑607.

16. Taylor SF, Sokol RJ: Infants with short bowel syndrome. In: Hay WW (ed). *Neonatal Nutrition and Metabolism*. Mosby Year Book Medical Publishers, St. Louis, 1991. pp 432‑51.

17. Sokol RJ: Copper Storage Disease. In: Kaplowitz N (ed): *Liver and Biliary Disease*. Williams and Wilkins. Baltimore, 1992; pp. 322‑333.

18. Sokol RJ: Vitamin deficiency and replacement in cholestasis. In: *Pediatric Cholestasis: novel approaches to treatment*. Proceedings of Falk Symposium No. 63. Kluwer Academic Publishers, Dordrecht, 1992, pp. 289‑304.

19. Sokol RJ: Lipid Peroxidation in cholestasis. In: *Pediatric Cholestasis: novel approaches to treatment.* Proceedings of Falk Symposium No. 63. Kluwer Academic Publishers, Dordrecht, 1992, pp. 75‑81.

20. Balistreri WF, A‑Kader HH, Ryckman FC, Heubi JE, Setchell KDR and UDCA Study Group (Sokol RJ): Ursodeoxycholic acid therapy in paediatric patients with chronic cholestasis. IN: *Pediatric cholestasis: Novel approaches to treatment*. Kluwer Academic Publishers, Dordrecht, 1992; pp. 333‑344.

21. Silverman A, Sokol RJ. Liver and Pancreas. IN: Hathaway W, Hay W, Paisley J, Groothuis J (eds), *Current Pediatric Diagnosis and Treatment*. 11th Edition. Lange Medical Publications. Los Altos, 1992, pp 610‑647.

22. Sokol RJ: Vitamin E deficiency and neurologic disorders. In: Packer L, Fuchs J (eds). *Vitamin E in Health and Disease*. Marcel‑Dekker, New York 1993; pp. 815‑850.

23. Sokol RJ: Fulminant hepatic failure and hepatic coma. In: Roy CC, Alagille D, Silverman A (eds). *Pediatric Clinical Gastroenterology*. CV Mosby, St. Louis, 4th Edition, 1995, pp 734-760.

24. Hambidge M, Sokol RJ, Krebs N: Energy and nutrient requirements. In: Roy CC, Alagille D, Silverman A (eds). *Pediatric Clinical Gastroenterology*. CV Mosby, St. Louis, 4th Edition, 1995, pp 1005-1019.

25. Sokol RJ: Acquired and Non‑acquired Vitamin E Deficiency States. In: *Japanese Journal of Pediatric Gastroenterology*. 1995.

26. Ramirez RO, Sokol RJ: Medical management of cholestasis. In: Suchy FJ (ed). *Liver Disease in Children*. Mosby, St. Louis, 1994, pp 356-388.

27. Sokol RJ: Wilson's disease and Indian childhood cirrhosis. In: Suchy FJ (ed). *Liver Diseases in Children*. Mosby, St. Louis, 1994, pp 747-772.

28. Sokol RJ, Narkewicz MR: Mitochondrial hepatopathies. In: Suchy FJ (ed). *Liver Diseases in Children*. Mosby, St. Louis, 1994, pp 888-896.

29. Hambidge M, Sokol RJ, Krebs N: Infant feeding. IN: Roy CC, Alagille D, Silverman A (eds). *Pediatric Clinical Gastroenterology*. CV Mosby, St. Louis, 4th Edition, 1995, pp 1020-1029.

30. Hambidge M, Sokol RJ, Krebs N: Enteral and parenteral alimentation. In: Roy CC, Alagille D, Silverman A (eds). *Pediatric Clinical Gastroenterology*. CV Mosby, St. Louis, 4th Edition, 1995, pp 1030-1045.

31. Sokol RJ, Narkewicz MR, Silverman A: Liver and Pancreas. In: Hay W, Groothuis J, Hayward AR, Levin MJ (eds). *Current Pediatric Diagnosis and Treatment*. 12th Edition, Appleton & Lange, Norwalk, Conn., 1994; pp. 643-682.

32. Sokol RJ: Fat-soluble vitamins and their importance in patients who have cholestatic liver disease. Gastroenterol Clin North Am, 1994; 23:673-705.

33. Sokol RJ: At long last - an animal model for Wilson's disease. Hepatology Elsewhere section of Hepatology, 1994; 20:533-535.

34. Sokol RJ, Breeling JL: Vitamin E - A spectrum of therapeutic and preventive applications. VERIS, La Grange, 1994.

35. Sokol RJ: Copper storage diseases. In: Kaplowitz N (ed). *Liver and Biliary Disease*, 2nd Edition, Williams and Wilkins, Baltimore, MD, 1996, pp. 363-376.

36. Sokol RJ: Metabolism and disorders of vitamin E in infancy and childhood. International Seminars in Pediatric Gastroenterology and Nutrition, 1995; 4:8-15.

37. Sokol RJ, Hoffenberg EJ: Antioxidants in pediatric gastrointestinal disease. Pediatr Clin North Am, 1996; 43:471-488.

38. Sokol RJ: Vitamin E. In: Ziegler EE, Filer LJ, Jr. (eds) *Present Knowledge in Nutrition.* 7th Edition. ILSI Press, Washington, DC, 1996:130-136.

39. Balistreri WF, Grand R, Suchy FJ, Ryckman FC, Perlmutter DH, Sokol RJ: Biliary atresia: Current concepts and research directions. Summary of a symposium. Hepatology 1996;23:1682-1692.

40. Sokol RJ: Antioxidant defenses in metal induced liver damage. Sem Liver Dis 1996;16:39-46..

41. Ferenci P, Gilliam PC, Gitlin JD, Packman S, Schilsky ML, Sokol RJ and Sternlieb I: An international symposium on Wilson’s and Menkes’ diseases. Hepatology 1996;24:952-58.

1. Sokol RJ, Narkewicz MR: Liver and Pancreas. In: Hay W, Groothuis J, Hayward AR, Levin MJ (eds). *Current Pediatric Diagnosis and Treatment*. 13th Edition, Appleton & Lange, Norwalk, Conn., 1997, pp. 568-606.
2. Sokol RJ. Management of nutritional complications of cholestasis. In: Nousia-Arvanitakis S, Karagiozoglou-Lampoudi T (eds). *Frontiers of treatment in paediatric gastroenterology*. University Studio Press, Thessaloniki, 1997, pp. 84-100.
3. Colletti RB, Winter HS, Sokol RJ, Suchy FJ, Klish WJ, Durie PR. Pediatric gastroenterology workforce survey and future supply and demand. J Pediatr Gastroenterol Nutr 1998;26:106-115.
4. Sokol RJ. Total parenteral nutrition-related liver disease. Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih. (Acta Pediatrica Sinica) 1998;38:418-428.
5. Sokol, RJ, Papas AM. Antioxidants and neurologic diseases. In: Papas AM (ed), *Antioxidant Status, Diet, Nutrition and Health*. CRC Press, Boca Raton, 1999; pp. 567-590.
6. Sokol RJ, Narkewicz MR. Liver and Pancreas. In: Hay, W, Hayward AR, Levin MJ, Sondheimer J (eds). *Current Pediatric Diagnosis and Treatment*. 14th Edition, Appleton & Lange, Norwalk, Conn., 1999, pp. 559-598.
7. Treem WR, Sokol RJ. Disorders of mitochondria. Sem Liv Dis 1998;18:237-253.
8. Sokol RJ, Treem WE. Mitochondria and childhood liver diseases. J Pediatr Gastroenterol Nutr. 1999;28:4-16.
9. Sokol RJ, Durie P, and the Cystic Foundation Hepatobiliary Disease Consensus Group*. Recommendations for management of liver and biliary tract disease in Cystic Fibrosis*. Cystic Fibrosis Foundation Consensus Document, 1998.
10. Setchell KDR, Schwarz M, O’Connell NC, Lund EG, Davis DL, Lathe R, Sokol RJ, Russell DW. A mutation in the oxysterol 7α-hydroxylase gene causes severe liver disease and highlights the quantitative importance of the acidic pathway for bile acid synthesis in humans. Proceedings of Falk Symposium No. 108, “Bile acids and cholestasis”, Kluwer Academic Publishers, Lancaster, England, 1999; pp. 213-219.
11. Sokol RJ. Alagille syndrome: a nutritional niche for Notch. J Pediatr 1999;134:136-138. (Editorial)
12. Feranchak A, Sokol RJ. How many wrongs make a right (or a left)? - Vertebrate asymmetry unraveled.

*New and Views section*, J Pediatr Gastroenterol Nutr, 1999;28:239-41.

1. Sokol RJ, Jonas M, Picolli D. Training in hepatobiliary disorders. In:  *NASPGN Guidelines for Training in Pediatric Gastroenterology*. J Pediatr Gastroenterol Nutr 1999;29 (Suppl 1):S15-S18
2. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D, and participants (… Sokol RJ…) of the Cystic Fibrosis Foundation Consensus Conference on Adult Care. Cystic fibrosis adult care consensus conference report. *CF Consensus Conferences- Concepts in CF Care*. Volume IX, Section 3, July 1999, pp. 1-57.
3. Sokol RJ. The chronic disease of childhood obesity - the sleeping giant has awakened. J Pediatr (Editorial) 2000;136:711-713.
4. Suchy FJ, Burdelski, M, Fujisawa T, Sokol RJ, Tomar BS. Working Group on Cholestatic Liver Diseases, In: Sokol RJ (ed). *Report of the Working Groups of the World Congress of Pediatric Gastroenterology, Hepatology and Nutrition - a global plan for the future of the digestive and nutritional health of children*, 2000; pp. 49-60.
5. Sokol RJ. Liver cell injury and fibrosis. In: Sokol RJ (editor). *Pediatric Liver Research Agenda*, Children's Liver Council of the American Liver Foundation, 2000; pp. 20-26.
6. Sokol RJ, Treem WE. Mitochondrial hepatopathies in infants and children: primary and secondary disorders (Hepatopatias Mitocondriais em Lactentes e em Criancas: Disturbios Primarios e Secundarios) In: da Costa Gayotto LC, Alves VAF (eds.). *Diseases of the Liver and Biliary Tract, (Doencas do Figado e Vias Biliares)* , Atheneu, Sao Paulo, 2001; pp. 335-347.
7. Sokol RJ, Narkewicz MR. Liver and Pancreas. In: Hay, W, Hayward AR, Levin MJ, Sondheimer J (eds). *Current Pediatric Diagnosis and Treatment*. 15th Edition, Lange Medical Books/McGraw Hill, NewYork, 2001; pp.569-608.
8. Sokol RJ, Narkewicz MR. Copper and iron storage disorders. In: Suchy F, Sokol RJ, Balistreri WF (eds). *Liver Disease in Children*, 2*nd Edition*, Lippincott, Williams &Wilkins, Philadelphia, 2001; pp. 595-640 .
9. Feranchak AP, Ramirez RO, Sokol RJ. Medical and nutritional management of cholestasis. In: Suchy F, Sokol RJ, Balistreri WF (eds). *Liver Disease in Children*, 2*nd Edition*, Lippincott, Williams &Wilkins, Philadelphia, 2001; pp. 195-238.
10. Sokol RJ, Treem W. Mitochondrial hepatopathies. In: Suchy F, Sokol RJ, Balistreri WF (eds). *Liver Disease in Children*, *2nd Edition*, Lippincott, Williams &Wilkins, Philadelphia, 2001; pp. 787-810.
11. Sokol RJ: American Liver Foundation Releases Pediatric Liver Research Agenda. *News and Views*, J Pediatric Gastroenterol Nutr 2001;32:236
12. Bonacini M, Gelfand EW, Sjogren MH, Sokol RJ, Hoefs JC, Martin P, Bain VG, Louie SG. Immunoprophylaxis of Hepatitis A and B. Inter@ctive Information Solutions. 2001
13. Sokol RJ, Feranchak AM. Forward. Seminars in Liver Disease. 2001; 21:469-70
14. Sokol RJ, Mack C. Etiopathogenesis of biliary atresia. Seminars in Liver Disease. 2001; 21:517-24.
15. Feranchak AM, Sokol RJ. Cholangiocyte biology and cystic fibrosis liver disease. Seminars in Liver Disease. 2001; 21:471-488
16. Sokol RJ. Introduction to the Pediatric Liver Research Agenda: a blueprint for the future. In: *Pediatric Liver Research Agenda*, Journal of Pediatr Gastroenterol and Nutr, 2002(Suppl. 1);35:S2-S3
17. Sokol RJ. Liver injury and fibrosis. In: *Pediatric Liver Research Agenda*, Journal of Pediatric Gastroenterology and Nutrition, 2002 (Suppl. 1);35:S7-S10
18. Sokol RJ. Report of the Working Groups of the First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition: A global plan for the future of the digestive and nutritional health of children. Journal of Pediatr Gastroenterol and Nutr 2002(Suppl. 2);35:S61

1. Suchy FJ, Burdelski, M, Fujisawa T, Sokol RJ, Tomar BS. Cholestatic liver diseases - Working Group Report for the First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatr Gastroenterol and Nutr 2002(Suppl. 2);35: S89-S99
2. Sokol RJ: 50 Years Ago in The Journal of Pediatrics. Congenital biliary atresia. Report of three cases; two occurring in one family. J Pediatr, 2002;140:546.
3. Sokol RJ, Narkewicz MR. Liver and Pancreas. In: Hay, W, Hayward AR, Levin MJ, Sondheimer J (eds). *Current Pediatric Diagnosis and Treatment*. 16th Edition, Lange Medical Books/McGraw Hill, NewYork, 2003, pp. 647-692.
4. Sokol RJ. Metabolic diseases of the liver. Chapter 113, In: Yamada T (ed). *Textbook of Gastroenterology and Hepatology*. Lippincott Williams & Wilkins, Philadelphia. 2003:2397-2415.
5. Sokol RJ, Lovell MA. Metabolic diseases of the liver. *In:* Yamada T (ed)*. Atlas of Gastroenterology*, *Third Edition*. Lippincott Williams & Wilkins, Philadelphia. 2003:661-665
6. Sokol RJ. New North American research network focuses on biliary atresia and neonatal liver disease. *J Pediatr Gastroenterol Nutr* 2003;36:1
7. Gillis LA, Sokol RJ. Gastrointestinal Manifestations of Mitochondrial Disease. *Gastroenterol Clin North Am* 2003;32:789-817
8. O’Connor JA, Sokol RJ. Neonatal Cholestasis and Biliary Atresia. In: Jonson LR (ed). *Encyclopedia of Gastroenterology*, Elsevier, USA, 2004; 696-706
9. Feranchak AP, Sokol RJ. Vitamins. In*: Pediatric Nutrition Handbook*, 5th edition, American Academy of Pediatrics, 2003: 339-365.
10. Sokol RJ, Narkewicz MR. Liver and Pancreas. In: Hay, W, Levin MJ, Sondheimer J, Deterding R (eds). *Current Pediatric Diagnosis and Treatment*, 17th Edition, Lange Medical Books/McGraw Hill, NewYork, 2005:660-706
11. Sokol RJ, Bruno R, Traber M. Vitamin E and Vitamin K Metabolism (Chapter 70). In: Johnson LR (ed), *Physiology of the Gastrointestinal Tract, Fourth Edition*, Academic Press, 2006: 1773-1789.
12. Hoofnagle JH, Sokol RJ. Neonatal Screening for Biliary Atresia. *Hepatology* 2006;43:646.
13. Sokol RJ, Narkewicz MR. Liver and Pancreas (Chapter 21). In: Hay, WS, Levin MJ, Sondheimer JM, Deterding RR (eds). *Current Pediatric Diagnosis and Treatment*, 18th Edition, Lange Medical Books/McGraw Hill, NewYork, 2007: 638-83.
14. Feranchak A, Sokol RJ. Medical and Nutritional Management of Cholestasis in the Infant and Child. (Chapter 10) In: Suchy FJ, Sokol RJ, Balistreri WF. *Liver Disease in Children,* Cambridge University Press, New York, 2007:190-231
15. O’Connor J, Sokol RJ. Copper metabolism and copper storage disorders. (Chapter 26) In: Suchy FJ, Sokol RJ, Balistreri WF. *Liver Disease in Children*, Cambridge University Press, New York, 2007:626-660.
16. Sokol RJ. Mitochondrial hepatopathies. (Chapter 33) In: Suchy FJ, Sokol RJ, Balistreri WF. *Liver Disease in Children*, Cambridge University Press, New York, 2007:803-829.
17. Sokol RJ. Presentation of the 2006 Shwachman Award to Judith M. Sondheimer, MD. J Pediatr Gastroenterol Nutr 2007:44:1.
18. Sokol RJ. Pediatric liver disease: translating discoveries into practice. *Semin Liver Dis*, 2007;27:231-32
19. Lee W, Sokol RJ. Liver disease in mitochondrial disorders. *Semin Liver Dis*, 2007;27:259-273
20. Sokol RJ. Corticosteroid treatment in biliary atresia: tonic or toast? (Editorial) Hepatology 2007;46:1675-78
21. Sokol RJ, Daniels S. The Future of Pediatrics: Festschrift for M. Douglas Jones, Jr., MD. *J Pediatr* 2007 151(Suppl):S1-S2.
22. Feranchak AP, Sokol RJ. Vitamins. In*: Pediatric Nutrition Handbook, 6th edition*, American Academy of Pediatrics, 2007
23. Sundaram SS, Sokol RJ. The multiple facets of ABCB4 (MDR3) deficiency. *Curr Treat Options Gastroenterol.* 2007;10:495-503.
24. Sokol RJ. Swiss outcomes in Biliary Atresia: Are there lessons to be learned? (Editorial) J Pediatr Gastroenterol Nutr 2008;46:238-40
25. Sokol RJ, Narkewicz MR. Liver and Pancreas (Chapter 21). In: Hay, WS, Levin MJ, Sondheimer JM, Deterding RR (eds). *Current Pediatric Diagnosis and Treatment*, 19th Edition, Lange Medical Books/McGraw Hill, NewYork, 2009;609-650
26. Kurbegov AC, Sokol RJ. Hepatitis B therapy in children. Expert Rev Gastroenterol Hepatol. 2009;3:39-49
27. Sokol RJ. Biliary atresia screening: why, when and how? (Commentary). Pediatrics 2009;123: e951-2
28. Sokol RJ. Metabolic diseases of the liver. In: Yamada T (ed). *Textbook of Gastroenterology and Hepatology*. Wiley-Blackwell Publishing, Oxford 2009; 2223-2246.
29. Sokol RJ, Lovell MA. Metabolic diseases of the liver. *In:* Yamada T (ed)*. Atlas of Gastroenterology*, *Fourth Edition*. Wiley-Blackwell Publishing, Oxford; 2009: 676-679.
30. Brumbaugh D, Sokol RJ. Treatment of chronic hepatitis B virus infection in children. Current Hepatitis Reports 2010 (in press).
31. Sokol RJ. Reloading against rare liver diseases. (Editorial). J Pediatr Gastroenterol Nutr. 2010 Jan;50(1):9-10. 2009 Nov 12. [Epub ahead of print] PMID: 19915492
32. Sokol RJ, Mack CL. Biliary atresia and the Ductal Plate. In: Murray KF and Larson AM (ed.), *Fibrocystic Diseases of the Liver*, Humana Press, New York, 2010:179-199
33. Sokol RJ, Narkewicz MR. Liver and Pancreas (Chapter 21). In: Hay, WS, Levin MJ, Sondheimer JM, Deterding RR (eds). *Current Pediatric Diagnosis and Treatment*, 20th Edition, Lange Medical Books/McGraw Hill, NewYork, 2011: 631-73.
34. Waasdorp-Hurtado C, Sokol RJ, Rosen H. Alpha-1 Antitrypsin Deficiency and Other Metabolic Liver Diseases. In: Friedman LS, Keeffe EB (eds). *Handbook of Liver Disease, 3rd Edition,* Elsevier, Philadelphia, 2011; 245-258
35. Lu BR, Sokol RJ. Special considerations in pediatric liver transplantation. (Chapter 38)In: Clavien P-A and Trotter JF (eds). *Medical Care of the Liver Transplant Patient (Fourth Edition)*. Wiley-Blackwell, Oxford England, 2012; 419- 429
36. Sundaram SS, Sokol RJ. Inborn Errors of Bile Acid Biosynthesis. In: Valle D, Beaudet A, Vogelstein B, Kinzler K, Antonarakis S, Ballabio A (ed), *Metabolic and Molecular Basis of Inherited Disease*, McGraw-Hill, 2012.
37. Sokol RJ, Narkewicz MR. Liver and Pancreas (Chapter 22). In: Hay, WS, Levin MJ, Sondheimer JM, Deterding RR (eds). *Current Pediatric Diagnosis and Treatment*, 21st Edition, Lange Medical Books/McGraw Hill, NewYork, 2012 pp. 663-706
38. Feldman A, Sokol RJ. Neonatal cholestasis. NeoReviews 2013; 14:e63-e73
39. Feldman A, Sokol RJ. Alpha-1 antitrypsin deficiency: an important cause of pediatric liver disease. Lung Health Professional Magazine. 2013;4:8-11
40. Feranchak A, Suchy FJ, Sokol RJ. Medical and Nutritional Management of Cholestasis in the Infant and Child. (Chapter 10) In: Suchy FJ, Sokol RJ, Balistreri WF (eds.). *Liver Disease in Children,*Fourth Edition Cambridge University Press, Cambridge, 2014; pp. 419-434
41. Sokol RJ. Copper metabolism and copper storage disorders. (Chapter 28) In: Suchy FJ, Sokol RJ, Balistreri WF (eds.). *Liver Disease in Children*, Fourth Edition Cambridge University Press, Cambridge, 2014, pp. 465-492
42. Sokol RJ. Mitochondrial hepatopathies. (Chapter 35) In: Suchy FJ, Sokol RJ, Balistreri WF (eds.). *Liver Disease in Children*, Fourth Edition, Cambridge University Press, Cambridge, 2014, pp. 603-630.
43. Soden J, Sokol RJ. Intestinal failure-associated liver disease. (Chapter 15) In: Suchy FJ, Sokol RJ, Balistreri WF (eds.). *Liver Disease in Children*, Fourth Edition, Cambridge University Press, Cambridge, 2014, pp. 234-246.
44. Sokol RJ, Narkewicz MR, Sundaram SS, Mack CL. Liver and Pancreas (Chapter 22). In: Hay, WS, Levin MJ, Deterding RR, Abzug M (eds.). *Current Diagnosis & Treatment: Pediatrics.* 22nd Edition, McGraw-Hill Education, NewYork, 2014; pp. 695-741.
45. Sundaram SS, Sokol RJ. Metabolic Diseases of the Liver. In: Podolsky DK, Camilleri M, Fitz JG, Kalloo AN, Shanahan F, Wang TC (eds). *Yamada’s* *Textbook of Gastroenterology and Hepatology*, 6th Edition, Wiley-Blackwell Publishing, Oxford, 2015 (in press).
46. Sokol RJ, Lovell M. Metabolic Diseases of the Liver. In: Podolsky DK, Camilleri M, Fitz JG, Kalloo AN, Shanahan F, Wang TC (eds). *Yamada’s Atlas of Gastroenterology and Hepatology*, 5th Edition, Wiley-Blackwell Publishing, Oxford, 2016; pp. 419-22.
47. Feldman A, Sokol RJ. Non-cirrhotic portal hypertension in the pediatric population. Clinical Liver Disease, 2015;5:116-19.
48. Sokol RJ, Narkewicz MR, Sundaram SS, Mack CL. Liver and Pancreas (Chapter 22). In: Hay, WS, Levin MJ, Deterding RR, Abzug M (eds.). *Current Diagnosis & Treatment: Pediatrics.* 23rd Edition, McGraw-Hill Education, NewYork, 2016; pp.653-698
49. Waasdorp-Hurtado C, Sokol RJ, Rosen H. Alpha-1 Antitrypsin Deficiency and Other Metabolic Liver Diseases (Chapter 20). In: Friedman LS, Martin P (eds). *Handbook of Liver Disease 4th Edition,* Elsevier, Philadelphia, 2018; pp. 269-281
50. Sokol RJ, Narkewicz MR, Sundaram SS, Mack CL. Liver and Pancreas (Chapter 22). In: Hay, WS, Levin MJ, Deterding RR, Abzug MJ (eds.). *Current Diagnosis & Treatment: Pediatrics.* 24th Edition, McGraw-Hill Education, NewYork, 2018: 669-715.
51. Sokol RJ, Narkewicz MR, Mark J, Mack CL Feldman AG, Sundaram SS. Liver and Pancreas (Chapter 22). In: Hay, WS, Levin MJ, Abzug MJ, Bunik M (eds.). *Current Diagnosis & Treatment: Pediatrics.* 25th Edition, McGraw-Hill Education, NewYork, 2020;657-703.
52. Larsen, A, Sokol RJ. Mitochondrial hepatopathies. Chapter 35. In: Suchy FJ, Sokol RJ, Balistreri WF (eds.). *Liver Disease in Children*, Fifth Edition, Cambridge University Press, Cambridge, 2021:628-652.
53. Sokol RJ. Copper metabolism and copper storage disorders. Chapter 28. In: Suchy FJ, Sokol RJ, Balistreri WF (eds.). *Liver Disease in Children*, Fifth Edition, Cambridge University Press, Cambridge, 2021; 484-514.
54. Suchy FJ, Sokol RJ. Medical and Nutritional Management of Cholestasis in the Infant and Child. Chapter 9. In: Suchy FJ, Sokol RJ, Balistreri WF (eds.). *Liver Disease in Children,* Fifth Edition, Cambridge University Press, Cambridge, 2021:166-146.
55. Sokol RJ, Mark J, Mack CL, Feldman AG, Sundaram SS. Liver and Pancreas (Chapter 22). In: Hay, WS, Levin MJ, Abzug MJ, Bunik M (eds.). *Current Diagnosis & Treatment: Pediatrics.* 26th Edition, McGraw-Hill Education, NewYork, 2022
56. Sokol RJ, Mark JA, Mack CL, Feldman AG, Sundaram SS, Boster J. Liver and Pancreas (Chapter 22). In: Hay, WS, Levin MJ, Abzug MJ, Bunik M (eds.). *Current Diagnosis & Treatment: Pediatrics.* 27th Edition, McGraw-Hill Education, NewYork, 2024 (submitted)
	* 1. **OTHER PUBLICATIONS, NON-PUBLISHED DOCUMENTS, REPORTS, RESEARCH OR POLICY PAPERS, LAY PRESS**
57. Sokol RJ: A progressive neurologic syndrome in children with chronic liver disease. (Selected Review). J Pediatr Gastroenterol and Nutr 1982; 1:153.

1. Sokol RJ: Arteriohepatic dysplasia I. Pitfalls in diagnosis and management. Arteriohepatic dysplasia II: Hepatobiliary morphology. (Selected Review), J Pediatr Gastroenterol Nutr 1984; 3:317‑318.
2. Sokol RJ and Balistreri WF: Vitamin E deficiency ‑ a "new" consequence of cholestatic liver disease. Nutrition and the M.D. 1984; X:1‑3.
3. Sokol RJ: Chronic diarrhea in childhood. Audio Digest © 1984.
4. Sokol RJ and Heubi JE: "Vitamin E and Cholestasis". (Reply to Selected Summary). Gastroenterology 1985; 88:589.
5. Lilly JR and Sokol RJ: On the bile sludge syndrome or is TPN cholestasis a surgical disease? (Commentary). Pediatrics 1985; 76:992‑993.
6. Sokol RJ: Bovine milk lipoprotein lipase transfers tocopherol to human fibroblasts during triglyceride hydrolysis in vitro. (Selected Review). J Ped Gastroenterol Nutr 1986; 5:336.
7. Sokol RJ: Assessing vitamin E status in childhood cholestasis. (Editorial). J Pediatr Gastroenterol Nutr 1987; 6:10‑13.
8. Sokol RJ: Eferol(R) hepatotoxicity (Commentary). Yearbook of Pediatrics, 1987. pp. 50‑51.
9. Sokol RJ: Progressive neuronal degeneration of childhood with liver disease‑‑a pathological study. (Selected Review). J Pediatr Gastroenterol Nutr 1987; 6:484‑485.
10. Sokol RJ: The coming of age of vitamin E (Editorial). Hepatology 1989; 9:649‑653.
11. Sokol RJ et al: Intestinal malabsorption of vitamin E in primary biliary cirrhosis. Gastroenterology Digest 1989; 6:21‑22.
12. Schwarz S, Neu J, Sokol RJ: "All About Infant Formulas". AAP‑Pediatric Update ­Audio Tape for American Academy of Pediatrics, 1991.
13. Tsang RE, Greer FR, Sokol RJ: "Fat‑soluble vitamins". AAP‑Pediatric Update ­Audio tape for American Academy of Pediatrics 1992; 13(2):1‑12.
14. Sokol RJ, Balistreri WF, Suchy FJ: Liver Diseases in Childhood. IN: Kaplowitz N (Ed). A Research Agenda for 25 Million Americans: Research Goals and Strategies to Treat, Prevent, and Conquer Liver Disease, 1995, pp 5-11.
15. Sokol RJ: The expanding spectrum of mitochondrial disorders (Editorial). J Pediatr 1996;128:597-599.
16. Sokol RJ: Liver injury - factors in recovery. In: Children's Liver Research Agenda, American Liver Foundation, 1997, p. 14.
17. Sokol RJ: Moderator, Questions and answers. "Intestinal problems in children", Audio-Digest Gastroenterology, 1997; volume 11, number 07.
18. Sokol RJ: "New recommendations for managing liver disease in cystic fibrosis," *Highlights from Postgraduate Course sponsored by the North American Society for Pediatric Gastroenterology and Nutrition*, Audio-Digest, Gastroenterology, Volume 14, Issue 06, June, 2000
19. Sokol RJ: The price tag of living donor liver transplantation. (This Month in the Journal: The Editors’ perspective). J Pediatr 2004;144:1A
20. Bezerra J, Sokol RJ. A challenge on the use of the words *embryonic* and *perinatal* in the context of biliary atresia. Reply to Letter to the Editor. Hepatology. 2005 41:404-405
21. Whitworth J, Sokol RJ. Hepato-portopulmonary Disorders – Not Just in Adults! (Editorial) J Pediatr Gastroenterol Nutr. 2005;41:393-395
22. Sokol RJ. Trading one disease for another. J Pediatr. 2006;148:A1.
23. Sokol RJ. Selection bias and vitamin E status in cystic fibrosis. J Pediatr 2007;150:e85
24. Woodruff SA, Sokol RJ. Colonic polyp as lead point for intussusception. Image of the Month. J Pediatr Gastroenterol Nutr 2007;45:270-80.
25. Sokol RJ. A new larger look to inflammatory bowel disease. J Pediatr. 2007;15:A2.
26. Sokol RJ. 50 Years Ago in the Journal of Pediatrics. A role for tocopherol in human nutrition. J Pediatr 2009;155:221.
27. Sokol RJ. Mitochondrial Liver Disease: amping up the liver. Audio-Digest Gastroenterology; 2010, vol. 24: issue 7. ISSN 0892-9386
28. Balistreri WF, Sokol RJ, Narkewicz MR. Hepatitis. Critical Conversations with Pediatric Experts, American Academy of Pediatrics, PREP Audio, 2012; Vol. 7, No. 9
	* 1. **E. LETTERS TO THE EDITOR**
			1. Sokol RJ: Vitamin E status in cystic fibrosis (Letter). J Pediatr 1982; 100:512.
			2. Sokol RJ, Heubi JE, Balistreri WF: Kasai procedure and vitamin E. (Letter). Pediatrics 1983; 71:668.
			3. Sokol RJ, Heubi JE, Balistreri WF: Vitamin E deficiency in cholestatic liver disease (Letter). J Pediatr 1983; 103:663‑664
			4. Sokol RJ, Heubi JE, Balistreri WF: Facies of Alagille Syndrome. (Reply to Letter). J Pediatr 1984; 104:487‑488.
			5. Sokol RJ: Vitamin E deficiency in adults. (Letter). Ann Int Med 1984; 100:769.
			6. Sokol RJ: Vitamin E Toxicity. (Letter). Pediatrics 1984; 74:564.
			7. Iannaccone ST, Sokol RJ: Vitamin E deficiency in neuropathy of abetalipoproteinemia. (Letter to the Editor). Neurology 1986; 36:1009
			8. Sokol RJ, Silverman A, Heubi JE: Vitamin E deficiency and neurologic dysfunction in children (Reply to Letter). N Engl J Med 1986; 34:1390.
			9. Sokol RJ: Vitamin E status in cholestasis. (Letter to the Editor). J Pediatr 1988; 112:324
			10. Sokol RJ: Adoption of hepatitis B virus‑infected foreign‑born children. (Letter to the Editor). Pediatrics 1990; 85:890‑891.
			11. Abman SH, Accurso FJ, Sokol RJ: Hypoalbuminemia in young infants with cystic fibrosis. (Letter to the Editor). J Pediatr 1990; 116:840‑841.
			12. Sokol RJ: Reply to “Letter to Editor”, “Intracranial hemorrhages in Alagille syndrome”. J Pediatr 2000;136;709-10
			13. Sokol RJ: Re: Article by Kamath et al.-"Facial features in Alagille Syndrome". (Letter to the Editor), Am J Med Genet, 2004;124A:220-221
			14. Shneider BL, Bezerra JA, Sokol RJ, Whitington PF. Reply to Letter : Multicenter biliary atresia outcome studies – the importance of surgical aspects. J Pediatr 2007;150:e89-90
			15. Soden JS, Sokol RJ. Reply to Letter, Assessing portal fibrosis in parenteral nutrition-dependent patients treated with omega-3 fatty acid lipid emulsion. J Pediatr 2010 June 25 (Epub ahead of print).
			16. Colson SB, Siparsky GL, Capocelli KE, Pan Z, Sokol RJ, Hoffenberg EJ. Inflammatory Bowel Disease in Pediatric Patients with Cerebral Palsy. (Letter to the Editor). J Pediatr Gastroenterol Nutr 2013 Jun;56(6):e50, PMID: 23518488
		2. **SCIENTIFIC ABSTRACTS PUBLISHED OR PRESENTED AT SCIENTIFIC MEETINGS (ALL COMPETITIVE)**
29. Black RJ, Martin WL, Sokol RJ: Endoscopic retrograde cholangiopancreatography in diagnosing pancreatic calculi in children. Submitted to the American Surgical Association Meeting, May, 1981.
30. Sokol RJ, Heubi JE, Farrell MK, Daugherty CC, Lichtenstein PK, Hug G, Suchy FJ, Balistreri WF: Reye's Syndrome: Primary cause of vomiting and hepatic dysfunction following varicella or URI. Pediatr Res 1982; 16:596.
31. Sokol RJ, Heubi JE, Iannaccone ST, Bove KE, Harris RE, Balistreri WF: Vitamin E malabsorption and deficiency in childhood chronic cholestatic liver disease. Presented at AASLD Plenary Session, May, 1982. Gastroenterology 1982; 82(2):1246.
32. Oestreich ARE, Sokol RJ, Suchy FJ, Heubi JE: Renal imaging abnormalities in arteriohepatic dysplasia and nonsyndromic intrahepatic biliary hypoplasia. Presented at European Society for Pediatric Radiology ‑ Prague, April 22‑24, 1982.
33. Iannaccone ST, Sokol RJ, Bove KE, Heubi JE, Harris RE, Balistreri WF: Vitamin E deficiency and neuromuscular disease in children with chronic cholestatic liver disease. Presented at the 5th International Congress on Neuromuscular Disease, 1982, Marseille, France.
34. Sokol RJ, Heubi JE, Iannaccone ST, Bove KE, Harris RE, Balistreri WF: Vitamin E malabsorption and deficiency in childhood chronic cholestatic liver disease. Presented at the Mead‑Johnson Symposium on Pediatric Gastroenterology, Chicago, IL, 1982.
35. Lichtenstein PK, Sokol RJ, Rothbaum RJ, Heubi JE, Farrell MK, Daugherty CC, Hug G, Suchy FJ, Balistreri WF: Reye's Syndrome is the primary cause of vomiting and hepatic dysfunction following varicella or URI. Presented at the Mead‑Johnson Symposium on Pediatric Gastroenterology, Chicago, IL, 1982.
36. Sokol RJ and Heubi JE: Vitamin E malabsorption/deficiency related to low intraluminal bile acid concentrations in childhood chronic cholestasis. Presented at Poster Session at The Second International Symposium on Infant Nutrition and the Development of the Gastrointestinal Tract, Niagara Falls, Ontario, Canada, 1982.
37. Farrell MK, Sokol RJ, Heubi JE, Daugherty CC, Lichtenstein PK, Rothbaum RJ, Hug G, Suchy FJ, Balistreri WF: Reye's Syndrome: Stage 1, the tip of the iceberg. Clinical Research 1982; 30:723.
38. Sokol RJ, Farrell MK, Heubi JE, Lichtenstein PK, Balistreri WF: Comparison of vitamin E and 25‑OH vitamin D absorption during prolonged neonatal cholestasis. Presented at AASLD Annual Meeting Poster Session, November, 1982. J Pediatr 1983; 103:712‑717.
39. Sokol RJ, Balistreri WF, Hoofnagle JH, Jones EA: Vitamin E deficiency during primary biliary cirrhosis. Presented at AASLD Annual Meeting Poster Session, November, 1982. Hepatology 1982; 2:710.
40. Oestreich ARE, Sokol RJ, Suchy FJ, Heubi JE: Renal imaging abnormalities in arteriohepatic dysplasia and nonsyndromic intrahepatic biliary hypoplasia. Pediatr Radiol 1982; 11:319.

13. Sokol RJ, Heubi JE, Balistreri WB: Intrahepatic cholestasis facies: Is it specific for Alagille's syndrome? Presented at the Society for Pediatric Research Annual Meeting, May, 1983, Washington, D.C. Pediatr Res 1983; 17(2):201.

14. Sokol RJ, Iannaccone ST, Bove KE, Heubi JE: Vitamin E deficiency neurologic syndrome during chronic cholestasis: Beneficial effect of early alpha‑tocopherol therapy. Pediatr Res 1983; 17(2):367.

15. Anderson TM, Sokol RJ, Meyer RA, Heubi JE, Kaplan S: Cardiac size and function in patients with vitamin E deficiency. Pediatr Res 1983; 17(2):108.

16. Sokol RJ, Heubi JE, Balistreri WF: Ratio of serum vitamin E to total serum lipids: The preferred measure of vitamin E status during cholestasis. Presented at the American Gastroenterological Association Annual Meeting, May, 1983, Washington, D.C. Gastroenterology 1983; 84:1398.

17. Sokol RJ, Iannaccone ST, Bove KE, Heubi JE: Vitamin E deficiency neurologic syndrome during chronic choicstasis: Beneficial effect of early alpha‑tocopherol therapy. Presented at the Second Annual Mead Johnson Research Forum for Pediatric Gastroenterology, Hunt Valley, MD, May, 1983.

18. Sokol RJ, Heubi JE, Tsang RC, Balistreri WF: Differential intestinal absorption of vitamin E and 25‑hydroxy vitamin D in homozygous hypobetalipoproteinemia. Presented at the Central Society for Clinical Research, Chicago, IL, November, 1983. Clin Res 1983; 31:766A.

19. Sokol RJ, Heubi JE, Balistreri WF: Improved hepatic function following vitamin E repletion during chronic childhood cholestasis. Presented at poster session at the American Association for the Study of Liver Disease Annual Meeting, November, 1983. Hepatology 1983; 3:848.

20. Harris RE, Sokol RJ, Heubi JE: Correction of neutrophil chemotactic defect in chronic cholestasis coincident with improvement in liver function following vitamin E repletion. Submitted to the American Society of Hematology, 1983. Blood 1983; 62:81a.

21. Sokol RJ, Heubi JE, Bove KE, Balistreri WF: Vitamin E deficiency with normal serum vitamin E concentrations during childhood cholestasis. Presented at poster session, Western Society for Pediatric Research Meeting, February, 1984. Clin Research 1984; 32:98A.

22. Sokol RJ, Guggenheim MA, Iannaccone ST, Miller CA, Silverman A, Heubi JE: Reversibility of vitamin E deficiency neurologic syndrome during chronic childhood cholestasis. Presented at the Society for Pediatric Research Annual Meeting, May, 1984. Pediatr Res 1984; 18:213A.

23. Sokol RJ, Heubi JE, Milostan FF, Jr, Cameron B, Balistreri WF: Does vitamin E deficiency reduce intestinal absorption of vitamin E during chronic childhood cholestasis? Gastroenterology 1984; 86(2):1259.

24. Sokol RJ, Heubi JE, Milostan FF, Jr, Cameron B, Balistreri WF: Vitamin E deficiency does not impair intestinal absorption of vitamin E during chronic childhood cholestasis. Presented at the American College of Nutrition Annual Meeting, 1984. J Amer Coll Nutr 1984; 3:236.

25. Libbey L and Sokol RJ: Vitamin E deficiency in adult cystic fibrosis. Presented at the Current Research in Cystic Fibrosis Conference, June 29, 1984, Minneapolis MN.

26. Sokol RJ, Harris RE, Heubi JE: Effect of vitamin E on neutrophil chemotaxis in chronic childhood cholestasis. Presented at Poster Session at the American Association for the Study of Liver Diseases Annual Meeting, November, 1984. Hepatology 1984; 4:1048.

27. Sokol RJ: Intestinal absorption of tocopherol polyethylene glycol‑1000 succinate during chronic childhood cholestasis. Presented at Poster Session of American Society of Parenteral and Enteral Nutrition Annual Meeting, January, 1985. JPEN 1985; 9:119.

28. Sokol RJ, Butler‑Simon NA, Silverman A: Treatment of vitamin E deficiency in chronic childhood cholestasis with oral d‑alpha‑tocopherol polyethylene glycol‑1000 succinate (TPGS). Submitted to Society for Pediatric Research, 1984. Pediatr Res 1985; 19:232.

29. Stumpf DA, Sokol RJ, Bettis D, Neville H, Ringel S, Angelini C, Bell R: Clinical picture mimicking Friedreich's ataxia associated with vitamin E deficiency and normal fat absorption. Presented at the American Academy of Neurology Annual Meeting, 1985. Neurol 1985; 35(Suppl 1):145.

30. Sokol RJ, Heubi JE, Balistreri WF: Treatment of vitamin E (E) deficiency during chronic childhood cholestasis (CCC). Presented at the North American Society for Pediatric Gastroenterology Annual Meeting, New York City, May 17, 1985.

31. Reardon MC, Hammond KB, Jacobson LT, Sokol RJ: Abnormalities in fat‑soluble vitamin status at the time of diagnosis in infants with cystic fibrosis identified by newborn screen. Submitted to Society for Pediatric Research, 1985. Pediatr Res 19:230A, 1985. Presented at Cystic Fibrosis Foundation Annual Meeting, May, 1985.

32. Sokol RJ and Devereaux M: Effect of vitamin E on copper toxicity in isolated rat hepatocytes. Presented at Poster Session at the American Gastroenterological Association Annual Meeting, New York City, May, 1985. Gastroenterology 1985; 88(2):1696.

33. Sokol RJ, Guggenheim MA, Iannaccone ST, Silverman A, Balistreri WF, Heubi JE: Treatment of vitamin E deficiency neurologic syndrome in children with chronic cholestasis. Presented at the Poster Session American Gastroenterological Association Annual Meeting, New York City, May, 1985. Gastroenterology 1985; 88(2):1696.

34. Sokol RJ, Devereaux M: Relationship between vitamin E deficiency, lipid peroxidation and copper toxicity in isolated rat hepatocytes. Presented at the Poster Session of the American Association for the Study of Liver Diseases Annual Meeting, November, 1985. Hepatology 1985; 5:1009.

35. Fisher CD, Ford DM, Sokol RJ, Lum GM: Nocturnal nasogastric feeds in children with chronic renal failure on dialysis. Presented at American Society for Parenteral and Enteral Nutrition Annual Meeting, February, 1986. JPEN 1986; 10:16S.

36. Sokol RJ, Bettis DB, Neville HE, Stumpf DA: Isolated vitamin E deficiency in the absence of fat malabsorption: a new cause of progressive ataxia. Presented at Western Society for Pediatric Research Annual Meeting, February, 1986. Clin Res 1986; 138A.

37. Broxson EH, Jr, Sokol RJ, Githens JH: Normal vitamin E status in homozygous sickle cell anemia (SS) and hemoglobin SC disease (SC). Presented at Western Society for Pediatric Research Annual Meeting, 1986. Clin Res 1986; 34:137A.

38. Sokol RJ, Bettis DB, Neville HE, Stumpf DA: Isolated vitamin E deficiency in the absence of fat malabsorption: a new cause of progressive ataxia. Presented at the Society for Pediatric Research Annual Meeting, May, 1986. Pediatr Res 1986; 20:467A.

39. Sokol RJ, Heubi JE, Butler‑Simon NA, McClung HJ: Oral D‑alpha‑tocopherol polyethylene glycol‑1000 succinate (TPGS) treatment for vitamin E deficiency in chronic childhood cholestasis. Presented at the Society for Pediatric Research Annual Meeting, May, 1986. Pediatr Res 1986; 20:249A.

40. Stall C, Reardon MC, Hammond K, Abman SH, Sokol RJ, Accurso FI: Fat malabsorption in infants with cystic fibrosis less than three months of age diagnosed through newborn screening. Presented at the Poster Session of the Cystic Fibrosis Club Annual Meeting, May, 1986, Washington, D.C.

41. Kayden HJ, Sokol RJ, Traber MG: Familial vitamin E deficiency in the absence of lipid malabsorption. Presented at the International Symposium on Vitamin E, Kyoto, Japan, December, 1986.

42. Sokol RJ: Diagnosis and treatment of vitamin E deficiency during chronic cholestasis. Presented at the International Symposium on Vitamin E, Kyoto, Japan, December, 1986.

43. Traber MG, Sokol RJ, Ringel SP, Thellman CA, Kayden HJ: Is the cause of peripheral neuropathy in vitamin E deficient humans due to a lack of tocopherol in the peripheral nervous system? Presented at FASEB meeting, April, 1987, Washington, D.C.

44. Hambidge KM, Casey CE, Sokol RJ, Fidanza SJ: Elevated serum manganese (Mn) in total parenteral nutrition (TPN) cholestatic liver disease. Submitted to Society for Pediatric Research Meeting, 1987.

45. Sokol RJ, Devereaux M: In vitro vitamin E repletion restores resistance to copper toxicity in vitamin E deficient isolated rat hepatocytes. Presented at Western Society for Pediatric Research meeting, February, 1987. Clin Res 1987; 35:209A.

46. Brown W, Sokol RJ, Levin M, Silverman A, Tamaru T, Lilly J, Cheney M, Lee E: An immunological search for evidence that infection with reovirus 3 causes extrahepatic biliary atresia or neonatal hepatitis. Presented at Poster Session of American Gastroenterological Association Annual Meeting, Chicago, IL, May, 1987. Gastroenterol 1987; 92(2):1721.

47. Sokol RJ, Butler‑Simon N, Bettis D, Lilly JR, Silverman A: Treatment of vitamin E deficiency during chronic childhood cholestasis with tocopherol polyethylene glycol­-1000 succinate: neurologic outcome. Presented at Poster Session of American Gastroenterological Association Annual Meeting, Chicago, IL, May, 1987. Gastroenterol 1987; 92(2):1779.

48. Sokol RJ, Devereaux M, Kayden HJ, Traber MG: In vitro vitamin E repletion restores resistance to copper toxicity in vitamin E‑deficient isolated rat hepatocytes. Submitted to American Gastroenterological Association meeting, 1987. Gastroenterol 1987; 92(2):1779.

49. Accurso FJ, Abman SH, Reardon MC, Stall CD, Pinney MA, Hanunond KB, Sokol RJ: Prospective longitudinal evaluation of growth in young infants with cystic fibrosis diagnosed through newborn screening. Presented at North American Cystic Fibrosis Conference, 1987.

50. Sokol RJ, Hoofnagle JH, Heubi JE, Jones EA, Balistreri WF: Intestinal absorption of vitamin E in primary biliary cirrhosis. Presented at Poster Session of American Association for the Study of Liver Diseases Annual Meeting, October, 1987, Chicago, IL. Hepatology 1987; 7:1043.

51. Sokol RJ, Devereaux MW, Shikes RH: Vitamin E protects against copper hepatotoxicity in a dietary copper overload rat model. Presented at Poster Session of American Association for the Study of Liver Diseases Annual Meeting, October, 1987, Chicago, IL. Hepatology 1987; 7:1044.

52. Narkewicz MR, Sokol RJ, Beckwith B, Sondheimer J, Finkel R, Silverman A: Course of liver disease in cerebrohepatic degeneration syndrome. Hepatology 1987; 7:1099.

53. Hambidge KM, Sokol RJ, Jacobs‑Goodall M, Fidanza SJ: Plasma manganese (MN) in infants and children receiving parenteral nutrition (PN). Presented at A. S. P. E. N. annual meeting, January, 1988, Las Vegas, Nevada. JPEN 1988; 12(Suppl 1):4.

54. Stall, C, Fidanza S, Andrews D, Hambidge MD, Sokol RJ: Weight gain in chronically‑ill infants and children tube fed at home. Presented at A.S.P.E.N. Annual Meeting, January, 1988, Las Vegas, Nevada. JPEN 1988; 12(Suppl 1):19.

55. Chatfield B, Abman S, Stall C, Sokol RJ, Accurso F: Growth, fat malabsorption, and nitrogen balance in young infants with cystic fibrosis (CF) diagnosed by newborn screening. Submitted to Western Society for Pediatric Research meeting, February, 1988.

57. Sokol RJ, Stall C, Lilly JR: Anthropometric evaluation of children with chronic cholestatic liver disease. Submitted to Society for Pediatric Research meeting, 1988. Pediatr Res 1988; 23:313A.

58. Broxson EH, Jr, Sokol RJ, Githens JH: Normal vitamin E (E) status in homozygous sickle cell anemia (SS) and hemoglobin SC disease (SC). Submitted to Society for Pediatric Research meeting, 1988. Pediatr Res 1988; 23:337A.

59. Chatfield BA, Abman SH, Hammond KB, Stall CD, Sokol RJ, Accurso FJ: Poor growth and steatorrhea in infants with cystic fibrosis (CF) under 3 months of age. Submitted to Society for Pediatric Research meeting, 1988. Pediatr Res 1988; 23:300A.

60. Poh‑Fitzpatrick MB, Zaider E, Sciales C, Knobler E, Grossman M, Sadick N, Sokol RJ: Cutaneous photosensitivity and coproporphyrin abnormalities in serum and urine in Alagille syndrome. Presented at American Society for Clinical Investigation Annual Meeting, 1988.

61. Sokol RJ: Vitamin E deficiency neuropathy in children with fat malabsorption. Presented at New York Academy of Sciences Meeting on Vitamin E. November, 1988,

62. Sokol RJ, Devereaux MW, Khandwala R, Narkewicz MR: Effect of vitamin E on taurocholate and ouabain uptake by isolated rat hepatocytes. Submitted to American Association for the Study of Liver Diseases Annual Meeting, Chicago, November, 1988. Hepatology 1988; 8:1360.

63. Sokol RJ, Devereaux MW, Hambidge KM, Jacobs M: In vivo lipid peroxidation of hepatic mitochondria during liver injury in chronically copper‑overloaded rats: effect of vitamin E. Presented at American Association for the Study of Liver Diseases Annual Meeting, Chicago, November, 1988. Hepatology 1988; 8:1241.

64. Felber S, Sondheimer JM, Sokol RJ, Silverman A, Wilson H: "Short gut colitis": characterization and response to treatment. Presented at North American Society for Pediatric Gastroenterology Annual Meeting, November, 1988.

65. Sokol RJ, Stall C: Effect of hepatosplenomegaly on nutritional assessment in children with chronic liver disease. Presented at American Society for Parenteral and Enteral Nutrition Annual Meeting, February, 1989. JPEN 1989; 13(Suppl): 18S.

66. Accurso FJ, Abman SH, Sokol RJ, Hammond KB: Newborn screening for cystic fibrosis (CF): laboratory diagnosis and early clinical course. Submitted to Society for Pediatric Research Annual Meeting, 1989.

67. Sokol RJ: Effect of vitamin E on hepatic structure and function during dietary copper overload in the rat. Presented at the Fourth Conference of Federally Funded Nutrition Research, Bethesda, MD, February, 1989.

68. Sokol RJ, Traber MG, Burton GW, Ingold KU, Kayden HJ: Familial vitamin E deficiency ‑‑ studies using deuterated tocopherol. Presented at Mini symposium at FASEB meeting, New Orleans, LA, March, 1989.

69. Sokol RJ, Devereaux MW, Khandwala RA: Vitamin E (E) deficiency and high dietary fat intake increase hepatic injury in bile duct‑ligated rats. Hepatology 1989; 10:743.

70. Taylor SF, Devereaux MW, Khandwala R, Sokol RJ: Hepatic oxidant injury in weanling rats during administration of total parenteral nutrition. Presented at American Association for the Study of Liver Diseases Annual Meeting, November, 1989. Hepatology 1989; 10:609.

71. Sokol RJ, Devereaux MW, Khandwala RA: Dietary intake of fat and vitamin E may modify hepatic injury in bile duct‑ligated rats. Presented at North American Society for Pediatric Gastroenterology and Nutrition Annual Meeting, Chicago, IL, November, 1989.

72. Narkewicz MR, Sokol RJ, Beckwith B, Sondheimer J, Silverman A: Course of liver disease in cerebrohepatic degeneration syndrome (Alpers disease). Presented at North American Society for Pediatric Gastroenterology and Nutrition Annual Meeting, Chicago, IL, November, 1989.

73. Sokol RJ, Devereaux MW, Khandwala RA: Role of free‑radical damage to hepatic mitochondrial lipids in cholestatic hepatic injury. Presented at Western Society for Pediatric Research meeting, February, 1990. Clin Res 1990; 38:176A.

74. Kam I, Everson G, Sokol RJ, Schroter G, Lawton C, Armstead V, Karrer F: Liver transplantation: 1 year activity report of new program. Presented at Colorado Chapter, American College of Surgeons Annual Meeting, 1990.

75. Sokol RJ, Devereaux MW, Khandwala RA: Role of free‑radical damage to mitochondrial lipids in cholestatic hepatic injury. Presented at American Gastroenterological Association Annual Meeting, May, 1990, San Antonio, TX. Gastroenterology 1990; 98:A634.

76. Sokol RJ, Butler‑Simon N, Heubi JE, Sinatra F, Heyman M, Perrault J, Riely C, Suchy F, Levy J, Rothbaum R: D‑alpha‑tocopherol polyethylene glycol‑1000 succinate (TPGS) therapy for vitamin E deficiency in chronic childhood cholestasis. Submitted to ESPGN/NASPGN meeting, 1990.

77. Sokol RJ, Devereaux MW, Khandwala RA, Shikes R: Deferoxamine reduces cholestatic and oxidative hepatic injury in bile duct‑ligated rats. Presented at AASLD Annual Meeting, November, 1990. Hepatology 1990; 12:894.

78. Sokol RJ, Butler‑Simon N, Conner C, Heubi JE, Sinatra F, Heyman M, Perrault J, Riely C, Suchy F, Levy J, Rothbaum R: Multi‑center trial of d‑alpha‑tocopherol polyethylene glycol‑1000 succinate (TPGS) therapy for vitamin E deficiency in chronic childhood cholestasis. Presented at NASPGN Annual Meeting, November, 1990.

79. Sokol RJ, Karrer FM, Narkewicz MR, Johnson KE, Schroter GPJ, Kam I: Use of water‑soluble vitamin E to improve cyclosporin (CS) absorption in pediatric liver transplantation patients. Presented at AASLD Annual Meeting, November, 1990. Hepatology 1990; 12:865.

80. Taylor SF, Devereaux MW, Khandwala RJ, Sokol RJ: Hepatic glutathione depletion precedes oxidative injury in weanling rats on total parenteral nutrition. Presented at AASLD Annual Meeting, November, 1990. Hepatology 1990; 12:935.

81. Fidanza SJ, Sokol RJ, Andrews D: The impact of a pediatric nutritional support team on the survival of central venous catheters. Submitted to American Society for Parenteral and Enteral Nutrition Annual Meeting, 1991.

82. Rusakow L, Abman S, Hammond K, Sokol RJ, Accurso F: Immunoreactive trypsin (IRT) in infants with cystic fibrosis (CF) complicated by meconium ileus (MI). Presented at IVth International Conference on Newborn Screening for Cystic Fibrosis, October 8‑9, 1990, Estes Park, Colorado. Pediatr Pulmonology 1991; Suppl. 7:89.

83. Sokol RJ, Butler‑Simon N, Conner C, Heubi JE, Sinatra F, Heyman M, Perrault J, Riely C, Suchy F, Levy J, Rothbaum R: Multi‑center trial of d‑alpha‑tocopherol polyethylene glycol‑1000 succinate (TPGS) therapy for vitamin E deficiency in chronic childhood cholestasis. Presented at American Gastroenterological Association Annual Meeting, May 1991. Gastroenterology 1991; 100:A799.

84. Sondheimer JM, Sokol RJ, Taylor SF, Silverman A: Intestinal lavage for colonoscopy preparation in pediatric patients ‑‑ efficacy, safety and tolerance. Presented at American Gastroenterological Association Annual Meeting, May 1991. Gastroenterology 100:A19, 1991.

85. Sokol RJ, Devereaux M, Khandwala RA, Hambidge KM: Parenteral vitamin E reduces hepatic injury in dietary copper overload in the rat. Presented at FASEB Annual Meeting, April 1991. FASEB J 1991; 5:A919.

86. Bronstein MN, Accurso FJ, Hambidge KM, Sokol RJ, Hammond K. Assessment of nutritional status in cystic fibrosis infants identified through newborn screening. Presented at FASEB meeting, April 1991, Atlanta, GA. FASEB J 1991; 5:Al328.

87. Traber MG, Sokol RJ, Burton GW, Ingold KU, Kayden HJ. Further evidence for the impaired function of an hepatic ‑tocopherol (‑t) binding protein in patients with familial isolated vitamin E deficiency. Presented at American Heart Association Annual Meeting, 1991.

88. Bronstein MN, Accurso FJ, Hambidge KM, Sokol RJ, Hammond K. Assessment of early nutritional status in cystic fibrosis infants identified through newborn screening. Presented at 5th Annual North American Cystic Fibrosis Conference, October, 1991, Dallas, Texas. Pediatr Pulmonol 1991; Suppl 6:237.

89. Sokol RJ, Devereaux M, Khandwala R, Lehr J: Altered hepatic mitochondrial electron transport in copper‑overloaded rats. Presented at American Association for the Study of Liver Diseases Annual Meeting, November 1991, Chicago, Illinois. Hepatology 1991;14:162A.

90. Sokol RJ, Endo N, Ohara JI, Lilly JR, Levin, MJ, Silverman A, Brown WR: Reovirus 3 RNA not detected by polymerase chain reaction in tissues from infants with extrahepatic biliary atresia. Presented at American Association for the Study of Liver Diseases Annual Meeting, November 1991, Chicago, Illinois. Hepatology 1991;14:125A.

91. Occena RO, Taylor SF, Sokol RJ, Robinson CC: Association of Cytomegalovirus with Menetrier's disease in childhood. Presented at NASPGN Annual Meeting, Nov. 1991, Chicago, Illinois.

92. Fidanza S, Kushner RM, Sokol RJ, Sondheimer JM: Temporary neurological dysfunction in children with short bowel syndrome (SBS) related to D‑lactic acidosis. Presented at A.S.P.E.N. Annual Meeting, Feb. 1992.

93. Sokol RJ, Devereaux MW, Khandwala R, O'Brian K: Protective effect of free radical inhibitors and scavengers against bile acid toxicity in isolated rat hepatocytes. Presented at WSPR Plenary Session, Carmel, CA., Feb. 1992. Clin Res 1992; 40:10A.

94. Walker BE, Shub MD, Ingebo KR, Bernes SM, Williams JW, O'Conner PJ, Sanowski RA, Sokol RJ: Liver disease in patients with Navajo neuropathy. Presented at 1992 AGA Annual Meeting, San Francisco, CA. Gastroenterology 1992; 102(2):A907.

95. Narkewicz MR, Sokol RJ, Smith D, Gregory C, Lear JL: Ursodeoxycholic acid (UDCA) does not improve quantitative tests of hepatic function in children with intrahepatic cholestasis despite clinical improvement. Hepatology 1992; 16:258A.

96. Sokol RJ, Twedt D, Devereaux MW, Karrer F, Kam 1, Hambidge KM: Role of free radicals in copper hepatotoxicity: Evidence from the Bedlington terrier and Wilson's disease patients. Presented at Poster Session at 1992 AASLD Annual Meeting, Chicago, IL Hepatology 1992; 16:159A.

97. Sokol RJ, Devereaux MW, Khandwala R, O'Brien K, Terada LS: Evidence of free radical generation in bile acid toxicity to isolated rat hepatocytes. Presented at Plenary Session at 1992 AASLD Annual Meeting, Chicago, IL Hepatology 1992; 16:134A.

98. Manco‑Johnson MJ, Nuss R, Narkewicz MR, Sokol RJ: Hepatitis C virus (HCV)-­infected children with hemophilia have significant liver pathology despite near‑normal aminotransferase (ALT) levels. Presented at 1993 American Society for Hematology Annual Meeting.

99. Allshouse M, Sokol RJ, Martinez‑Frontanilia LA: Life with very short intestine: Long‑term follow up of eight patients. Submitted to American Pediatric Surgery Association Annual Meeting, 1993.

100. Sokol RJ, Devereaux MW, McKim Jr. JM, Hambidge KM: Prevention of oxidant hepatocyte injury by alpha tocopherol and metal chelators in copper‑loaded isolated rat hepatocytes. Presented at 1993 AGA/AASLD Annual Meeting, Washington, DC, Gastroenterology 1993; 104:A997.

101. Sokol RJ, Devereaux MW, Narkewicz MR, Karrer F, Kam 1, Hambidge KM: Free radical alteration of hepatic mitochondrial lipids in end‑stage liver disease. Presented at 1993 APS/SPR Annual Meeting, Boston, MA. Pediatr Res 1993; 33: 110A.

102. Ambruso DR, Thurman GW, Cusack NA, Occena RO, Sokol RJ: G‑CSF treatment of a patient with glycogen storage disease (GSD) 1B improves ulcerative colitis but has no effect on functional capacity of neutrophils (PMNs). Pediatr Res 1993; 33:135A.

103. Ramirez RO, Sokol RJ, Ambruso DR, Thurman GW and Cusack NA: Ulcerative colitis in glycogen storage disease type 1B: Treatment with human recombinant granulocyte-colony stimulating factor (rG-CSF). Presented at North American Society for Pediatric Gastroenterology and Nutrition Annual Meeting, November, 1993, Chicago, Ill.

104. Sokol RJ, Erskine J, Abman S, Wagener J, Hammond K, Accurso F: Prospective study of fat-soluble vitamin status in 101 infants with cystic fibrosis identified by newborn screening. Presented at 7th Annual North American Cystic Fibrosis Conference, October, 1993, Dallas, TX, and at North American Society for Pediatric Gastroenterology and Nutrition Annual Meeting, Chicago, Ill., November, 1993.

105. Piccoli DA, Mokadam NA, Rand EB, Hoffenberg EJ, Sokol RJ, Narkewicz MR, Spinner NS: Phenotypic and genetic analysis of syndromic bile duct paucity (Alagille syndrome). Presented at North American Society for Pediatric Gastroenterology and Nutrition Annual Meeting, November, 1993, Chicago, Ill.

106. McKim JM Jr., Devereaux MW, Petersen DR, Hambidge KM, Ruyle SZ, Schilsky ML, Sternlieb I and Sokol RJ: Mitochondrial oxidant injury in Long-Evans Cinnamon (LEC) rat liver containing high copper. Oral presentation at AGA/AASLD Annual Meeting, May 15-18, 1994, New Orleans, LA. Gastroenterology 1994;106:A941.

107. Sokol RJ, McKim JM Jr., Devereaux MW: Increased hydroperoxide generation during taurochenodeoxycholic acid (TCDC) toxicity in isolated rat hepatocytes. AGA/AASLD Annual Meeting, May 15-18, 1994, New Orleans, LA. Gastroenterology 1994;106:A988.

108. Goff MC, McKim JM Jr., Ruyle SZ, Devereaux MW and Sokol RJ: Mitochondrial lipid peroxidation accompanies intravenous taurochenodeoxycholic acid-induced hepatic injury in the rat. Presented at AGA/AASLD Annual Meeting, May 15-18, 1994, New Orleans, LA. Gastroenterology 1994;106:A1029.

109. Hoffenberg EJ, Schneider J, Narkewicz, MR, Sondheimer JM, Silverman A, and Sokol RJ: Poor outcome of childhood Alagille syndrome (Syndromic paucity of interlobular bile ducts). Presented at poster session at AGA/AASLD Annual Meeting, May 15-18, 1994, New Orleans, LA. Gastroenterology 1994,106:A907.

1. Sokol RJ, Krebs NF, Bronstein MN, Stall CD, Abman SH, Hammond KB, Accurso FJ: Randomized trial of predigested formula vs. standard infant formula in infants with cystic fibrosis (CF) identified by newborn screening. Presented at Platform Session, Annual meeting of the American Pediatric Society and the Society for Pediatric Research, May, 1994. Pediatric Res 1994;35(2);136A.
2. Mierau GW, Greene CL, Sokol RJ, Valle DL. Ultra structural diagnosis of carbohydrate-déficient glycoprotein syndrome. Abstract. Pediatr Pathol Lab Med 15:356, 1995.

112. Sokol RJ, Seltzer WK, Reutenauer L, Koenig M: Linkage of gene for isolated vitamin E-deficiency syndrome (IVEDS) to chromosome 8q in a North American family. Presented at 4th Joint NASPGN/ESPGAN Meeting, Houston, TX, October 1994. JPGN 1994; 19:338.

113. Sokol RJ, McKim JM, Jr., Goff C, Ruyle SZ, Devereaux MW: Taurochenodeoxycholic acid hepatocyte toxicity is associated with hepatocyte hydroperoxide generation and mitochondrial lipid peroxidation. Presented at 4th Joint NASPGN/ESPGAN Meeting, Houston, TX, October, 1994. JPGN 1994; 19:340.

114. Ambruso DR, Thurman GW, Cusack NA, Occena R, Sokol RJ: G-CSF treatment of a patient with glycogen storage disease (GSD) 1B resolved ulcerative colitis but had no effect on functional capacity of neutrophils (PMNs). Presented at American Federation of Clinical Research Annual Meeting, April 1994.

115. Narkewicz MR, Sokol RJ, Wagener JS, Accurso FJ: Effect of ursodeoxycholic acid (UDCA) therapy for CF liver disease on fat-soluble vitamin status and growth. Submitted to Eighth Annual North American CF Conference, 1994.

116. Narkewicz RM, Sokol RJ, Lear JL, Wagener JS, Accurso FJ: Effect of ursodeoxycholic acid (UDCA) therapy for CF liver disease on indirect tests of hepatic function. Presented at Eighth Annual North American CF Conference, 1994. Pediatr Pulmonol Suppl 10:274; 1994.

117. Sokol RJ, Carroll NM, Narkewicz MR, Wagener JS, Accurso FJ: Liver blood tests during the first decade of life in children with cystic fibrosis identified by newborn screening. Presented at the Eighth Annual North American CF Conference, 1994. Pediatr Pulmonol Suppl 10: 275;1994.

118. Accurso FJ, Wagener JS, Abman SH, Sokol RJ, Carroll NM, Hammond KB: Growth and pulmonary function outcome in children with cystic fibrosis identified through newborn screening. Presented at Eighth Annual North American CF Conference, 1994. Pediatr Pulmonol Suppl 10: 296; 1994.

119. Winklhofer-Roob BM, McKim JM Jr., Devereaux MW, Sokol RJ: Increased generation of hydrogen peroxide by isolated rat hepatic mitochondria exposed to chenodeoxycholic acid. Presented at Annual AASLD Meeting, November 1994. Hepatology 20:180A; 1994.

120. Sokol RJ, McKim JM Jr., Devereaux MW, Everson G: Vitamin E ameliorates oxidant injury to hepatic mitochondria caused by intravenous taurochenodeoxycholic acid. Presented at Annual AASLD Meeting, November 1994. Hepatology 20:178A; 1994.

121. Sokol RJ, Narkewicz MR, Karrer FM, Smith D, Lilly JR: Use of rifampin for severe pruritus in children with chronic cholestasis. Presented at Annual AASLD Meeting, November 1994. Hepatology 20:178A, 1994.

122. Sokol RJ, Narkewicz MR, Carroll NM, Wagener JS, Accurso FJ: Prospective evaluation of liver blood tests during the first 8 years of life in children with cystic fibrosis identified by newborn screening. Hepatology 20:402A, 1994.

123. Sokol RJ, Narkewicz MR, Greene C, Karrer FM, Vladutiu GD, DiMauro S. Successful liver transplantation for fulminant hepatic failure in infant with severe lactic acidosis caused by hepatic mitochondrial electron transport defect. Hepatology 20:402A, 1994.

124. Alonso EM, Sokol RJ, Hart J, Tyson W, Allswang M, Narkewicz MR, Whitington PF: Unusual outbreaks of fulminant hepatitis in young children: Possible association with acetaminophen. Presented at Annual AASLD Meeting, November, 1994. Hepatology 20:190A, 1994.

125. Narkewicz MR, Smith D, Vierling J, Sokol RJ: Clearance of chronic hepatitis B virus infection in young children by interferon treatment. Presented at Annual AASLD Meeting, November, 1994. Hepatology 20:300A, 1994.

126. Shivaram K, Straka M, Devereaux MW, Sokol RJ. Idebenone inhibits taurocheno-deoxycholic acid toxicity and reduces oxidant stress in isolated rat hepatocytes. Presented at AGA Annual Meeting, Gastroenterology 1995; 108:A1169.

127. Winklhofer-Roob BM, McKim JM, Jr., Straka MS, Devereaux MW, Sokol RJ: Dose-dependent increase in hydrogen peroxide generation by rat hepatic mitochondria exposed to chenodeoxycholic acid and its attenuation by catalase. Presented at “Oxidant Stress and Liver Disease”, AASLD Research Symposium, June, 1995.

128. Karrer FM, Price MR, Sokol RJ, Narkewicz MR, Smith DJ: Long-term results with Kasai’s operation for biliary atresia. Presented at Western Surgical Association, 1995.

129. Winklhofer-Roob BM, Devereaux MW, Straka MS, McKim JM, Jr., Sokol RJ: Generation of hydrogen peroxide by isolated hepatic mitochondria during in vivo and in vitro exposure to hydrophobic bile acids. Presented at AASLD Annual Meeting, November, 1995, Chicago, IL. Hepatology 1995; 22:377A.

130. Sokol RJ, Devereaux MW, Khandwala R: Xanthine oxidase inhibition reduces cholestatic liver injury in the bile duct-ligated rat model without affecting hepatocyte lipid peroxidation. Presented at AASLD Annual Meeting, November, 1995, Chicago, IL. Hepatology 1995; 22:317A.

131. Sokol RJ, Devereaux MW, Khandwala R: Oxypurinol attenuates cholestatic liver injury in the bile duct-ligated rat. Presented at NASPGN Annual Meeting, Plenary Session, November 3, 1995, Chicago, IL. J Pediatr Gastroenterol Nutr 1995; 21:326.

132. Winklhofer-Roob BM, Devereaux MW, Straka M, McKim JM, Sokol RJ: Dose-dependent increase in hydrogen peroxide generation by rat hepatic mitochondria exposed to chenodeoxycholic acid and its attenuation by catalase. Presented at Poster Session, November 4, 1995, NASPGN Annual Meeting, Chicago, IL. J Pediatr Gastroenterol Nutr 1995; 21:351.

133. Feranchak AP, Occena-Ramirez R, Shivaram K, Corkill M, King R, Smith D, Narkewicz MR, Sokol RJ: Comparison of 5 indices for evaluation of vitamin A deficiency in children with chronic cholestatic liver disease. Oral Presentation at the Annual Meeting of AGA, 1996. Gastroenterology 1996;110:A801.

134. Sokol RJ, Tyler KL, Oberhaus S, Low R, Le M, Smith D, Tyson RW, Lilly JR, Karrer FM, Narkewicz MR, Brown WR. Association between Reovirus RNA and childhood choledochal cysts (CDC). Presented at Plenary Session at Annual Meeting of NASPGN, 1996. J Pediatr Gastroenterol Nutr 1996; 23:344.

135. Straka MS, Devereaux MW, Sokol RJ. Vitamin E attenuates the mitochondrial membrane permeability transition (MMPT) induced by glycochenodeoxycholic acid (GCDC). Presented at Annual Meeting of NASPGN, 1996. J Pediatr Gastroenterol Nutr 1996;23;350.

136. Feranchak AP, Ramirez R, Shivaram K, Smith D, Narkewicz MR, Sokol RJ. Assessment of vitamin A status in children with chronic cholestatic liver disease using a modified oral relative dose response test. Presented at Annual Meeting of NASPGN, 1996. J Pediatr Gastroenterol Nutr 1996;23:351.

137. Otani YS, Ziegler JW, Sokol RJ, Horgan JG, Sondheimer HM, Narkewicz MR. Hepatic function after the Fontan procedure. Presented at Annual Meeting of NASPGN, 1996. J Pediatr Gastroenterol Nutr 1996; 23:351.

138. Tudor S, Uhlhorn C, Lieberman M, Bao F, Eisenbarth G, Sokol RJ, Hoffenberg E, Rewers M. Prevalence of antio-endomysial antibodies in healthy relatives of persons with insulin dependent diabetes. Presented at Annual Meeting of NASPGN, 1996. J Pediatr Gastroenterol Nutr 1996;23:362.

139. Narkewicz MR, Karrer F, Smith D, Orban-Eller K, Krebs NF, Sokol RJ. Effect of OLT on zincuria and plasma zinc in children with liver disease. Presented at Annual Meeting of NASPGN, 1996. J Pediatr Gastroenterol Nutr 1996;23:352.

140. Winklhofer-Roob BM, Devereaux MW, Sokol RJ. Attenuation by idebenone of hydrophobic bile acid-induced mitochondrial hydroperoxide generation in succinate respiration. Presented at American Association for the Study of Liver Disease Annual Meeting, 1996. Hepatology 1996;24 (2):338A.

141. Sokol RJ, Devereaux MW, Straka MS, Everson G. Melatonin attenuates hydrophobic bile acid toxicity to isolated rat hepatocytes. Presented at AASLD Annual Meeting, 1996. Hepatology 1996;24(2):338A.

142. Winklhofer-Roob BM, McKim JM, Jr., Devereaux MW, Sokol RJ. Characterization of site of reactive oxygen species (ROS) generation in mitochondria exposed to glycochenodeoxycholic acid. Presented at AASLD Annual Meeting, 1996. Hepatology 1996;24 (2):338A.

143. Sokol RJ, Tyler KL, Oberhaus S, Low R, Le M, Smith D, Tyson RW, Lilly JR, Karrer FM, Narkewicz MR, Brown WB. Presence of Reovirus RNA in biliary tissues of children with choledochal cysts. Presented at AASLD Annual Meeting, 1996. Hepatology 1996:24 (2):34A.

144. Sokol RJ, Devereaux MW, Straka MS. Gadolinium chloride blockade of Kupffer cells increases hepatic injury in bile duct ligated rats. Presented at AASLD Annual Meeting, 1996. Hepatology 1996;24 (2): 339A.

145. Straka MS, Devereaux MW, Sokol RJ. Evidence for oxidant stress in the mitochondrial membrane permeability transition induced by glycochenodeoxycholic acid. Presented at AASLD Annual Meeting, 1996. Hepatology 1996:24 (2):237A.

146. Wagener JS, Erskine JM, Krebs NF, Sokol RJ, Accurso FJ. Airway inflammation and nutrition in young children with cystic fibrosis. Symposium session at Tenth Annual North American Cystic Fibrosis Conference, October 25, 1996, Orlando, FL. Pediatric Pulmonology;1996:Suppl 13: 163-164.

147. Sokol RJ, Tyler KL, Oberhaus S, Low R, Le M, Smith D, Tyson RW, Lilly JR, Karrer FM, Narkewicz MR, Brown WR. Detection of reovirus RNA by nested RT-PCR in hepatobiliary tissues of infants with biliary atresia. Presented at American Gastroenterological Association Annual meeting, Washington, D.C., May, 1997. Gastroenterology 112: A1386, 1997.

148. Setchell KDR, O'Connell NC, Russell DW, Sokol RJ. Identification of a new inborn error in bile acid synthesis involving 7-hydroxylation - a cause of severe liver disease. Presented at American Gastroenterological Association Annual Meeting, Washington, D.C., May, 1997. Gastroenterology 112: A1379, 1997.

149. Feranchak AP, Accurso F, Wegener J, Sontag M, Sokol RJ. Prospective long-term study of fat soluble vitamin status in 150 children with cystic fibrosis diagnosed by newborn screen. Presented at American Gastroenterological Association Annual Meeting, Washington, D.C., May, 1997. Gastroenterology 112:A874, 1997.

150. Rewers M, Eisenbarth G, Tudor S, Uhlhorn C, Bao F, Erlich H, Hoffenberg E, Sokol R. Increased risk of celiac disease in relatives of IDDM patients. Presented at American Diabetes Association Meeting, Jan. 5, 1997. Diabetes 1997;46 (Suppl 1):8A.

151. Sokol RJ, Devereaux MW, Straka MS. Induction of the permeability transition in hepatic mitochondria by physiologic bile acid concentrations. Presented at Parallel Oral Session at American Association for the Study of Liver Diseases annual meeting, November 9, 1997, Chicago, IL. Hepatology 1997;26 (2);188A.

1. Sokol RJ, Narkewicz MR, Karrer FR, Hoffenberg EJ, Sondheimer JM, Wachs ME, Kam I. Outcome of acute hepatic failure in children. Presented at North American Society for Pediatric Gastroenterology and Nutrition annual meeting, October, 1997, Toronto, ON. J Pediatr Gastroenterol Nutr 1997;25:480.

153. Houck WS, Devereaux M, Narkewicz MR, Sokol RJ. Parenteral nutrition-associated liver injury and hepatic glutathione depletion are attenuated by improved nutrition in weanling rats. Presented at North American Society for Pediatric Gastroenterology and Nutrition annual meeting, October, 1997, Toronto, ON. J Pediatr Gastroenterol Nutr 1997;25;453.

154. Hoffenberg EJ, Tudor S, Bao F, Sokol RJ, Eisenbarth G, Rewers M. Prevalence of celiac disease in children at genetic risk. Presented at North American Society for Pediatric Gastroenterology and Nutrition annual meeting, October, 1997, Toronto, ON. J Pediatr Gastroenterol Nutr 1997;25:469.

1. Feranchak AP, Karrer FM, Narkewicz MR, Tyson RW, Sokol RJ. Successful liver transplantation (OLT) in a child with fulminant hepatic failure due to primary EBV infection. Presented at North American Society for Pediatric Gastroenterology and Nutrition annual meeting, October, 1997, Toronto, ON. J Pediatr Gastroenterol Nutr 1997;25:480.
2. Sokol RJ, Straka MS, Devereaux MW. Characterization of the mitochondrial membrane permeability transition (MMPT) induced by hydrophobic bile acids. Presented at Plenary Session at the ESPGHAN/ NASPGN 5th Joint Meeting, Toulouse, France, May, 1998. J Pediatr Gastroenterol Nutr 1998;26:584.
3. Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Lilly JR, Karrer FM. Efficacy of rifampin treatment for severe pruritus in children with chronic cholestasis. Presented at poster session at the ESPGHAN/ NASPGN 5th Joint Meeting, Toulouse, France, May, 1998. J Pediatr Gastroenterol Nutr 1998;26:586.
4. Yerushalmi B, Ingram RD, Karrer FM, Hoffenberg EJ, Tyson RW, Albino E, Sokol RJ. Infantile hemangioendothelioma or hepatoblastoma? Presented at poster session at the ESPGHAN/NASPGN 5th Joint Meeting, Toulouse, France, May, 1998. J Pediatr Gastroenterol Nutr 1998;26:586.
5. Twedt DC, Sokol RJ, Devereaux MW, Gumpricht E. Vitamin E protects against oxidative damage of bile acids in isolated hepatocytes. Presented at American College of Veterinary Internal Medicine Annual Meeting, May, 1998. J Vet Int Med 1998, 12:215.
6. Sokol RJ, Narkewicz MR, Rowe DR, Orban-Eller K, Christopher M, Dovel D, Kam I, Wachs M, Karrer F. Epstein-Barr (EBV) DNA levels in pediatric liver transplantation (OLT) patients. Presented at Third International Congress on Pediatric Transplantation, Boston, Massachusetts, July, 1998.
7. McDiarmid SV, on behalf of SPLIT (RJ Sokol). Report from the Studies of Pediatric Liver Transplantation (SPLIT). Presented at the XVII World Congress on Transplantation, Montreal, Quebec, July, 1998.
8. Gumpricht E, Dahl R, Devereaux MW, Sokol RJ. Glycochenodeoxycholic acid (GCDC) causes depletion of intracellular glutathione in isolated rat liver hepatocytes. Presented at FASEB Summer Research Conferences, Molecular and Biological Mechanisms of Antioxidant Action, August 2-7, 1998, Copper Mountain Resort, CO
9. Gumpricht E, Devereaux M, Dahl R, Sokol RJ. Glycochenodeoxycholic acid (GCDC) causes depletion of intracellular glutathione in isolated rat hepatocytes. Presented at Annual Meeting of the American Association for the Study of Liver Diseases, November, 1998, Chicago, IL. Hepatology 1998;28:326A.
10. Dahl R, Gumpricht E, Devereaux M, Sokol RJ. Bile acid-induced apoptosis and necrosis: differential response of cultured and suspended hepatocytes to hydrophobic and hydrophilic bile acids. Submitted to Annual Meeting of the American Association for the Study of Liver Diseases, November, 1998, Chicago, IL. Hepatology 1998;28:627A.
11. Miga, D, Sokol RJ, Smith D, MacKenzie T, Narkewicz MR, Lilly JR, Karrer FR. Relationship of serum bilirubin concentration to outcome after first esophageal variceal hemorrhage in children with biliary atresia. Presented at Annual Meeting of the American Association for the Study of Liver Diseases, November, 1998, Chicago, IL. Hepatology 1998;28:552A.
12. Sokol RJ, Dahl R, Gumpricht E, Devereaux M. Generation of reactive oxygen species in hepatocytes undergoing bile acid-induced apoptosis. Presented at Annual Meeting of the American Association for the Study of Liver Diseases, November, 1998, Chicago, IL. Hepatology 1998;28:325A.
13. Miga DP, Sokol RJ, MacKenzie T, Narkewicz MR, Lilly JR, Karrer FR. Survival after first esophageal variceal hemorrhage in children with biliary atresia. Presented at Annual Meeting of North American Society for Pediatric Gastroenterology and Nutrition , October, 1998, Orlando, FL. J Pediatr Gastroenterol Nutr 1998;27:492.
14. Holve S, Tyson RW, Hu D, Shub MD, Sokol RJ. Fatal liver disease in Navajo Neuropathy. Presented at Annual Meeting of North American Society for Pediatric Gastroenterology and Nutrition, October, 1998, Orlando, FL. J Pediatr Gastroenterol Nutr 1998;27:492.
15. Hoffenberg EJ, Smith D, Sauaia A, Narkewicz MR, Sokol RJ. Growth is not related to the presence of vertebral anomalies in Alagille syndrome. Presented at Annual Meeting of North American Society for Pediatric Gastroenterology and Nutrition, October, 1998, Orlando, FL. J Pediatr Gastroenterol Nutr 1998;27:469.
16. Sokol RJ, Devereaux M, Dahl R, Gumpricht E. Oxidant stress, apoptosis and necrosis in isolated rat hepatocytes exposed to bile acids. Presented at Annual Meeting of North American Society for Pediatric Gastroenterology and Nutrition, October, 1998, Orlando, FL. J Pediatr Gastroenterol Nutr 1998;27:467.
17. Setchell KDR, Schwarz M, O’Connell NC, Lund E, Davis DL, Lathe R, Sokol RJ, Russell DW. A mutation in the oxysterol 7α-hydroxylase gene causes severe liver disease and highlights the quantitative importance of the acidic pathway for bile acid synthesis in humans. Presented at Falk Symposium, October, 1998.
18. Hoffenberg EJ, Rewers M, Eisenbarth G, Bao F, Tyson RW, Sokol RJ, Uhlhorn C. Predictive value of autoantibodies for small bowel histology in young children at risk for celiac disease. Presented at Annual Meeting of the American Gastroenterological Association, May, 1999, Orlando, FL. Gastroenterology 1999;116:A888.
19. Studies of Pediatric Liver Transplantation (…Sokol RJ…). Waiting list mortality for pediatric patients with chronic liver disease. Presented at American Society of Transplant Physicians 18th Annual Scientific Meeting, May 15-19, 1999.
20. Sokol RJ, Osberg I, Smith D, Narkewicz MR. Low serum beta-carotene concentrations are common in children with cholestatic liver disease. Presented at North American Society for Pediatric Gastroenterology and Nutrition Annual Meeting, October, 1999, Denver, CO. J Pediatr Gastroenterol Nutr 1999;29:509.
21. Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Wenger DA. Neimann-Pick type C and neonatal cholestasis: not as rare as we thought. Presented at North American Society for Pediatric Gastroenterology and Nutrition Annual Meeting, October, 1999, Denver, CO. J Pediatr Gastroenterol Nutr 1999;29:507.
22. Kramer R, Sokol RJ, Yerushalmi B, Thompson HR, Hoffenberg E, Narkewicz MR. Large volume paracentesis in the management of ascites in the pediatric population. Presented at North American Society for Pediatric Gastroenterology and Nutrition Annual Meeting, October, 1999, Denver, CO. J Pediatr Gastroenterol Nutr 1999;29:510.
23. Sokol RJ, Dahl R, Yerushalmi B, Gumpricht E, Devereaux MW. Role of reactive oxygen species in induction of the mitochondrial permeability transition by bile acids. Presented at Annual Meeting of the American Association for the Study of Liver Diseases, Nov., 1999, Dallas, TX. Hepatology 1999;30(Pt.2):398A.
24. Sokol RJ, Dahl R, Yerushalmi B, Gumpricht E, Devereaux MW. Bile acid-induced hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Presented at Annual Meeting of the American Association for the Study of Liver Diseases, Nov., 1999, Dallas, TX. Hepatology 1999;30(Pt.2):398A.
25. Kasaragod AB, Narkewicz MR, Stenmark KR, Pflaummer SM, Lucia MS, Sokol RJ. Connective tissue growth factor (CTGF) in situ mRNA expression and hepatic fibrosis in pediatric liver diseases. Presented at Annual Meeting of the American Association for the Study of Liver Diseases, Nov., 1999, Dallas, TX. Hepatology 1999;30(Pt.2):329A.
26. Studies of Pediatric Liver Transplantation (…Sokol RJ…). Outcome of cyclosporine and tacrolimus treat5ed pediatric patients enrolled in the SPLIT registry. Submitted to American Society for Transplantation Annual Meeting, May, 2000.
27. Studies of Pediatric Liver Transplantation (…Sokol RJ…). School attendance and growth of school age children following liver transplantation. Submitted to American Society for Transplantation Annual Meeting, May, 2000.
28. McDiarmid S, Anand R, and Studies of Pediatric Liver Transplantation (…Sokol RJ…). EBV disease and lymphoproliferative disease (LPD) after a first liver transplant in children enrolled in the SPLIT registry. Submitted to International Pediatric Transplantation Society Annual Meeting, Venice, Italy, August, 2000.
29. McDiarmid S, Anand R, and Studies of Pediatric Liver Transplantation (…Sokol RJ…). Outcome of cyclosporine and tacrolimus treated pediatric patients enrolled in the SPLIT registry. Presented at First Congress of the International Pediatric Transplantation Society, Venice, Italy, August, 2000. Pediatr Transplant 2000;4 (Suppl 2):96.
30. Millis M, Amiri, Anand, and Studies of Pediatric Liver Transplantation group (…Sokol RJ…). Risk factors for hepatic artery thrombosis. Presented at First Congress of the International Pediatric Transplantation Society, Venice, Italy, August, 2000. Pediatr Transplant 2000;4 (Suppl 2):48.
31. Sokol RJ, Millis JM, McDiarmid S, Anand R, and SPLIT Research Group. Growth of children following liver transplantation in North America - results from the SPLIT registry**.** Presented at First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Boston, MA, August 5-9, 2000. J Pediatr Gastroenterol Nutr 2000;31 (Suppl 2):S276.
32. Liu E, Hoffenberg EJ, Kaye RD, Sokol RJ. Endoscopic balloon dilation of an ileo-colonic anastomotic stricture in an infant with short gut syndrome. Presented at First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Boston, MA, August 5-9, 2000. J Pediatr Gastroenterol Nutr 2000;31 (Suppl 2):S257.
33. Sokol RJ, Dahl R, Yerushalmi B, Gumpricht E, Devereaux M. Bile acid induction of the mitochondrial permeability transition involves generation of reactive oxygen species. Presented at First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Boston, MA, August 5-9, 2000. J Pediatr Gastroenterol Nutr 2000;31 (Suppl 2):S185-6.
34. Yerushalmi B, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Mitochondrial dysfunction and oxidant stress mediate bile acid-induced hepatocyte apoptosis. Presented at First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Boston, MA, August 5-9, 2000. J Pediatr Gastroenterol Nutr 2000;31 (Suppl 2):S186.
35. Shneider BLMirza R, Novak R, Anand R, Emre S and The SPLIT Research Group (… Sokol RJ…). Early liver transplantation (OLT) in children with extrahepatic biliary Atresia (EHBA) and failed or no hepatoportoenterostomy (F/N HPE). Presented at First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Boston, MA, August 5-9, 2000. J Pediatr Gastroenterol Nutr 2000;31 (Suppl 2):S198.
36. Kramer RE, Sokol RJ, Yerushalmi B, Liu E, Narkewicz MR. A comparison of the Caldwell needle/cannula and the angiocatheter for large volume paracentesis in the pediatric population. Presented at First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Boston, MA, August 5-9, 2000. J Pediatr Gastroenterol Nutr 2000;31 (Suppl 2):S113-14.
37. Burch JM, Sokol RJ, Narkewicz M, Reichlin M, Frank B, Marchbank A, Lee LA. The role of maternal antibodies in cholestatic liver disease in infants: a new isolated finding in Neonatal Lupus? Presented at First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Boston, MA, August 5-9, 2000. J Pediatr Gastroenterol Nutr 2000;31 (Suppl 2):S108.
38. Holmes RD, Sokol RJ, Rowe DT, Orban-Eller K, Karrer F, Narkewicz MR. Response of elevated EBV DNA levels to therapeutic changes in liver transplantation patients. Presented at First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Boston, MA, August 5-9, 2000. J Pediatr Gastroenterol Nutr 2000;31 (Suppl 2):S112.
39. Emerick KM, Keating G, Osberg I, Whitington PF, Sokol RJ. Pseudotumor cerebri related to idiopathic hypervitaminosis A in Alagille Syndrome. Presented at the 51st Annual meeting of the American Association for Study Liver Diseases, Dallas, TX, October, 2000. Hepatology 2000;32 (Pt. 2):334A
40. Sokol RJ, Devereaux MW, Dahl R, Gumpricht E, Yerushalmi B. Nitric oxide: a key radical species in bile acid-induced apoptosis of isolated hepatocytes. Presented at the 51st Annual meeting of the American Association for Study Liver Diseases, Dallas, TX, October, 2000. Hepatology 2000;32 (Pt. 2):430A
41. Hoffenberg EJ, Barriga K, Eisenbarth GS, Bao F, Erlich H, Haas JE, Mackenzie T, Sokol RJ, Taki I, Rewers M. Prospective study of the frequency of celiac disease in children in Colorado: initial results. Presented at 14th Annual Meeting of North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, Orlando, FL, October 25-28, 2001. J Pediatr Gastroenterol Nutr 2001;33:357
42. Kobak GE, Claassen M, Sokol RJ, Narkewicz MR. Interferon treatment for chronic hepatitis B: enhanced response in children less than 5 years old. Presented at 14th Annual Meeting of North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, Orlando, FL, October 25-28, 2001. J Pediatr Gastroenterol Nutr 2001;33:365
43. Lee LA, Sokol RJ, Buyon JB. Hepatobiliary disease in neonatal lupus: prevalence and clinical

characteristics in cases enrolled in a national registry. Submitted to American College of Rheumatology 65th Annual Scientific Meeting, San Francisco, CA, November 11-15, 2001

1. Squires RH, Shneider BL, Sokol RJ, Bucuvalas JC,Soriano H, Rosenthal P, Schwartz KB, and the Pediatric Acute Liver Failure Study Group. Acute liver failure and acetaminophen: A report of the Pediatric Acute Liver Failure Study Group (PALFSG). Presented at the 14th annual meeting of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, Orlando, FL, October 25-28, 2001. J Pediatr Gastroenterol Nutr 2001;33:363
2. Sokol RJ, Devereux M, Traber M. Delivery of subcutaneously administered emulsified alpha tocopherol to the liver and hepatocyte organelles. Presented at 52st Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, TX, November, 2001. Hepatology 2001;34(2):277A
3. Sokol RJ, Devereaux M, Gumpricht E. Inhibition of bile acid-induced mitochondrial permeability transition by dietary antioxidants. Presented at 52st Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, TX, November, 2001. Hepatology 2001;34(2):277A
4. Liu E, Dobyns E, Nrakewicz MR, Karrer FR, Sokol RJ. Acute hepatic failure in children: a seven year experience at a Children’s Hospital. Presented at 52st Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, TX, November, 2001. Hepatology 2001;34(2):197A
5. Bezerra JA, Ryckman FC, Alonso M, Sabbla G, Schneider B, Sokol RJ, Karrer FR, Aronow B. Functional genomics identifies an unique transcriptional program and a suppressed immune response in infants with biliary atresia. Presented at 52st Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, TX, November, 2001. Hepatology 2001;34(2):240A
6. Gumpricht E, Devereaux MW, Dahl R, Sokol RJ. Nitric oxide donor, but not endogenous nitric oxide generation, prevents bile acid-induced hepatocyte apoptosis by non-mitochondrial pathways. Presented at 52st Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, TX, November, 2001. Hepatology 2001;34(2):272A
7. Squires RH, Shneider BL, Sokol RJ, Bucuvalas JC, Soriano H, Rosenthal P, Schwartz KB, and the Pediatric Acute Liver Failure Study Group. Acute liver failure in children: A report of the first 43 patients from the Pediatric Acute Liver Failure Study Group. Presented at 52st Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, TX, November, 2001. Hepatology 2001;34(2):200A
8. Kobak G, Deutsch G, Devereaux M, Dahl R, Gumpricht E, Sokol RJ. Fat-laden hepatocytes are more prone to cellular necrosis than apoptosis when exposed to hydrophobic bile acids. Presented at the AASLD Presidential Plenary Session, Digestive Disease Week, San Francisco, May, 2002. Gastroenterology 2002;122 (Suppl): A-642
9. Stork LC, Broxson EH, Sather H, Gaynon P, Matloub YH, Yanosfsky R, Sorrell A, Wells L, Masterson M, Hutchinson RJ, Blake M, Sokol RJ.Oral 6-thioguanine causes late-onset splenomegaly and portal hypertension in a subset of children with acute lymphoblastic leukemia. Presented at Digestive Disease Week, San Francisco, May, 2002. Gastroenterology 2002;122:A833
10. Kurbegov AC, Haas J, Narkewicz MR, Mierau G, Sokol. RJ. Improved liver histology and ultrastructure following partial external biliary diversion in patients with progressive familial intrahepatic cholestasis. Presented at Digestive Disease Week, San Francisco, May, 2002. Gastroenterology 2002;122 (Suppl): A-645
11. Hoffenberg EJ, MacKenzie T, Barriga KJ, Eisenbarth GS, Bao F, Erlich H, Haas JE, Sokol RJ, Taki I, Norris J, Rewers M. Clinical features of childhood celiac disease identified in a prospective cohort study. Presented at Digestive Disease Week, San Francisco, May, 2002. Gastroenterology 2002;122 (Suppl): A-18
12. Brady HL, Ross C, Rewers M, Sokol RJ, Eisenbarth G, Norris JM. Plasma Vitamin D Status and Development of Beta-Cell Autoimmunity (BCA) in Young Children. Submitted to American Diabetes Association Meeting, 2002.
13. Hoffenberg EJ, Mackenzie T, Barriga KJ, Eisenbarth GS, Bao F, Erlich H, Haas J, Sokol RJ, Taki I, Norris J, Rewers M. Clinical features of screening-identified celiac disease in early childhood. Presented at the 10th International Symposium on Coeliac Disease, Paris, France, June, 2002.
14. Hoffenberg EJ, Mackenzie T, Barriga KJ, Eisenbarth GS, Bao F, Erlich H, Haas J, Sokol RJ, Taki I, Norris J, Rewers M. A prospective study of the incidence of childhood celiac disease. Presented at the 10th International Symposium on Coeliac Disease, Paris, France, June, 2002
15. Narkewicz MR, Sontag M, Accurso F, Sokol, RJ, Wagener J. Prevalence and persistence of abnormal aminotransferases in children with cystic fibrosis diagnosed by newborn screen. Presented at the North American Cystic Fibrosis Conference, October 3-6, 2002
16. Kobak GE, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Antioxidants improve survival in fat-laden hepatocytes after exposure to hydrophobic bile acids. Presented at 15th Annual Meeting of North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, San Antonio, TX, October, 2002. J Pediatr Gastroenterol Nutr 2002;35:457
17. Sokol RJ, Haskin J, Smith D, Horgan JG, Narkewicz MR, MacKenzie T. Colchicine therapy in children with alpha-1 antitrypsin (A1AT) deficiency and metabolic causes of hepatic fibrosis. Accepted for presentation at 15th Annual Meeting of North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, San Antonio, TX, October, 2002. J Pediatr Gastroenterol Nutr 2002;35:413
18. Sokol RJ, Devereaux MW, Dahl R, Kobak GE, Gumpricht E, Karrer F. Antioxidants prevent the mitochondrial permeability transition and oxidative stress in human liver mitochondria induced by toxic bile acids. Presented at 53st Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA,. November, 2002. Hepatology 2002;36 (pt. 2): 327A
19. Gumpricht E, Devereaux MW, Dahl RH, Kobak GE and Sokol RJ. β-Carotene protects isolated rat hepatocytes from bile acid-induced hepatocyte apoptosis and necrosis. Hepatology 2002;36 (pt. 2): 473A
20. Kobak GE, Gumpricht E, Dahl RH, Devereaux MW, Sokol RJ. Antioxidants ameliorate bile acid-induced cell necrosis in fat-laden hepatocytes by non-mitochondrial pathways. Presented at 53st Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA,. November, 2002. Hepatology 2002;36 (pt. 2): 325A
21. Squires RH, Sokol RJ, Shneider B, Bucuvalas J, Soriano H, Murray K, Rosenthal P, Narkewicz MR, Jonas M, Hynan LS, Simonds N and the Pediatric Acute Liver Failure Study Group (PALFSG). Encephalopathy (EN) at presentation predicts outcome for children with acute liver failure (ALF). Presented at 53st Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA,. November, 2002. Hepatology 2002;36 (pt. 2):167A
22. Zhang D, TiaoG, SablaG, SokolRJ, MackC, ShneiderB, Aronow B, BezerraJ. Coordinate expression of regulatory genes differentiates embryonic from perinatal forms of biliary atresia. Presented at AASLD Single Topic Conference on Biliary Atresia, Atlanta, GA, December 6-8, 2002.
23. Kobak GE, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Evidence for necro-apoptosis in lean and fat-laden hepatocytes exposed to hydrophobic bile acids. Presented by oral presentation at the American Gastroenterologic Association annual meeting, Orlando, FL, May, 2003. Gastroenterology 2003;124(Suppl 1):A-715.
24. Tucker RM, Sokol RJ, Kotzin BL, Mack CL. Immune cell mediated biliary destruction in a murine model of biliary atresia. Presented at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting, October 2-5, 2003, Montreal, Quebec. J Pediatr Gastroenterol Nutr 2003;37:345
25. Liu E, Moriyama H, Finkelman FD, Sokol RJ, Eisenbarth GS. Preventing anaphylaxis during peptide immunotherapy for autoimmune diseases. Presented at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting, October 2-5, 2003, Montreal, Quebec. J Pediatr Gastroenterol Nutr 2003;37:352
26. Mack CL, Tucker RM, Kotzin BL, Sokol RJ, Whitington PF. Biliary atresia is associated with CD4+ TH1-cell mediated portal tract inflammation. Presented at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting, October 2-5, 2003, Montreal, Quebec. J Pediatr Gastroenterol Nutr 2003;37:399
27. Sokol, RJ, Osberg I, Sontag M, Wagener JS, Accurso FJ. Reduced serum coenzyme Q-10 concentrations in children with cystic fibrosis. Presented at Oral and Poster sessions at the 2003 North American Cystic Fibrosis Meeting, October 10-14, 2003, Anaheim, CA. Pediatr Pulmonol 2003;36:338
28. Squires RH, Shneider B, Sokol RJ, Narkewicz MR, Dhawan A, Jonas M, Bucuvalas J, and the Pediatric Acute Liver Failure Study Group. Autoimmune Hepatitis is an Important Cause of Acute Liver Failure in Children. Presented at 54th Annual Meeting of the American Association for the Study of Liver Disease, Boston, MA, Oct. 2003. Hepatology 2003;38(Suppl 1):552A
29. Liu E, Dobyns E, Parikh CR, MacKenzie T, Karrer FM, Narkewicz MR, Sokol RJ. Staging severity of illness for acute liver failure in children. Presented at 54th Annual Meeting of the American Association for the Study of Liver Disease, Boston, MA., Oct. 2003. Hepatology 2003;38(Suppl 1):545A
30. Sokol RJ, Kobak G, Devereaux M, Dahl R, Gumpricht E. Enhanced bile acid-induced hepatic oxidative injury in the obese Zucker rat: an in vivo model of "steatocholestasis". Presented at the 2nd World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Paris, France, July 3-7, 2004. J Pediatr Gastroenterol Nutr 2004;39(Suppl 1): S131
31. Condino AA, O’Connor JA, Narkewicz M, Claussen L, Doran A, Ivy DD, Sokol RJ. Portopulmonary hypertension in pediatric patients. Presented at the 2nd World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Paris, France, July 3-7, 2004. J Pediatr Gastroenterol Nutr 2004;39(Suppl 1):S11-12
32. Emery LM, Hoffenberg EJ, Taki I, Sokol RJ, Haas JE, Rewers M. Prevalence of liver function abnormalities in pediatric celiac disease. Presented at the 2nd World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Paris, France, July 3-7, 2004. J Pediatr Gastroenterol Nutr 2004;39(Suppl 1): S209
33. Bezerra JA, Zhang D-Y, SablaG, Shivakumar P,TiaoG, SokolRJ, MackC, ShneiderBL, AronowB.. Coordinate expression of regulatory genes differentiates embryonic and perinatal forms of biliary atresia. Presented at the 2nd World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Paris, France, July 3-7, 2004. J Pediatr Gastroenterol Nutr 2004;39(Suppl 1):S9
34. Soden JS, Sokol RJ, Narkewicz MR, Condino A, Haas J. Hepatic veno-occlusive disease and HHV-7 in Bruton’s agammaglobulinemia.  Presented at the 2nd World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Paris, France, July 3-7, 2004. J Pediatr Gastroenterol Nutr 2004;39(Suppl 1): S159-60
35. Sokol RJ, Gumpricht E, Dahl R, Devereaux M. Glycyrrhizin (GL) and its metabolite 18-beta-glycyrrhetinic acid (GA) modulate bile acid-induced apoptosis and necrosis in isolated rat hepatocytes. Presented at the 2nd World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Paris, France, July 3-7, 2004. J Pediatr Gastroenterol Nutr 2004;39(Suppl 1):S70
36. Utterson EC, Shepherd RW, Sokol RJ, Bucuvalas JC, Rosenthal P, Schneider B, McDiarmid SV, Anand R, Zeng L and The SPLIT Research Group. Antecedents and Outcomes of 755 Patients with Biliary Atresia Listed for Liver Transplant in the United States and Canada. Presented at the 2nd World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Paris, France, July 3-7, 2004. J Pediatr Gastroenterol Nutr 2004;39(Suppl 1):S27
37. Norris JM, Barriga K, Hoffenberg E, Taki I, Emery LM, Eisenbarth GS, Sokol RJ, Bugawan TL, Erlich HA, Rewers M. Timing of gluten introduction in the infant diet affects risk of celiac disease autoimmunity. Presented at the 11th International Symposium on Coeliac Disease, April 28-30, 2004..
38. Emery LM, Hoffenberg EJ, Taki I, Sokol RJ, Haas JE, Rewers M. Prevalence of liver function abnormalities in pediatric celiac disease. Presented at the 11th International Symposium on Coeliac Disease, April 28-30, 2004.
39. Nadeau KJ, Love-Osborne K, Sokol RJ. Screening for fatty liver disease in insulin-resistant adolescents without diabetes. Presented at Pediatric Academic Societies meeting, April, 2004. Pediatr Res 2004;55(Suppl. Part 2):146A
40. Sokol RJ, Kobak G, Devereaux M, Dahl R, Gumpricht E. Enhanced bile acid-induced hepatic oxidative injury in the obese Zucker rat: an in vivo model of "steatocholestasis". Presented at Annual Meeting of American Gastroenterological Association, New Orleans, LA, May, 2004. Gastroenterology 2004;126 (Suppl 2): A270
41. Norris JM, Barriga K, Hoffenberg E, Taki I, Emery LM, Eisenbarth GS, Sokol RJ, Erlich HA, Rewers M. Timing of gluten introduction in the infant diet affects risk of celiac disease autoimmunity. Presented at 7th Conference of Immunology of Diabetes Society, Cambridge, UK, March 28-30, 2004.
42. Mack CL, Tucker R, Sokol RJ, Kotzin B. Validation of rhesus rotavirus (RRV)-induced murine model for human biliary atresia (BA): evaluation of immune-mediated bile duct injury. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA,. November, 2004. Hepatology 2004;40 (Suppl. 1):199A
43. Shneider B, Brown M, Sokol RJ, Whitington P, Schwarz K, Squires R, Bucuvalas J, Haber B, Sheperd R, Rosenthal P, Robuck P, and BARC. A Multi-center analysis of outcome at 24 months of age in children with biliary atresia in the United States. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA,. November, 2004. Hepatology 2004;40 (Suppl. 1):201A
44. Haber B, Brown M, Shneider B, Sokol RJ, Whitington P, Derusso P, Squires R, Bezerra J, Sheperd R, Rosenthal P, Robuck P, and BARC. Patient Demographics and Clinical Practices in a US Multi-center Study of Biliary Atresia. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA,. November, 2004. Hepatology 2004;40 (Suppl. 1):472A
45. Whitworth, JR, Sokol RJ, O’Connor JA, Narkewicz MR, Haas JE, Mack CL. Acute hepatitis associated with Influenza A infection and therapeutic acetaminophen usage in children. Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, November, 2004. Hepatology 2004;40 (Suppl. 1):469A
46. Soden JS, Devereaux MW, Gumpricht E, Dahl R, Traber M, Sokol RJ. Subcutaneous emulsified vitamin E ameliorates bile acid-induced hepatic and mitochondrial injury in the obese Zucker rat. Presented at American Association for the Study of Liver Disease Meeting at Digestive Disease Week, May, 2005, Chicago, IL. Gastroenterology 2005;128 (Suppl. 2):A-709
47. Brown LM, Sokol RJ, Mack CL, Duncan MW. Comparative proteomics of neonatal liver disease: use of difference gel electrophoresis and mass spectrometry in biomarker discovery. Presented at American Society for Mass Spectrometry Meeting, June, 2005, San Antonio, TX.
48. DeRusso PA, Ye W, Haber B, Shneider BL, Sokol RJ, Whitington PF, Squires R, Bezerra J, Shepherd R, Rosenthal P, Hoofnagle JH for the Biliary Atresia Research Consortium. Early growth failure after portoenterostomy is associated with liver transplantation or death in infants with biliary atresia. Presented at 56th Annual Meeting of the American Association for the Study of Liver Diseases, November, 2005, San Francisco, CA. . Hepatology 2005;42 (Suppl. 1): 222A-223A.
49. Sokol RJ, Dahl R, Devereaux MW, Soden J, Gumpricht E. Neonatal hepatic mitochondria are resistant to bile acid induced mitochondrial permeability transition. Presented at 56th Annual Meeting of the American Association for the Study of Liver Diseases, November 11-14, 2005, San Francisco, CA. Hepatology 2005;42 (Suppl. 1): 501A.
50. Mack CL, Falta M, Sokol RJ, Karrer F, Hendrickson R, Fontenot A. Expansion of oligoclonal T-cell subsets expressing particular T-cell receptor variable regionis in biliary atresia. Submitted to 56th Annual Meeting of the American Association for the Study of Liver Diseases, November 11-14, 2005, San Francisco, CA.
51. Papas G, Pardee C, Accurso F, Sokol R, Wagener J. Treatment of Cystic Fibrosis Patients with Antioxidant Solution: A Pilot Study. Presented at North American Cystic Fibrosis Conference, October 22-25, 2005.
52. Whitworth JR, Ivy DD, Gralla J, Narkewicz MR, O’Connor JA, Mack CL, Condino A, Karrer FM, Sokol RJ. Prevalence of intrapulmonary vascular shunting in asymptomatic children with portal hypertension. Presented at American Association for the Study of Liver Diseases Meeting at Digestive Disease Week, May, 2006, Los Angeles, CA. Gastroenterology 2006;130 (Suppl. 2): 803
53. Hoffenberg, EJ, Emery LM, Taki I,Rewers M, Sokol RJ. Liver function tests early in the course of pediatric celiac disease. Submitted to American Gastroenterological Association annual meeting at Digestive Disease Week, May, 2006.
54. Wagener J, Sontag M, Pardee C, Sokol RJ, Accurso F, Papas G. Impact of an antioxidant solution on airway inflammation in patients with cystic fibrosis. Presented at North American Cystic Fibrosis Conference, Nov., 2006, Denver, CO. Pediatr Pulmonology 2006; Suppl 29:390
55. Soden J, Devereaux M, Gumpricht E, Sokol RJ. Effects of antioxidants and steatosis in bile acid-induced injury to primary cultured rat hepatocytes. Presented at NASPGHAN Annual Meeting, Orlando, FL, Oct., 2006. J Pediatr Gastroenterol Nutr 2006;43:E70
56. Shneider B, Norton K, Superina R, Erlichman J, Magee J, Bucuvalas J, Whitington P, Rosenthal P, Squires R, Benson J, Karpen S, Shepherd R, Sokol RJ, for the Biliary Atresia Research Consortium. Diagnostic imaging in neonatal cholestasis: a multi-center prospective analysis. Presented at AASLD Annual Meeting, Boston, MA, Oct. 2006. Hepatology 2006;44 (Suppl 1):437A
57. Russo P, Boitnott J, Bove K, Brown M, FinegoldM, Haas J, Jaffe R, Kim GE, Magee J, Magid M, Melin H, Sokol RJ, White F, for the Biliary Atresia Research Consortium. A multi-institutional study of interobserver agreement on the histologic diagnosis of biliary obstruction in liver biopsies of cholestatic infants less than six months of age. Presented at AASLD Annual Meeting, Boston, MA, Oct. 2006. Hepatology 2006;44 (Suppl 1):208A

1. Sokol RJ, Devereaux MW, Dahl R, Sparagna GC, Gumpricht E. Cardiolipin subspecies and resistance of neonatal liver mitochondria to bile acid-induced permeability transition. Submitted to AASLD Annual Meeting, Boston, MA, Oct. 2006.
2. Soden J, Devereaux M, Gumpricht E, Sokol RJ. Reactive oxygen species-independent pathways are involved in bile acid-induced injury in a dietary model of hepatic steatosis. Presented at AASLD Annual Meeting, Boston, MA, Oct. 2006. Hepatology 2006;44 (Suppl 1):583A-584A
3. Mack C, Falta M, Freed B, Sokol RJ, Fontenot AP. Oligoclonal Expansions of CD4+ and CD8+ T cells in Liver and Extrahepatic Duct Remnants of Patients with Biliary Atresia. Presented at AASLD Annual Meeting, Boston, MA, Oct. 2006. Hepatology 2006;44 (Suppl 1):208A-209A
4. Russo P, Boitnott J, Bove K, Brown M, Finegold M, Haas J, Jaffe R, Kim G, Magee J, Magid M, Melin-Aldana H, Sokol R, White F. A multi-institutional study of interobserver agreement on the histologic diagnosis of biliary obstruction in liver biopsies of cholestatic infants less than six months of age. Presented at AASLD Annual Meeting, Boston, MA, Oct. 2006. Hepatology 2006;44 (Suppl 1):208A

1. Sokol RJ, Bezerra J, Haber B, Karpen S, Perlmutter D, Rosenthal P, Schwarz K, Shepherd R, Shneider B, Whitington P, Brown M, Magee J, Robuck P, and Hoofnagle J for BARC. Biliary Atresia Research Consortium (BARC): NIH funded network to advance knowledge and improve care and outcomes in biliary atresia. Presented at Poster Session of *NIH Workshop on Screening and Outcomes in Biliary Atresia*, Bethesda, MD., Sept. 11, 20006.
2. Sokol SP, Pan Z, Sokol RJ. Analysis of the incidence of biliary atresia in counties in the state of Colorado. Presented at Poster Session of *NIH Workshop on Screening and Outcomes in Biliary Atresia*, Bethesda, MD. Sept. 11, 20006.
3. Sokol RJ, Murray K, Boyd J, Thompson H, Shepherd R, Mack CL, Karrer FM, Duncan M. Upregulation of redox pathway proteins in livers from infants with parenteral nutrition-associated liver disease (PNALD). Oral presentation at Annual NASPGHAN meeting. October 25-27, 2007, Salt Lake City, UT. J Pediatr Gastroenterol Nutr 2007;45:E58
4. Sokol RJ, Devereaux MW, Sparagna GS, LeonardSW, TraberMG, Gumpricht E. Mitochondrial -tocopherol and cardiolipin in young rats may afford protection against bile acid-induced mitochondrial pathways of cell death. Poster presentation at the AASLD Annual Meeting, Nov. 2007, Boston, MA. Hepatology 2007;46 (Suppl 1):466A-467A
5. Kevan E, Sokol SP, Holmes R, Pan Z, Sokol RJ. Analysis of the incidence and demographics of biliary atresia in Colorado. Submitted to AASLD Annual Meeting, Nov. 2007, Boston, MA.
6. Shneider B, Shepherd R, Magee J, Bucuvalas J, Haber B, Karpen S, Rosenthal P, Schwarz K, Suchy F, Whitington P, Sokol RJ for BARC. Discriminating features of biliary atresia -a prospective multi-centered analysis. Oral presentation at the AASLD Annual Meeting, Nov. 2007, Boston, MA. Hepatology 2007;46 (Suppl 1):279A
7. Lu B, Gralla J, Liu E, Dobyns E, Narkewicz MR, Sokol RJ. Evaluation of a scoring system for assessing prognosis in pediatric acute liver failure. Oral presentation at the AASLD Annual Meeting, Nov. 2007, Boston, MA. Hepatology 2007;46(Suppl 1):276A-277A
8. Sokol RJ, Murray K, Boyd J, Thompson H, Shepherd R, Karrer FM, Mack C, Duncan M. Comparative proteomic analysis of parenteral nutrition-associated liver disease (PNALD) in infants with intestinal failure. Oral presentation at the AASLD Annual Meeting, Nov. 2007, Boston, MA. Hepatology 2007;46 (Suppl 1):278A
9. Lu B, Gralla J, Liu E, Dobyns E, Narkewicz MR, Sokol RJ. Development of an admission scoring system for predicting outcome in pediatric acute liver failure. Oral presentation at Pediatric Academic Societies meeting, May, 2008, Honolulu, Hawaii. E-PAS 2008:5345.7
10. Soden JS, Lovell MA, Brown K, Mazariegos G, Sokol RJ. Progression of portal fibrosis despite reversal of cholestasis during Omegaven therapy in a patient with intestinal failure. Presented at Third World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, August 20, 2008.
11. Haber B, Fredericks EM, Magee J, Bezerra J A, Karpen SJ,Kerkar N, Rosenthal P, Schwarz KB, Shepherd R, Shneider BL, Whitington PF, Robuck PR, Sokol RJ and BARC. Predictors of neurodevelopmental outcome in non-transplanted children with biliary atresia at one year of age. Presented at AASLD annual meeting, October, 2008, San Francisco. Hepatology 2008;48 (Suppl): 1028A.
12. Schwarz KB, Shepherd R, Magee J, Rosenthal P, Mack C, Raghumathan T, Bezerra J, Haber B, Karpen S, Suchy F, Whitington P, Robuck P, Sokol RJ, and BARC. Clinical and Demographic Features of Three Major Biliary Atresia Phenotypes in the BARC study. Presented at AASLD annual meeting, October, 2008, San Francisco. Hepatology 2008;48 (Suppl): 1028A-1029A.
13. Black DD, Ravinder A, Yin W, Whitington GL, and the STOPSC research Group (…Sokol RJ…). Preliminary results from a North American pediatric and adult primary sclerosing cholangitis (PSC) Registry (STOPSC). Submitted to AASLD annual meeting, October, 2008.
14. Black DD, Ravinder A, Yin W, Whitington GL, and the STOPSC research Group (…Sokol RJ…). Use of International Autoimmune Hepatitis (AIH) Working Group criteria for pediatric patients in a North American Primary Sclerosing Cholangitis (PSC)/AIH Registry (STOPSC). Presented at AASLD annual meeting, October, 2008. Hepatology 2008;48 (Suppl): 1032A
15. Soden J, Lovell M, Sokol RJ. Progression in portal fibrosis during Omegaven therapy in two patieints with intestinal failure. Presented at NASPGHAN/CDHNF conference, Nov. 13-15, 2008, San Diego, CA.
16. Lu BR, Zhang S, Narkewicz MR, Belle SH, Squires R, Sokol RJ. Validation of a scoring system to predict survival in 455 patients with Pediatric Acute Liver Failure. Presented at AASLD annual meeting, November 2009, Boston, MA. Hepatology 2009;50(Suppl): 368A:424A.
17. Campsen J, Zimmerman MA, Narkewicz MR, Sokol RJ, Kam I, Dovel D, Karrer F. Choledochoduodenostomy is an alternative for biliary reconstruction in pediatric liver transplantation. Submitted to AASLD annual meeting, November, 2009, Boston, MA.
18. Sundaram SS, Salazar E, Sokol RJ, Halbower A. Relationship of obstructive sleep apnea and hypoxia with Non-Alcoholic Fatty Liver Disease in children. Submitted to AASLD annual meeting, November 2009, Boston, MA.
19. Sundaram SS, Fredericks EM, Kamath B, Haber BA, Raghumathan T, Magee J, Bezerra J, Karpen SH, Kerkar N, Rosethal P, Schwarz KB, Shepherd R, Schneider BL, Whitington PF, Robuck P, Sokol RJ and BARC. A multicenter cross sectional assessment of Quality of Life in biliary aresia patients ages 2-25 years. Presented at AASLD annual meeting, November 2009, Boston, MA. Hepatology 2009;50:632A-633A
20. Shneider BL, Abel R, Raghunathan T, Magee J, Bezerra J, Haber B, Karpen SJ, Rosenthal P, Schwarz KB, Shepherd R, Suchy FJ, Whitington PF, Robuck PR, Sokol RJ, and BARC. A Prospective Multi-Centered Investigation of Vitamin Supplementation in Infants with Biliary Atresia: Interim Analysis from the Biliary Atresia Research Consortium (BARC). Presented at AASLD annual meeting, November 2009, Boston, MA. Hepatology 2009; 50:631A–632A
21. El Kasmi KC, Anderson A, Devereaux M, Sokol RJ. Development of a novel model of Total Parenteral Nutrition-associated liver injury (TPNALI) characterized by an inflammatory response. Presented at Oral Abstract Session at AASLD annual meeting, November 2009, Boston, MA. Hepatology 2009;50(Suppl): 368A.
22. Sokol RJ, Magee JC, Hahn C, Robuck, PR for ChiLDREN. The new Childhood Liver Disease Research and Education Network (ChiLDREN): a new cooperative effort between NIDDK, academic centers and patient advocacy groups. Presented at NASPGHAN annual meeting, November, 2009, National Harbor, MD.
23. Sokol RJ, Hines J for CLiC. The Cholestatic Liver Disease Consortium (CLiC): a multi-instituional collaboration to better understand and treat liver disease in children. Presented at NIH conference “Advancing Rare Diseases Research through Networks and Collaboration.” Bethesda, MD, July 16, 2009.
24. Hahn C, Sokol RJ, Hines J for the CLiC Patient Advocacy Group Committee. The Patient Advocacy Group Committee of the Cholestatic Liver Disease Consortium: giving families, parents and patients a partnership with researchers. Presented at NIH conference “Advancing Rare Diseases Research through Networks and Collaboration.” Bethesda, MD, July 16, 2009
25. El Kasmi KC, Anderson AL, Devereaux MW, Harris JK, Sokol RJ. Analysis of intestinal microbiome in a mouse model of parenteral nutrition associated liver injury. Presented at the Butcher Symposium, University of Colorado, Boulder, CO., November 6, 2009.
26. El KasmiKC, AndersonAL, DevereauxMW, KangJX, SokolRJ. Endogenous Omega 3 fatty acids down-regulate LPS induced Kupffer cell and macrophage activation and protect mice from endotoxin shock. Presented at “The Macrophage: intersection of pathogenic and protective inflammation” conference, Bannf, Alberta, Feb. 12-17, 2010.
27. Sokol RJ, Anderson AA, Devereaux MW, Fillon SA, El Kasmi KC. Role of intestinal microbiome and kupffer cell activation in a novel mouse model of parenteral nutrition-associated liver injury. Oral platform presentation at Pediatric Academic Societies Annual Meeting, May, 2009, Vancouver, B.C.
28. El Kasmi, KC, Anderson AL, Devereaux MW, Kang JX, Sokol RJ. Omega-3-fatty Acids Downregulate Kupffer Cell Activation and Cytokine Production during Lipopolysaccharide (LPS) Challenge. Oral presentation at Digestive Disease Week, May, 2009, New Orleans, Louisiana.
29. Lothlorien E, Hammack BN, Sokol RJ. Facilitating the scientific review: an integrated and streamlined process. Presented at Clinical Research Management Workshop of the National CTSA Consortium, Washington DC, June 2010.
30. Miller MR, Sokol RJ, Narkewicz MR, Sontag MK. Lung fuction in individuals with cystic fibrosis who had undergone liver transplant. Presented at the North American Cystic Fibrosis Meeting, October, 2010.
31. El Kasmi KC, Anderson, AL Devereaux MW, Fillon SA, Harris JK, Sokol RJ. Specific Alterations in the Intestinal Microbiome are Associated with Kupffer Cell Activation and Liver Injury in a Novel Mouse Model of Parenteral Nutrition Associated Liver Injury (PNALI). Presented at Annual Meeting of the American Association for the Study of Liver Disease, November 2010, Boston, MA. Hepatology 2010;52 (Suppl): 1036A.
32. El Kasmi KC, Anderson, AL Devereaux MW, Sokol RJ. Parenteral Omega-3-Fatty Acid (ω3-FA) Infusion is Protective in a Mouse Model of Parenteral Nutrition Associated Liver Injury (PNALI). Presented at Annual Meeting of the American Association for the Study of Liver Disease, November 2010, Boston, MA. Hepatology 2010;52 (Suppl): 420A.
33. El Kasmi KC, Anderson, AL Devereaux MW, Sokol RJ. Omega-3-fatty acids signal through PPARγ-dependent pathways, independent of IL-10, to attenuate the TLR-IFNγ-induced inflammatory macrophage/Kupffer cell phenotype. Presented at Annual Meeting of the American Association for the Study of Liver Disease, November 2010, Boston, MA. Hepatology 2010;52 (Suppl): 1254A.
34. Shneider BL, Abel RB, Haber B, Karpen SJ, Magee JC, Romero R, Schwartz KB, Bass LM, Kerkar N, Miethke AG, Rosenthal P, Turmelle YP, Sokol RJ, and the Childhood Liver Disease Research and Education Network (ChiLDREN). Cross-sectional Multi-center Analysis of Portal Hypertension in 163 Children with Biliary Atresia. Presented at Annual Meeting of the American Association for the Study of Liver Disease, November 2010, Boston, MA. Hepatology 2010;52 (Suppl): 347A.
35. Colson SB, Siparsky G, Sokol RJ, Hoffenberg EJ. Inflammatory Bowel Disease in Pediatric Patients with Cerebral Palsy. Presented at the Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, October, 2010, New Oleans, LA. J Pediatri Gastroenterol Nutr 2010; 51(Suppl 2): E94-5.
36. Colson SB, Siparsky G, Sokol RJ, Hoffenberg EJ. Inflammatory Bowel Disease in Pediatric Patients with Cerebral Palsy. Presented at the 2010 Advances in Inflammatory Bowel Diseases- Crohn's & Colitis Foundation's Clinical & Research Conference, December 9 -12, 2010 , Hollywood, FL.
37. Li M, Riddle SR, FLockton AR, Barajas C, Yeager ME, Frid MG, Anderson AL, Sokol RJ, El Kasmi KC, Stenmark KR. Chronic Hypoxia Leads To Emergence Of Pro-Inflammatory Pulmonary Adventitial Fibroblasts Capable Of Inducing Alternative Activation In Monocytes/Macrophages. Poster presentation at annual meeting of the American Thoracic Society, May 16, 2011, Denver, Colorado,
38. Sullivan JS, Sundaram SS, Pan Z, Sokol RJ. Effect of parenteral nutrition in biliary atresia patients listed for liver transplant. Poster presentation at annual meeting of the Pediatric Academic Societies, May 1, 2011, Denver, Colorado
39. El Kasmi KC, Anderson AL, Devereaux MW, Lovell MA, and Sokol RJ. Parenteral Nutrition Associated Liver Injury Involves Recruitment of Macrophages and Activation of Kupffer Cells through Innate Immune Pathways. Platform presentation at annual meeting of the Pediatric Academic Societies, May 1,2011, Denver, Colorado
40. El Kasmi KC, Anderson AL, Devereaux MW, Lovell MA, Sokol RJ. Parenteral Nutrition Associated Liver Injury Involves TLR4 Signaling-Dependent Activation of Kupffer Cells by Intestinal Microbiota. Platform presentation at annual meeting of the Pediatric Academic Societies, May 1, 2011, Denver, Colorado
41. Colson S, Siparsky G, Sokol RJ, Hoffenberg E. Inflammatory bowel disease in patients with cerebral palsy: a more aggressive phenotype? Poster presentation at annual meeting of the Pediatric Academic Societies, May 1, 2011, Denver, Colorado
42. Shneider B, Magee JC, Karpen SJ, Rand E, Narkewicz MR, Schwarz K, Whitington PF, Bezerra JA, Kerkar N, Rosenthal P, Turmelle Y, Molleston J, Murray KF, Ng V, Wang KS, Romerol R, Moore J, Robuck PR, Sokol RJ for the Childhood Liver Disease Research and Education Network (ChiLDREN). Prospective Multi-center Analysis of Post-operative Total Serum Bilirubin as a Biomarker for Short-term Outcome After Hepatoportoenterostomy for Biliary Atresia. Presented as platform presentation at AASLD annual meeting, November 4-8, 2011. Hepatology 2011;54 (Number 4 Suppl): 468A
43. El Kasmi KC, Andreson AL, Deverereaux MW, Sokol RJ. Soy Lipid Derived Phytosterols promote Parenteral Nutrition Associated Liver Injury (PNALI) in a Mouse Model. Presented as platform presentation at AASLD annual meeting, November 4-8, 2011. Hepatology 2011;54 (Number 4 Suppl): 412A
44. Ng VL, Haber B, Magee JC, Bezerra JA, Whitington PF, Schwarz K, Karpen SJ, Rosenthal P, Shneider BL, Kerkar N, Turmelle Y, Molleston J, Murray K, Wang K, Romero R, Able R, Robuck P, Sokol RJ for the Childhood Liver Disease Research and Education Network (ChiLDREN).Medical Status of 192 Children with Biliary Atresia Surviving >5 Years After Kasai Portoenterostomy With Their Native Liver. Presented at AASLD annual meeting, November 4-8, 2011. Hepatology 2011;54 (Number 4 Suppl): 697A-698A
45. El Kasmi KC, Harris JK, Andreson AL, Devereaux MW, Fillon SA, Sokol RJ. Specific alterations in the intestinal microbiome in a novel mouse model of parenteral nutrition associated liver injury (PNALI) are associated with Kupffer cell activation and liver injury. Presented at Keystone Conference on Innate Immunity and Microbiome, February, 2012, Keystone, Colorado.
46. Lam C, Gallagher RC, Wong D, Cederbaum S, Sokol RJ and the Urea Cycle Disorder consortium. Liver failure, liver dysfunction and hepatocellular injury are common in Ornithine Transcarbamylase deficiency. Presented at Society for Inherited Metabolic Disease annual meeting, March 2012.
47. Russo P, Kim G, White F, Bove K, Finegold M, Anders R, Melin-Aldana H, Lovell M, Magid M, Jaffe R, Cummings B, Finn L, Wang L, Shehata B, Spino C, , Sokol RJ, Magee JC and Childhood Liver Disease Research and Education Network (ChiLDREN). Key histopathological features on initial liver biopsy correlate with biliary atresia and outcome post Kasai. Platform presentation at the Society for Pediatric Pathology Spring Meeting, March 2012, Vancouver, BC, Canada.
48. Sundaram SS, Sokol RJ, Robbins K, Capocelli K, Pan Z, Halbower A. Obstructive Sleep Apnea and Hypoxia are Associated with More Advanced Fibrosis in Pediatric Non-Alcoholic Fatty Liver Disease. Oral presentation at Digestive Disease Week, May, 2012. San Diego, CA.
49. Sullivan JS, Le M, Pan Z, Johnson R, Sokol RJ, Robbins K, Sundaram SS. Oral Fructose Absorption in Children with Non-Alcoholic Fatty Liver Disease. Oral presentation at Digestive Disease Week, May, 2012. San Diego, CA.
50. Molleson JP, Sokol RJ, Karnsakul W, Miethke A, Magee J, Squires R, VanHove J, for the ChiLDREN Network. Evaluation guidelines for suspected mitochondrial hepatopathies. Poster presentation at the NASPGHAN annual meeting, Salt Lake City, October 2012
51. Peiffer EK, Boguniewicz J, Tucker R, Sokol RJ, Mack CL. High dose IgG therapy in murine biliary atresia results in decreased bile duct injury through expansion of regulatory T cells and inhibition of CD4+ Th1 cytokine production. Oral presentation at AASLD Anuual Meeting, Nov. 11, 2012, Boston, MA. Hepatology 2012;56 (Suppl), 199A.
52. Mack CL, Anderson K, Aubrey MT, Sokol RJ, Freed BM. Lack of HLA predominance and HLA shared eptiopes in biliary atresia. Poster presentation at AASLD Anuual Meeting, Nov. 10, 2012, Boston, MA. Hepatology 2012;56 (Suppl), 724A.
53. El Kasmi KC, Anderson AL, Devereaux MW, Noe MS, Sokol RJ. Phytosterols in Soy Lipid-based Parenteral Nutrition (PN) solutions are responsible for PN Associated Liver Injury (PNALI) in a Mouse Model. Oral presentation at World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Taipei, Taiwan, November 16, 2012
54. Molleson JP, Sokol RJ, Karnsakul W, Miethke A, Magee J, Squires R, Horslen S, VanHove J, for the ChiLDREN Network. Evaluation guidelines for suspected mitochondrial hepatopathies. Oral presentation at the World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Taipei, Taiwan, November 15, 2012
55. El Kasmi K, Harris K, Devereaux M, Anderson A, Pace N, Sokol RJ, Fillon S, Robertson C, Wagner B; Stevens M. Specific Microbiome Changes in a Mouse Model of Parenteral Nutrition Induced Liver Injury and Intestinal inflammation. Presented at Keystone Symposium, “The Gut Microbiome: The Effector/Regulatory Immune Network”, Taos, NM, February 11, 2013.
56. Flass T, Tong S, Hoffenberg EJ, Sokol RJ, Narkewicz MR. High frequency of intestinal lesions and slow intestinal transit in CF patients with cirrhosis. Accepted for Oral Presentation at the 2013 North American Cystic Fibrosis Conference, October 17-19, 2013, Salt Lake City, UT.
57. Vue PM, Anderson AL, Devereaux MW, Balasubramaniyan N, Sokol RJ, El Kasmi KC. Hepatic Phytosterol Accumulation During Parenteral Nutrition Involves Activation of Macrophages and Cytokine-mediated Suppression of Hepatocellular Sterol Export Systems (ABCG5/8)**.** Presented as Oral Presentation at Annual Meeting of the American Association for the Study of Liver Diseases, Nov. 1-5 2013. Washington, D.C.
58. Sundaram SS, Colgan S, Pan Z, Halbower A, Robbins K, Capocelli K, Bayless A, Sokol RJ. Association of HIF 1α in pediatric non-alcoholic fatty liver disease. Presented at Poster Session at Annual Meeting of the American Association for the Study of Liver Diseases, Nov. 1-5 2013, Washington, D.C.
59. Bezerra JA, Spino C, Magee JC, Shneider BL, Rosenthal P, Wang KS, Erlichman J, Haber B, Hertel PM, Karpen SJ, Kerkar N, Loomes KM, Molleston JP, Murray KF, Romero R, Schwarz KB, Shepherd R, Suchy FJ, Turmelle YP, Whitington PF, Moore J, Sherker AH, Robuck PR, Sokol RJ for the Childhood Liver Disease Research and Education Network (ChiLDREN).. High-dose corticosteroid therapy following portoenterostomy in infants with biliary atresia does not improve outcome: The multi-center, randomized, double-blind, placebo-controlled START Trial. Presented at Plenary Session presentation at Annual Meeting of the American Association for the Study of Liver Diseases, Nov. 1-5 2013, Washington, D.C.
60. Albino J, Moss M, Sokol RJ. The Colorado Leadership for Innovative Team Science (LITeS) Program: Creating Effective Teams. Accepted for oral presentation at CTSA Consortium Steering Committee In-Person Meeting, December 2013, Bethesda, MD.
61. VandeWoude S, Thamm DH, Jensen W, Sokol RJ. Natural Animal Models Core: advancing T0.5 translational research. Submitted to CTSA Consortium Steering Committee In-Person Meeting, October 2013, Bethesda, MD.
62. Tamez M, Green L, Sokol RJ. The PACT Council: a solution to community engagement challenges in Colorado. Submitted to CTSA Consortium Steering Committee In-Person Meeting, October 2013, Bethesda, MD.
63. Vue PM, Anderson AL, Devereaux MW, Balasubramaniyan N, Suchy FJ, Sokol RJ, and El Kasmi KC. Hepatic macrophage-derived IL1β suppresses hepatocyte sterol export (Abcg5/8) to cause hepatic phytosterol accumulation and cholestasis in a parenteral nutrition mouse model. Presented at Plenary Session, Pediatric Academic Societies Annual Meeting, April 5, 2014, Vancouver, BC, Canada
64. Sambrotta M, Strautnieks S, Papouli E, Rushton P, Clark BE, Parry DA, Brett L, Logan CV, Newbury LJ, Kamath BM, Ling S, Grammatikopoulos T, Wagner BE, Magee JC, Sokol RJ, Mieli-Vergani G, University of Washington Center for Mendelian Genomics, Smith JD, Johnson CA, Davison S, McClean P, Simpson MA, Knisely AS, Bull LN, Thompson RJ. *TJP2* deficiency: a new cholestatic liver disease. Presented at European Human Genetics Conference, May 31- June 3, 2014, Milan, Italy.
65. Sundaram SS, Halbower A , Pan Z, Robbins K, Capocelli K, Christians U, Sokol RJ. Oxidative Stress Caused by Nocturnal Hypoxia is Related to the Severity of Pediatric Non-Alcoholic Fatty Liver Disease. Presented as poster presentation at AASLD annual meeting, November 2014, Boston MA. Hepatology 2014; 60(Suppl):523A-524A.
66. El Kasmi KC, Vue PM, Anderson AL, Devereaux MW, Balasubramaniyan N, Suchy FJ, and Sokol RJ. IL1-β is a Critical Mediator of Parenteral Nutrition Associated Cholestasis in Mice. Presented as oral presentation at AASLD annual meeting, November 2014, Boston MA. Hepatology 2014; 60(Suppl):274A-275A
67. Vue PM, El Kasmi KC, Anderson AL, Devereaux MW, Balasubramaniyan N, Suchy JF, Sokol RJ . IL-1 β generated by LPS-activated CCR2-positive Hepatic Macrophages regulates expression of Hepatocellular Sterol and Bile Transport Systems. Presaented at poster presentation at AASLD annual meeting, November 2014, Boston MA. Hepatology 2014; 60(Suppl):766A.
68. El Kasmi KC, Anderson AL, Devereaux MW, Sokol RJ. Pharmacological TNFα blockade prevents Parenteral Nutrition Associated Cholestasis in Mice. Submitted as Late Breaking Abstract to at AASLD annual meeting, November 2014, Boston MA.
69. El Kasmi KC, Anderson AL, Devereaux MW, Sokol RJ. Pharmacological TNFα blockade prevents Parenteral Nutrition Associated Cholestasis in Mice. Presented at Platform Session at Pediatric Academic Societies Meeting, April 27, 2015, San Diego, CA.
70. Shneider BL, Magee J, Kerkar N, Moore J, Ye W, Karpen S, Whitington P, Bezerra J, Hertel P, Molleston J, Wang K, Lin H, Squires R, Rosenthal P, Ng V, Turmelle Y, Schwarz K, Sherker A, Sokol RJ for ChiLDReN. Prospective Analysis of Presenting Features of Neonatal Cholestasis – Limitations in Predictive Models of Biliary Atresia. Oral presentation at NASPGHAN annual meeting, October 7-11, 2015, Washington D.C.
71. Ng VL, Sorensen LG, Alonso EM, Fredericks EM, Ye W, Karpen S, Shneider BL, Bezerra JA, Molleston JP, Murray KF, Rosenthal P, Wang KS, Loomes K, Hertel PM, Kerkar N, Schwarz KB, Turmelle Y, Haber BH, Sherker AH, Magee JC, Sokol RJ for the ChiLDReN Networ. Neurodevelopmental Outcomes in Patients with Biliary Atresia and Native Liver at Ages 1 and 2 Years: Results from ChiLDReN. Platform presentation at AASLD annual meeting, November 2015, San Francisco, CA. Hepatology 2015;62, Number 1 (Suppl):277A
72. Loomes KL, Spino C, Goodrich N, Hangartner T, Marker A, Heubi JE, Kamath BM, Shneider BL, Rosenthal P, Hertel PM, Karpen SJ, Kerkar N, Molleston JP, Murray KF, Schwarz KB, Teckman J, Turmelle YP, Whitington PF, Sherker AH, Magee JC, Sokol RJ for the Childhood Liver Disease Research Network (ChiLDReN). DXA bone density in Alagille syndrome correlates with fracture history and degree of cholestasis**.**  Poster presentation at AASLD annual meeting, November 2015, San Francisco, CA. Hepatology 2015;62, Number 1 (Suppl):1034A.
73. Sundaram SS, Swiderska-Syn M, Sokol RJ, Pan Z, Capocelli K, Robbins K and Diehl AM. Nocturnal Hypoxia is associated with Hedgehog Signaling and Severity of Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD). Poster presentation at AASLD annual meeting, November 2015, San Francisco, CA. Hepatology 2015;62, Number 1 (Suppl):1044A
74. Feldman AG, Sokol RJ, Hardison RM, Alonso EM, Squires RH, Narkewiciz MR. Screening for mitochondrial disease in pediatric acute liver failure: the role of lactate and pyruvate. Poster of Distinction presentation at AASLD annual meeting, November 2015, San Francisco, CA. Hepatology 2015;62, Number 1 (Suppl):1044A.
75. El Kasmi KC, Anderson AL, Devereaux MW, Balasubramaniyan N, Suchy FJ, and Sokol RJ. Macrophage activation through hypoxia inducible factor 1 alpha (HIF1α) signaling is essential in Parenteral Nutrition Associated Cholestasis in mice. Poster presentation at AASLD annual meeting, November 2015, San Francisco, CA Hepatology 2015;62, Number 1 (Suppl):1246A
76. El Kasmi KC, Anderson AL, Devereaux MW, Balasubramaniyan N, Suchy FJ, and Sokol RJ. Molecular mechanism of transcriptional suppression of the sterol transporter *Abcg5/8* in a parenteral nutrition mouse model. Poster presentation at AASLD annual meeting, November 2015, San Francisco, CA. Hepatology 2015;62, Number 1 (Suppl):1031A.
77. El Kasmi KC, Anderson AL, Devereaux MW, Sokol RJ. Hepatic macrophage IL-1beta expression and suppression of bile and sterol transporters precedes cholestasis in a parenteral nutrition mouse model. Poster presentation at AASLD annual meeting, November 2015, San Francisco, CA Hepatology 2015;62, Number 1 (Suppl):1031A.
78. El Kasmi KC, Anderson AL, Devereaux MW, Balasubramaniyan N, Suchy FJ, and Sokol RJ. TNFα promotes Parenteral Nutrition Associated Cholestasis in Mice with Intestinal Injury. Poster presentation at NASPGHAN annual meeting, October 7-11, 2015, Washington D.C.
79. Sokol RJ, Hoffenberg E, Moe P, Dovel DJ, Karrer FM. A Very Unusual Gastrointestinal Cause of Vitamin E Deficiency. Poster presentation at 5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, October 5-8, 2016, Montreal, Quebec, Canada.
80. El Kasmi KC, Anderson AL, Devereaux MW, Vue P, Balasubramaniyan N, Wright C, McKenna S, Woods C, D’Alessandro A, Suchy FJ, Sokol RJ. Macrophage derived IL-1β suppresses Liver X Receptor and hepatic phytosterol transporters ABCG5/8 to promote Parenteral Nutrition Associated Cholestasis in Mice. Oral presentation at 5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, October 5-8, 2016, Montreal, Quebec, Canada.
81. Loomes KM, Spino C, Goodrich NP, Hangartner T, Marker A, Heubi JE, Kamath BM, Shneider BL, Rosenthal P, Hertel PM, Karpen SJ, Kerkar N, Molleston JP, Murray KF, Teckman J, Whitington PF, Sherker AH, Magee JC, Sokol RJ for the Childhood Liver Disease Research Network (ChiLDReN). DXA Bone Density Deficits Differ in Alagille Syndrome and Chronic Intrahepatic Cholestasis.Poster presentation at 5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, October 5-8, 2016, Montreal, Quebec, Canada.
82. Molla Hosseini D, Capocelli, K, Hoffenberg EJ, Sokol, RJ. Gastrointestinal Polypoid Lesions Associated with Cavernous Transformation of the Portal Vein. Poster presentation at 5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, October 5-8, 2016, Montreal, Quebec, Canada.
83. Alonso EM, Ye W, Hawthorne K, Venkat V, Loomes KM, Mack C, Hertel PM, Karpen SJ, Kerker N, Molleston JP, Murray KF, Romero R, Rosenthal P, Schwarz KB, Shneider BL, Turmelle YP, Wang KS, Whitington PF, Sherker AH, Sokol RJ, Bezerra JA, Magee JC and the ChiLDReN Network. Impact of Steroid Therapy on Early Growth in Infants with Biliary Atresia. Oral presentation at The Liver Meeting, the AASLD Annual Meeting, November 11-15, 2016, Boston, MA. Hepatology 2016; 64 (Suppl 1): 43A
84. El Kasmi KC, Anderson AL, Devereaux MW, Vue P, Balasubramaniyan N, Wright C, McKenna S, Woods C, D’Alessandro A, Suchy FJ, Sokol RJ. IL-1b/NFkB pathway promotes Parenteral Nutrition Associated Cholestasis (PNAC) in mice through inhibiting LXR signaling and phytosterol transporter expression. Oral presentation at The Liver Meeting, the AASLD Annual Meeting, November 11-15, 2016, Boston, MA. Hepatology 2016: 64 (Suppl 1): 69A
85. Sundaram SS, Halbower A , Pan Z, Colgan S, Robbins K, Capocelli K, Sokol RJ. Treating Obstructive Sleep Apnea (OSA) and Intermittent Hypoxia Improves Severity of Non-Alcoholic Fatty Liver Disease (NAFLD) in Obese Pediatric Patients. Submitted to The Liver Meeting, the AASLD Annual Meeting, November 2016, Boston, MA.
86. Sokol RJ, Spino C, Moore J, Bezerra JA, Whitington PF, Karpen SJ, Loomes KM, Ng VL, Venkat VL, Wang KS, Goddhue CJ, Sherker AH, Magee JC, Mack CL. Intravenous Immunoglobulin (IVIG) Following Portoenterostomy in Infants with Biliary Atresia: a Phase 1/2A Trial. Lata Breaking Abstract Plenary Session oral presentation at The Liver Meeting, the AASLD Annual Meeting, November 11-15, 2016, Boston, MA. Hepatology 2016; 64 (Suppl) 1123A
87. El Kasmi KC, Anderson AL, Devereaux MW, Balasubramaniyan N, Suchy FJ, Friedman JE, and Sokol RJ. Intravenous FXR agonist GW4064 prevents Parenteral Nutrition Associated Cholestasis (PNAC) in mice. Oral presentation at 2017 Keystone Symposia on *Bile Acid Receptors as Signal Integrators in Liver and Metabolism*, March 3-8, 2017, Hyatt Regency Monterey, Monterey, California.
88. Sundaram SS, Halbower A , Pan Z, Robbins K, Capocelli K, Klawitter J. Sokol RJ. Treating Obstructive Sleep Apnea (OSA) and Intermittent Hypoxia Improves Severity of Non-Alcoholic Fatty Liver Disease (NAFLD) in Obese Pediatric Patients. Presented at Emerging Trends in Non-Alcoholic Fatty Liver Disease AASLD Conference, March 18-19, 2017, Washington D.C.
89. Kamath BM, Shneider BL, Spino A, Magee JC, Whitington PF, Setchell KD, Miethke A, Molleston JP, Mack CL, Squires RH, Murray KF, Loomes KM, Rosenthal P, Karpen SJ, Leung DH, Guthery SL, Thomas D, Sherker AH, Sokol RJ, for the Childhood Liver Disease Research Network (ChiLDReN). Unraveling the Relationship between Itching, Scratch Scales and Biomarkers in Children with Alagille Syndrome. Poster presentation at The Liver Meeting, AASLD annual meeting, Washington DC, October 2017. Hepatology 2017; 66 (Suppl 1):. Hepatology 2017; 66 (Suppl 1):653A-654A.
90. Shneider BL, Spino A, Kamath BM, Magee JC, Whitington PF, Setchell KD, Miethke A, Molleston JP, Mack CL, Squires RH, Murray KF, Loomes KM, Rosenthal P, Karpen SJ, Leung DH, Guthery SL, Thomas D, Sherker AH, Sokol RJ**,** for the Childhood Liver Disease Research Network (ChiLDReN). Results of ITCH, A Multi-center Randomized Double-blind Placebo-controlled Trial of Maralixibat, an Intestinal Bile Salt Transport Inhibitor, for Pruritus in Alagille Syndrome. Presented as Plenary Session oral presentation at The Liver Meeting, AASLD annual meeting, Washington DC, October 2017. Hepatology 2017; 66 (Suppl 1):84A.
91. Squires JE, Miethke AG, Hawthorne K, Van Hove J, Molleston JP, Kerkar N, Squires RH, Horslen S, Valencia CA, Barasa N, Alonso E, Bezerra J, Hertel PM, Kamath B, Karpen SJ, Loomes KM, Rosenthal P, Teckman J, Wang KS, Magee JC, and Sokol RJ for the ChiLDReN Network. Spectrum of clinical presentation and genetic causes of mitochondrial hepatopathies. Poster presentation at The Liver Meeting, AASLD annual meeting, Washington DC, October 2017. Hepatology 2017; 66 (Suppl 1):661A-662A.
92. Mack CL, Moore J, Kim A, Spino C, Whitingto PF, Bezerra JA, Goodhue CJ, Ng VL, Karpen SJ, Venkat V, Loomes KM, Wang KS, SAherker AH, Magee J, Sokol RJ, for ChiLDReN. Correlation of Immune Markers with Short-term Outcomes in Biliary Atresia following IVIg Treatment. Poster presentation at The Liver Meeting, AASLD annual meeting, Washington DC, October 2017. Hepatology 2017; 66 (Suppl 1):650A-651A.
93. Leung DH, Sorensen LG, Ye W, Hawthorne K, Kamath BM, Ng VL, Loomes KM, Fredericks EM, Sokol RJ, Squires JE, Karpen SJ, Molleston HP, Heubi JE, Murray KF, Wang KS, Rosenthal R, Teckman J, Sherker AH, Magee JC for ChiLDReN. Neurocognitive status in Alagille syndrome: results of a multi-center prospective observational study. Poster presentation at The Liver Meeting, AASLD annual meeting, Washington DC, October 2017. Hepatology 2017; 66 (Suppl 1):647A-648A.
94. Sundaram SS, Halbower A, Pan Z, Klawitter J, Colgan S, Robbins K, Capocelli K, Sokol RJ. Treating Obstructive Sleep Apnea and Intermittent Hypoxia with CPAP Improves Severity of Non-Alcoholic Fatty Liver Disease (NAFLD) in Obese Pediatric Patients. Poster presentation at The Liver Meeting, AASLD annual meeting, Washington DC, October 2017. Hepatology 2017; 66 (Suppl 1):664A-665A.
95. El Kasmi KC, Ghosh S, Anderson AL, Devereaux MW, Balasubramaniyan N, Johnson L, Haines JR, Suchy FJ, D’Alessandro A, and Sokol RJ. FXR Agonist GW4064 Prevents Parenteral Nutrition Associated Cholestasis (PNAC) in Mice. Oral presentation at The Liver Meeting, AASLD annual meeting, Washington DC, October 2017. Hepatology 2017; 66 (Suppl 1): 58A-59A.
96. Ghosh S, Devereaux MW, Anderson AL, Hayne J, D’Alessandro A, El Kasmi KC, Sokol RJ. Suppression of the hepatocyte canalicular sterol transporter ABCG5/8 enhances the inhibitory effects of phytosterols on FXR signaling. Poster presentation at The Liver Meeting, AASLD annual meeting, Washington DC, October 2017. Hepatology 2017; 66 (Suppl 1):230A-231A.
97. Berauer J-P, Mezina A, Okou DT, Sabo A, Hegde M, Chopra P, Perlmutter DH, Bull L, Thompson RJ, Spinner NB, Loomes KM, Rajagopalan R, Guthery SL, Moore B, Shneider BL, Kamath BM, Molleston JP, Rosenthal P, Squires RH, Sokol RJ, Wang KS, Magee JC, Sherker AH, Karpen SJ. Identification of PKD1L1 gene variants in biliary atresia patients with structural malformations (BASM). Oral Plenary presentation in Late Breaking Abstract Session at The Liver Meeting, AASLD annual meeting, Washington DC, October 2017. Hepatology 2017; 66: 1258A-1259A.
98. Shneider BL, Spino A, Kamath BM, Magee JC, Whitington PF, Setchell KD, Miethke A, Molleston JP, Mack CL, Squires RH, Murray KF, Loomes KM, Rosenthal P, Karpen SJ, Leung DH, Guthery SL, Thomas D, Sherker AH, Sokol RJ**,** for the Childhood Liver Disease Research Network (ChiLDReN). Results of ITCH, A Multi-center Randomized Double-blind Placebo-controlled Trial of Maralixibat, an Intestinal Bile Salt Transport Inhibitor, for Pruritus in Alagille Syndrome. Oral presentation at NASPGHAN annual meeting, Las Vegas, NV, November 2017.
99. Leung DH, Sorensen LG, Ye W, Hawthorne K, Kamath BM, Ng VL, Loomes KM, Fredericks EM, Sokol RJ, Squires JE, Karpen SJ, Molleston HP, Heubi JE, Murray KF, Wang KS, Rosenthal R, Teckman J, Sherker AH, Magee JC for ChiLDReN. Neurocognitive status in Alagille syndrome: results of a multi-center prospective observational study. Poster presentation at the NASPGHAN annual meeting, Las Vegas, NV, November 2017.
100. El Kasmi KC, Devereaux MW, Anderson AL, Ghosh S, Suchy FJ, Sokol RJ. Intravenous FXR Agonist GW4064 prevents Parenteral Nutrition Associated Cholestasis in Mice. Poster presentation at *Biliary Atresia: A Clinical and Translational Science Research Workshop*, National Institute of Diabetes, Digestive and Kidney Disease, NIH, June 28, 2017, Bethesda, MD
101. Bass L, Ye W, Hawthorn K, Leung DH, Murray KF, Molleston JP, Romero R, Sokol RJ, Karpen SJ, Rosenthal P, Loomes K, Wang K, Squires RH, Bezerra JA, Ng VL, Guthery S, Magee JC, Shneider, for ChiLDReN. Natural history and risk factors for variceal hemorrhage in biliary atresia: results of a prospective multi-center longitudinal analysis. Presented at AASLD Plenary session at Digestive Disease Week, Washington D.C., June 2018.
102. Squires JE, Sorensen LG, Fredericks EM, Ng VL, Hawthorne K, Henn L, Murray KF, Loomes KM, Karpen SJ, Shneider BL, Molleston JP, Bezerra JA, Rosenthal P, Squires RH, Wang K, Schwarz KB, Guthery SL, Kamath BM, Alonso EM, Magee JC, and Sokol RJ, for the ChiLDReN Network. Neurocognitive outcomes in older children with biliary atresia and native liver: Results from the Childhood Liver Disease Research Network (ChiLDReN) Study. Oral presentation at AASLD Annual Meeting, San Francisco, CA, November 2018. Hepatology 2018; 68 (Suppl 1):85A
103. Ghosh S, Devereaux MW, Anderson AL, El Kasmi KC, Sokol RJ. NFκB suppression of LRH1 and subsequent *ABCG5/8* suppression are involved in the pathogenesis of parenteral nutrition associated cholestasis. Oral presentation at Basic Science Plenary session presentation at AASLD Annual Meeting, San Francisco, CA, November 2018. Hepatology 2018; 68 (Suppl 1):14A.
104. Balasubramaniyan N, Devereaux MW, Sokol RJ, Suchy FJ. MicroRNA let-7a-5p Controls Poster for presentation at AASLD Annual Meeting, San Francisco, CA, November 2018. Hepatology 2018; 68 (Suppl 1):874A
105. Harpavat S, Heubi JE, Karpen SJ, Ng V, Setchell KD, Shneider BL, Alonso EM, Bezerra JA, Guthery SL, Loomes KM, Magee JC, Molleston JP, Murray KF, Rosenthal P, Sherker AH, Squires RH, Wang KS, and Sokol RJ for the Childhood Liver Disease Research Network (ChiLDReN). Prognostic Value of Serum Bile Acids after Kasai Portoenterostomy in Biliary Atresia. Oral presentation at AASLD Annual Meeting, San Francisco, CA, November 2018. Hepatology 2018; 68 (Suppl 1):85A-86A
106. Venkat VL, Ng VL, Magee JC, Ye W, Hawthorne K, Harpavat S, Murray KF, Wang KS, Mack CL, Molleston JP, Lin HC, Bass L, Soufi N, Bezerra JA, Guthery SL, Rosenthal P, Sokol RJ and Karpen SJ for the Childhood Liver Disease Research Network (ChiLDReN). Predictors of Outcome in Children with Biliary Atresia Surviving with Native Liver at Two Years of Age. Oral presentation at Clinical Plenary Session at AASLD Annual Meeting, San Francisco, CA, November 2018. Hepatology 2018; 68 (Suppl 1):10A-11A.
107. Jaramillo C, Sokol RJ. Elevated serum vitatmin E levels in infants receiving new intravenous lipid emulsions. Poster Presentation at Pediatric Academic Societies Meeting, Baltimore, MD, April 27, 2019.
108. Leung DH, Devaraj S, Goodrich NP, Chen X, Rajapakshe D, Ye W, Andreev V, Minard CG, Guffey D, Molleston JP, Bass LM, Karpen SJ, Kamath BM, Wang KS, Rosenthal P, McKiernan P, Loomes KM, Horslen S, Guthery S, Sunderam SS, Bezerra JA, Sherker A, Magee JC, Merion R, Sokol RJ, Shneider BL for ChiLDReN. Association of serum biomarkers with liver stiffness assessed by transient elastography in 330 children with cholestatic liver disease. Oral presentation at AASLD Annual Meeting, November 2020, Boston, MA.
109. Sanjiv Harpavat, Kieran Hawthorne, Benjamin L. Shneider, Lisa Henn, Charlette Beil, Saul J.

Karpen, Vicky Ng, Kenneth Setchell, Estella Alonso, Jorge Bezerra, Stephen Guthery, Simon

Horslen, Binita Kamath, Kathy M. Loomes, Patrick McKiernan, John Magee, Robert Merion,

Jean P. Molleston, Philip Rosenthal, Richard Thompson, Kasper S. Wang, Ronald Sokol, and James Heubi for ChiLDReN. Prognostic value of serum bile acids after achieving bile flow with the Kasai Portoenterostomy in biliary atresia. Oral presentation, AASLD Annual Meeting, November 2020, Boston, MA.

1. Ghosh S, Anderson AL, Devereaux MW, El Kasmi KC, SokolRJ. STAT 3 signaling may mediate protective effect of FXR agonist in parenteral nutrition associated cholestasis. Oral presentation at AASLD Annual Meeting, November 2020, Boston, MA.
2. Daan van Wessel, Richard J. Thompson, Emmanuel M. Gonzales, Irena Jankowska, Benjamin L. Shneider, Etienne Sokal, Tassos Grammatikopoulos , Agustina Kadaristiana , Emmanuel Jacquemin, Anne Spraul, Patryk Lipiński , Piotr Czubkowski , Nathalie Rock, Mohammad Shagrani, Dieter Broering, Talal Algou, Nejat Mazhar, Emanuele Nicastro, Deirdre Kelly, Gabriela Nebbia, Henrik Arnell, Bjorn Fischler, Jan Hulscher, Daniele Serranti, Cigdem Arikan, Esra Polat, Dominique Debray , Florence Lacaille, Cristina Gonçalves, Loreto Hierro, Gema Muñoz Bartolo, Yael Mozer-Glassberg, Amer Azaz, Jernej Brecelj, Antal Dezső, Pier Luigi Calvo , Enke Grabhorn Jr. , Ste􀃠en Hartleif , Wendy Van Der Woerd , Jian-She Wang , Liting Li , Ozlem Durmaz, Nanda Kerkar, Marianne Hørby Jørgensen, Ryan T. Fischer, Carolina Jimenez-Rivera , Seema Alam, Mara Cananzi , Noémie Laverdure, Cristina Targa Ferreira, Felipe Ordoñez Ferrero , Heng Wang, Valerie Sency , Kyung Mo Kim , Prof. Huey-Ling Chen , Elisa Carvalho, Alexandre Fabre, Jesus Quintero Bernabeu , Estella M Alonso, Ronald J. Sokol, Frederick J Suchy, Kathleen M. Loomes, Patrick J. McKiernan, Philip Rosenthal, Yumirle Padron Turmelle, Girish S. Rao, Simon Horslen, Binita M Kamath, Alexandra Papadopoulou, Wikrom Karnsakul, Bettina E. Hansen, Henkjan J. Verkade. Natural course and Prognosis of PFIC and Effect of biliary Diversion (NAPPED) consortium. Native liver survival in patients with FIC1 deficiency: impact of genotype, serum bile acid concentrations and surgical biliary diversion. Poster presentation, AASLD Annual Meeting, November 2020, Boston, MA.
3. Antonia Felzen, Daan van Wessel, Richard J. Thompson, Emmanuel M. Gonzales, Irena Jankowska, Benjamin L. Shneider, Etienne Sokal, Tassos Grammatikopoulos, Agustina Kadaristiana, Emmanuel Jacquemin, Anne Spraul, Patryk Lipiński, Piotr Czubkowski, Nathalie Roc , Mohammad Shagrani, Dieter Broering, Talal Algou, Nejat Mazhar, Emanuele Nicastro, Deirdre Kelly, Gabriella Nebbia, Henrik Arnell, Björn Fischle , Jan Hulscher, Daniele Serranti, Cigdem Arikan, Esra Polat , Dominique Debray, Florence Lacaille, Cristina Goncalves, Loreto Hierro, Gema Muñoz Bartolo, Yael Mozer-Glassberg, Amer Azaz, Jernej Brecelj, Antal Dezső, Pier Luigi Calvo, Enke Grabhorn Jr., Steven Hartleif, Wendy Van Der Woerd, Binita M. Kamath, Jian-She Wang, Liting Li, Özlem Durmaz , Nanda Kerkar, Marianne Hørby Jørgensen, Ryan T. Fischer, Carolina Jimenez-Rivera, Seema Alam Mara Cananzi , Mathias Ruiz , Cristina Targa Ferreir , Felipe Ordoñez Ferrero, Heng Wang, Valerie Sency, Kyung Mo Kim , Huey-Ling Che, Elisa Carvalho, Alexandre Fabre, Jesus Quintero Bernabeu, Estella M Alonso, Ronald J Sokol, Frederick J Suchy, Kathleen M. Loomes, Patrick J. McKiernan, Philip Rosenthal, Yumirle Turmelle, Simon P. Horslen, Kathleen Schwarz , Jorge A. Bezerra, Kasper S. Wang, Bettina E. Hansen and Henkjan J.Verkade. The presence of a truncating mutation in ABCB11 abrogates the beneficial effect of a residual function mutation on the course of severe bile salt export pump deficiency.Poster presentation, AASLD Annual Meeting, November 2020, Boston, MA
4. Porto A, Pan Z, Zhou W, Klaczkiewicz K, Sokol RJ, Sundaram SS. NAFLD Histologic Disease Severity Worsens with Diets High in Carbohdryates and Added Sugar. Presented at NASPGHAN Annual Meeting, November 2020, Nashville, TN.
5. Benjamin L. Shneider, Cathie Spino, Binita M Kamath, John C. Magee, Estella M Alonso, Alexander Miethke, Jean Pappas Molleston, Patrick James McKiernan, Simon P. Horslen, Kathleen M. Loomes, Cara Lynn Mack, Philip Rosenthal, Saul J. Karpen, Daniel H. Leung,

Stephen L Guthery, Rohit Kohli and Ronald J Sokol. Preliminary analysis of ITCH and IMAGINE II– Outcome of long-term administration of Maralixibat in children with Alagille syndrome. Presented as Late-Breaking Abstract to AASLD Annual Meeting, November 2020, Boston, MA

1. Daan van Wessel, Richard J. Thompson, Emmanuel M. Gonzales, Irena Jankowska, Benjamin L. Shneider, Etienne Sokal, Tassos Grammatikopoulos , Agustina Kadaristiana , Emmanuel Jacquemin, Anne Spraul, Patryk Lipiński , Piotr Czubkowski , Nathalie Rock, Mohammad Shagrani, Dieter Broering, Talal Algou, Nejat Mazhar, Emanuele Nicastro, Deirdre Kelly, Gabriela Nebbia, Henrik Arnell, Bjorn Fischler, Jan Hulscher, Daniele Serranti, Cigdem Arikan, Esra Polat, Dominique Debray , Florence Lacaille, Cristina Gonçalves, Loreto Hierro, Gema Muñoz Bartolo, Yael Mozer-Glassberg, Amer Azaz, Jernej Brecelj, Antal Dezső, Pier Luigi Calvo , Enke Grabhorn Jr. , Steven Hartleif , Wendy Van Der Woerd , Jian-She Wang , Liting Li , Ozlem Durmaz, Nanda Kerkar, Marianne Hørby Jørgensen, Ryan T. Fischer, Carolina Jimenez-Rivera , Seema Alam, Mara Cananzi , Noémie Laverdure, Cristina Targa Ferreira, Felipe Ordoñez Ferrero , Heng Wang, Valerie Sency , Kyung Mo Kim , Prof. Huey-Ling Chen , Elisa Carvalho, Alexandre Fabre, Jesus Quintero Bernabeu , Estella M Alonso, Ronald J. Sokol, Frederick J Suchy, Kathleen M. Loomes, Patrick J. McKiernan, Philip Rosenthal, Yumirle Padron Turmelle, Girish S. Rao, Simon Horslen, Binita M Kamath, Alexandra Papadopoulou, Wikrom Karnsakul, Bettina E. Hansen, Henkjan J. Verkade. Natural course and Prognosis of PFIC and Effect of biliary Diversion (NAPPED) consortium. Native liver survival in patients with FIC1 deficiency: impact of genotype, serum bile acid concentrations and surgical biliary diversion. Oral presentation at 6th World Congress of Pediatric GI, Hepatology and Nutrition, June 4, 2021, Vienna, Austria.
2. Antonia Felzen, Daan van Wessel, Richard J. Thompson, Emmanuel M. Gonzales, Irena Jankowska, Benjamin L. Shneider, Etienne Sokal, Tassos Grammatikopoulos, Agustina Kadaristiana, Emmanuel Jacquemin, Anne Spraul, Patryk Lipiński, Piotr Czubkowski, Nathalie Roc , Mohammad Shagrani, Dieter Broering, Talal Algou, Nejat Mazhar, Emanuele Nicastro, Deirdre Kelly, Gabriella Nebbia, Henrik Arnell, Björn Fischle , Jan Hulscher, Daniele Serranti, Cigdem Arikan, Esra Polat , Dominique Debray, Florence Lacaille, Cristina Goncalves, Loreto Hierro, Gema Muñoz Bartolo, Yael Mozer-Glassberg, Amer Azaz, Jernej Brecelj, Antal Dezső, Pier Luigi Calvo, Enke Grabhorn Jr., Ste"en Hartleif, Wendy Van Der Woerd, Binita M. Kamath, Jian-She Wang, Liting Li, Özlem Durmaz , Nanda Kerkar, Marianne Hørby Jørgensen, Ryan T. Fischer, Carolina Jimenez-Rivera, Seema Alam Mara Cananzi , Mathias Ruiz , Cristina Targa Ferreir , Felipe Ordoñez Ferrero, Heng Wang, Valerie Sency, Kyung Mo Kim , Huey-Ling Che, Elisa Carvalho, Alexandre Fabre, Jesus Quintero Bernabeu, Estella M Alonso, Ronald J Sokol, Frederick J Suchy, Kathleen M. Loomes, Patrick J. McKiernan, Philip Rosenthal, Yumirle Turmelle, Simon P. Horslen, Kathleen Schwarz , Jorge A. Bezerra, Kasper S. Wang, Bettina E. Hansen and Henkjan J.Verkade. The presence of a truncating mutation in ABCB11 abrogates the beneficial effect of a residual function mutation on the course of severe bile salt export pump deficiency.Oral presentation at 6th World Congress of Pediatric GI, Hepatology and Nutrition, June 4, 2021, Vienna, Austria.
3. Shearn CT, Anderson AL, Devereux MW, Balasubramaniyam N, Suchy FJ, Orlicky DJ, PetersenDR and Sokol RJ. Colocalization of elevated oxidative stress and autophagy in periportal hepatocytes in human and murine cholangiopathies. Oral presentation at 2021 Digestive Disease Week Virtual Meeting, May 2021.
4. Ghosh S, Anderson AL, Devereaux MW, El Kasmi KC, SokolRJ. STAT 3 signaling may mediate protective effect of FXR agonist in parenteral nutrition associated cholestasis. Plenary session oral presentation at 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, June 4, 2021, Vienna, Austria.
5. Stahl, M, Shaw, JR, Rachubinski AL, Galbraith MD, Sokol RJ, Norman P, Sameer C, Leaton LA, Lieu E, Espinosa J. Is it all in the genes? HLA risk for celiac disease in a Down syndrome cohort. Top 5 Poster Award presentation at Down Syndrome Medical Interest Group – USA 2021 Annual Symposium (Virtual), June 17-19, 2021.
6. Chaidez A, Lovell MA, Sokol RJ, Sundaram SS, Mack CL. Fibrscan correlates with Ishak fibrosis stage in pediatric liver disease and Fibroscan-AST score predicts severity of pediatric NAFLD/NASH. Oral presentation at American Association for the Study of Liver Diseases Annual Meeting (The Liver Meeting), November 2021, Anaheim, CA. Hepatology 2021; 74 (Oct 2021) (Suppl 1): 32A.
7. Ghosh S, Devereaux MW Liu C, Sokol RJ. LRH-1 Agonist (DLPC) Prevents Macrophage Activation and Parenteral Nutrition Associated Cholestasis in Mice. Presented at Poster Presentation at American Association for the Study of Liver Diseases Annual Meeting (The Liver Meeting), November 2021, Anaheim, CA. Hepatology 2021; 74 (Suppl 1): 1169A.
8. Sindhu Panduranji, Reena Mourya, Shreya Nalluri, Lin Fei, Shun Dong, Sanjiv Harpavat, Stephen L. Guthery, Girish S. Rao, Philip Rosenthal, Ronald J. Sokol, Kasper S. Wang, Estella M. Alonso, Evelyn K. Hsu, Saul J. Karpen, Kathleen M. Loomes, John C. Magee, Benjamin L. Shneider, Robert H. Squires, Jeffrey H. Teckman, Jorge A. Bezerra on behalf of ChiLDReN. Accuracy of serum MMP-7 as a diagnostic biomarker for biliary atresia in a large U.S. cohort. Oral parallel session presentation at American Association for the Study of Liver Diseases Annual Meeting (The Liver Meeting), November 2021, Anaheim, CA. Hepatology 2021; 74 (Oct 2021) (Suppl 1): 132A.
9. Shneider BL, Kamath BM, Ye W, Goodrich NP, Magee JC, Loomes KM, Jones K, Spino C, Wang KS, Squires RH, Rosenthal P, Molleston JP, Karpen SJ, Jensen MK, Horslen SP, Bezerra JA, Alonso EM, Sokol RJ for the Childhood Liver Disease Research Network.  Utilization of Multi-center Prospective Longitudinal Databases to Inform Clinical Trials in Rare Diseases – Examination of Cholestatic Liver Disease in Alagille Syndrome (ALGS). Presented at poster session presentation at American Association for the Study of Liver Diseases Annual Meeting (The Liver Meeting), November 2021, Anaheim, CA. Hepatology 2021; 74 (Oct 2021) (Suppl 1): 1182A.
10. Colin T. Shearn, Aimee L. Anderson, Michael W. Devereux, David J. Orlicky, Dennis R. Petersen and Ronald J. Sokol. The autophagic protein p62 is a target of reactive aldehydes in human cholestatic liver disease. Presented at poster session presentation at American Association for the Study of Liver Diseases Annual Meeting (The Liver Meeting), November 2021, Anaheim, CA. Hepatology 2021; 74 (Oct 2021) (Suppl 1): 784A.
11. Sokol RJ, Gonzales E, Kamath B, Baker A, Vig P, Tucker E, Garner W, Hansen BE, Jacquemin E, Thompson RJ. Predictors of 6-Year Event-Free Survival in Patients with Alagille Syndrome Treated with Maralixibat, an IBAT Inhibitor. Presented at Late Breaking Abstract Poster Session at American Association for the Study of Liver Diseases Annual Meeting (The Liver Meeting), November 2021, Anaheim, CA.
12. Stahl, MG, Shaw, JR, Rachubinski AL, Galbraith, MD, Norman, P, Sameer C, Leaton LA, Sokol, RJ, Liu, E, Espinosa, JM.Assessment of a genetic risk score for celiac disease in Down Syndrome. Presented as Poster at Digestive Disease Week, May 2022, Chicago, IL.
13. Kemme S, Canniff JD, Feldman AG, Garth K, Li S, Pan Z, Sokol RJ, Wienberg A, Mack CL. Cytomegalovirus Positivity at Diagnosis of Biliary Atresia Correlates more severe initial liver injury and worse survival with native liver. Oral presentation at Pediatric Academic Societies Annual Meeting, April 23, 2022, Denver, Colorado.
14. Kemme S, Garth K, Canniff J, Li S, Weinberg A, Feldman AG, Sokol RJ, Mack CL. Cytomegalovirus Positivity at Diagnosis of Biliary Atresia Correlates with Higher Risk of Mortality. Presented at Poster Presentation at European Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting, June 23-25, 2022, Copenhagen, Denmark.
15. Sokol RJ, Emmanuel Gonzales, Binita M Kamath, Alastair Baker, Pamela Vig,
Will Garner, Bettina E Hansen,6Emmanuel Jacquemin, Richard J Thompson. Predictors of 6-year event-free survival in patients with Alagille syndrome treated with maralixibat, an IBAT inhibitor. Oral Presentation at Hepatology Plenary Session, European Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting, June 23-25, 2022, Copenhagen, Denmark.
16. GhoshS, DevereauxMW, LiuC, Sokol RJ. Pharmacological targeting of LRH-1 prevents macrophage activation during parenteral nutrition associated cholestasis in mice. Oral Presentation at Plenary Session, European Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting, June 23-25, 2022, Copenhagen, Denmark.
17. Van Hove JLK, Friederich MW, Streode DK, Van Hove RA, Miller K, Gabel L, Horslen S, Lovell M, Miethke A, Moleston J, Romero R, Squires J, Squires R, Sundaram S, Magee J, Sokol RJ, on behalf of Childhood Liver Disease Research Network (ChiLDReN). Analysis of protein biomarkers to identify mitochondrial hepatopathies from other liver diseases. Poster presentation at Society for Study Inborn Errors of Metabolism meeting, August 30, 2022, Freiberg, Germany.
18. Sokol RJ, Friederich MW, Strode DK, Van Hove RA, Miller K, Gabel L, Horslen S, Kohli R, Lovell M, Miethke A, Molleston J, Romero R, Squires J, Squires R, Sundaram SS, Magee J, Van Hove JLK, and Childhood Liver Disease Research Network (ChiLDReN). Accuracy of GDF15 and FGF21 to Differentiate Mitochondrial Hepatopathies from Other Pediatric Liver Diseases. Accepted for oral presentation at The Liver Meeting, AASLD annual meeting, November 2022, Washington, DC.
19. Yoeli D, Rolfes P, Feldman A, Adams M, Wachs M, Sokol RJ. Liver Transplantation for Mitochondrial Hepatopathies: A Review of the National Experience. Poster presentation at The Liver Meeting, AASLD annual meeting, November 2022, Washington, DC.
20. Shearn CT, Anderson AL, Devereaux MW, El Kasmi KC, Sokol RJ. Hepatic circadian rhythms are dysregulated by increased cytokine production in mice subjected to concomitant intestinal injury and parenteral nutrition. Poster presentation at The Liver Meeting, AASLD annual meeting, November 2022, Washington, DC.
21. Sundaram SS, Ben Abdallah M, Cooper E, Nadeau K, Kelsey M, Pickett K, Sokol RJ, Inge TH. Significant Histologic Improvement of NAFLD in Severely Obese Adolescents following Bariatric Surgery. Oral presentation at The Liver Meeting, AASLD annual meeting, November 2022, Washington, DC.
22. Ghosh S, Devereaux MW, Orlicky DJ, Sokol RJ. HNF4α antagonist prevents parenteral nutrition associated cholestasis in mice by inhibiting NFκB signaling. Oral presentation at The Liver Meeting, AASLD annual meeting, November 2022, Washington, DC.
23. Shneider BL, Kanchi R, Grimm SL, Schraw J, Bezerra JA, Loomes K, Magee J, Sokol RJ, Wang K, Alonso EM, Hsu EK, Molleston JP, Rosenthal P, Karpen SJ, Horslen SP, Jensen MK, Kamath BM, Lupo PH, Corfa C, and Childhood Liver Disease Research Network. The Plasma Proteome in Pediatric Cholestasis Reveals Biomarkers of Liver Stiffness and Suggests a role for Epithelial-to-Mesenchymal Transition in Fibrogenesis. Oral presentation at The Liver Meeting, AASLD annual meeting, November 2022, Washington, DC.
24. Taylor SA, Harpavat S, Miska J, Gromer KD, Karpen SJ, Sokol RJ, Chandel NS, Alonso EM, Mack CL and Childhood Liver Disease Research Network. Distinct immune-metabolic signatures at diagnosis of biliary atresia are associated with future survival with native liver. Oral plenary session presentation at The Liver Meeting, AASLD annual meeting, November 2022, Washington, DC.
25. Kemme S, Canniff JD, Garth K, Feldman A, Li S, Pan Z, Sokol RJ, Weinberg A, Mack CL. Association of cytomegalovirus infection at time of diagnosis of biliary atresia with higher risk of pre-transplant mortality. Poster presentation at Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, October 13-25, 2022, Orlando, FL.
26. Sokol RJ, Gonzales E, Kamath B, Baker A, Tokman T, Vig P, Garner W, Hansen BE, Jacquemin E, Thompson RJ. Predictors of 6-year event-free survival in patients with Alagille syndrome treated with maralixibat, an IBAT inhibitor. Submitted to AMCP Nexus 2023 meeting.